
<html lang="en"     class="pb-page"  data-request-id="fea8898e-f8f2-4eef-ac2e-fcbf45ea45cf"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2013.56.issue-22;article:article:10.1021/jm400856t;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Polypharmacology – Foe or Friend?" /></meta><meta name="dc.Creator" content="Jens-Uwe  Peters" /></meta><meta name="dc.Description" content="Polypharmacology describes the activity of compounds at multiple targets. Current research focuses on two aspects of polypharmacology: (1) unintended polypharmacology can lead to adverse effects; (..." /></meta><meta name="Description" content="Polypharmacology describes the activity of compounds at multiple targets. Current research focuses on two aspects of polypharmacology: (1) unintended polypharmacology can lead to adverse effects; (..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 22, 2013" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm400856t" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2013 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm400856t" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm400856t" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm400856t" /></link>
        
    
    

<title>Polypharmacology – Foe or Friend? | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm400856t" /></meta><meta property="og:title" content="Polypharmacology – Foe or Friend?" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0011.jpeg" /></meta><meta property="og:description" content="Polypharmacology describes the activity of compounds at multiple targets. Current research focuses on two aspects of polypharmacology: (1) unintended polypharmacology can lead to adverse effects; (2) polypharmacology across several disease-relevant targets can improve therapeutic efficacy, prevent drug resistance, or reduce therapeutic-target-related adverse effects. This perspective reviews these interconnected aspects of polypharmacology. The first part discusses the relevance of polypharmacology for the safety of drugs, the mitigation of safety risks, and methods to identify polypharmacological compounds early in the drug discovery process. The second part discusses the advantages of polypharmacology in the treatment of multigenic diseases and infections, and opportunities for drug discovery and drug repurposing. This perspective aims to provide a balanced view on polypharmacology, which can compromise the safety of drugs, but can also confer superior efficacy." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm400856t"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm400856t">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm400856t&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm400856t&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm400856t&amp;href=/doi/10.1021/jm400856t" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2013</span><span class="cit-fg-volume">, 56</span><span class="cit-fg-issue">, 22</span><span class="cit-fg-pageRange">, 8955-8971</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/56/22" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/jm4007752" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Polypharmacology – Foe or Friend?</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jens-Uwe++Peters">Jens-Uwe Peters</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">F. Hoffmann-La Roche Ltd., pRED, Pharma Research and Early Development, Discovery Chemistry, CH-4070 Basel, Switzerland</span></div><div class="corresp-info"><strong>*</strong>Phone: +41 61 68 82636. E-mail: <a href="/cdn-cgi/l/email-protection#81ebe4eff2acf4f6e4aff1e4f5e4f3f2c1f3eee2e9e4afe2eeec"><span class="__cf_email__" data-cfemail="8de7e8e3fea0f8fae8a3fde8f9e8fffecdffe2eee5e8a3eee2e0">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm400856t&amp;href=/doi/10.1021%2Fjm400856t" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2013</span></span><span class="cit-volume">, 56</span><span class="cit-issue">, 22</span><span class="cit-pageRange">, 8955–8971</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 6, 2013</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>11 June 2013</li><li><span class="item_label"><b>Published</b> online</span>22 August 2013</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 November 2013</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm400856t" title="DOI URL">https://doi.org/10.1021/jm400856t</a></div><div class="article_header-article-copyright"><strong>Copyright © 2013 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8955%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJens-Uwe%2BPeters%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D56%26issueNum%3D22%26contentID%3Djm400856t%26title%3DPolypharmacology%2B%25E2%2580%2593%2BFoe%2Bor%2BFriend%253F%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8971%26publicationDate%3DNovember%2B2013">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm400856t"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">7097</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">268</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm400856t" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Polypharmacology – Foe or Friend?&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Jens-Uwe&quot;,&quot;last_name&quot;:&quot;Peters&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2013&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;22&quot;,&quot;issue&quot;:&quot;22&quot;,&quot;volume&quot;:&quot;56&quot;,&quot;pages&quot;:&quot;8955-8971&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm400856t&quot;},&quot;abstract&quot;:&quot;Polypharmacology describes the activity of compounds at multiple targets. Current research focuses on two aspects of polypharmacology: (1) unintended polypharmacology can lead to adverse effects; (2) polypharmacology across several disease-relevant targets can improve therapeutic efficacy, prevent drug resistance, or reduce therapeutic-target-related adverse effects. This perspective reviews these interconnected aspects of polypharmacology. The first part discusses the relevance of polypharmacology for the safety of drugs, the mitigation of safety risks, and methods to identify polypharmacological compounds early in the drug discovery process. The second part discusses the advantages of polypharmacology in the treatment of multigenic diseases and infections, and opportunities for drug discovery and drug repurposing. This perspective aims to provide a balanced view on polypharmacology, which can compromise the safety of drugs, but can also confer superior efficacy.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm400856t&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400856t" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm400856t&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400856t" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm400856t&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400856t" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm400856t&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400856t&amp;href=/doi/10.1021/jm400856t" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm400856t" /></input><a href="/doi/pdf/10.1021/jm400856t" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm400856t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm400856t%26sid%3Dliteratum%253Aachs%26pmid%3D23919353%26genre%3Darticle%26aulast%3DPeters%26date%3D2013%26atitle%3DPolypharmacology%2B%25E2%2580%2593%2BFoe%2Bor%2BFriend%253F%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D56%26issue%3D22%26spage%3D8955%26epage%3D8971%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292461" title="Neurophysiology">Neurophysiology</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a>,</li><li><a href="/action/doSearch?ConceptID=292202" title="Drug discovery">Drug discovery</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/56/22" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jmcmar.2013.56.issue-22/production/jmcmar.2013.56.issue-22.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_null" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/medium/jm-2013-00856t_0011.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400856t&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Polypharmacology describes the activity of compounds at multiple targets. Current research focuses on two aspects of polypharmacology: (1) unintended polypharmacology can lead to adverse effects; (2) polypharmacology across several disease-relevant targets can improve therapeutic efficacy, prevent drug resistance, or reduce therapeutic-target-related adverse effects. This perspective reviews these interconnected aspects of polypharmacology. The first part discusses the relevance of polypharmacology for the safety of drugs, the mitigation of safety risks, and methods to identify polypharmacological compounds early in the drug discovery process. The second part discusses the advantages of polypharmacology in the treatment of multigenic diseases and infections, and opportunities for drug discovery and drug repurposing. This perspective aims to provide a balanced view on polypharmacology, which can compromise the safety of drugs, but can also confer superior efficacy.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1 Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73767" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73767" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The pharmaceutical industry withdrew a large number of drugs during the years 1996–2001. Some of these drugs interacted with nontherapeutic targets and thereby caused severe side-effects. For instance, the widely used anorexigen, fenfluramine, led to pulmonary hypertension and heart valve damage, because its metabolite activated the serotonin 5-HT<sub>2B</sub> receptor.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1-3)</a> When fenfluramine was withdrawn in 1997, many patients were already permanently injured, and the case sparked a public debate on drug safety and vigilance.</div><div class="NLM_p">At about the same time, advances in molecular biology allowed the set up of “safety panels”. New drug candidates were now screened against dozens of safety-relevant targets,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> such as the 5-HT<sub>2B</sub> receptor. Today, most researchers pursue high affinity for a single therapeutic target combined with high selectivity, believing that this will maximize efficacy, will minimize side-effects, and will give their drug a therapeutic window.</div><div class="NLM_p">However, this view has been challenged in recent years.<a onclick="showRef(event, 'ref5 ref6 ref7 ref8 ref9 ref10 ref11 ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7 ref8 ref9 ref10 ref11 ref12 ref13 ref14">(5-14)</a></div><div class="NLM_p">Polypharmacological drugs can be unprecedentedly efficacious, and they can be developed in a modern drug discovery setting. Prominent examples are the multikinase inhibitors, which have been entering the clinic since 2005, and have been providing new hope for the treatment of previously refractory cancers. The efficacy of these drugs results from their disruption of multiple processes which sustain cancer growth, such as proliferation, angiogenesis, and recruitment of surrounding tissues.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div><div class="NLM_p">Polypharmacology also benefits other complex diseases, such as psychiatric diseases.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16, 17)</a> For example, all marketed antipsychotics are polypharmacological, including recently approved drugs. Modern concepts explain the efficacy of these drugs by their modulation of a network of disease-relevant targets.<a onclick="showRef(event, 'ref5 ref18'); return false;" href="javascript:void(0);" class="ref ref5 ref18">(5, 18)</a> If individual targets are redundant in such a network, then drugs must interact with multiple targets to correct a pathological imbalance. Indeed, some multikinase inhibitors and antipsychotics bind to more than 20 targets.</div><div class="NLM_p">Also, multitarget drugs can be safer than single-target drugs. For reasons explained below, multitarget drugs can be less liable to adverse reactions, which originate from a therapeutic target. For instance, tapentadol is a powerful analgesic combining μ-opioid receptor agonism with norepinephrine reuptake inhibition; this dual-acting compound is safer and has fewer side-effects than classical opioids at equianalgesic doses.</div><div class="NLM_p last">Thus, while activity at nontherapeutic targets can lead to toxicity, activity at multiple therapeutic targets can result in superior efficacy or safety. Unintended polypharmacology must therefore be avoided, whereas targeted polypharmacology holds opportunities for the discovery of better drugs. This perspective discusses both of these aspects.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2 New Trends in Safety Panel Screening and Promiscuity Prediction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54835" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54835" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.1 Why Safety Panel Screening?</h3><div class="NLM_p">Many adverse drug reactions (ADRs) stem from a drug’s unintended activity at an “antitarget”;<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> some antitargets are frequently encountered and well-known (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Animal toxicity studies<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21, 22)</a> do not reliably predict antitarget-related ADRs in humans due to species differences. For example, rodent models poorly predict cardiovascular ADRs in humans, because of different contributions of ion channels in the cardiovascular system of humans and rodents.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The ICH S7A guidelines for safety studies therefore recommend antitarget screening — “ligand binding or enzyme assay data suggesting a potential for adverse effects”.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24, 25)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Frequently Encountered Antitargets</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">antitarget</th><th class="colsep0 rowsep0" align="center">hit rate<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> (displacement assay) (%)</th><th class="colsep0 rowsep0" align="center">associated adverse effects</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hERG channel</td><td class="colsep0 rowsep0" align="left">(see text)</td><td class="colsep0 rowsep0" align="left">arrhythmia</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">serotonin 5-HT<sub>2B</sub> receptor</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">agonists: valvulopathy, pulmonary hypertension</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">serotonin 5-HT<sub>2A</sub> receptor</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">agonists: cognition impairment, hallucination</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">α<sub>1A</sub> adrenergic receptor</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">agonists: arrhythmia; antagonists: orthostatic hypotension</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dopamine D<sub>2</sub> receptor</td><td class="colsep0 rowsep0" align="left">9</td><td class="colsep0 rowsep0" align="left">agonists: confusion, emesis; antagonists: orthostatic hypotension</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">histamine H<sub>1</sub> receptor</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">antagonists: weight gain, sedation, somnolence</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">α<sub>2A</sub> adrenergic receptor</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">agonists: hypotension, sedation</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dopamine D<sub>1</sub> receptor</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">antagonists: dyskinesia, tremor</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">M<sub>1–5</sub> muscarinic receptors</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">multiple cardiovascular and metabolic adverse effects, cognition impairment</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">μ-opioid receptor</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">agonists: sedation, respiratory depression, abuse potential</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Hit rate: percentage of druglike compounds, which bind to this target with an IC<sub>50</sub> < 1 μM in the BioPrint data set.</p></div></div></div><div class="NLM_p">In addition to protecting volunteers in clinical trials, antitarget screening also reduces preclinical and clinical attrition: ADRs and preclinical toxicity account for 30% of all drug candidate terminations in clinical trials.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><div class="NLM_p">Not only specific antitarget interactions but also pharmacological profiles (“fingerprints”) can be predictive of ADRs, for instance, if a novel compound binds to a similar set of targets as a drug with known ADRs.<a onclick="showRef(event, 'ref27 ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29 ref30">(27-30)</a></div><div class="NLM_p last">For these reasons, many research organizations screen their drug candidates against panels of up to 180 safety-relevant targets.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">2.2 Recent Developments in Safety Panel Screening</h3><div class="NLM_p">Traditionally, only a few advanced compounds and development candidates underwent safety panel screening, due to the restrictive costs and low throughput of large panels. However, the identification of antitarget activities at a late stage requires the modification of a highly optimized compound and is often a major setback. It is therefore desirable to assess off-target activities earlier in the drug discovery process. Over the last few years, major drug discovery organizations have established smaller panels for the screening of early compounds. Such panels are intended to flag promiscuous compounds and to predict antitarget-related adverse effects, rather than to demonstrate high selectivity. Consequently, they contain only key antitargets and avoid a redundancy of targets. For instance, such panels include muscarinic receptors, because these receptors attract high hit rates and cause a range of cardiovascular, CNS, and endocrine-related side-effects. However, it would be redundant to include more than two muscarinic receptors in an early panel, because compounds are rarely selective for one muscarinic receptor subtype – activity at one subtype predicts activity across all five of them.</div><div class="NLM_p">Novartis, Pfizer and Roche have recently set up screening strategies for early compounds: Novartis implemented a “primary assay panel” of 24 targets associated with serious ADRs and high hit rates,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Pfizer screens initially against 15 “targets of most concern”,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> and Roche uses a panel of 48 diverse targets.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Collaborating scientists from AstraZeneca, GlaxoSmithKline, Pfizer and Novartis identified 44 targets, which were part of the screening panels in at least three of the four companies, and proposed these 44 targets as a “minimal panel” for early safety screening.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> These 44 targets have a high relevance for safety and attract high hit rates.</div><div class="NLM_p">Early panels should combine predictivity for ADRs with sufficient throughput and should therefore only include targets of high importance, that is, frequently hit targets with a clear relevance for safety. Targets with no clear links to ADRs should be omitted. For example, the melatonin MT<sub>3</sub> receptor and some serotonergic receptors (5-HT<sub>4–7</sub>) attract high hit rates but are not known to be involved in ADRs.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The serotonergic 5-HT<sub>5A</sub> receptor may be a case in point: ligands of this receptor do not produce any adverse behavioral or physiological responses,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> and knockout animals show a very mild phenotype.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Also, targets with low hit rates can be omitted: proteases and kinases are often safety-relevant but attract hit rates of <1% from random compounds (which are not designed to be protease or kinase inhibitors)<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> and are therefore rarely included in early safety screens.</div><div class="NLM_p">Thus, criteria for the selection of targets for early safety screening should be association with adverse effects, hit rate, and redundancy. See the cited reviews for linkages of targets to adverse effects and target hit rates (note that these publications define hit rates differently).<a onclick="showRef(event, 'ref20 ref34 ref38'); return false;" href="javascript:void(0);" class="ref ref20 ref34 ref38">(20, 34, 38)</a></div><div class="NLM_p">Radioligand displacement assays have been the workhorse of safety panel screening. However, functional assays are emerging as primary screens for certain G protein-coupled receptors (GPCRs), for a 2-fold reason: first, displacement assays do not reliably detect agonists, especially if the radioligand is an antagonist.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Novartis researchers noted that many agonists of aminergic receptors have only micromolar affinity in displacement assays but low nanomolar or sub-nanomolar activity in functional assays. For example, their muscarinic M<sub>2</sub> receptor displacement assay did not detect acetylcholine and other potent M<sub>2</sub> receptor agonists.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Other publications report similar findings.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> A second reason for the use of functional assays is their predictivity for ADRs: for a number of receptors, ADRs are only associated with agonistic activity, rather than antagonistic activity.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> For instance, agonism of the serotonin 5-HT<sub>2B</sub> receptor causes valvulopathy and pulmonary hypertension, whereas 5-HT<sub>2B</sub> antagonists produce no ADRs. Several safe, marketed drugs are 5-HT<sub>2B</sub> antagonists,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> and 5-HT<sub>2B</sub> antagonism even shows promise as a therapeutic target.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The 5-HT<sub>2B</sub> receptor displacement assay attracts the highest number of hits in the Novartis<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> and Roche<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> safety screens, and approximately 90% of the hits are antagonists.<a onclick="showRef(event, 'ref38 ref41'); return false;" href="javascript:void(0);" class="ref ref38 ref41">(38, 41)</a> In this case, a functional assay for 5-HT<sub>2B</sub> receptor agonism avoids the unnecessary deprioritization of a large number of compounds.</div><div class="NLM_p">Also, functional assays reflect the rich pharmacology of many ion channels more reliably than displacement assays. Displacement assays address only one of multiple binding sites within an ion channel’s pore, and such assays are often not predictive of functional activity. Therefore, most organizations characterize their investigative compounds in electrophysiological experiments to assess the potential for ion channel blockade.</div><div class="NLM_p">Arguably, the most notorious antitarget in current drug discovery is the cardiac human ether-à-go-go-related gene (hERG) potassium channel: this channel attracts hit rates of 60%<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> from compounds with a large structural variety,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> and as little as 20% hERG blockade can lead to potentially lethal arrhythmias.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Because of the eminent significance of this antitarget, the assessment of hERG blockade is a regulatory requirement for the in vitro pharmacological profiling of new drug candidates.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Many advanced compounds are thus profiled in electrophysiological assays with hERG-expressing recombinant cell lines. These assays are work-intensive and have a low throughput. Displacement assays have a higher throughput, but produce many false positives and negatives,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> and are therefore not deemed predictive enough in some organizations. Ion-flux-based, functional assays also have a higher throughput and reproduce the activity of a wide range of hERG channel blockers,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> but such assays have not yet found widespread use.</div><div class="NLM_p last">Apart from hERG, five other ion channels contribute importantly to the heart rhythm: Nav1.5, Cav1.2, KCNQ1, Kv4.2/4.3, and Kir2.1.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The first three of these channels attract hit rates of 4–10% (IC<sub>50</sub> < 30 μM)<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> and may also be assessed by electrophysiology experiments, e.g., at the clinical candidate selection stage. It is however challenging to integrate the different ion channel data into an overall judgment on the arrhythmic potential of a compound.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">2.3 Early Alerts of Potential Polypharmacology</h3><div class="NLM_p">Since 2006, numerous studies investigated the dependence of pharmacological promiscuity on molecular properties, such as lipophilicity, ionization state, and molecular weight (MW). These studies have been reviewed.<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46, 47)</a> In almost all studies, lipophilic compounds tend to be more promiscuous. For instance, the promiscuity potential increases at a threshold of ClogP ∼ 2 in the BioPrint data set (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) and at similar thresholds in Pfizer<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> and Roche<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> project compounds. An illustrative example is marketed beta-blockers, which are structurally similar, but span a wide lipophilicity range (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>): beta-blockers with a ClogP < 2 do not hit more than five off-targets in the BioPrint panel,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> whereas all beta-blockers with a ClogP > 2.5 hit between 7 and 20 off-targets.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> However, the degree of promiscuity varies greatly between compounds of similar lipophilicity (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Thus, lipophilicity alone is generally not a useful parameter to predict or to optimize the promiscuity of individual compounds, even though this has been successful in some instances.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Rather, these studies affirm the importance of low lipophilicity as a key goal for lead optimization and as a criterion for the selection of hit and lead series.<a onclick="showRef(event, 'ref52 ref53 ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref52 ref53 ref54 ref55">(52-55)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/medium/jm-2013-00856t_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0003.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Dependence of pharmacological promiscuity (hit rate) on ionization state and lipophilicity in the BioPrint data set. The majority of promiscuous compounds are bases, which carry a positive charge under assay conditions. Compounds with a ClogP > 2 tend to be more promiscuous. The “hit rate” of a compound is the percentage of targets, to which this compound binds with sub-micromolar affinity (cytochrome P450 [CYP] enzymes are excluded). For instance, the topmost blue data point represents a compound, which “hits” 19% of the BioPrint targets (25 out of 132). Reproduced with permission from <i>Drug Discovery Today</i><b>2012</b>, <i>17</i>(7–8), 325–335. Copyright 2012 Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400856t&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/medium/jm-2013-00856t_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0004.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Dependence of pharmacological promiscuity (off-target hits) on the lipophilicity of marketed beta-blockers. Lipophilic beta-blockers tend to be more promiscuous. “Off-target hits” denote the number of submicromolar hits in a safety screening panel of 129 targets (BioPrint data set excluding β-adrenergic receptors and CYP enzymes). Number-labeled data points represent, in order of increasing ClogP: atenolol (1), sotalol (2), nadolol (3), timolol (4), carteolol (5), metoprolol (6), pindolol (7), acebutolol (8), esmolol (9), bisoprolol (10), celiprolol (11), oxprenolol (12), levobunolol (13), betaxolol (14), labetalol (15), alprenolol (16).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400856t&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Basic compounds with a pK<sub>a</sub>[B] > 6 are (partly) protonated at assay and physiological pH. Such compounds are frequently promiscuous in safety screens (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>),<a onclick="showRef(event, 'ref37 ref40'); return false;" href="javascript:void(0);" class="ref ref37 ref40">(37, 40)</a> especially if they contain two or more aromatic rings in the vicinity of the basic center. The promiscuity of these compounds stems from their interaction with a limited set of targets, such as aminergic GPCRs, cationic ion channels, opioid receptors, and biogenic amine transporters.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Safety panels contain usually a high percentage of such targets (∼15–25%). Thus, the connection of basicity with promiscuity could be interpreted as an artifact, due to a bias of safety panels toward “aminergic” targets. However, “aminergic” activity is also the dominant source of polypharmacology of clinically used drugs, as suggested by publications on drug-target network analyses, in-silico profiling, and database mining.<a onclick="showRef(event, 'ref56 ref57 ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref56 ref57 ref58 ref59">(56-59)</a> On average, drugs with activity for an aminergic target bind to six other GPCRs.<a onclick="showRef(event, 'ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref60 ref61">(60, 61)</a> In safety panels, some aminergic targets attract a surprisingly high hit rate from compounds with a basic center. For example, the serotonergic 5-HT<sub>2B</sub> receptor binds more than one-third of the basic compounds in the BioPrint data set with sub-micromolar affinity, and even more than half of all basic compounds with two or more aromatic rings. Numerous other aminergic targets bind more than every fifth basic compound. Consequently, “aminergic” interactions dominate safety-screening data sets. For instance, even though only 12% of the data points in the BioPrint data set represent basic compounds tested at aminergic and similar targets, these data points account for 70% of the sub-micromolar “hits”. (“Basic” means here the presence of a basic center, which is protonated at pH 7.)<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div><div class="NLM_p">Many studies investigated the dependence of promiscuity on MW. The results are contradictory: binned MW correlates inversely with promiscuity in a large set of Pfizer high-throughput screening (HTS) data,<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> whereas Novartis safety panel data<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> and Roche HTS data<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> show the opposite trend. The BioPrint data set shows a more complex relationship,<a onclick="showRef(event, 'ref37 ref52'); return false;" href="javascript:void(0);" class="ref ref37 ref52">(37, 52)</a> and ligands of proteins in the Protein Data Bank (PDB) show no correlation.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> High potency promiscuity increases with MW among ChEMBL database compounds,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> but not within a small set of Roche project compounds.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Altogether, MW does not seem to be a useful predictor of promiscuity, at least not in the druglike MW range (200–600).</div><div class="NLM_p">The influence of other parameters on promiscuity is often predictable from their relationship with lipophilicity. For example, compounds with a low polar surface area tend to be more lipophilic and also tend to be more promiscuous.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> The same is true for compounds with few hydrogen bond donors and acceptors or for compounds with multiple aromatic rings.<a onclick="showRef(event, 'ref37 ref52 ref65'); return false;" href="javascript:void(0);" class="ref ref37 ref52 ref65">(37, 52, 65)</a></div><div class="NLM_p">Finally, compounds tend to be less promiscuous if they are of high complexity, of little flexibility, or decorated with many side chains,<a onclick="showRef(event, 'ref63 ref66 ref67 ref68'); return false;" href="javascript:void(0);" class="ref ref63 ref66 ref67 ref68">(63, 66-68)</a> probably because such compounds require a high shape complementarity from a protein’s binding site.<a onclick="showRef(event, 'ref69 ref70'); return false;" href="javascript:void(0);" class="ref ref69 ref70">(69, 70)</a></div><div class="NLM_p">An important cause of promiscuity is the binding site similarity within some target families and also between unrelated proteins.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Aminergic GPCRs and kinases are the two largest target families associated with frequent promiscuity; they are also highly safety-relevant. Certain structural features are an alert for promiscuity within these target families. The prototypical pharmacophore of aminergic GPCRs is a secondary or tertiary amine with a pK<sub>a</sub>[B] > 6, which is connected by a 2–5-atom linker to an aromatic ring.<a onclick="showRef(event, 'ref71 ref72'); return false;" href="javascript:void(0);" class="ref ref71 ref72">(71, 72)</a> Compounds with such a pharmacophore are often promiscuous. Some more defined structural motifs lead almost invariably to high promiscuity across aminergic and related targets, for instance, the tricyclic motif in older antidepressants and many antipsychotic drugs. Similarly, the trained eye recognizes certain patterns of hydrogen bond donors, acceptors, and aromaticity as potential kinase hinge-binding motifs.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Hinge-binders inhibit often several kinases, and some show high promiscuity across the kinome.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> The “2–0” rule helps to identify compounds with an increased likelihood of kinase activity by counting typical structural fragments: more than two heteroaromatic nitrogens (N or NH), or any (more than 0) aromatic NH substituents and nitriles. Much more predictive is the presence of a bisarylaniline motif, in particular, of a “heteroaryl-NH-aryl” motif as defined in Chart <a class="ref internalNav" href="#cht1" aria-label="1">1</a>; such compounds often inhibit a wide variety of kinases.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></div><figure id="cht1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/medium/jm-2013-00856t_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0001.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. The “Heteroaryl-NH-aryl” Motif Is Predictive of Kinase Activity<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400856t&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The promiscuity potential of lead series with aminergic or hinge-binding motifs should be assessed early in the drug discovery process by screening against six diverse aminergic targets,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> or six kinases,<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> respectively.</div><div class="NLM_p">Several functionalities are associated with promiscuity across smaller target families. For instance, a large structural variety of drugs with a primary sulfonamide bind to carbonic anhydrases<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> and many hydroxamic acids are inhibitors of matrix metalloproteases.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a></div><div class="NLM_p">Very recently, a computational method for predicting off-target activities has been receiving much attention: the similarity ensemble approach (SEA). This method predicts the binding of a compound to a target by the compound’s noncoincidental similarity to known ligands of this target. A comparison with ligands of many targets generates a pharmacological profile. In a profiling study of 656 marketed drugs at 73 “side-effect” targets, this method predicted numerous nonobvious interactions, half of which were confirmed either by database mining, or by in vitro pharmacological measurements. For example, it was predicted and confirmed that the synthetic estrogen chlorotriasine inhibits cyclooxygenase-1 (COX-1). This provided an explanation for a side effect of chlorotriasine, abdominal pain.<a onclick="showRef(event, 'ref79 ref80 ref81'); return false;" href="javascript:void(0);" class="ref ref79 ref80 ref81">(79-81)</a></div><div class="NLM_p last">Other in silico tools flag compounds either for general propensity toward promiscuity,<a onclick="showRef(event, 'ref62 ref82 ref83 ref84'); return false;" href="javascript:void(0);" class="ref ref62 ref82 ref83 ref84">(62, 82-84)</a> or for potential activity at specific antitargets.<a onclick="showRef(event, 'ref85 ref86 ref87'); return false;" href="javascript:void(0);" class="ref ref85 ref86 ref87">(85-87)</a> These tools have not (yet) found widespread use.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">2.4 Pharmacological Promiscuity – Prevalence, and Significance for Toxicity and Attrition</h3><div class="NLM_p">Many established drugs are not selective,<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> and a significant percentage of compounds in large databases bind to more than one target:<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> 33% of the compounds in the BioPrint database,<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> 35% in a large proprietary database,<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> 38% in the ChEMBL database,<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> 50% in the PubChem database,<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> and 52% of oral drugs in the ChEMBL database<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> (target binding is defined differently in the cited publications). The Psychoactive Drug Screening Program (PDSP) database contains an even larger number of promiscuous compounds.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> These databases cover only a fraction of the estimated 3000 druggable targets of the human genome,<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> so the actual prevalence of promiscuity is likely higher than the indicated 33–52%.<a onclick="showRef(event, 'ref61 ref88 ref94'); return false;" href="javascript:void(0);" class="ref ref61 ref88 ref94">(61, 88, 94)</a></div><div class="NLM_p">Beta-blockers and selective serotonin reuptake inhibitors (SSRIs) illustrate the promiscuity of established drugs: beta-blockers are rarely selective for their principal target, the adrenergic β<sub>1</sub>-receptor, but bind to up to 20 out of 129 BioPrint targets with submicromolar activity (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>).<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Carvedilol has a particularly rich pharmacology, which is responsible for its unique therapeutic profile: in contrast to other beta-blockers, carvedilol treats congestive heart failure,<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> and has been described as a “powerful cardioprotector”.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> Similarly, SSRI antidepressants target the serotonin reuptake transporter as their main mechanism of action, but weak off-target activities are common. For instance, fluoxetine binds to 7 out of 129 BioPrint targets with submicromolar activity.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Some of these off-target activities may contribute to the efficacy of fluoxetine and other SSRIs. For instance, the sigma receptor is a depression target in its own right,<a onclick="showRef(event, 'ref97 ref98'); return false;" href="javascript:void(0);" class="ref ref97 ref98">(97, 98)</a> and paroxetine, fluoxetine, citalopram, escitalopram, fluvoxamine and sertraline bind to the sigma receptor with low micromolar or sub-micromolar activity.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></div><div class="NLM_p">Despite this prevalence of promiscuity, only a quarter of drug withdrawals<a onclick="showRef(event, 'ref99 ref100 ref101'); return false;" href="javascript:void(0);" class="ref ref99 ref100 ref101">(99-101)</a> since 1980 can be traced back to unintended pharmacological activities (mainly hERG and 5-HT<sub>2B</sub> activities, Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). Other mechanistic reasons seem equally or more important: a second quarter of withdrawals is linked to adverse effects mediated through the drug’s therapeutic target. Almost half of all withdrawals are likely due to reactive metabolite induced toxicity, bile salt export pump (BSEP) inhibition, and mitochondrial toxicity, which occur in combination for some withdrawn drugs (for instance, the hepatotoxicity of troglitazone has been attributed to all three mechanisms).<a onclick="showRef(event, 'ref102 ref103'); return false;" href="javascript:void(0);" class="ref ref102 ref103">(102, 103)</a></div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/medium/jm-2013-00856t_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0005.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Mechanistic reasons for drug withdrawals since 1980. Withdrawn drugs were classified by the presumed mechanism of their main adverse effects: (a) hERG blockade: astemizole, cisapride, grepafloxacin, levomethadyl, terfenadine, terodiline, thioridazine; (b) serotonin 5-HT<sub>2B</sub> receptor agonism: benfluorex, dexfenfluramine, fenfluramine, pergolide; (c) muscarinic M<sub>2</sub> receptor antagonism: rapacuronium; (d) CYP interaction: mibefradil; (e) therapeutic-target related: alosetron, cerivastatin, encainide, etretinate, flosequinan, hydromorphone extended-release (Palladone), methaqualone, phenylpropanolamine, rimonabant, rofecoxib, rosiglitazone, valdecoxib; (f) reactive metabolite formation, bile salt export pump (BSEP) inhibition, or mitochondrial toxicity: alpidem, amineptine, benoxaprofen, benzbromarone, bromfenac, chlormezanone, levamisole, lumiracoxib, nefazodone, nomifensine, pemoline, phenacetin, remoxipiride, sitaxentan, suprofen, temafloxacin, ticrynafen, tolcapone, tolrestat, troglitazone, trovafloxacin, ximelagatran, zimelidine, zomepirac; (g) unknown: gatifloxacin, sibutramine (likely therapeutic target related), tegaserod.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400856t&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Also, promiscuity did not increase the likelihood for adverse effects in a set of 87 development candidates from Astra Zeneca: compounds terminated for safety findings in preclinical or phase I studies had a similar prevalence of promiscuity, as compounds terminated for other reasons, such as portfolio decisions.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a></div><div class="NLM_p">However, off-target activities must not be disregarded as an important cause of toxicity and attrition, and the above discussion should be seen in perspective: drugs will never reach the market, and will thus not contribute to withdrawals, if their off-target activities cause acute, nonidiosyncratic toxicity. Similarly, compounds will not be selected as development candidates if they have safety-relevant off-target activities; such compounds may not be included in the Astra Zeneca set.</div><div class="NLM_p">Also, severe side-effects of marketed drugs have been traced back to off-target activities. For example, antipsychotics cause severe metabolic adverse effects, such as weight gain, hyperprolactinaemia, and diabetes, by antagonism of the histamine H<sub>1</sub>, the serotonin 5-HT<sub>2C</sub>, and the muscarinic receptors.<a onclick="showRef(event, 'ref17 ref105'); return false;" href="javascript:void(0);" class="ref ref17 ref105">(17, 105)</a> Antagonism at further antitargets is responsible for the CNS-related and cardiovascular side-effects of antipsychotics, such as movement disturbances (extrapyramidal symptoms), sedation, heart rhythm changes (QT prolongation), and orthostatic hypotension (“dizzy spells”, fainting when standing up).<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></div><div class="NLM_p last">Thus, promiscuity is not uncommon among druglike compounds and does not necessarily translate into toxicity. However, numerous targets are linked to adverse effects. A compound’s safety potential should therefore be assessed by a careful interpretation of its secondary pharmacology.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">3 Is There a Case for Polypharmacological Drug Discovery?</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12323" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12323" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">3.1 Multigenic and Infectious Diseases Benefit from Polypharmacological Treatment</h3><div class="NLM_p">Over the last 20 years, most drug discovery efforts were aimed at single-target compounds. However, not all diseases succumb to this “one disease–one target” approach. For instance, no selective antipsychotic has reached the market in a 60-year quest for better drugs.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> Rather, all established antipsychotics bind to multiple GPCRs and ion channels, and their polypharmacological profile underlies their antipsychotic efficacy, even though the dopamine D<sub>2</sub> and serotonin 5-HT<sub>2A</sub> receptors are recognized as principal targets.<a onclick="showRef(event, 'ref16 ref108 ref109 ref110'); return false;" href="javascript:void(0);" class="ref ref16 ref108 ref109 ref110">(16, 108-110)</a> The antipsychotic gold-standard, clozapine, is a weak D<sub>2</sub> receptor antagonist (<i>K</i><sub>i</sub> > 100 nM) but has an exceptionally rich polypharmacology.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a></div><div class="NLM_p">Systems biology explains the efficacy of polypharmacological drugs by their modulation of networks of targets.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> Such networks have evolved to be robust to perturbation,<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> and blockade of a single target in such a network has little effect — it is compensated for by redundant pathways.<a onclick="showRef(event, 'ref114 ref115'); return false;" href="javascript:void(0);" class="ref ref114 ref115">(114, 115)</a> In yeast, the individual blockade of 85–90% of targets does not produce any observable effects, and knockout studies in mice suggest that only 10% of all druggable genes may be of value as single therapeutic targets.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Thus, a drug should often modulate a pharmacological network, rather than block or activate a single target.</div><div class="NLM_p">Multikinase inhibitors for the therapy of tumors illustrate this concept.<a onclick="showRef(event, 'ref15 ref116'); return false;" href="javascript:void(0);" class="ref ref15 ref116">(15, 116)</a> Tumors and their surrounding tissue exchange several growth factors and thereby mutually stimulate angiogenesis and tumor growth (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). Tumors secrete vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), which trigger angiogenesis from endothelial cells and pericytes. PDGF also activates fibroblasts. Activated fibroblasts, in turn, secrete other growth factors and thereby stimulate the tumor to proliferate; the growing tumor is sustained by angiogenesis. Activated fibroblasts also secrete enzymes, which degrade the extracellular matrix and thereby open room for the growing tumor, and contribute to the escape of metastatic cells. Tumors may additionally release cytokines, which attract leukocytes; leukocytes also secrete growth factors and matrix-degrading enzymes. Multikinase anticancer drugs disrupt several of these signaling processes, either by inhibiting receptor kinases or by inhibiting downstream intracellular signaling.<a onclick="showRef(event, 'ref15 ref117'); return false;" href="javascript:void(0);" class="ref ref15 ref117">(15, 117)</a> For instance, the multikinase inhibitor sunitinib<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> blocks the receptor kinases of many of the above-mentioned growth factors and thereby prevents angiogenesis, tumor proliferation, and malignancy (compare targets in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a> and Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Recently Approved Multi-Kinase Inhibitors as Anticancer Drugs</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">drug</th><th class="colsep0 rowsep0" align="center">first approval</th><th class="colsep0 rowsep0" align="center">targets</th><th class="colsep0 rowsep0" align="center">FDA approval for (status April 2013)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sorafenib</td><td class="colsep0 rowsep0" align="left">2005</td><td class="colsep0 rowsep0" rowspan="2" align="left">B-Raf, vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), c-Kit, Fms-like tyrosine kinase 3 (Flt-3), RET</td><td class="colsep0 rowsep0" align="left">liver cancer</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">kidney cancer</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sunitinib</td><td class="colsep0 rowsep0" align="left">2006</td><td class="colsep0 rowsep0" rowspan="3" align="left">VEGFR, PDFGR, c-Kit, Flt-3, RET, colony stimulating factor 1 receptor (CSF-1R)</td><td class="colsep0 rowsep0" align="left">kidney cancer</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">gastrointestinal stromal tumors (GIST)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">pancreatic neuroendocrine tumors</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dasatinib</td><td class="colsep0 rowsep0" align="left">2006</td><td class="colsep0 rowsep0" align="left">BCR/ABL, Src, c-Kit, ephrin receptors</td><td class="colsep0 rowsep0" align="left">chronic cyelogenous leukemia (Philadelphia chromosome positive)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">lapatinib</td><td class="colsep0 rowsep0" align="left">2007</td><td class="colsep0 rowsep0" align="left">ErbB1, ErbB2, epidermal growth factor receptor (EGFR)</td><td class="colsep0 rowsep0" align="left">hormone-positive and human epidermal growth factor receptor 2 (HER2) positive advanced breast cancer</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pazopanib</td><td class="colsep0 rowsep0" align="left">2009</td><td class="colsep0 rowsep0" rowspan="2" align="left">VEGFR, PDGFR, c-Kit</td><td class="colsep0 rowsep0" align="left">advanced renal cell carcinoma</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">advanced soft tissue sarcoma</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">vandetanib</td><td class="colsep0 rowsep0" align="left">2011</td><td class="colsep0 rowsep0" align="left">EGFR, VEGFR, RET, BRK, TIE2, Src, ephrin receptors</td><td class="colsep0 rowsep0" align="left">unresectable, locally advanced, or metastatic medullary thyroid cancer.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">crizotinib</td><td class="colsep0 rowsep0" align="left">2011</td><td class="colsep0 rowsep0" align="left">ALK, Ros-1, hepatocyte growth factor receptor (HGFR)</td><td class="colsep0 rowsep0" align="left">locally advanced or metastatic nonsmall cell lung cancer (anaplastic lymphoma kinase-positive)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">axitinib</td><td class="colsep0 rowsep0" align="left">2012</td><td class="colsep0 rowsep0" align="left">VEGFR, PDGFR, c-Kit</td><td class="colsep0 rowsep0" align="left">advanced renal cell carcinoma after failure of prior systemic therapy</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bosutinib</td><td class="colsep0 rowsep0" align="left">2012</td><td class="colsep0 rowsep0" align="left">BCR/ABL, Src</td><td class="colsep0 rowsep0" align="left">chronic myelogenous leukemia (Philadelphia chromosome positive)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">regorafenib</td><td class="colsep0 rowsep0" align="left">2012</td><td class="colsep0 rowsep0" rowspan="2" align="left">VEGFR, PDGFR, fibroblast growth factor receptor (FGFR), TIE-2, B-Raf, c-Kit, RET</td><td class="colsep0 rowsep0" align="left">advanced gastrointestinal stromal tumors (GIST)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">previously treated metastatic colorectal cancer</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cabozantinib</td><td class="colsep0 rowsep0" align="left">2012</td><td class="colsep0 rowsep0" align="left">RET, MET, VEGFR, c-Kit, Flt-3</td><td class="colsep0 rowsep0" align="left">progressive, metastatic medullary thyroid cancer</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ponatinib</td><td class="colsep0 rowsep0" align="left">2012</td><td class="colsep0 rowsep0" align="left">BCR/ABL, c-Kit, RET, Flt-3</td><td class="colsep0 rowsep0" align="left">chronic, accelerated or blast-phase chronic myeloid leukemia</td></tr></tbody></table></div></div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/medium/jm-2013-00856t_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0006.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Tumors and their surrounding tissue exchange growth factors and cytokines and thereby stimulate angiogenesis and tumor growth. The receptor kinases of these growth factors are targets of multikinase inhibiting anticancer drugs. (Reproduced with permission from <i>Polypharmacology in Drug Discovery</i>; Peters, J.-U., Ed.; Wiley, New York, 2012; the picture is courtesy of Annalisa Petrelli, University of Turin).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400856t&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Polypharmacological anticancer drugs are also believed to prevent drug resistance.<a onclick="showRef(event, 'ref117 ref119'); return false;" href="javascript:void(0);" class="ref ref117 ref119">(117, 119)</a> Drug resistance to a single-target kinase inhibitor can emerge from several mechanisms, such as mutations or up-regulation of the targeted kinase, or other kinases in parallel or downstream pathways. Multikinase inhibitors can block multiple targets in parallel signaling pathways and thereby prevent drug resistance due to mutations or expression changes.</div><div class="NLM_p">Multitarget treatments also prevent rapid drug resistance in infectious diseases.<a onclick="showRef(event, 'ref120 ref121 ref122'); return false;" href="javascript:void(0);" class="ref ref120 ref121 ref122">(120-122)</a> Nearly all systemically efficacious antibiotics bind to multiple targets, or to targets encoded by multiple genes, so that single mutations do not lead to drug resistance. For example, β-lactam antibiotics bind to the target family of penicillin-binding proteins; several of such proteins are present in every bacterium. Physicians apply fluoroquinolone antibiotics at “mutation prevention concentrations”, at which bacterial gyrase and topoisomerase IV are dually inhibited, even though the inhibition of only one enzyme would be sufficient to stop bacterial growth. On the other hand, single-target antibiotics rapidly select resistance mutations and are only used in combination, or as topical agents. Interestingly, practically all clinically efficacious antibiotics were discovered by whole-cell screening, which allows for the discovery of multitarget drugs. Since the mid-1990s, antibiotic research focused increasingly on single targets derived from bacterial genomes; these endeavors seem to have been generally fruitless. Similarly, polypharmacological treatment prevents drug resistance in viral and parasite infections.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> For neglected tropical diseases, polypharmacological drugs are expected to combat several strains of parasites<a onclick="showRef(event, 'ref124 ref125'); return false;" href="javascript:void(0);" class="ref ref124 ref125">(124, 125)</a> or to treat both primary and opportunistic infections.<a onclick="showRef(event, 'ref125 ref126'); return false;" href="javascript:void(0);" class="ref ref125 ref126">(125, 126)</a></div><div class="NLM_p">Apart from schizophrenia, cancer, and infections, polypharmacological treatments may benefit a range of other diseases, such as depression,<a onclick="showRef(event, 'ref127 ref128 ref129'); return false;" href="javascript:void(0);" class="ref ref127 ref128 ref129">(127-129)</a> other psychiatric disorders,<a onclick="showRef(event, 'ref107 ref130 ref131'); return false;" href="javascript:void(0);" class="ref ref107 ref130 ref131">(107, 130, 131)</a> neurodegeneration,<a onclick="showRef(event, 'ref132 ref133 ref134 ref135'); return false;" href="javascript:void(0);" class="ref ref132 ref133 ref134 ref135">(132-135)</a> epilepsy,<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> cardiovascular disorders,<a onclick="showRef(event, 'ref96 ref137 ref138'); return false;" href="javascript:void(0);" class="ref ref96 ref137 ref138">(96, 137, 138)</a> arrhythmia<a onclick="showRef(event, 'ref139 ref140 ref141'); return false;" href="javascript:void(0);" class="ref ref139 ref140 ref141">(139-141)</a> airway diseases,<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> autoimmune disorders,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> inflammation,<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> and pain.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> The Food and Drug Administration (FDA) approved numerous polypharmacological drugs in recent years, for example, asenapine, sunitinib, and dronedarone (Chart <a class="ref internalNav" href="#cht2" aria-label="2">2</a>). The majority of these approved drugs are multikinase anticancer drugs, followed by antipsychotics and antidepressants. For an overview, see Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>–<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>.</div><figure id="cht2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Chart 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/medium/jm-2013-00856t_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0002.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 2. Recently Approved, Polypharmacological Drugs for Different Indications and Target Classes</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400856t&amp;id=cht2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Recently Approved and Advanced Investigational Antipsychotics</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">drug</th><th class="colsep0 rowsep0" align="center">status</th><th class="colsep0 rowsep0" align="center">low nanomolar affinity for</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">paliperidone</td><td class="colsep0 rowsep0" align="left">approved (FDA), 2006</td><td class="colsep0 rowsep0" align="left">dopamine D<sub>2</sub>, serotonin 5-HT<sub>2A</sub>, 5-HT<sub>7</sub>, α<sub>1</sub>, α<sub>2</sub> adrenergic, histamine H<sub>1</sub> receptor</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">iloperidone</td><td class="colsep0 rowsep0" align="left">approved (FDA), 2009</td><td class="colsep0 rowsep0" align="left">dopamine D<sub>2</sub> – D<sub>4</sub>, serotonin 5-HT<sub>2A</sub>, 5-HT<sub>6</sub>, 5-HT<sub>7</sub>, and α<sub>1</sub> adrenergic receptors</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">asenapine</td><td class="colsep0 rowsep0" align="left">approved (FDA), 2009</td><td class="colsep0 rowsep0" align="left">dopamine D<sub>1</sub> – D<sub>4</sub>, serotonin 5-HT<sub>1A</sub>, 5-HT<sub>1B</sub>, 5-HT<sub>2A-C</sub>, 5-HT<sub>5A</sub>, 5-HT<sub>6</sub>, 5-HT<sub>7</sub>, α<sub>1</sub>, α<sub>2A-C</sub> adrenergic, histamine H<sub>1</sub>, H<sub>2</sub> receptors</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">lurasidone</td><td class="colsep0 rowsep0" align="left">approved (FDA), 2010</td><td class="colsep0 rowsep0" align="left">dopamine D<sub>2</sub>, serotonin 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>7</sub>, α<sub>2C</sub> adrenergic receptors</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cariprazine</td><td class="colsep0 rowsep0" align="left">clinical studies, phase III</td><td class="colsep0 rowsep0" align="left">dopamine D<sub>2</sub>, D<sub>3</sub>, serotonin 5-HT<sub>1A</sub>, 5-HT<sub>2A-C</sub> receptors</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">zicronapine</td><td class="colsep0 rowsep0" align="left">clinical studies, phase III</td><td class="colsep0 rowsep0" align="left">dopamine D<sub>2</sub>, D<sub>3</sub>, serotonin 5-HT<sub>2</sub>, α<sub>1</sub> adrenergic receptors</td></tr></tbody></table></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Recently Approved and Advanced Investigational Multi-Target Antidepressants</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">drug</th><th class="colsep0 rowsep0" align="center">status</th><th class="colsep0 rowsep0" align="center">targets</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">agomelatine</td><td class="colsep0 rowsep0" align="left">approved (Europe), 2009</td><td class="colsep0 rowsep0" align="left">melatonin MT<sub>1</sub>, MT<sub>2</sub>, and serotonin 5-HT<sub>2C</sub> receptors</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">vilazodone</td><td class="colsep0 rowsep0" align="left">approved (FDA), 2011</td><td class="colsep0 rowsep0" align="left">serotonin reuptake, serotonin 5-HT<sub>1A</sub> receptor</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">vortioxetine</td><td class="colsep0 rowsep0" align="left">clinical studies, phase III</td><td class="colsep0 rowsep0" align="left">serotonin reuptake, serotonin 5-HT<sub>1A</sub>, 5-HT<sub>1B</sub>, 5-HT<sub>3A</sub>, 5-HT<sub>7</sub> receptors</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tedatioxetine</td><td class="colsep0 rowsep0" align="left">clinical studies, phase II</td><td class="colsep0 rowsep0" align="left">serotonin, norepinephrine and dopamine reuptake, serotonin 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>, 5-HT<sub>3</sub>, α<sub>1A</sub> adrenergic receptors</td></tr></tbody></table></div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">3.2 Why Polypharmacological Drugs Can Be Safer</h3><div class="NLM_p">Selective drugs are often perceived as inherently safer, because they cannot cause side-effects via nontherapeutic targets. However, many side-effects stem from interaction with the therapeutic target itself. Therapeutic-target-related side-effects are similarly common reasons for drug withdrawals, as are off-target-related side-effects (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). Polypharmacological drugs may be less liable for such side-effects, because the therapeutic effects of multiple modes of action are often synergistic, whereas the adverse effects are not. For instance, a combination of antihypertensives with different modes of action leads to an improved therapeutic effect, without an equal exacerbation of side-effects.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> This concept of “selective synergy”<a onclick="showRef(event, 'ref145 ref146'); return false;" href="javascript:void(0);" class="ref ref145 ref146">(145, 146)</a> may be particularly obvious when the therapeutic targets are expressed together only in the diseased tissue or targeted cell but not in the tissue that may be affected by side-effects related to the therapeutic targets. For instance, glucocorticoids are efficacious anti-inflammatory drugs, because they activate the glucocorticoid receptor in lymphocytes and thereby suppress inflammatory signaling. Inflammatory signaling is also suppressed by an activation of the lymphocyte’s β-adrenergic receptors by norepinephrine (NE). NE reuptake inhibitors target this second, complementary pathway by increasing extracellular levels of NE. The anti-inflammatory effects of glucocorticoid receptor activation and NE reuptake inhibition are synergistic. On the other hand, chronic glucocorticoid treatment causes severe side-effects, for example, hyperglycemia, via glucocorticoid receptors in the liver and the pituitary gland. NE reuptake inhibitors do not increase these side-effects because those tissues express fewer β-adrenergic receptors. Thus, NE reuptake inhibitors, such as nortriptyline, improve the therapeutic effect of glucocorticoids, such as prednisolone, but do not exacerbate the side-effects.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a></div><div class="NLM_p">A notable example of side-effect reduction by multitargeting is the analgesic, tapentadol, which was designed as a safer alternative to the classical opioids.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> Opioids such as morphine exert a strong analgesic effect through μ-opioid receptor agonism but are used only for the treatment of the most severe pain. This limited use is due to therapeutic-target-related side-effects: dependence, nausea, constipation, and respiratory depression. Also, because of these side-effects, failure to reach full efficacy cannot be overcome by dose escalation. Physicians found that NE reuptake inhibitors increase the efficacy of opioids in such cases. On the basis of this observation, Grünenthal researchers designed tapentadol as a relatively weak, dual-acting μ-receptor agonist/NE reuptake inhibitor. Tapentadol turned out to have a much more benign side-effect profile than morphine at equianalgesic doses, especially with respect to emetic potential and respiratory depression, and the development of tolerance is delayed.</div><div class="NLM_p">Many current research programs aim for multitarget antidepressants with reduced side-effects.<a onclick="showRef(event, 'ref127 ref128'); return false;" href="javascript:void(0);" class="ref ref127 ref128">(127, 128)</a> While especially the SSRI antidepressants are exceptionally safe drugs, they have unpleasant effects, which limit patient compliance and contribute to a high discontinuation rate: sexual dysfunction, disrupted sleep, and acute anxiety at the beginning of the treatment. These side-effects are likely due to the stimulation of serotonin 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>, and 5-HT<sub>3</sub> receptors by increased serotonin levels; combined serotonin reuptake inhibition and antagonism at these receptors is thus a desirable profile for novel antidepressants.</div><div class="NLM_p last">Target-related adverse effects are sometimes “outbalanced” by additional pharmacological activities. Selective cyclooxygenase-2 (COX-2) inhibitors (“coxibs”) were withdrawn due to an increased risk of cardiovascular events,<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> whereas dual COX-1/COX-2 inhibitors (nonsteroidal anti-inflammatory drugs) remain widely used. Rapacuronium was withdrawn because of bronchospasms during treatment, likely due to selective muscarinic M<sub>2</sub> receptor antagonism in absence of M<sub>3</sub> receptor antagonism.<a onclick="showRef(event, 'ref149 ref150'); return false;" href="javascript:void(0);" class="ref ref149 ref150">(149, 150)</a> Other drugs, which antagonize both the M<sub>2</sub> and the M<sub>3</sub> receptor, remain in use (atracurium, pancuronium, rocuronium, doxacurium). Fluoxetine, haloperidol, verapamil, and citalopram are potent hERG blockers (IC<sub>50</sub> = 10 nM – 1 μM) but have a low pro-arrhythmic potential, probably because their hERG activity is offset by additional activities at cardiac Ca<sup>2+</sup> and Na<sup>+</sup> channels.<a onclick="showRef(event, 'ref151 ref152'); return false;" href="javascript:void(0);" class="ref ref151 ref152">(151, 152)</a></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">3.3 Drug Polypharmacology: Opportunities for Repurposing and for the Discovery of New Drugs</h3><div class="NLM_p">“Drug repurposing” or “repositioning” refers to the use of an old drug for a new indication and has received much interest in recent years.<a onclick="showRef(event, 'ref153 ref154'); return false;" href="javascript:void(0);" class="ref ref153 ref154">(153, 154)</a> The development of an already established drug for a new indication is usually faster and less risky than the development of a novel drug, because an established drug’s second development is facilitated by previous studies, such as formulation, human pharmacokinetic, and toxicity studies.</div><div class="NLM_p">Polypharmacological drugs can be repurposed based on their “off-target” activities.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> An astonishing case is the revival of thalidomide, which was first introduced in 1957 as a hypnotic. As is known today, thalidomide nearly always causes malformations in babies when taken during the first 3–6 weeks of pregnancy, likely due to induction of oxidative stress<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> or due to interference with transcription.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> Tragically, the drug was recommended particularly for pregnant women for the alleviation of morning sickness and caused birth defects in thousands of cases. Thalidomide was withdrawn in 1961 after these disastrous effects were recognized. In 1964, a serendipitous discovery led to the repurposing of thalidomide for the treatment of erythema nodosum leprosum (ENL), a painful inflammatory complication of leprosy. An ENL patient had been in so much pain that he had not slept in weeks, and his physician turned to thalidomide as a last resort — the banned hypnotic was still available in his infirmary. Thalidomide not only allowed this patient to sleep, it also eliminated the pain and the other symptoms of ENL. Clinical trials followed and demonstrated that thalidomide effected complete remission of ENL in nearly all treated patients. This efficacy is due to thalidomide’s off-target activity on tumor necrosis factor α (TNF-α), which is inappropriately produced in inflamed tissue. Today, thalidomide is used primarily for the treatment of multiple myeloma; its efficacy in this disease is due to still other, multiple off-target activities.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a></div><div class="NLM_p">More typical is the repurposing of contemporary kinase inhibitors for the treatment of different cancers. The first marketed kinase inhibitor, imatinib,<a onclick="showRef(event, 'ref159 ref160'); return false;" href="javascript:void(0);" class="ref ref159 ref160">(159, 160)</a> was originally approved in 2001 for the treatment of chronic myelogenous leukemia (CML). Imatinib was initially intended to be a selective inhibitor of a kinase expressed from the fusion gene Bcr/Abl, which is the oncogene responsible for CML. Later, it was discovered that imatinib also inhibits the kinase c-Kit, whose gain-of-function mutations are responsible for many gastrointestinal tumors (GISTs).<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> Imatinib showed high efficacy in the treatment of GISTs, a cancer type that had previously been resistant to chemotherapy, and the FDA approved imatinib for this indication in 2002. A similarly repurposed drug is sunitinib,<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> which was originally intended for renal cell carcinoma therapy. Like imatinib, sunitinib inhibits c-Kit and was therefore also developed for the treatment of GISTs. In 2006, the FDA approved sunitinib simultaneously for both indications. Additionally, sunitinib inhibits FLT3, RET, and CSF1R, which are drug targets for acute myeloid leukemia, neuroendocrine tumors, and metastatic breast cancer, respectively. Sunitinib is currently being developed for these and other indications. Also, sorafenib was originally intended to be a Raf kinase inhibitor for the treatment of Raf-dependent melanoma, but failed in clinical trials. However, early clinical safety studies indicated unexpected efficacy in kidney and liver cancer, which led to a successful development of sorafenib for these cancer types. This unexpected efficacy is attributed to sorefenib’s (originally unintended) activity at VEGFR and PDGFR.<a onclick="showRef(event, 'ref15 ref117 ref163'); return false;" href="javascript:void(0);" class="ref ref15 ref117 ref163">(15, 117, 163)</a></div><div class="NLM_p">Polypharmacology-based repurposing also led to the discovery of several important drug classes in the early years of drug discovery. For example, antihistamines were a popular research topic in the 1940s, because these compounds were easy to synthesize and easy to test in animals. Antihistamines entered the market in large numbers, and physicians experimented with them in a variety of diseases.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> For instance, promethazine (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>) was used experimentally to sedate patients before surgery. The promising results led to experimentation with similar, investigational antihistamines. Chlorpromazine<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> was particularly efficacious and was thus recommended to be used as a sedative also in psychiatry. When chlorpromazine was tested in schizophrenic patients, it showed an astonishing efficacy, which went far beyond its sedative effects. This discovery revolutionized the treatment of schizophrenia: for the first time, a pharmacological management of schizophrenia was available and allowed patients to live a relatively normal life outside locked wards. This success prompted many research companies to discover and develop their own antipsychotics. One of these investigational compounds, imipramine,<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> was completely ineffective in a large number of schizophrenic patients and was therefore tested in other psychiatric indications. Antidepressant efficacy was recognized after the treatment of only three patients and was later confirmed in larger trials. Imipramine became the first of several “tricyclic” antidepressants. Only after the advent of radioligand binding assays, was it confirmed in 1976 that the efficacy of the phenothiazine antipsychotics correlated with their dopamine D<sub>2</sub> receptor affinity<a onclick="showRef(event, 'ref167 ref168'); return false;" href="javascript:void(0);" class="ref ref167 ref168">(167, 168)</a> and not with their antihistaminic activity. Similarly, it was shown that the tricyclic antidepressants inhibit serotonin and noradrenaline reuptake as their principal mode of action.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a></div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/medium/jm-2013-00856t_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0007.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Experimentation with early, polypharmacological antihistamines led to the discovery of antipsychotics and antidepressants.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400856t&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In other cases, established drugs had therapeutically useful side-effects and were derivatized to maximize these side-effects into a main activity. Such derivatization shifted the affinity profile of an unselective compound class from one molecular therapeutic target to another, even though these targets were often not known at the time. For instance, sulfacarbamide (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>) became an important sulfonamide antibacterial after World War II in Germany’s Soviet Occupation Zone, because it could be prepared from the limited stocks of then available chemicals. However, sulfacarbamide suffered from a short half-life. Loranil (<b>1</b>)<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> was a follow-up compound with a longer half-life, but produced side-effects, which were reminiscent of hypoglycemia. The director of the sulfacarbamide-producing company Heyden AG took a massive dose of <b>1</b>, reversed the adverse effects by ingestion of sugar, and thus proved the hypoglycemic activity of <b>1</b>. The drug was banned thereafter and replaced by carbutamide, which was not only investigated as an antibiotic but also as a hypoglycemic drug for the treatment of noninsulin-dependent diabetes. Even though carbutamide was later marketed in Europe as an oral antidiabetic, it raised concerns because of its residual antibiotic activity and the possibility of the development of treatment-resistant bacteria. Also, carbutamide was not approved in the U.S. due to unacceptable side-effects. It was therefore followed up by tolbutamide, which had no antibiotic activity, and became an important treatment of noninsulin-dependent diabetes.<a onclick="showRef(event, 'ref171 ref172'); return false;" href="javascript:void(0);" class="ref ref171 ref172">(171, 172)</a></div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/medium/jm-2013-00856t_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0008.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Sulfonylurea antidiabetics were derived from antibiotics with hypoglycemic side-effects.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400856t&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">This strategy to obtain a new drug by maximizing the side-effects of an existing drug, and by minimizing its main activity, has been termed “selective optimization of side activities” (SOSA).<a onclick="showRef(event, 'ref173 ref174 ref175'); return false;" href="javascript:void(0);" class="ref ref173 ref174 ref175">(173-175)</a> SOSA was recently recommended as an alternative to the optimization of high-throughput screening hits. The main advantage of SOSA is the use of an established drug as a starting point for drug discovery, which should increase the chances of identifying clinical candidates with drug-like properties.</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">3.4 How Could Polypharmacological Drug Discovery Be Put into Practice?</h3><div class="NLM_p">Multitarget or polypharmacological drugs have been advocated mainly by academic groups in recent years. Industrial drug hunters have not yet widely embraced polypharmacological drug research (except for anticancer and psychiatry drugs), in part because lead-to-drug optimization is much more complex for multitarget compounds: druglike molecular properties must be balanced with multiple pharmacological activities, rather than single activities. Unintended interactions with additional targets can often not be avoided, which raises safety concerns. The translatability of animal disease models to human patients may be even less reliable. Finally, the optimal ratio of pharmacological activities for different targets may not be 1:1 and can be a matter of debate. For instance, antipsychotics are believed to have an optimal ratio of serotonin 5-HT<sub>2A</sub>/dopamine D<sub>2</sub> receptor antagonism of 10:1 to reduce extrapyramidal side-effects; triple reuptake inhibitors as antidepressants may need a higher inhibitory activity for the serotonin and norepinephrine transporters than for the dopamine transporter to avoid abuse liabilities.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a></div><div class="NLM_p">The combination of individual single-target drugs may appear as a viable alternative to polypharmacological drug discovery and is common practice in the therapy of hypertension,<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> metabolic disorders, cancer, and infections (in particular, human immunodeficiency virus [HIV], and tuberculosis infections). However, an increasing number of individual drugs put patients at an exponentially increasing risk of drug–drug interactions or of poor compliance due to complex dosing regimens. To avoid these risks, two or three single-target drugs can be combined in a single pill. Such “fixed-dose combinations” are for instance common in anti-HIV drugs.<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> But combination pills are often not feasible for more than three active ingredients, because of pharmacokinetic differences between the individual drugs. Perhaps more importantly, drugs are rarely developed to be used solely in combination: for the regulatory approval of a drug combination, safety must be demonstrated for the combination, as well as for the individual drugs, which is often prohibitively costly for novel drugs. Additional difficulties arise when investigational drugs originate from different companies.<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a></div><div class="NLM_p">Consequently, there is a need for single drugs with multiple targets.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> But how can starting points for multitarget drug discovery projects be obtained and optimized? In the recent past, three main strategies have been pursued: design, multitarget screening, and phenotypical screening.</div><div class="NLM_p">Polypharmacological leads can be designed by a combination of known pharmacophores into a single compound.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> Dissimilar pharmacophores (for different target classes) have been connected by linkers. This strategy leads often to a high MW and extreme lipophilicity,<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> and the development of such hybrid drugs has met little success.<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a> For example, the beta-blocker pindolol was connected to the angiotensin-converting enzyme (ACE) inhibitor enalaprilat to give the dual-target <b>2</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>),<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a> with a high MW well outside the Lipinski rules. Compound <b>2</b> was antihypertensive in vivo, but was never developed, possibly due to extreme molecular properties. Thus, multitargeting across different target classes is challenging; only 2% of the drugs in the ChEMBL database are annotated to targets of different classes.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> However, if pharmacophores are similar, they may overlap in a single molecule. Such “fused” or “merged” pharmacophores<a onclick="showRef(event, 'ref180 ref181'); return false;" href="javascript:void(0);" class="ref ref180 ref181">(180, 181)</a> have often acceptable molecular properties, especially if the individual pharmacophores have a low MW to start with. For instance, Pfizer researchers merged naphtylpiperazine and dopamine into <b>3</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>) in a search for multitarget serotonin/dopamine receptor antagonists as novel antipsychotics. Naphtylpiperazine binds to practically all serotonin receptors, and dopamine is an endogenous ligand of all dopamine receptors. Compound <b>3</b> combines much of the serotonin and dopamine receptor affinities of the individual compounds and has a drug-like MW. Further optimization resulted in ziprasidone, which was successfully developed. Many more examples for the design of multitarget compounds can be found in reviews.<a onclick="showRef(event, 'ref180 ref181 ref182 ref183 ref184'); return false;" href="javascript:void(0);" class="ref ref180 ref181 ref182 ref183 ref184">(180-184)</a> Automated denovo design of compounds with a desired pharmacological profile is also possible.<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> A special case is multitarget peptides, which combine the pharmacophores of two or more related peptide hormones.<a onclick="showRef(event, 'ref186 ref187'); return false;" href="javascript:void(0);" class="ref ref186 ref187">(186, 187)</a></div><figure id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/medium/jm-2013-00856t_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0009.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. The connection of two dissimilar pharmacophores led to the dual-target antihypertensive <b>2</b> with a high molecular weight.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400856t&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/medium/jm-2013-00856t_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0010.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. The antipsychotic ziprasidone was discovered by merging serotonin and dopamine receptor pharmacophores.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400856t&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Multitarget leads can also be identified in high-throughput screens against several targets. Screens are usually performed subsequently, rather than in parallel.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> For instance, serotonin reuptake transporter inhibitors with additional serotonin 5-HT<sub>1A</sub> receptor antagonism are believed to have a faster onset of antidepressant action. To identify starting points for a dual SERT/5-HT<sub>1A</sub> receptor blocker, GlaxoSmithKline scientists first screened their compound library in a functional serotonin 5-HT<sub>1A</sub> receptor assay and then screened identified antagonists for blockade of the serotonin reuptake mechanism.<a onclick="showRef(event, 'ref188'); return false;" href="javascript:void(0);" class="ref ref188">(188)</a> In similar approaches, compounds with an already known pharmacology are screened against other targets of interest. Sometimes, “screening” for multitarget compounds can even be reduced to a data-mining effort: multitarget discovery projects usually pursue established targets, rather than novel targets. Consequently, multitarget “hits” may be found by mining public or proprietary databases of established targets and ligands.<a onclick="showRef(event, 'ref12 ref189'); return false;" href="javascript:void(0);" class="ref ref12 ref189">(12, 189)</a> For example, dual antagonism at the serotonin reuptake transporter (SERT) and the 5-HT<sub>2A</sub> receptor is regarded as a desirable profile for novel antidepressants with a reduced liability for disrupted sleep and sexual dysfunction.<a onclick="showRef(event, 'ref107 ref127'); return false;" href="javascript:void(0);" class="ref ref107 ref127">(107, 127)</a> Mining of Roche legacy HTS data yielded 50 compounds with potent SERT and 5-HT<sub>2A</sub> receptor antagonism as hits for a proposed antidepressant discovery project. Multitarget fragment screening is another option and was successful in the discovery of the pan-peroxisome-proliferator-activated-receptor (pan-PPAR) agonist, indeglitazar.<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a></div><div class="NLM_p">Virtual screening (pharmacophore-based) and computational docking (biostructure-based) have also been used to discover multitarget compounds.<a onclick="showRef(event, 'ref191 ref192 ref193'); return false;" href="javascript:void(0);" class="ref ref191 ref192 ref193">(191-193)</a> Researchers from the Peking University and the Beijing National Laboratory for Molecular Sciences combined both methods in a search for multitarget anti-inflammatory compounds: in a first step, they sought inflammation targets, which accommodated similar pharmacophores, and could thus be inhibited by a single drug. In a second step, they docked commercially available compounds into these targets and screened them against the common pharmacophore. This approach led to the identification of a dual leukotriene A4 hydrolase/phospholipase A2 inhibitor.<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a></div><div class="NLM_p">However, future polypharmacological drugs may not necessarily be discovered by deliberate design or screening. More likely, they will emerge from new approaches to drug discovery. Our current single-target-based paradigm results in single-target drugs by implication. The dominance of this paradigm has been challenged and has been associated with the productivity decline of the pharmaceutical industry.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Many research organizations are therefore considering alternatives.<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a> Particularly, they revisit phenotypic screening, which is generally more successful for the discovery of first-in-class medicines.<a onclick="showRef(event, 'ref196'); return false;" href="javascript:void(0);" class="ref ref196">(196)</a> In the “golden era” of drug discovery, phenotypical approaches often led to polypharmacological drugs. As we “rediscover” such approaches, we may again encounter polypharmacology by serendipity.</div><div class="NLM_p">Alternatively, we can apply phenotypic screening to the rational discovery of polypharmacological drugs with maximal efficacy and minimal toxicity. Researchers from the Mount Sinai School of Medicine and University of California, San Francisco, screened unselective RET kinase inhibitors in a fruit fly (<i>Drosophila</i>) model of RET-driven cancer and identified a compound which rescued fruit fly larvae to adulthood. In a next step, they performed a kinome scan in the presence of this compound. Raf and Src inhibition (in addition to RET inhibition) increased survival rates, whereas inhibition of the mammalian target of rapamycin (mTOR) was toxic. On the basis of these findings, they designed an improved compound, which was highly efficacious and well tolerated in the fruit fly model, and which performed 500 times better on human cell lines than the thyroid cancer drug vandetanib. In a mouse model, this improved compound was far more effective than vandetanib and again very well tolerated.<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a></div><div class="NLM_p last">Phenotypic screening with polypharmacological compounds exploits an extended target space. Often, an individual blockade or knockout of single targets does not result in an observable effect, whereas a combined multiple blockade of the same targets leads to a phenotype (“synthetic behavior”).<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> For example, glycine transporter 2 (GlyT<sub>2</sub>) antagonists with additional purinergic P2X<sub>3</sub> and serotonergic 5-HT<sub>2A</sub> receptor antagonism were efficacious in electrophysiological and in animal pain models, whereas selective antagonists of the same targets were not (but were again effective when dosed together).<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a> Thus, polypharmacological compounds can recruit a target space which is unavailable for single-target compounds. This is not only an opportunity for drug discovery but also increases the chances of finding polypharmacological lead compounds in phenotypic approaches.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">4 Summary</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77350" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77350" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Since the 1990s, industrial drug discovery has been aiming for highly selective drugs to avoid adverse effects mediated through “antitargets”. Lack of selectivity has usually been discovered late in a drug discovery project and has typically led to substantial delays or late-stage attrition. Major research organizations have therefore begun to screen early compounds against small panels of frequently hit antitargets and made selectivity a matter of early optimization.</div><div class="NLM_p">On the other hand, the opportunities of polypharmacological drug discovery are increasingly being appreciated. The FDA has approved numerous polypharmacological drugs for different target classes and indications in recent years. Many multigenic diseases do not succumb to single-target therapies but rather require a polypharmacological modulation of a network of targets. Some authors have even associated the “one disease – one target” philosophy with the productivity decline of the pharmaceutical industry<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and have advocated network pharmacology as the “next paradigm in drug discovery”.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div><div class="NLM_p">However, many researchers perceive a gap between theoretical network concepts and the practical discovery of polypharmacological drugs: how can they achieve a desired polypharmacological profile, especially across different target classes? Will polypharmacology increase the incidences of adverse effects? Will the optimization of polypharmacological compounds be prohibitively complex?</div><div class="NLM_p last">The pharmaceutical industry currently revisits phenotypical screening as an alternative to the ubiquitous target-based drug discovery. In the “golden era” of drug discovery, phenotypical approaches delivered many polypharmacological drugs. It is quite possible that we will encounter polypharmacology again in such approaches without explicitly looking for it.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/jm400856t" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10131" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10131" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jens-Uwe Peters</span> - <span class="hlFld-Affiliation affiliation">F. Hoffmann-La Roche
Ltd., pRED, Pharma Research and Early Development, Discovery
Chemistry,
CH-4070 Basel, Switzerland</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a3c9c6cdd08ed6d4c68dd3c6d7c6d1d0e3d1ccc0cbc68dc0ccce"><span class="__cf_email__" data-cfemail="543e313a27792123317a24312031262714263b373c317a373b39">[email protected]</span></a></span></div></li></ul></li><li><ul></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Biography</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22141" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22141" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Jens-Uwe Peters</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400856t&amp;id=BIO-d1677e1684-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jens-Uwe Peters</b> studied chemistry at the University of Göttingen and the University of California, San Diego. After receiving his diploma, he worked in Siegfried Blechert’s laboratories at the TU Berlin, obtained his Ph.D., and then did a postdoc with Julius Rebek at the Scripps Institute in La Jolla. In 1999, he joined the Discovery Chemistry department of F. Hoffmann-La Roche Ltd. in Basel and has since contributed to numerous drug discovery projects. In parallel to his project work, he has been active in several work groups concerned with the assessment, interpretation, and optimization of molecular properties, especially properties related to early safety pharmacology.</p></figure></div><div class="ack" id="ACK-d1677e1689-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12780" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12780" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">I would like to thank the following for their advice: Annalisa Petrelli from the University of Turin, the anonymous reviewers, and my Roche colleagues Luke Green, Wolfgang Guba, Jérôme Hert, Susanne Mohr, Liudmila Polonchuk, and Hervé Schaffhauser.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i22" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i22"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i23" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i23"> Abbreviations Used</h2><tr><td class="NLM_term">ACE</td><td class="NLM_def"><p class="first last">angiotensin-converting enzyme</p></td></tr><tr><td class="NLM_term">ADR</td><td class="NLM_def"><p class="first last">adverse drug reaction</p></td></tr><tr><td class="NLM_term">BSEP</td><td class="NLM_def"><p class="first last">bile salt export pump</p></td></tr><tr><td class="NLM_term">CML</td><td class="NLM_def"><p class="first last">chronic myelogenous leukemia</p></td></tr><tr><td class="NLM_term">COX</td><td class="NLM_def"><p class="first last">cyclooxygenase</p></td></tr><tr><td class="NLM_term">CSF-1</td><td class="NLM_def"><p class="first last">colony stimulating factor 1</p></td></tr><tr><td class="NLM_term">CSF-1R</td><td class="NLM_def"><p class="first last">colony stimulating factor 1 receptor</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">EGF</td><td class="NLM_def"><p class="first last">epidermal growth factor</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">ENL</td><td class="NLM_def"><p class="first last">erythema nodosum leprosum</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">FGFR</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptor</p></td></tr><tr><td class="NLM_term">Flt-3</td><td class="NLM_def"><p class="first last">Fms-like tyrosine kinase 3</p></td></tr><tr><td class="NLM_term">GIST</td><td class="NLM_def"><p class="first last">gastrointestinal stromal tumor</p></td></tr><tr><td class="NLM_term">GlyT2</td><td class="NLM_def"><p class="first last">glycine transporter 2</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G protein-coupled receptor</p></td></tr><tr><td class="NLM_term">HER-2</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor 2</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-à-go-go-related gene</p></td></tr><tr><td class="NLM_term">HGF</td><td class="NLM_def"><p class="first last">hepatocyte growth factor receptor</p></td></tr><tr><td class="NLM_term">HGFR</td><td class="NLM_def"><p class="first last">hepatocyte growth factor receptor</p></td></tr><tr><td class="NLM_term">HIV</td><td class="NLM_def"><p class="first last">human immunodeficiency virus</p></td></tr><tr><td class="NLM_term">5-HT</td><td class="NLM_def"><p class="first last">5-hydroxytryptamine (serotonin)</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high-throughput screen</p></td></tr><tr><td class="NLM_term">MW</td><td class="NLM_def"><p class="first last">molecular weight</p></td></tr><tr><td class="NLM_term">NE</td><td class="NLM_def"><p class="first last">norepinephrine</p></td></tr><tr><td class="NLM_term">NSAID</td><td class="NLM_def"><p class="first last">nonsteroidal anti-inflammatory drug</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">Protein Data Bank</p></td></tr><tr><td class="NLM_term">PDGF</td><td class="NLM_def"><p class="first last">platelet-derived growth factor</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor</p></td></tr><tr><td class="NLM_term">PDSP</td><td class="NLM_def"><p class="first last">Psychoactive Drug Screening Program</p></td></tr><tr><td class="NLM_term">PPAR</td><td class="NLM_def"><p class="first last">peroxisome proliferator-activated receptor</p></td></tr><tr><td class="NLM_term">RET</td><td class="NLM_def"><p class="first last">(“rearranged during transfection”) a proto-oncogene</p></td></tr><tr><td class="NLM_term">SEA</td><td class="NLM_def"><p class="first last">similarity ensemble approach</p></td></tr><tr><td class="NLM_term">SERT</td><td class="NLM_def"><p class="first last">serotonin reuptake transporter</p></td></tr><tr><td class="NLM_term">SOSA</td><td class="NLM_def"><p class="first last">selective optimization of side activities</p></td></tr><tr><td class="NLM_term">SDF-1</td><td class="NLM_def"><p class="first last">stromal cell-derived factor-1</p></td></tr><tr><td class="NLM_term">Src</td><td class="NLM_def"><p class="first last">(short for sarcoma) a proto-oncogene</p></td></tr><tr><td class="NLM_term">SSRI</td><td class="NLM_def"><p class="first last">selective serotonin reuptake inhibitor</p></td></tr><tr><td class="NLM_term">TIE2</td><td class="NLM_def"><p class="first last">tyrosine kinase with immunoglobulin-like and EGF-like domains 2</p></td></tr><tr><td class="NLM_term">TNF-α</td><td class="NLM_def"><p class="first last">tumor necrosis factor α</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin</p></td></tr><tr><td class="NLM_term">VEGF</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor</p></td></tr><tr><td class="NLM_term">VEGFR</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62307" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62307" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 198 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Rothman, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumann, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauser, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hufeisen, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x"> (</span><span class="NLM_issue">23</span><span class="NLM_x">) </span> <span class="NLM_fpage">2836</span><span class="NLM_x">–</span> <span class="NLM_lpage">2841</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2000&pages=2836-2841&issue=23&author=R.+B.+Rothmanauthor=M.+H.+Baumannauthor=J.+E.+Savageauthor=L.+Rauserauthor=A.+McBrideauthor=S.+J.+Hufeisenauthor=B.+L.+Roth&title=Evidence+for+possible+involvement+of+5-HT2B+receptors+in+the+cardiac+valvulopathy+associated+with+fenfluramine+and+other+serotonergic+medications"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRothman%26aufirst%3DR.%2BB.%26aulast%3DBaumann%26aufirst%3DM.%2BH.%26aulast%3DSavage%26aufirst%3DJ.%2BE.%26aulast%3DRauser%26aufirst%3DL.%26aulast%3DMcBride%26aufirst%3DA.%26aulast%3DHufeisen%26aufirst%3DS.%2BJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DEvidence%2520for%2520possible%2520involvement%2520of%25205-HT2B%2520receptors%2520in%2520the%2520cardiac%2520valvulopathy%2520associated%2520with%2520fenfluramine%2520and%2520other%2520serotonergic%2520medications%26jtitle%3DCirculation%26date%3D2000%26volume%3D102%26issue%3D23%26spage%3D2836%26epage%3D2841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Connolly, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crary, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mcgoon, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hensrud, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaff, H. V.</span><span> </span><span class="NLM_article-title">Valvular heart disease associated with fenfluramine-phentermine</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">337</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">581</span><span class="NLM_x">–</span> <span class="NLM_lpage">588</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1056%2FNEJM199708283370901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADyaK2sXmtVGntLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=337&publication_year=1997&pages=581-588&issue=9&author=H.+M.+Connollyauthor=J.+L.+Craryauthor=M.+D.+Mcgoonauthor=D.+D.+Hensrudauthor=B.+S.+Edwardsauthor=W.+D.+Edwardsauthor=H.+V.+Schaff&title=Valvular+heart+disease+associated+with+fenfluramine-phentermine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Valvular heart disease associated with fenfluramine-phentermine</span></div><div class="casAuthors">Connolly, Heidi M.; Crary, Jack L.; Mcgoon, Michael D.; Hensrud, Donald D.; Edwards, Brooks S.; Edwards, William D.; Schaff, Hartzell V.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">337</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">581-588</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Fenfluramine and phentermine have been individually approved as anorectic agents by the Food and Drug Administration (FDA).  When used in combination the drugs may be just as effective as either drug alone, with the added advantages of the need for lower doses of each agent and perhaps fewer side effects.  Although the combination has not been approved by the FDA, in 1996 the total no. of prescriptions in the United States for fenfluramine and phentermine exceeded 18 million.  We identified valvular heart disease in 24 women treated with fenfluramine-phentermine who had no history of cardiac disease.  The women presented with cardiovascular symptoms or a heart murmur.  As increasing nos. of these patients with similar clin. features were identified, there appeared to be an assocn. between these features and fenfluramine-phentermine therapy.  Twenty-four women (mean [±SD] age, 44±8 yr) were evaluated 12.3±7.1 mo after the initiation of fenfluramine-phentermine therapy.  Echocardiog. demonstrated unusual valvular morphol. and regurgitation in all patients.  Both right-side and left-sided heart values were involved.  Eight women also had newly documented pulmonary hypertension.  To date, cardiac surgical intervention has been required in five patients.  The heart valves had a glistening white appearance.  Histopathol. findings included plaque-like encasement of the leaflets and chordal structures with intact valve architecture.  The histopathol. features were identical to those seen in carcinoid or ergotamine-induced valve disease.  These cases arouse concern that fenfluramine-phentermine therapy may be assocd. with valvular heart disease.  Candidates for fenfluramine-phentermine therapy should be informed about serious potential adverse effects, including pulmonary hypertension and valvular heart disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAXd7m-oabsLVg90H21EOLACvtfcHk0lhhqO6s3O4iQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmtVGntLc%253D&md5=f206b00f5881d0d50b2d710ea41f44fe</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJM199708283370901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199708283370901%26sid%3Dliteratum%253Aachs%26aulast%3DConnolly%26aufirst%3DH.%2BM.%26aulast%3DCrary%26aufirst%3DJ.%2BL.%26aulast%3DMcgoon%26aufirst%3DM.%2BD.%26aulast%3DHensrud%26aufirst%3DD.%2BD.%26aulast%3DEdwards%26aufirst%3DB.%2BS.%26aulast%3DEdwards%26aufirst%3DW.%2BD.%26aulast%3DSchaff%26aufirst%3DH.%2BV.%26atitle%3DValvular%2520heart%2520disease%2520associated%2520with%2520fenfluramine-phentermine%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1997%26volume%3D337%26issue%3D9%26spage%3D581%26epage%3D588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Hutcheson, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merryman, W. D.</span><span> </span><span class="NLM_article-title">Serotonin receptors and heart valve disease-It was meant 2B</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">146</span><span class="NLM_x">–</span> <span class="NLM_lpage">157</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1016%2Fj.pharmthera.2011.03.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFaksLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2011&pages=146-157&issue=2&author=J.+D.+Hutchesonauthor=V.+Setolaauthor=B.+L.+Rothauthor=W.+D.+Merryman&title=Serotonin+receptors+and+heart+valve+disease-It+was+meant+2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin receptors and heart valve disease-It was meant 2B</span></div><div class="casAuthors">Hutcheson, Joshua D.; Setola, Vincent; Roth, Bryan L.; Merryman, W. David</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">146-157</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Carcinoid heart disease was one of the first valvular pathologies studied in mol. detail, and early research identified serotonin produced by oncogenic enterochromaffin cells as the likely culprit in causing changes in heart valve tissue.  Researchers and physicians in the mid-1960s noted a connection between the use of several ergot-derived medications with structures similar to serotonin and the development of heart valve pathologies similar to those obsd. in carcinoid patients.  The exact serotonergic target that mediated valvular pathogenesis remained a mystery for many years until similar cases were reported in patients using the popular diet drug Fen-Phen in the late 1990s.  The Fen-Phen episode sparked renewed interest in serotonin-mediated valve disease, and studies led to the identification of the 5-HT2B receptor as the likely mol. target leading to heart valve tissue fibrosis.  Subsequent studies have identified numerous other activators of the 5-HT2B receptor, and consequently, the use of many of these mols. has been linked to heart valve disease.  Herein, we: review the mol. properties of the 5-HT2B receptor including factors that differentiate the 5-HT2B receptor from other 5-HT receptor subtypes, discuss the studies that led to the identification of the 5-HT2B receptor as the mediator of heart valve disease, present current efforts to identify potential valvulopathogens by screening for 5-HT2B receptor activity, and speculate on potential therapeutic benefits of 5-HT2B receptor targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4R8A9Ia-r3LVg90H21EOLACvtfcHk0lh-96oRuIbL-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFaksLnO&md5=b97c1992208a501b1959c2f48f3ca9cd</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2011.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2011.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DHutcheson%26aufirst%3DJ.%2BD.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DMerryman%26aufirst%3DW.%2BD.%26atitle%3DSerotonin%2520receptors%2520and%2520heart%2520valve%2520disease-It%2520was%2520meant%25202B%26jtitle%3DPharmacol.%2520Ther.%26date%3D2011%26volume%3D132%26issue%3D2%26spage%3D146%26epage%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Whitebread, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bojanic, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, L.</span><span> </span><span class="NLM_article-title">In vitro safety pharmacology profiling: an essential tool for successful drug development</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">21</span><span class="NLM_x">) </span> <span class="NLM_fpage">1421</span><span class="NLM_x">–</span> <span class="NLM_lpage">1433</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=1421-1433&issue=21&author=S.+Whitebreadauthor=J.+Hamonauthor=D.+Bojanicauthor=L.+Urban&title=In+vitro+safety+pharmacology+profiling%3A+an+essential+tool+for+successful+drug+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWhitebread%26aufirst%3DS.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DBojanic%26aufirst%3DD.%26aulast%3DUrban%26aufirst%3DL.%26atitle%3DIn%2520vitro%2520safety%2520pharmacology%2520profiling%253A%2520an%2520essential%2520tool%2520for%2520successful%2520drug%2520development%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2005%26volume%3D10%26issue%3D21%26spage%3D1421%26epage%3D1433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Hopkins, A. L.</span><span> </span><span class="NLM_article-title">Network pharmacology: the next paradigm in drug discovery</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">682</span><span class="NLM_x">–</span> <span class="NLM_lpage">690</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fnchembio.118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=18936753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=682-690&issue=11&author=A.+L.+Hopkins&title=Network+pharmacology%3A+the+next+paradigm+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Network pharmacology: the next paradigm in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">682-690</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The dominant paradigm in drug discovery is the concept of designing maximally selective ligands to act on individual drug targets.  However, many effective drugs act via modulation of multiple proteins rather than single targets.  Advances in systems biol. are revealing a phenotypic robustness and a network structure that strongly suggests that exquisitely selective compds., compared with multi-target drugs, may exhibit lower than desired clin. efficacy.  This new appreciation of the role of polypharmacol. has significant implications for tackling the two major sources of attrition in drug development, efficacy and toxicity.  Integrating network biol. and polypharmacol. holds the promise of expanding the current opportunity space for druggable targets.  However, the rational design of polypharmacol. faces considerable challenges in the need for new methods to validate target combinations and optimize multiple structure-activity relationships while maintaining drug-like properties.  Advances in these areas are creating the foundation of the next paradigm in drug discovery: network pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqHy4FqkK-h7Vg90H21EOLACvtfcHk0lh-96oRuIbL-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK&md5=03b8be3ddbcab7dc65afd17df7ee8395</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.118%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DNetwork%2520pharmacology%253A%2520the%2520next%2520paradigm%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26issue%3D11%26spage%3D682%26epage%3D690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Gleeson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hersey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montanari, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overington, J.</span><span> </span><span class="NLM_article-title">Probing the links between in vitro potency, ADMET and physicochemical parameters</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">197</span><span class="NLM_x">–</span> <span class="NLM_lpage">208</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fnrd3367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=21358739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFemsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=197-208&issue=3&author=M.+P.+Gleesonauthor=A.+Herseyauthor=D.+Montanariauthor=J.+Overington&title=Probing+the+links+between+in+vitro+potency%2C+ADMET+and+physicochemical+parameters"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Probing the links between in vitro potency, ADMET and physicochemical parameters</span></div><div class="casAuthors">Gleeson, M. Paul; Hersey, Anne; Montanari, Dino; Overington, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">197-208</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  A common underlying assumption in current drug discovery strategies is that compds. with higher in vitro potency at their target(s) have greater potential to translate into successful, low-dose therapeutics.  This has led to the development of screening cascades with in vitro potency embedded as an early filter.  However, this approach is beginning to be questioned, given the bias in physicochem. properties that it can introduce early in lead generation and optimization, which is due to the often diametrically opposed relationship between physicochem. parameters assocd. with high in vitro potency and those assocd. with desirable absorption, distribution, metab., excretion and toxicity (ADMET) characteristics.  Here, we describe analyses that probe these issues further using the ChEMBL database, which includes more than 500,000 drug discovery and marketed oral drug compds.  Key findings include: first, that oral drugs seldom possess nanomolar potency (50 nM on av.); second, that many oral drugs have considerable off-target activity; and third, that in vitro potency does not correlate strongly with the therapeutic dose.  These findings suggest that the perceived benefit of high in vitro potency may be negated by poorer ADMET properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovOslFSgIkUbVg90H21EOLACvtfcHk0ljt8RAZyrml3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFemsr8%253D&md5=e275044516e9b0245b71c9603477ef74</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrd3367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3367%26sid%3Dliteratum%253Aachs%26aulast%3DGleeson%26aufirst%3DM.%2BP.%26aulast%3DHersey%26aufirst%3DA.%26aulast%3DMontanari%26aufirst%3DD.%26aulast%3DOverington%26aufirst%3DJ.%26atitle%3DProbing%2520the%2520links%2520between%2520in%2520vitro%2520potency%252C%2520ADMET%2520and%2520physicochemical%2520parameters%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26issue%3D3%26spage%3D197%26epage%3D208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Ainsworth, C.</span><span> </span><span class="NLM_article-title">Networking for new drugs</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">1166</span><span class="NLM_x">–</span> <span class="NLM_lpage">1168</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fnm1011-1166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht12iu7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=1166-1168&issue=10&author=C.+Ainsworth&title=Networking+for+new+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Networking for new drugs</span></div><div class="casAuthors">Ainsworth, Claire</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1166-1168</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Many of today's most celebrated drugs are designed to hit only one biol. target with great precision.  But a novel clin. trial aims to turn this idea on its head by using 'network pharmacol.' to more effectively tackle a common neurol. disorder affecting limb movement.  Claire Ainsworth looks into how medicine's proverbial 'magic bullet' might soon give way to a more sophisticated arsenal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP6ub5TqNMc7Vg90H21EOLACvtfcHk0ljt8RAZyrml3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht12iu7vF&md5=ee8ad6c3bccc296c49d55398ce2d5eb7</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnm1011-1166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1011-1166%26sid%3Dliteratum%253Aachs%26aulast%3DAinsworth%26aufirst%3DC.%26atitle%3DNetworking%2520for%2520new%2520drugs%26jtitle%3DNat.%2520Med.%26date%3D2011%26volume%3D17%26issue%3D10%26spage%3D1166%26epage%3D1168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Mencher, Simon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Long, G.</span><span> </span><span class="NLM_article-title">Promiscuous drugs compared to selective drugs (promiscuity can be a virtue)</span> <span class="citation_source-journal">BMC Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">3</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1186%2F1472-6904-5-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A280%3ADC%252BD2M3ktVartA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=3&issue=1&author=K.+Mencher%2C+Simonauthor=G.+Wang%2C+Long&title=Promiscuous+drugs+compared+to+selective+drugs+%28promiscuity+can+be+a+virtue%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Promiscuous drugs compared to selective drugs (promiscuity can be a virtue)</span></div><div class="casAuthors">Mencher Simon K; Wang Long G</div><div class="citationInfo"><span class="NLM_cas:title">BMC clinical pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The word selectivity describes a drug's ability to affect a particular cell population in preference to others.  As part of the current state of art in the search for new therapeutic agents, the property of selectivity is a mode of action thought to have a high degree of desirability.  Consequently there is a growing activity in this area of research.  Selectivity is generally a worthy property in a drug because a drug having high selectivity may have a dramatic effect when there is a single agent that can be targeted against the appropriate molecular-driver involved in the pathogenesis of a disease.  An example is chronic myeloid leukemia (CML).  CML has a specific chromosomal abnormality, the Philadelphia chromosome, that results in a single gene that produces an abnormal protein.  DISCUSSION:  There is a burgeoning understanding of the cellular mechanisms that control the etiology and pathogeneses of diseases.  This understanding both enables and motivates the development of drugs that induce a specific action in a selected cell population; i.e., a targeted treatment.  Consequently, drugs that can target distinct molecular targets involved in pathologic/pathogenetic processes, or signal-transduction pathways, are being developed.  However, in most cases, diseases involve multiple abnormalities.  A disease may be associated with more than one dysfunctional protein and these may be out-of-balance with each other.  Likewise a drug might strongly target a protein that shares a similar active domain with other proteins.  A drug may also target pleiotropic cytokines, or other proteins that have multi-physiological functions.  In this way multiple normal cellular pathways can be simultaneously influenced.  Long term experience with drugs supposedly designed for only a single target, but which unavoidably involve other functional effects, is uncovering the fact that molecular targeting is not medically flawless.  SUMMARY:  We contend that an ideal drug may be one whose efficacy is based not on the inhibition of a single target, but rather on the rebalancing of the several proteins or events, that contribute to the etiology, pathogeneses, and progression of diseases, i.e., in effect a promiscuous drug.  Ideally, if this could be done at minimum drug concentration, side effects could be minimized.  Corollaries to this argument are that the growing fervor for researching truly selective drugs may be imprudent when considering the totality of responses; and that the expensive screening techniques used to discover these, may be both medically and financially inefficient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQc3Gp004wjH9yzdcP07UmufW6udTcc2eZBwyWVCmSdDLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M3ktVartA%253D%253D&md5=bfc2421479ee2f2169efd58bdc0238ec</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1186%2F1472-6904-5-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1472-6904-5-3%26sid%3Dliteratum%253Aachs%26aulast%3DMencher%252C%2BSimon%26aufirst%3DK.%26aulast%3DWang%252C%2BLong%26aufirst%3DG.%26atitle%3DPromiscuous%2520drugs%2520compared%2520to%2520selective%2520drugs%2520%2528promiscuity%2520can%2520be%2520a%2520virtue%2529%26jtitle%3DBMC%2520Clin.%2520Pharmacol.%26date%3D2005%26volume%3D5%26issue%3D1%26spage%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Hopkins, A. L.</span><span> </span><span class="NLM_article-title">The Case for Polypharmacology</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed.; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=1-6&author=A.+L.+Hopkinsauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DThe%2520Case%2520for%2520Polypharmacology%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D1%26epage%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Abbenante, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reid, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairlie, D. P.</span><span> </span><span class="NLM_article-title">‘Clean’ or ‘Dirty’ - Just How Selective Do Drugs Need To Be?</span> <span class="citation_source-journal">Aust. J. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">654</span><span class="NLM_x">–</span> <span class="NLM_lpage">660</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2008&pages=654-660&issue=9&author=G.+Abbenanteauthor=R.+C.+Reidauthor=D.+P.+Fairlie&title=%E2%80%98Clean%E2%80%99+or+%E2%80%98Dirty%E2%80%99+-+Just+How+Selective+Do+Drugs+Need+To+Be%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAbbenante%26aufirst%3DG.%26aulast%3DReid%26aufirst%3DR.%2BC.%26aulast%3DFairlie%26aufirst%3DD.%2BP.%26atitle%3D%25E2%2580%2598Clean%25E2%2580%2599%2520or%2520%25E2%2580%2598Dirty%25E2%2580%2599%2520-%2520Just%2520How%2520Selective%2520Do%2520Drugs%2520Need%2520To%2520Be%253F%26jtitle%3DAust.%2520J.%2520Chem.%26date%3D2008%26volume%3D61%26issue%3D9%26spage%3D654%26epage%3D660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Korcsmaros, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szalay, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovacs, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Csermely, P.</span><span> </span><span class="NLM_article-title">How to design multi-target drugs: target search options in cellular networks</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">799</span><span class="NLM_x">–</span> <span class="NLM_lpage">808</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=799-808&issue=6&author=T.+Korcsmarosauthor=M.+S.+Szalayauthor=C.+Bodeauthor=I.+A.+Kovacsauthor=P.+Csermely&title=How+to+design+multi-target+drugs%3A+target+search+options+in+cellular+networks"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKorcsmaros%26aufirst%3DT.%26aulast%3DSzalay%26aufirst%3DM.%2BS.%26aulast%3DBode%26aufirst%3DC.%26aulast%3DKovacs%26aufirst%3DI.%2BA.%26aulast%3DCsermely%26aufirst%3DP.%26atitle%3DHow%2520to%2520design%2520multi-target%2520drugs%253A%2520target%2520search%2520options%2520in%2520cellular%2520networks%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2007%26volume%3D2%26issue%3D6%26spage%3D799%26epage%3D808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Reddy, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span> </span><span class="NLM_article-title">Polypharmacology: drug discovery for the future</span> <span class="citation_source-journal">Expert Rev. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">47</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1586%2Fecp.12.74" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=23272792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntlei" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=41-47&issue=1&author=A.+S.+Reddyauthor=S.+Zhang&title=Polypharmacology%3A+drug+discovery+for+the+future"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: drug discovery for the future</span></div><div class="casAuthors">Reddy, A. Srinivas; Zhang, Shuxing</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-47</span>CODEN:
                <span class="NLM_cas:coden">ERCPAG</span>;
        ISSN:<span class="NLM_cas:issn">1751-2433</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  In recent years, even with remarkable scientific advancements and a significant increase of global research and development spending, drugs are frequently withdrawn from markets.  This is primarily due to their side effects or toxicities.  Drug mols. often interact with multiple targets, coined as polypharmacol., and the unintended drug-target interactions could cause side effects.  Polypharmacol. remains one of the major challenges in drug development, and it opens novel avenues to rationally design the next generation of more effective, but less toxic, therapeutic agents.  This review outlines the latest progress and challenges in polypharmacol. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh9arBzCHL27Vg90H21EOLACvtfcHk0lhuE4C_QKPWZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntlei&md5=651b742d7e8254d8f4ef00f225dfa39e</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1586%2Fecp.12.74&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fecp.12.74%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DA.%2BS.%26aulast%3DZhang%26aufirst%3DS.%26atitle%3DPolypharmacology%253A%2520drug%2520discovery%2520for%2520the%2520future%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D6%26issue%3D1%26spage%3D41%26epage%3D47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Sams-Dodd, F.</span><span> </span><span class="NLM_article-title">Target-based drug discovery: is something wrong?</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">139</span><span class="NLM_x">–</span> <span class="NLM_lpage">147</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=139-147&issue=2&author=F.+Sams-Dodd&title=Target-based+drug+discovery%3A+is+something+wrong%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSams-Dodd%26aufirst%3DF.%26atitle%3DTarget-based%2520drug%2520discovery%253A%2520is%2520something%2520wrong%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2005%26volume%3D10%26issue%3D2%26spage%3D139%26epage%3D147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Hornberg, J. J.</span><span> </span><span class="NLM_article-title">Simple Drugs Do Not Cure Complex Diseases: The Need for Multi-Targeted Drugs</span>. In  <span class="citation_source-book">Designing Multi-Target Drugs</span>; <span class="NLM_contrib-group">Morphy, J. R.; Harris, C. J.</span>, Eds.; <span class="NLM_publisher-name">RSC Publishing</span>: <span class="NLM_publisher-loc">Cambridge</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">13</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1039%2F9781849734912-00001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=1-13&author=J.+J.+Hornbergauthor=J.+R.+Morphy&author=C.+J.+Harris&title=Designing+Multi-Target+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1039%2F9781849734912-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1039%252F9781849734912-00001%26sid%3Dliteratum%253Aachs%26aulast%3DHornberg%26aufirst%3DJ.%2BJ.%26atitle%3DSimple%2520Drugs%2520Do%2520Not%2520Cure%2520Complex%2520Diseases%253A%2520The%2520Need%2520for%2520Multi-Targeted%2520Drugs%26btitle%3DDesigning%2520Multi-Target%2520Drugs%26aulast%3DMorphy%26aufirst%3DJ.%2BR.%26pub%3DRSC%2520Publishing%26date%3D2012%26spage%3D1%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Petrelli, A.</span><span> </span><span class="NLM_article-title">Polypharmacological Kinase Inhibitors: New Hopes for Cancer Therapy</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed., <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">149</span><span class="NLM_x">–</span> <span class="NLM_lpage">165</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=149-165&author=A.+Petrelliauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch8%26sid%3Dliteratum%253Aachs%26aulast%3DPetrelli%26aufirst%3DA.%26atitle%3DPolypharmacological%2520Kinase%2520Inhibitors%253A%2520New%2520Hopes%2520for%2520Cancer%2520Therapy%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D149%26epage%3D165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Kroeze, W. K.; Roth, B. L.</span><span> </span><span class="NLM_article-title">Polypharmacological Drugs: Magic Shotguns for Psychiatric Diseases</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed., <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">135</span><span class="NLM_x">–</span> <span class="NLM_lpage">148</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=135-148&author=W.+K.+Kroeze&author=B.+L.+Rothauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch7%26sid%3Dliteratum%253Aachs%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26atitle%3DPolypharmacological%2520Drugs%253A%2520Magic%2520Shotguns%2520for%2520Psychiatric%2520Diseases%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D135%26epage%3D148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheffler, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroeze, W. K.</span><span> </span><span class="NLM_article-title">Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">353</span><span class="NLM_x">–</span> <span class="NLM_lpage">359</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fnrd1346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=15060530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=353-359&issue=4&author=B.+L.+Rothauthor=D.+J.+Shefflerauthor=W.+K.+Kroeze&title=Magic+shotguns+versus+magic+bullets%3A+selectively+non-selective+drugs+for+mood+disorders+and+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia</span></div><div class="casAuthors">Roth, Bryan L.; Sheffler, Douglas J.; Kroeze, Wesley K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">353-359</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Most common central nervous system disorders - such as depression, bipolar disorder, and schizophrenia - seem to be polygenic in origin, and the most effective medications have exceedingly complex pharmacologies.  Attempts to develop more effective treatments for diseases such as schizophrenia and depression by discovering drugs selective for single mol. targets (i.e., 'magic bullets') have, not surprisingly, been largely unsuccessful.  Here the authors propose that designing selectively non-selective drugs (i.e., 'magic shotguns') that interact with several mol. targets will lead to new and more effective medications for a variety of central nervous system disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnSsuUXzmbirVg90H21EOLACvtfcHk0lj3Y1DS1NdT2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D&md5=77196583acccca65457fec7a67218463</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnrd1346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1346%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DSheffler%26aufirst%3DD.%2BJ.%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26atitle%3DMagic%2520shotguns%2520versus%2520magic%2520bullets%253A%2520selectively%2520non-selective%2520drugs%2520for%2520mood%2520disorders%2520and%2520schizophrenia%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26issue%3D4%26spage%3D353%26epage%3D359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Hopkins, A. L.</span><span> </span><span class="NLM_article-title">Network pharmacology</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">1110</span><span class="NLM_x">–</span> <span class="NLM_lpage">1111</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fnbt1007-1110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=17921993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFagt7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=1110-1111&issue=10&author=A.+L.+Hopkins&title=Network+pharmacology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Network pharmacology</span></div><div class="casAuthors">Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1110-1111</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Network biol. illuminates our understanding of drug action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBLPM5MyYqHbVg90H21EOLACvtfcHk0lj3Y1DS1NdT2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFagt7vO&md5=7d88f8f8d6b6e76017475bc59a314e4c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnbt1007-1110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1007-1110%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DNetwork%2520pharmacology%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26issue%3D10%26spage%3D1110%26epage%3D1111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Vaz, R. J.; Klabunde, T.</span>, Eds.  <span class="citation_source-book">Antitargets</span>; <span class="NLM_publisher-name">Wiley-VCH</span>: <span class="NLM_publisher-loc">Weinheim</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9783527621460" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=R.+J.+Vaz&author=T.+Klabunde&title=Antitargets"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2F9783527621460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527621460%26sid%3Dliteratum%253Aachs%26aulast%3DVaz%26aufirst%3DR.%2BJ.%26btitle%3DAntitargets%26pub%3DWiley-VCH%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Urban, L.; Whitebread, S.; Hamon, J.; Mikhailov, D.; Azzaoui, K.</span><span> </span><span class="NLM_article-title">Screening for Safety-Relevant Off-Target Activities</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed., <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">46</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=15-46&author=L.+Urban&author=S.+Whitebread&author=J.+Hamon&author=D.+Mikhailov&author=K.+Azzaouiauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch2%26sid%3Dliteratum%253Aachs%26aulast%3DUrban%26aufirst%3DL.%26atitle%3DScreening%2520for%2520Safety-Relevant%2520Off-Target%2520Activities%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D15%26epage%3D46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Olson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Betton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolaja, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lilly, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanders, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sipes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bracken, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Deun, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heller, A.</span><span> </span><span class="NLM_article-title">Concordance of the Toxicity of Pharmaceuticals in Humans and in Animals</span> <span class="citation_source-journal">Regul. Toxicol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">56</span><span class="NLM_x">–</span> <span class="NLM_lpage">67</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1006%2Frtph.2000.1399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=11029269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntF2gu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2000&pages=56-67&issue=1&author=H.+Olsonauthor=G.+Bettonauthor=D.+Robinsonauthor=K.+Thomasauthor=A.+Monroauthor=G.+Kolajaauthor=P.+Lillyauthor=J.+Sandersauthor=G.+Sipesauthor=W.+Brackenauthor=M.+Doratoauthor=K.+Van+Deunauthor=P.+Smithauthor=B.+Bergerauthor=A.+Heller&title=Concordance+of+the+Toxicity+of+Pharmaceuticals+in+Humans+and+in+Animals"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Concordance of the Toxicity of Pharmaceuticals in Humans and in Animals</span></div><div class="casAuthors">Olson, Harry; Betton, Graham; Robinson, Denise; Thomas, Karluss; Monro, Alastair; Kolaja, Gerald; Lilly, Patrick; Sanders, James; Sipes, Glenn; Bracken, William; Dorato, Michael; Van Deun, Koen; Smith, Peter; Berger, Bruce; Heller, Allen</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory Toxicology and Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-67</span>CODEN:
                <span class="NLM_cas:coden">RTOPDW</span>;
        ISSN:<span class="NLM_cas:issn">0273-2300</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review is given with 29 refs. on the results of a multinational pharmaceutical company survey and the outcome of an International Life Sciences Institute (ILSI) Workshop (Apr. 1999), which served to better understand concordance of the toxicity of pharmaceuticals obsd. in humans with that obsd. in exptl. animals.  The Workshop included representatives from academia, the multinational pharmaceutical industry, and international regulatory scientists.  The main aim of this project was to examine the strengths and weaknesses of animal studies to predict human toxicity (HT).  The database was developed from a survey which covered only those compds. where HTs were identified during clin. development of new pharmaceuticals, detg. whether animal toxicity studies identified concordant target organ toxicities in humans.  Data collected included codified compds., therapeutic category, the HT organ system affected, and the species and duration of studies in which the corresponding HT was either 1st identified or not obsd.  This survey includes input from 12 pharmaceutical companies with data compiled from 150 compds. with 221 HT events reported.  Multiple HTs were reported in 47 cases.  The results showed the true pos. HT concordance rate of 71% for rodent and nonrodent species, with nonrodents alone being predictive for 63% of HTs and rodents alone for 43%.  The highest incidence of overall concordance was seen in hematol., gastrointestinal, and cardiovascular HTs, and the least was seen in cutaneous HT.  Where animal models, in 1 or more species, identified concordant HT, 94% were 1st obsd. in studies of 1 mo or less in duration.  These survey results support the value of in vivo toxicol. studies to predict for many significant HTs assocd. with pharmaceuticals and have helped to identify HT categories that may benefit from improved methods.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEmD_XsaoSaLVg90H21EOLACvtfcHk0liyStlinGnt7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntF2gu7k%253D&md5=8555af1a059d6e3811ade843d77e5f04</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1006%2Frtph.2000.1399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Frtph.2000.1399%26sid%3Dliteratum%253Aachs%26aulast%3DOlson%26aufirst%3DH.%26aulast%3DBetton%26aufirst%3DG.%26aulast%3DRobinson%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DK.%26aulast%3DMonro%26aufirst%3DA.%26aulast%3DKolaja%26aufirst%3DG.%26aulast%3DLilly%26aufirst%3DP.%26aulast%3DSanders%26aufirst%3DJ.%26aulast%3DSipes%26aufirst%3DG.%26aulast%3DBracken%26aufirst%3DW.%26aulast%3DDorato%26aufirst%3DM.%26aulast%3DVan%2BDeun%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DBerger%26aufirst%3DB.%26aulast%3DHeller%26aufirst%3DA.%26atitle%3DConcordance%2520of%2520the%2520Toxicity%2520of%2520Pharmaceuticals%2520in%2520Humans%2520and%2520in%2520Animals%26jtitle%3DRegul.%2520Toxicol.%2520Pharmacol.%26date%3D2000%26volume%3D32%26issue%3D1%26spage%3D56%26epage%3D67" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Zbinden, G.</span><span> </span><span class="NLM_article-title">Predictive value of animal studies in toxicology</span> <span class="citation_source-journal">Regul. Toxicol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">167</span><span class="NLM_x">–</span> <span class="NLM_lpage">77</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1016%2F0273-2300%2891%2990004-F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A280%3ADyaK387mvFajug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1991&pages=167-77&issue=2&author=G.+Zbinden&title=Predictive+value+of+animal+studies+in+toxicology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Predictive value of animal studies in toxicology</span></div><div class="casAuthors">Zbinden G</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory toxicology and pharmacology : RTP</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-77</span>
        ISSN:<span class="NLM_cas:issn">0273-2300</span>.
    </div><div class="casAbstract">The three main purposes of experimental toxicology are (1) determination of the toxicological spectrum in selected laboratory animal species; (2) extrapolation to other species and prediction of adverse effects in man; and (3) determination of safe levels of exposure.  Toxicology has reached a satisfactory level of performance in identifying toxicity in animals, and experimental techniques are now available to characterize the toxicological potential of chemical substances in great detail.  In many instances, extrapolation of toxicological findings in animals to man is possible.  It must also be admitted that toxicological studies have, at times, failed to predict human toxicity.  In many cases, this can be explained by biological differences between animals and man.  A particularly difficult problem is the "low incidence responses" that occur only in especially sensitive individuals.  They represent a challenge that can be met only be a determined research effort.  Failure to predict toxic responses in man is sometimes also brought about by the toxicologists' own faults.  It is essential, therefore, that we analyze the errors committed in the past and continuously evaluate and improve our performance.  Society's demand for specific safe levels of exposure is difficult to meet.  After a long period of confusion and confrontation, toxicology appears to be on the road to a truly science-based methodology for risk assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5nu87lg_jKdK0qsdY6Nc1fW6udTcc2eZrrU1bLmcNU7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK387mvFajug%253D%253D&md5=ae8e3eb02c49588188e26275208e9560</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2F0273-2300%2891%2990004-F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0273-2300%252891%252990004-F%26sid%3Dliteratum%253Aachs%26aulast%3DZbinden%26aufirst%3DG.%26atitle%3DPredictive%2520value%2520of%2520animal%2520studies%2520in%2520toxicology%26jtitle%3DRegul.%2520Toxicol.%2520Pharmacol.%26date%3D1991%26volume%3D14%26issue%3D2%26spage%3D167%26epage%3D77" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Kaczorowski, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bode, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, U. A.</span><span> </span><span class="NLM_article-title">The importance of being profiled: improving drug candidate safety and efficacy using ion channel profiling</span> <span class="citation_source-journal">Front. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">78</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.3389%2Ffphar.2011.00078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC38Xis1agsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=78&author=G.+J.+Kaczorowskiauthor=M.+L.+Garciaauthor=J.+Bodeauthor=S.+D.+Hessauthor=U.+A.+Patel&title=The+importance+of+being+profiled%3A+improving+drug+candidate+safety+and+efficacy+using+ion+channel+profiling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The importance of being profiled: improving drug candidate safety and efficacy using ion channel profiling</span></div><div class="casAuthors">Kaczorowski, Gregory J.; Garcia, Maria L.; Bode, Jacob; Hess, Stephen D.; Patel, Umesh A.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology of Ion Channels and Channelopathies</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">Dec.</span>),
    <span class="NLM_cas:pages">78</span>CODEN:
                <span class="NLM_cas:coden">FPICA4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Profiling of putative lead compds. against a representative panel of relevant enzymes, receptors, ion channels, and transporters is a pragmatic approach to establish a preliminary view of potential issues that might later hamper development.  An early idea of which off-target activities must be minimized can save valuable time and money during the preclin. lead optimization phase if pivotal questions are asked beyond the usual profiling at hERG.  The best data for crit. evaluation of activity at ion channels is obtained using functional assays, since binding assays cannot detect all interactions and do not provide information on whether the interaction is that of an agonist, antagonist, or allosteric modulator.  For ion channels present in human cardiac muscle, depending on the required throughput, manual-, or automated-patch-clamp methodologies can be easily used to evaluate compds. individually to accurately reveal any potential liabilities.  The issue of expanding screening capacity against a cardiac panel has recently been addressed by developing a series of robust, high-throughput, cell-based counter-screening assays employing fluorescence-based readouts.  Similar assay development approaches can be used to configure panels of efficacy assays that can be used to assess selectivity within a family of related ion channels, such as Nav1.X channels.  This overview discusses the benefits of in vitro assays, specific decision points where profiling can be of immediate benefit, and highlights the development and validation of patch-clamp and fluorescence-based profiling assays for ion channel (for examples of fluorescence-based assays, and for high-throughput patch-clamp assays).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobRRFIISqLOLVg90H21EOLACvtfcHk0liyStlinGnt7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xis1agsQ%253D%253D&md5=05f5ac4dd973d3509de02a7c2f1e2f74</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2011.00078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2011.00078%26sid%3Dliteratum%253Aachs%26aulast%3DKaczorowski%26aufirst%3DG.%2BJ.%26aulast%3DGarcia%26aufirst%3DM.%2BL.%26aulast%3DBode%26aufirst%3DJ.%26aulast%3DHess%26aufirst%3DS.%2BD.%26aulast%3DPatel%26aufirst%3DU.%2BA.%26atitle%3DThe%2520importance%2520of%2520being%2520profiled%253A%2520improving%2520drug%2520candidate%2520safety%2520and%2520efficacy%2520using%2520ion%2520channel%2520profiling%26jtitle%3DFront.%2520Pharmacol.%26date%3D2011%26volume%3D2%26spage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><a href="http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7A/Step4/S7A_Guideline.pdf" class="extLink">http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7A/Step4/S7A_Guideline.pdf</a></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=http%3A%2F%2Fwww.ich.org%2Ffileadmin%2FPublic_Web_Site%2FICH_Products%2FGuidelines%2FSafety%2FS7A%2FStep4%2FS7A_Guideline.pdf"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Pugsley, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Authier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtis, M. J.</span><span> </span><span class="NLM_article-title">Principles of Safety Pharmacology</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">154</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1382</span><span class="NLM_x">–</span> <span class="NLM_lpage">1399</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fbjp.2008.280" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=18604233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVajsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2008&pages=1382-1399&issue=7&author=M.+K.+Pugsleyauthor=S.+Authierauthor=M.+J.+Curtis&title=Principles+of+Safety+Pharmacology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Principles of Safety Pharmacology</span></div><div class="casAuthors">Pugsley, M. K.; Authier, S.; Curtis, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1382-1399</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Safety Pharmacol. is a rapidly developing discipline that uses the basic principles of pharmacol. in a regulatory-driven process to generate data to inform risk/benefit assessment.  The aim of Safety Pharmacol. is to characterize the pharmacodynamic/pharmacokinetic (PK/PD) relationship of a drug's adverse effects using continuously evolving methodol.  Unlike toxicol., Safety Pharmacol. includes within its remit a regulatory requirement to predict the risk of rare lethal events.  This gives Safety Pharmacol. its unique character.  The key issues for Safety Pharmacol. are detection of an adverse effect liability, projection of the data into safety margin calcn. and finally clin. safety monitoring.  This article sets out to explain the drivers for Safety Pharmacol. so that the wider pharmacol. community is better placed to understand the discipline.  It concludes with a summary of principles that may help inform future resoln. of unmet needs (esp. establishing model validation for accurate risk assessment).  Subsequent articles in this issue of the journal address specific aspects of Safety Pharmacol. to explore the issues of model choice, the burden of proof and to highlight areas of intensive activity such as testing for drug-induced rare event liability, and the challenge of testing the safety of so-called biologics (antibodies, gene therapy and so on).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpicQ5MbtK_VbVg90H21EOLACvtfcHk0li6DPk6Ma-K3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVajsLg%253D&md5=4636b0d84dc4b1bd2166e34ddcdf7a1a</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fbjp.2008.280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjp.2008.280%26sid%3Dliteratum%253Aachs%26aulast%3DPugsley%26aufirst%3DM.%2BK.%26aulast%3DAuthier%26aufirst%3DS.%26aulast%3DCurtis%26aufirst%3DM.%2BJ.%26atitle%3DPrinciples%2520of%2520Safety%2520Pharmacology%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D154%26issue%3D7%26spage%3D1382%26epage%3D1399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Kola, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landis, J.</span><span> </span><span class="NLM_article-title">Can the pharmaceutical industry reduce attrition rates?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">711</span><span class="NLM_x">–</span> <span class="NLM_lpage">716</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=711-716&issue=8&author=I.+Kolaauthor=J.+Landis&title=Can+the+pharmaceutical+industry+reduce+attrition+rates%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKola%26aufirst%3DI.%26aulast%3DLandis%26aufirst%3DJ.%26atitle%3DCan%2520the%2520pharmaceutical%2520industry%2520reduce%2520attrition%2520rates%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26issue%3D8%26spage%3D711%26epage%3D716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Muthas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyer, S.</span><span> </span><span class="NLM_article-title">Exploiting Pharmacological Similarity to Identify Safety Concerns - Listen to What the Data Tells You</span> <span class="citation_source-journal">Mol. Inf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">37</span><span class="NLM_x">–</span> <span class="NLM_lpage">45</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2Fminf.201200088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntFKruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=37-45&issue=1&author=D.+Muthasauthor=S.+Boyer&title=Exploiting+Pharmacological+Similarity+to+Identify+Safety+Concerns+-+Listen+to+What+the+Data+Tells+You"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Exploiting Pharmacological Similarity to Identify Safety Concerns - Listen to What the Data Tells You</span></div><div class="casAuthors">Muthas, Daniel; Boyer, Scott</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Informatics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37-45</span>CODEN:
                <span class="NLM_cas:coden">MIONBS</span>;
        ISSN:<span class="NLM_cas:issn">1868-1743</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">While most new drugs are designed to act on a single target or a small no. of targets, many do show broad pharmacol. activity.  In some cases this can be beneficial and necessary for efficacy and in others it can be detrimental, leading to increased safety liability.  To probe off-target pharmacol. most drug discovery programs include screening against a broad panel of targets that represent known troublesome pharmacol.  Hits against any one of these targets can then be subjected to a risk assessment for potential safety problems in preclin. or clin. studies.  In addn., the secondary pharmacol. profile can also be thought of as an alternative description of the compd. and as such can be used as a method for assessing similarity'.  Consequently, inspection of the in vivo findings of pharmacol. neighbors can give important insights into potential safety liabilities that are neither identified by pure chem. similarity searches nor by risk assessment on individual targets.  Here we show that the pharmacol. profile contains addnl. information as compared to chem. similarity, and also demonstrate how this can be used in the hazard assessment done during drug discovery and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofUE1Sy23AN7Vg90H21EOLACvtfcHk0li6DPk6Ma-K3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntFKruw%253D%253D&md5=af95ecc021c2227be4f043bd467d6008</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fminf.201200088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fminf.201200088%26sid%3Dliteratum%253Aachs%26aulast%3DMuthas%26aufirst%3DD.%26aulast%3DBoyer%26aufirst%3DS.%26atitle%3DExploiting%2520Pharmacological%2520Similarity%2520to%2520Identify%2520Safety%2520Concerns%2520-%2520Listen%2520to%2520What%2520the%2520Data%2520Tells%2520You%26jtitle%3DMol.%2520Inf.%26date%3D2013%26volume%3D32%26issue%3D1%26spage%3D37%26epage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Migeon, J.</span><span> </span><span class="NLM_article-title">Prediction of side-effects based on fingerprint profiling and data mining</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed., <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=111-132&author=J.+Migeonauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch6%26sid%3Dliteratum%253Aachs%26aulast%3DMigeon%26aufirst%3DJ.%26atitle%3DPrediction%2520of%2520side-effects%2520based%2520on%2520fingerprint%2520profiling%2520and%2520data%2520mining%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D111%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Mason, J. S.; Migeon, J.; Dupuis, P.; Otto-Bruc, A.</span><span> </span><span class="NLM_article-title">Use of Broad Biological Profiling as a Relevant Descriptor to Describe and Differentiate Compounds: Structure–In Vitro (Pharmacology–ADME)–In Vivo (Safety) Relationships</span>. In  <span class="citation_source-book">Antitargets</span>; <span class="NLM_contrib-group">Vaz, R. J.; Klabunde, T.</span>, Eds.; <span class="NLM_publisher-name">Wiley-VCH</span>: <span class="NLM_publisher-loc">Weinheim</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=3-22&author=J.+S.+Mason&author=J.+Migeon&author=P.+Dupuis&author=A.+Otto-Brucauthor=R.+J.+Vaz&author=T.+Klabunde&title=Antitargets"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMason%26aufirst%3DJ.%2BS.%26atitle%3DUse%2520of%2520Broad%2520Biological%2520Profiling%2520as%2520a%2520Relevant%2520Descriptor%2520to%2520Describe%2520and%2520Differentiate%2520Compounds%253A%2520Structure%25E2%2580%2593In%2520Vitro%2520%2528Pharmacology%25E2%2580%2593ADME%2529%25E2%2580%2593In%2520Vivo%2520%2528Safety%2529%2520Relationships%26btitle%3DAntitargets%26aulast%3DVaz%26aufirst%3DR.%2BJ.%26pub%3DWiley-VCH%26date%3D2008%26spage%3D3%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Fliri, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loging, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thadeio, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volkmann, R. A.</span><span> </span><span class="NLM_article-title">Biospectra analysis: model proteome characterizations for linking molecular structure and biological response</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x"> (</span><span class="NLM_issue">22</span><span class="NLM_x">) </span> <span class="NLM_fpage">6918</span><span class="NLM_x">–</span> <span class="NLM_lpage">6925</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050494g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6918-6925&issue=22&author=A.+F.+Fliriauthor=W.+T.+Logingauthor=P.+F.+Thadeioauthor=R.+A.+Volkmann&title=Biospectra+analysis%3A+model+proteome+characterizations+for+linking+molecular+structure+and+biological+response"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm050494g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050494g%26sid%3Dliteratum%253Aachs%26aulast%3DFliri%26aufirst%3DA.%2BF.%26aulast%3DLoging%26aufirst%3DW.%2BT.%26aulast%3DThadeio%26aufirst%3DP.%2BF.%26aulast%3DVolkmann%26aufirst%3DR.%2BA.%26atitle%3DBiospectra%2520analysis%253A%2520model%2520proteome%2520characterizations%2520for%2520linking%2520molecular%2520structure%2520and%2520biological%2520response%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D22%26spage%3D6918%26epage%3D6925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Urban, L.</span><span> </span><span class="NLM_article-title">Translational value of early target-based safety assessment and associated risk mitigation</span>. 4th Annual Predictive Toxicology Summit, London, February 15–17,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=L.+Urban&title=Translational+value+of+early+target-based+safety+assessment+and+associated+risk+mitigation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DUrban%26aufirst%3DL.%26atitle%3DTranslational%2520value%2520of%2520early%2520target-based%2520safety%2520assessment%2520and%2520associated%2520risk%2520mitigation%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, N.</span><span> </span><span class="NLM_article-title">Comparing Measures of Promiscuity and Exploring Their Relationship to Toxicity</span> <span class="citation_source-journal">Mol. Inf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">145</span><span class="NLM_x">–</span> <span class="NLM_lpage">159</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2Fminf.201100148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKju70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2012&pages=145-159&issue=2&author=X.+Wangauthor=N.+Greene&title=Comparing+Measures+of+Promiscuity+and+Exploring+Their+Relationship+to+Toxicity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Comparing Measures of Promiscuity and Exploring Their Relationship to Toxicity</span></div><div class="casAuthors">Wang, Xiangyun; Greene, Nigel</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Informatics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">145-159</span>CODEN:
                <span class="NLM_cas:coden">MIONBS</span>;
        ISSN:<span class="NLM_cas:issn">1868-1743</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Recent research has focused on algorithms to derive numerical measures of selectivity based on panels of in vitro pharmacol. assays so that one mol.'s activity profile may be compared easily with that of another.  However, the questions concerning which method or algorithm is best to use, the optimal no. of assays required to give an accurate measure of selectivity and the correlation of these measures to in vivo toxicity have remained largely unexplored.  In this manuscript we describe a systematic approach to compare and contrast different calcn. methods for promiscuity and det. the optimal no. and constitution of a panel of assays to measure the selectivity/promiscuity of compds. across all targets.  We then go on to examine their relationship to toxicity using a Pfizer proprietary compd. set that has both selectivity profiles and exploratory toxicol. study results.  From this study we conclude that all five methods studied are useful in estg. compd. selectivity; that a small panel of between 15 to 30 binding assays can be used as a surrogate for a broader panel enabling higher throughput with lower costs and this panel will most likely have the highest prediction power when correlating this measure to in vivo effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroFZPz4tPdDrVg90H21EOLACvtfcHk0liBRPnhB-2a0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKju70%253D&md5=1aa9606472722e3a7d18c153d34a8f10</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fminf.201100148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fminf.201100148%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGreene%26aufirst%3DN.%26atitle%3DComparing%2520Measures%2520of%2520Promiscuity%2520and%2520Exploring%2520Their%2520Relationship%2520to%2520Toxicity%26jtitle%3DMol.%2520Inf.%26date%3D2012%26volume%3D31%26issue%3D2%26spage%3D145%26epage%3D159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Bendels, S.; Bissantz, C.; Fasching, B.; Fischer, H.; Gerebtzoff, G.; Guba, W.; Hert, J.; Kansy, M.; Migeon, J.; Peters, J.-U.; Pflieger, P.; Tillier, F.</span><span> </span><span class="NLM_article-title">Safety screening in early drug discovery: An improved assay profile</span>. Poster presentation at the Gordon Research Conference on Computer Aided Drug Design, Mount Snow (VT), USA, July 21–26,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=S.+Bendels&author=C.+Bissantz&author=B.+Fasching&author=H.+Fischer&author=G.+Gerebtzoff&author=W.+Guba&author=J.+Hert&author=M.+Kansy&author=J.+Migeon&author=J.-U.+Peters&author=P.+Pflieger&author=F.+Tillier&title=Safety+screening+in+early+drug+discovery%3A+An+improved+assay+profile"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DBendels%26aufirst%3DS.%26atitle%3DSafety%2520screening%2520in%2520early%2520drug%2520discovery%253A%2520An%2520improved%2520assay%2520profile%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Bowes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarolimek, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridhar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waldron, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitebread, S.</span><span> </span><span class="NLM_article-title">Reducing safety-related drug attrition: the use of in vitro pharmacological profiling</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">909</span><span class="NLM_x">–</span> <span class="NLM_lpage">922</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fnrd3845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=23197038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslCnur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=909-922&issue=12&author=J.+Bowesauthor=A.+J.+Brownauthor=J.+Hamonauthor=W.+Jarolimekauthor=A.+Sridharauthor=G.+Waldronauthor=S.+Whitebread&title=Reducing+safety-related+drug+attrition%3A+the+use+of+in+vitro+pharmacological+profiling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Reducing safety-related drug attrition: the use of in vitro pharmacological profiling</span></div><div class="casAuthors">Bowes, Joanne; Brown, Andrew J.; Hamon, Jacques; Jarolimek, Wolfgang; Sridhar, Arun; Waldron, Gareth; Whitebread, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">909-922</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In vitro pharmacol. profiling is increasingly being used earlier in the drug discovery process to identify undesirable off-target activity profiles that could hinder or halt the development of candidate drugs or even lead to market withdrawal if discovered after a drug is approved.  Here, for the first time, the rationale, strategies and methodologies for in vitro pharmacol. profiling at four major pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Novartis and Pfizer) are presented and illustrated with examples of their impact on the drug discovery process.  We hope that this will enable other companies and academic institutions to benefit from this knowledge and consider joining us in our collaborative knowledge sharing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomVp3wnTONWrVg90H21EOLACvtfcHk0liBRPnhB-2a0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslCnur%252FJ&md5=7559001563ef3febd610535b8f096a45</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fnrd3845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3845%26sid%3Dliteratum%253Aachs%26aulast%3DBowes%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DA.%2BJ.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DJarolimek%26aufirst%3DW.%26aulast%3DSridhar%26aufirst%3DA.%26aulast%3DWaldron%26aufirst%3DG.%26aulast%3DWhitebread%26aufirst%3DS.%26atitle%3DReducing%2520safety-related%2520drug%2520attrition%253A%2520the%2520use%2520of%2520in%2520vitro%2520pharmacological%2520profiling%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26issue%3D12%26spage%3D909%26epage%3D922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Volk, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagy, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kostyalik, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simig, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagdy, G.</span><span> </span><span class="NLM_article-title">Medicinal chemistry of 5-HT5A receptor ligands: a receptor subtype with unique therapeutical potential</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">554</span><span class="NLM_x">–</span> <span class="NLM_lpage">578</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.2174%2F156802610791111588" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=20166946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsFKnur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=554-578&issue=5&author=B.+Volkauthor=B.+J.+Nagyauthor=S.+Vasauthor=D.+Kostyalikauthor=G.+Simigauthor=G.+Bagdy&title=Medicinal+chemistry+of+5-HT5A+receptor+ligands%3A+a+receptor+subtype+with+unique+therapeutical+potential"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of 5-HT5A receptor ligands: a receptor subtype with unique therapeutical potential</span></div><div class="casAuthors">Volk, Balazs; Nagy, Bence J.; Vas, Szilvia; Kostyalik, Diana; Simig, Gyula; Bagdy, Gyorgy</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">554-578</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Although the 5-HT5 receptor subfamily was discovered more than 15 years ago, it is unambiguously the least known 5-HT receptor subtype.  The Gi/G0-mediated signal transduction and its intensive presence in raphe and other brainstem and pons nuclei suggest mechanisms similar to those of 5-HT1 receptors, the ligands of which are already applied in the treatment of e.g. anxiety and migraine.  In addn., a unique coupling and inhibition of ADP-ribosyl cyclase have also been described.  High concns. of 5-HT5 receptor in other key regions including, e.g. locus coeruleus, nucleus of the solitary tract, arcuate and suprachiasmatic nuclei of the hypothalamus indicate a wide range of physiol. effects, thus its ligands are potential drug candidates in various areas, e.g. anxiety, sleep, incontinence, food intake, learning and memory, pain or chemoreception pathways.  These findings have motivated several institutes and pharmaceutical companies to participate in the research of this field.  Despite extensive research, no selective agonist and only two selective antagonists have been identified until now.  Beyond these compds., the present review provides a complete overview on all other published 5-HT5A receptor ligands as well as on the structure, function, distribution, genetics and possible therapeutic applications of this receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplqydEbNRArLVg90H21EOLACvtfcHk0lhXhz6WXE_2Vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsFKnur4%253D&md5=45fab50aa5ba9248fd7cbf6f0eaf0990</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.2174%2F156802610791111588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802610791111588%26sid%3Dliteratum%253Aachs%26aulast%3DVolk%26aufirst%3DB.%26aulast%3DNagy%26aufirst%3DB.%2BJ.%26aulast%3DVas%26aufirst%3DS.%26aulast%3DKostyalik%26aufirst%3DD.%26aulast%3DSimig%26aufirst%3DG.%26aulast%3DBagdy%26aufirst%3DG.%26atitle%3DMedicinal%2520chemistry%2520of%25205-HT5A%2520receptor%2520ligands%253A%2520a%2520receptor%2520subtype%2520with%2520unique%2520therapeutical%2520potential%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2010%26volume%3D10%26issue%3D5%26spage%3D554%26epage%3D578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Grailhe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waeber, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dulawa, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornung, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunner, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geyer, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hen, R.</span><span> </span><span class="NLM_article-title">Increased exploratory activity and altered response to LSD in mice lacking the 5-HT5A receptor</span> <span class="citation_source-journal">Neuron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">581</span><span class="NLM_x">–</span> <span class="NLM_lpage">591</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1999&pages=581-591&issue=3&author=R.+Grailheauthor=C.+Waeberauthor=S.+C.+Dulawaauthor=J.+P.+Hornungauthor=X.+Zhuangauthor=D.+Brunnerauthor=M.+A.+Geyerauthor=R.+Hen&title=Increased+exploratory+activity+and+altered+response+to+LSD+in+mice+lacking+the+5-HT5A+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGrailhe%26aufirst%3DR.%26aulast%3DWaeber%26aufirst%3DC.%26aulast%3DDulawa%26aufirst%3DS.%2BC.%26aulast%3DHornung%26aufirst%3DJ.%2BP.%26aulast%3DZhuang%26aufirst%3DX.%26aulast%3DBrunner%26aufirst%3DD.%26aulast%3DGeyer%26aufirst%3DM.%2BA.%26aulast%3DHen%26aufirst%3DR.%26atitle%3DIncreased%2520exploratory%2520activity%2520and%2520altered%2520response%2520to%2520LSD%2520in%2520mice%2520lacking%2520the%25205-HT5A%2520receptor%26jtitle%3DNeuron%26date%3D1999%26volume%3D22%26issue%3D3%26spage%3D581%26epage%3D591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Peters, J.-U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bissantz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hillebrecht, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerebtzoff, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendels, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tillier, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migeon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guba, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kansy, M.</span><span> </span><span class="NLM_article-title">Can we discover pharmacological promiscuity early in the drug discovery process?</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">7–8</span><span class="NLM_x">) </span> <span class="NLM_fpage">325</span><span class="NLM_x">–</span> <span class="NLM_lpage">335</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=325-335&issue=7%E2%80%938&author=J.-U.+Petersauthor=J.+Hertauthor=C.+Bissantzauthor=A.+Hillebrechtauthor=G.+Gerebtzoffauthor=S.+Bendelsauthor=F.+Tillierauthor=J.+Migeonauthor=H.+Fischerauthor=W.+Gubaauthor=M.+Kansy&title=Can+we+discover+pharmacological+promiscuity+early+in+the+drug+discovery+process%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.-U.%26aulast%3DHert%26aufirst%3DJ.%26aulast%3DBissantz%26aufirst%3DC.%26aulast%3DHillebrecht%26aufirst%3DA.%26aulast%3DGerebtzoff%26aufirst%3DG.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DTillier%26aufirst%3DF.%26aulast%3DMigeon%26aufirst%3DJ.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DGuba%26aufirst%3DW.%26aulast%3DKansy%26aufirst%3DM.%26atitle%3DCan%2520we%2520discover%2520pharmacological%2520promiscuity%2520early%2520in%2520the%2520drug%2520discovery%2520process%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26issue%3D7%25E2%2580%25938%26spage%3D325%26epage%3D335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Hamon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitebread, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Techer-Etienne, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Coq, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azzaoui, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, L.</span><span> </span><span class="NLM_article-title">vitro safety pharmacology profiling: what else beyond hERG?</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">645</span><span class="NLM_x">–</span> <span class="NLM_lpage">665</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.4155%2Ffmc.09.51" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFSgtbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2009&pages=645-665&issue=4&author=J.+Hamonauthor=S.+Whitebreadauthor=V.+Techer-Etienneauthor=H.+Le+Coqauthor=K.+Azzaouiauthor=L.+Urban&title=vitro+safety+pharmacology+profiling%3A+what+else+beyond+hERG%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro safety pharmacology profiling: what else beyond hERG?</span></div><div class="casAuthors">Hamon, Jacques; Whitebread, Steven; Techer-Etienne, Valerie; Le Coq, Helene; Azzaoui, Kamal; Urban, Laszlo</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">645-665</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  One of the main reasons for drug failures in clin. development, or postmarket launch, is lacking or compromised safety margins at therapeutic doses.  Organ toxicity with poorly defined mechanisms and adverse drug reactions assocd. with on- and off-target effects are the major contributors to safety-related shortfalls of many clin. drug candidates.  Therefore, to avoid high attrition rates in clin. trials, it is imperative to test compds. for potential adverse reactions during early drug discovery.  Beyond a small no. of targets assocd. with clin. acknowledged adverse drug reactions, there is little consensus on other targets that are important to consider at an early stage for in vitro safety pharmacol. assessment.  We consider here a limited no. of safety-related targets, from different target families, which were selected as part of in vitro safety pharmacol. profiling panels integrated in the drug-development process at Novartis.  The best way to assess these targets, using a biochem. or a functional readout, is discussed.  In particular, the importance of using cell-based profiling assays for the characterization of an agonist action at some GPCRs is highlighted.  A careful design of in vitro safety pharmacol. profiling panels allows better prediction of potential adverse effects of new chem. entities early in the drug-discovery process.  This contributes to the selection of the best candidate for clin. development and, ultimately, should contribute to a decreased attrition rate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdXUdqWitZC7Vg90H21EOLACvtfcHk0lhXhz6WXE_2Vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFSgtbbJ&md5=85e16bf431d07804e6bce443ffab0ed6</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.4155%2Ffmc.09.51&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.09.51%26sid%3Dliteratum%253Aachs%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DWhitebread%26aufirst%3DS.%26aulast%3DTecher-Etienne%26aufirst%3DV.%26aulast%3DLe%2BCoq%26aufirst%3DH.%26aulast%3DAzzaoui%26aufirst%3DK.%26aulast%3DUrban%26aufirst%3DL.%26atitle%3Dvitro%2520safety%2520pharmacology%2520profiling%253A%2520what%2520else%2520beyond%2520hERG%253F%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2009%26volume%3D1%26issue%3D4%26spage%3D645%26epage%3D665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Kvernmo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houben, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sylte, I.</span><span> </span><span class="NLM_article-title">Receptor-Binding and Pharmacokinetic Properties of Dopaminergic Agonists</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">1049</span><span class="NLM_x">–</span> <span class="NLM_lpage">1067</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.2174%2F156802608785161457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Ohtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=1049-1067&issue=12&author=T.+Kvernmoauthor=J.+Houbenauthor=I.+Sylte&title=Receptor-Binding+and+Pharmacokinetic+Properties+of+Dopaminergic+Agonists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor-binding and pharmacokinetic properties of dopaminergic agonists</span></div><div class="casAuthors">Kvernmo, Trond; Houben, John; Sylte, Ingebrigt</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1049-1067</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  This review describes symptoms and pathophysiol. of Parkinson's diseases (PD) and restless legs syndrome (RLS), and discusses the relation between clin. outcome of DA agonists and their receptor-binding and pharmacokinetics.  Oral DA agonists are divided into 2 classes; the ergots and the non-ergots.  Both classes are in general equally effective against PD motor symptoms.  Ergots (apart from bromocriptine) stimulate the DA D1 subreceptor and increase dyskinesia.  Furthermore, valvular heart disease (VHD) and pulmonary and retroperitoneal fibrosis appear to represent a class effect of 8β-aminoergolines as cabergoline and pergolide.  The side effects profile therefore seems more beneficial for non-ergots than ergots.  The main improvement of motor functions by DA agonists is related to D2 agonism.  However, in monotherapy, the selective D2-receptor DA agonist sumanirole seemed less effective than ropinirole which is selective for D2- like DA-receptors (D2, D3 and D4).  Given as adjunctive to L-dopa both drugs had equal efficacy on motor-symptoms, indicating that D2-receptor activity must be accompanied with stimulation of other DA receptors for optimizing the efficacy on motor symptoms.  Striatal D3 receptor loss may be more important than D2 receptor loss for reduced response to dopaminergic treatment.  D3 stimulation may also be beneficial for the non-motor symptom depression/mood in PD and for neuron-protection.  This makes D3-receptors a potential therapeutic target in PD.  5-HT1A-receptor agonism and α2 adrenergic antagonism may contribute to prevention of dyskinesia.  However, 5-HT-receptor activity is also assocd. with side effects.  5-HT2B agonism (and possibly 5-HT1B agonism) is assocd. with fibrotic reactions, and valvular heart disease (VHD).  By interfering with the CYP450 system DA agonists may contribute to drug-drug interactions.  Lack of CYP2D6 activity is also suggested as important for etiol. and CNS-symptoms of PD.  Based on current knowledge D2-like receptor activities (preferences for the D3 receptor) seem most beneficial.  5-HT1A-receptor agonism (prevention of dyskinesia), 5-HT2B antagonism or no 5-HT2B-receptor activity also seems beneficial.  Development of DA agonists contg. these properties, without interfering with CYP2D6 may be beneficial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-irkKqsAQfrVg90H21EOLACvtfcHk0ljHVzIyiboSrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Ohtb8%253D&md5=c966fbe7d38d1b376a654029d4706680</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.2174%2F156802608785161457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802608785161457%26sid%3Dliteratum%253Aachs%26aulast%3DKvernmo%26aufirst%3DT.%26aulast%3DHouben%26aufirst%3DJ.%26aulast%3DSylte%26aufirst%3DI.%26atitle%3DReceptor-Binding%2520and%2520Pharmacokinetic%2520Properties%2520of%2520Dopaminergic%2520Agonists%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26issue%3D12%26spage%3D1049%26epage%3D1067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Peters, J.-U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnider, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattei, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kansy, M.</span><span> </span><span class="NLM_article-title">Pharmacological Promiscuity: Dependence on Compound Properties and Target Specificity in a Set of Recent Roche Compounds</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">680</span><span class="NLM_x">–</span> <span class="NLM_lpage">686</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=680-686&issue=4&author=J.-U.+Petersauthor=P.+Schniderauthor=P.+Matteiauthor=M.+Kansy&title=Pharmacological+Promiscuity%3A+Dependence+on+Compound+Properties+and+Target+Specificity+in+a+Set+of+Recent+Roche+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.-U.%26aulast%3DSchnider%26aufirst%3DP.%26aulast%3DMattei%26aufirst%3DP.%26aulast%3DKansy%26aufirst%3DM.%26atitle%3DPharmacological%2520Promiscuity%253A%2520Dependence%2520on%2520Compound%2520Properties%2520and%2520Target%2520Specificity%2520in%2520a%2520Set%2520of%2520Recent%2520Roche%2520Compounds%26jtitle%3DChemMedChem%26date%3D2009%26volume%3D4%26issue%3D4%26spage%3D680%26epage%3D686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Huang, X.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yadav, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogan, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Revankar, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doucette, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">710</span><span class="NLM_x">–</span> <span class="NLM_lpage">722</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2009&pages=710-722&issue=4&author=X.-P.+Huangauthor=V.+Setolaauthor=P.+N.+Yadavauthor=J.+A.+Allenauthor=S.+C.+Roganauthor=B.+J.+Hansonauthor=C.+Revankarauthor=M.+Robersauthor=C.+Doucetteauthor=B.+L.+Roth&title=Parallel+functional+activity+profiling+reveals+valvulopathogens+are+potent+5-hydroxytryptamine%282B%29+receptor+agonists%3A+implications+for+drug+safety+assessment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DYadav%26aufirst%3DP.%2BN.%26aulast%3DAllen%26aufirst%3DJ.%2BA.%26aulast%3DRogan%26aufirst%3DS.%2BC.%26aulast%3DHanson%26aufirst%3DB.%2BJ.%26aulast%3DRevankar%26aufirst%3DC.%26aulast%3DRobers%26aufirst%3DM.%26aulast%3DDoucette%26aufirst%3DC.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DParallel%2520functional%2520activity%2520profiling%2520reveals%2520valvulopathogens%2520are%2520potent%25205-hydroxytryptamine%25282B%2529%2520receptor%2520agonists%253A%2520implications%2520for%2520drug%2520safety%2520assessment%26jtitle%3DMol.%2520Pharmacol.%26date%3D2009%26volume%3D76%26issue%3D4%26spage%3D710%26epage%3D722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Bell, I. M.; Bilodeau, M. T.; Lagrutta, A. A.</span><span> </span><span class="NLM_article-title">Activity at Cardiovascular Ion Channels: A Key Issue for Drug Discovery</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed., <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">83</span><span class="NLM_x">–</span> <span class="NLM_lpage">109</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=83-109&author=I.+M.+Bell&author=M.+T.+Bilodeau&author=A.+A.+Lagruttaauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch5%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DI.%2BM.%26atitle%3DActivity%2520at%2520Cardiovascular%2520Ion%2520Channels%253A%2520A%2520Key%2520Issue%2520for%2520Drug%2520Discovery%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D83%26epage%3D109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Redfern, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlsson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKenzie, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palethorpe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegl, P. K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strang, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cammi, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammond, T. G.</span><span> </span><span class="NLM_article-title">Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development</span> <span class="citation_source-journal">Cardiovasc. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">32</span><span class="NLM_x">–</span> <span class="NLM_lpage">45</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1016%2FS0008-6363%2802%2900846-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=12667944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit12gsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2003&pages=32-45&issue=1&author=W.+S.+Redfernauthor=L.+Carlssonauthor=A.+S.+Davisauthor=W.+G.+Lynchauthor=I.+MacKenzieauthor=S.+Palethorpeauthor=P.+K.+S.+Sieglauthor=I.+Strangauthor=A.+T.+Sullivanauthor=R.+Wallisauthor=A.+J.+Cammiauthor=T.+G.+Hammond&title=Relationships+between+preclinical+cardiac+electrophysiology%2C+clinical+QT+interval+prolongation+and+torsade+de+pointes+for+a+broad+range+of+drugs%3A+evidence+for+a+provisional+safety+margin+in+drug+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development</span></div><div class="casAuthors">Redfern, W. S.; Carlsson, L.; Davis, A. S.; Lynch, W. G.; MacKenzie, I.; Palethorpe, S.; Siegl, P. K. S.; Strang, I.; Sullivan, A. T.; Wallis, R.; Camm, A. J.; Hammond, T. G.</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-45</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review discussing attempts to det. the relative value of preclin. cardiac electrophysiol. data (in vitro and in vivo) for predicting risk of torsades de pointes (TdP) in clin. use.  Published data on human ether-a-go-go-related gene-encoded voltage-dependent potassium channel (hERG) (or IKr) activity, cardiac action potential duration (at 90% repolarization; APD90), and QT prolongation in dogs were compared against QT effects and reports of TdP in humans for 100 drugs.  These data were set against the free plasma concns. attained during clin. use (effective therapeutic plasma concns.; ETPCunbound).  The drugs were divided into five categories: (1) Class Ia and III antiarrhythmics; (2) withdrawn from market due to TdP; (3) measurable incidence/numerous reports of TdP in humans; (4) isolated reports of TdP in humans; (5) no reports of TdP in humans.  Data from hERG (or IKr) assays in addn. to ETPCunbound data were available for 52 drugs.  For Category 1 drugs, data for hERG/IKr IC50, APD90, QTc in animals and QTc in humans were generally close to or superimposed on the ETPCunbound values.  This relationship was uncoupled in the other categories, with more complex relationships between the data.  In Category 1 (except amiodarone), the ratios between hERG/IKr IC50 and ETPCunbound (max) ranged 0.1-31-fold.  Similar ranges were obtained for drugs in Category 2 (0.31-13-fold) and Category 3 (0.03-35-fold).  A large spread was found for Category 4 drugs (0.13-35,700-fold); this category embraced an assortment of mechanisms ranging from drugs which may well be affecting IKr currents in clin. use (e.g., sparfloxacin) to others such as nifedipine (35,700-fold) where channel block is not involved.  Finally, for the majority of Category 5 drugs there was a >30-fold sepn. between hERG/IKr activity and ETPCunbound values, with the notable exception of verapamil (1.7-fold), which is free from QT prolongation in man; this is probably explained by its multiple interactions with cardiac ion channels.  The dataset confirms the widely held belief that most drugs assocd. with TdP in humans are also assocd. with hERG K+ channel block at concns. close to or superimposed upon the free plasma concns. found in clin. use.  A 30-fold margin between Cmax and hERG IC50 may suffice for drugs currently undergoing clin. evaluation, but for future drug discovery programs, pharmaceutical companies should consider increasing this margin, particularly for drugs aimed at nondebilitating diseases.  However, interactions with multiple cardiac ion channels can either mitigate or exacerbate the prolongation of APD and QT that would ensue from block of IKr currents alone, and delay of repolarization per se is not necessarily torsadogenic.  Clearly, an integrated assessment of in vitro and in vivo data is required in order to predict the torsadogenic risk of a new candidate drug in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkpRDUH0rhyrVg90H21EOLACvtfcHk0lhXMOO3tEbezA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit12gsb8%253D&md5=a236c07febd2e05fe70e61604619bf2e</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2FS0008-6363%2802%2900846-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0008-6363%252802%252900846-5%26sid%3Dliteratum%253Aachs%26aulast%3DRedfern%26aufirst%3DW.%2BS.%26aulast%3DCarlsson%26aufirst%3DL.%26aulast%3DDavis%26aufirst%3DA.%2BS.%26aulast%3DLynch%26aufirst%3DW.%2BG.%26aulast%3DMacKenzie%26aufirst%3DI.%26aulast%3DPalethorpe%26aufirst%3DS.%26aulast%3DSiegl%26aufirst%3DP.%2BK.%2BS.%26aulast%3DStrang%26aufirst%3DI.%26aulast%3DSullivan%26aufirst%3DA.%2BT.%26aulast%3DWallis%26aufirst%3DR.%26aulast%3DCammi%26aufirst%3DA.%2BJ.%26aulast%3DHammond%26aufirst%3DT.%2BG.%26atitle%3DRelationships%2520between%2520preclinical%2520cardiac%2520electrophysiology%252C%2520clinical%2520QT%2520interval%2520prolongation%2520and%2520torsade%2520de%2520pointes%2520for%2520a%2520broad%2520range%2520of%2520drugs%253A%2520evidence%2520for%2520a%2520provisional%2520safety%2520margin%2520in%2520drug%2520development%26jtitle%3DCardiovasc.%2520Res.%26date%3D2003%26volume%3D58%26issue%3D1%26spage%3D32%26epage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Murphy, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poole, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padegimas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunady, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danzig, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ting, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherf, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunden, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stricker-Krongrad, A.</span><span> </span><span class="NLM_article-title">Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel</span> <span class="citation_source-journal">J. Pharmacol. Toxicol. Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">42</span><span class="NLM_x">–</span> <span class="NLM_lpage">55</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1016%2Fj.vascn.2005.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsFSktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2006&pages=42-55&issue=1&author=S.+M.+Murphyauthor=M.+Palmerauthor=M.+F.+Pooleauthor=L.+Padegimasauthor=K.+Hunadyauthor=J.+Danzigauthor=S.+Gillauthor=R.+Gillauthor=A.+Tingauthor=B.+Sherfauthor=K.+Brundenauthor=A.+Stricker-Krongrad&title=Evaluation+of+functional+and+binding+assays+in+cells+expressing+either+recombinant+or+endogenous+hERG+channel"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel</span></div><div class="casAuthors">Murphy, Steven M.; Palmer, Marc; Poole, Michelle Fontilla; Padegimas, Linas; Hunady, Karen; Danzig, Joel; Gill, Sikander; Gill, Rajwant; Ting, Anthony; Sherf, Bruce; Brunden, Kurt; Stricker-Krongrad, Alain</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">42-55</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The hERG (human ether-a-go-go related gene) potassium channel is required for normal cardiac repolarization, is susceptible to inhibition by a wide variety of compds., and its blockage can lead to cardiac QT interval prolongation and life threatening arrhythmias.  The present report examines the ability of hERG binding and functional assays to identify compds. with potential cardiovascular liabilities at the earliest stages of drug discovery.  Competitive binding assays were developed using 3H-dofetilide and membranes from HEK293EBNA cells stably expressing recombinant hERG (HEK293-hERG) and IMR-32 cells expressing hERG endogenously.  HERG functional assays were also developed using membrane potential indicator dye and rubidium efflux.  The ability of these assays to identify compds. with potential adverse cardiac effects was examd. using drugs with known cardiac effects ranging from those with no known adverse effects to drugs that were withdrawn from the market due to increased risk of sudden death assocd. with Torsades de Points.  Binding assays using HEK293-hERG membranes and 3H-dofetilide were robust (Z' = 0.69 ± 0.015, mean ± S.E.M.), highly reproducible (test-retest slope = 1.04, r2 = 0.98), and correlated well with IC50 values obtained by patch clamp (slope = 0.98, r 2 = 0.89).  Binding assays using IMR-32 membranes were less sensitive (Z' = 0.4±0.03, mean ± S.E.M., false neg. rate = 0.4) but still correlated well with patch clamp data (slope = 1.06, r2 = 0.83).  The hERG membrane potential assay could detect potent hERG inhibitors (defined by hERG patch clamp IC50 < 0.1 μM) using HEK293-hERG cells, but were prone to generate false-neg. results with less potent inhibitors (false neg. rate = 0.5).  Finally, the rubidium efflux assay gave highly reproducible results (Z' = 0.80 ± 0.02, mean ± S.E.M.) that correlated with patch clamp IC50 values (slope = 0.87, r2 = 0.73).  The hERG binding and rubidium efflux assays are robust, predictive of patch clamp results, and can be used at the earliest stages of drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtnBvVMZ8tdbVg90H21EOLACvtfcHk0lhXMOO3tEbezA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsFSktbc%253D&md5=7ec9afa4e333e5bd4fa3fbc69e0d8457</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.vascn.2005.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vascn.2005.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DS.%2BM.%26aulast%3DPalmer%26aufirst%3DM.%26aulast%3DPoole%26aufirst%3DM.%2BF.%26aulast%3DPadegimas%26aufirst%3DL.%26aulast%3DHunady%26aufirst%3DK.%26aulast%3DDanzig%26aufirst%3DJ.%26aulast%3DGill%26aufirst%3DS.%26aulast%3DGill%26aufirst%3DR.%26aulast%3DTing%26aufirst%3DA.%26aulast%3DSherf%26aufirst%3DB.%26aulast%3DBrunden%26aufirst%3DK.%26aulast%3DStricker-Krongrad%26aufirst%3DA.%26atitle%3DEvaluation%2520of%2520functional%2520and%2520binding%2520assays%2520in%2520cells%2520expressing%2520either%2520recombinant%2520or%2520endogenous%2520hERG%2520channel%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2006%26volume%3D54%26issue%3D1%26spage%3D42%26epage%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Schmalhofer, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swensen, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felix, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haedo, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solly, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiss, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaczorowski, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, M. L.</span><span> </span><span class="NLM_article-title">A Pharmacologically Validated, High-Capacity, Functional Thallium Flux Assay for the Human Ether-a-go-go Related Gene Potassium Channel</span> <span class="citation_source-journal">Assay Drug Dev. Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">714</span><span class="NLM_x">–</span> <span class="NLM_lpage">726</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=714-726&issue=6&author=W.+A.+Schmalhoferauthor=A.+M.+Swensenauthor=B.+S.+Thomasauthor=J.+P.+Felixauthor=R.+J.+Haedoauthor=K.+Sollyauthor=L.+Kissauthor=G.+J.+Kaczorowskiauthor=M.+L.+Garcia&title=A+Pharmacologically+Validated%2C+High-Capacity%2C+Functional+Thallium+Flux+Assay+for+the+Human+Ether-a-go-go+Related+Gene+Potassium+Channel"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchmalhofer%26aufirst%3DW.%2BA.%26aulast%3DSwensen%26aufirst%3DA.%2BM.%26aulast%3DThomas%26aufirst%3DB.%2BS.%26aulast%3DFelix%26aufirst%3DJ.%2BP.%26aulast%3DHaedo%26aufirst%3DR.%2BJ.%26aulast%3DSolly%26aufirst%3DK.%26aulast%3DKiss%26aufirst%3DL.%26aulast%3DKaczorowski%26aufirst%3DG.%2BJ.%26aulast%3DGarcia%26aufirst%3DM.%2BL.%26atitle%3DA%2520Pharmacologically%2520Validated%252C%2520High-Capacity%252C%2520Functional%2520Thallium%2520Flux%2520Assay%2520for%2520the%2520Human%2520Ether-a-go-go%2520Related%2520Gene%2520Potassium%2520Channel%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2010%26volume%3D8%26issue%3D6%26spage%3D714%26epage%3D726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Tarcsay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keseru, G. M.</span><span> </span><span class="NLM_article-title">Contributions of Molecular Properties to Drug Promiscuity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">1789</span><span class="NLM_x">–</span> <span class="NLM_lpage">1795</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm301514n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1789-1795&issue=5&author=A.+Tarcsayauthor=G.+M.+Keseru&title=Contributions+of+Molecular+Properties+to+Drug+Promiscuity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm301514n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301514n%26sid%3Dliteratum%253Aachs%26aulast%3DTarcsay%26aufirst%3DA.%26aulast%3DKeseru%26aufirst%3DG.%2BM.%26atitle%3DContributions%2520of%2520Molecular%2520Properties%2520to%2520Drug%2520Promiscuity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D5%26spage%3D1789%26epage%3D1795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Peters, J.-U.</span><span> </span><span class="NLM_article-title">Pharmacological Promiscuity and Molecular Properties</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed.; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">62</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=47-62&author=J.-U.+Petersauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch3%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.-U.%26atitle%3DPharmacological%2520Promiscuity%2520and%2520Molecular%2520Properties%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D47%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Hopkins, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overington, J. P.</span><span> </span><span class="NLM_article-title">Can we rationally design promiscuous drugs?</span> <span class="citation_source-journal">Curr. Opin. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">136</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1016%2Fj.sbi.2006.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=16442279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsFOjsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=127-136&issue=1&author=A.+L.+Hopkinsauthor=J.+S.+Masonauthor=J.+P.+Overington&title=Can+we+rationally+design+promiscuous+drugs%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Can we rationally design promiscuous drugs?</span></div><div class="casAuthors">Hopkins, Andrew L.; Mason, Jonathan S.; Overington, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-136</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Structure-based drug design is now used widely in modern medicinal chem.  The application of structural biol. to medicinal chem. has heralded the 'rational drug design' vision of discovering exquisitely selective ligands.  However, recent advances in post-genomic biol. are indicating that polypharmacol. may be a necessary trait for the efficacy of many drugs, therefore questioning the 'one drug, one target' assumption of current rational drug design.  By combining advances in chemoinformatics and structural biol., it might be possible to rationally design the next generation of promiscuous drugs with polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQWdh60x9AHrVg90H21EOLACvtfcHk0lhXMOO3tEbezA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsFOjsrc%253D&md5=8f9e95a41976b8e3ac790f2fff2c406f</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2006.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2006.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26atitle%3DCan%2520we%2520rationally%2520design%2520promiscuous%2520drugs%253F%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2006%26volume%3D16%26issue%3D1%26spage%3D127%26epage%3D136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><div class="note"><p class="first last">For a description of the BioPrint panel, see:</p></div><span class="NLM_contrib-group">Krejsa, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horvath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogalski, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penzotti, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migeon, J. C.</span><span> </span><span class="NLM_article-title">Predicting ADME properties and side-effects: The BioPrint approach</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">470</span><span class="NLM_x">–</span> <span class="NLM_lpage">480</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2003&pages=470-480&issue=4&author=C.+M.+Krejsaauthor=D.+Horvathauthor=S.+L.+Rogalskiauthor=J.+E.+Penzottiauthor=B.+Maoauthor=F.+Barbosaauthor=J.+C.+Migeon&title=Predicting+ADME+properties+and+side-effects%3A+The+BioPrint+approach"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKrejsa%26aufirst%3DC.%2BM.%26aulast%3DHorvath%26aufirst%3DD.%26aulast%3DRogalski%26aufirst%3DS.%2BL.%26aulast%3DPenzotti%26aufirst%3DJ.%2BE.%26aulast%3DMao%26aufirst%3DB.%26aulast%3DBarbosa%26aufirst%3DF.%26aulast%3DMigeon%26aufirst%3DJ.%2BC.%26atitle%3DPredicting%2520ADME%2520properties%2520and%2520side-effects%253A%2520The%2520BioPrint%2520approach%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2003%26volume%3D6%26issue%3D4%26spage%3D470%26epage%3D480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Peters, J.-U.</span><span> </span><span class="NLM_article-title">Opportunities and Challenges in Polypharmacological Drug Discovery</span>; AAPS Annual Meeting and Exposition, Chicago, October 14–18,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Peters%2C+J.-U.+Opportunities+and+Challenges+in+Polypharmacological+Drug+Discovery%3B+AAPS+Annual+Meeting+and+Exposition%2C+Chicago%2C+October+14%E2%80%9318%2C+2012."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1002%2F9781118098141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.-U.%26atitle%3DOpportunities%2520and%2520Challenges%2520in%2520Polypharmacological%2520Drug%2520Discovery%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Whitlock, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fish, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fray, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stobie, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakenhut, F.</span><span> </span><span class="NLM_article-title">Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">2896</span><span class="NLM_x">–</span> <span class="NLM_lpage">2899</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=2896-2899&issue=9&author=G.+A.+Whitlockauthor=P.+V.+Fishauthor=M.+J.+Frayauthor=A.+Stobieauthor=F.+Wakenhut&title=Pyridyl-phenyl+ether+monoamine+reuptake+inhibitors%3A+Impact+of+lipophilicity+on+dual+SNRI+pharmacology+and+off-target+promiscuity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWhitlock%26aufirst%3DG.%2BA.%26aulast%3DFish%26aufirst%3DP.%2BV.%26aulast%3DFray%26aufirst%3DM.%2BJ.%26aulast%3DStobie%26aufirst%3DA.%26aulast%3DWakenhut%26aufirst%3DF.%26atitle%3DPyridyl-phenyl%2520ether%2520monoamine%2520reuptake%2520inhibitors%253A%2520Impact%2520of%2520lipophilicity%2520on%2520dual%2520SNRI%2520pharmacology%2520and%2520off-target%2520promiscuity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26issue%3D9%26spage%3D2896%26epage%3D2899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springthorpe, B.</span><span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision-making in medicinal chemistry</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">881</span><span class="NLM_x">–</span> <span class="NLM_lpage">890</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&issue=11&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0ljnAEYqxeLfyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26issue%3D11%26spage%3D881%26epage%3D890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wager, T.</span><span> </span><span class="NLM_article-title">Physicochemical drug properties associated with in vivo toxicological outcomes: a review</span> <span class="citation_source-journal">Expert Opin. Drug Metab. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">921</span><span class="NLM_x">–</span> <span class="NLM_lpage">931</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1517%2F17425250903042318" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=19519283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1MXovVCjtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=921-931&issue=8&author=D.+A.+Priceauthor=J.+Blaggauthor=L.+Jonesauthor=N.+Greeneauthor=T.+Wager&title=Physicochemical+drug+properties+associated+with+in+vivo+toxicological+outcomes%3A+a+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Physicochemical drug properties associated with in vivo toxicological outcomes: a review</span></div><div class="casAuthors">Price, David A.; Blagg, Julian; Jones, Lyn; Greene, Nigel; Wager, Travis</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">921-931</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The genesis of any toxicol. or safety outcome is multifactorial and complex; for this reason, it can be difficult for drug discovery projects to factor the avoidance of toxicity outcomes into their target design.  A focus on readily measurable parameters from high-throughput in vitro assays (e.g., primary potency, clearance) is easier to handle and have become the mainstays of drug discovery projects.  However, the fundamental origins of adverse safety or toxicity findings can be considered as deriving from four parameters, all of which are in the control of the drug designer.  These can be described as primary pharmacol., off target pharmacol., the presence of a defined structural fragment that can be assocd. with adverse outcomes and the overall physicochem. properties of the mol. that may predispose it to adverse outcomes.  In the drug discovery community, there has been recognition for many years of the influence of physicochem. drug properties (in particular lipophilicity) on the toxicol. profile of compds., and recent research is now beginning to quantify that risk in a probabilistic sense.  This review focuses on the overall properties of classes of mols. that are assocd. with an increased probability of adverse outcomes in in vivo studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU8kwwUsaFIrVg90H21EOLACvtfcHk0ljnAEYqxeLfyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXovVCjtb0%253D&md5=bd1cca3634afda14de2f8aa115d7d55e</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1517%2F17425250903042318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425250903042318%26sid%3Dliteratum%253Aachs%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DL.%26aulast%3DGreene%26aufirst%3DN.%26aulast%3DWager%26aufirst%3DT.%26atitle%3DPhysicochemical%2520drug%2520properties%2520associated%2520with%2520in%2520vivo%2520toxicological%2520outcomes%253A%2520a%2520review%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2009%26volume%3D5%26issue%3D8%26spage%3D921%26epage%3D931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">van de Waterbeemd, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, B. C.</span><span> </span><span class="NLM_article-title">Lipophilicity in PK design: methyl, ethyl, futile</span> <span class="citation_source-journal">J. Comput.-Aided Mol. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">273</span><span class="NLM_x">–</span> <span class="NLM_lpage">286</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1023%2FA%3A1008192010023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=11289080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitlWjtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2001&pages=273-286&issue=3&author=H.+van+de+Waterbeemdauthor=D.+A.+Smithauthor=B.+C.+Jones&title=Lipophilicity+in+PK+design%3A+methyl%2C+ethyl%2C+futile"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Lipophilicity in PK design: methyl, ethyl, futile</span></div><div class="casAuthors">Van de Waterbeemd, Han; Smith, Dennis A.; Jones, Barry C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computer-Aided Molecular Design</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">273-286</span>CODEN:
                <span class="NLM_cas:coden">JCADEQ</span>;
        ISSN:<span class="NLM_cas:issn">0920-654X</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">A review with 39 refs.  Lipophilicity, often expressed as distribution coeffs. (log D) in octanol/water, is an important physicochem. parameter influencing processes such as oral absorption, brain uptake and various pharmacokinetic (PK) properties.  Increasing log D values increases oral absorption, plasma protein binding and vol. of distribution.  However, more lipophilic compds. also become more vulnerable to P 450 metab., leading to higher clearance.  Mol. size and hydrogen bonding capacity are two other properties often considered as important for membrane permeation and pharmacokinetics.  Interrelationships among these physicochem. properties are discussed.  Increasing size (mol. wt.) often gives higher potency, but inevitably also leads to either higher lipophilicity, and hence poorer dissoln./soly., or to more hydrogen bonding capacity, which limits oral absorption.  Differences in optimal properties between gastrointestinal absorption and uptake into the brain are addressed.  Special attention is given to the desired lipophilicity of CNS drugs.  In examples using β-blockers, Ca channel antagonists and peptidic renin inhibitors we will demonstrate how potency and pharmacokinetic properties need to be balanced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohNJonr7f2hbVg90H21EOLACvtfcHk0lijAyzIURxRMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitlWjtLo%253D&md5=04f94add93edc2b1a211bb53f676d908</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1023%2FA%3A1008192010023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1008192010023%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bde%2BWaterbeemd%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DJones%26aufirst%3DB.%2BC.%26atitle%3DLipophilicity%2520in%2520PK%2520design%253A%2520methyl%252C%2520ethyl%252C%2520futile%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2001%26volume%3D15%26issue%3D3%26spage%3D273%26epage%3D286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Arnott, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planey, S. L.</span><span> </span><span class="NLM_article-title">The influence of lipophilicity in drug discovery and design</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">863</span><span class="NLM_x">–</span> <span class="NLM_lpage">875</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=863-875&issue=10&author=J.+A.+Arnottauthor=S.+L.+Planey&title=The+influence+of+lipophilicity+in+drug+discovery+and+design"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DArnott%26aufirst%3DJ.%2BA.%26aulast%3DPlaney%26aufirst%3DS.%2BL.%26atitle%3DThe%2520influence%2520of%2520lipophilicity%2520in%2520drug%2520discovery%2520and%2520design%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2012%26volume%3D7%26issue%3D10%26spage%3D863%26epage%3D875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Yildirim, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cusick, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barabasi, A.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vidal, M.</span><span> </span><span class="NLM_article-title">Drug-target network</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">1119</span><span class="NLM_x">–</span> <span class="NLM_lpage">1126</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=1119-1126&issue=10&author=M.+A.+Yildirimauthor=K.-I.+Gohauthor=M.+E.+Cusickauthor=A.-L.+Barabasiauthor=M.+Vidal&title=Drug-target+network"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYildirim%26aufirst%3DM.%2BA.%26aulast%3DGoh%26aufirst%3DK.-I.%26aulast%3DCusick%26aufirst%3DM.%2BE.%26aulast%3DBarabasi%26aufirst%3DA.-L.%26aulast%3DVidal%26aufirst%3DM.%26atitle%3DDrug-target%2520network%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26issue%3D10%26spage%3D1119%26epage%3D1126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Gregori-Puigjane, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestres, J.</span><span> </span><span class="NLM_article-title">A ligand-based approach to mining the chemogenomic space of drugs</span> <span class="citation_source-journal">Comb. Chem. High Throughput Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">669</span><span class="NLM_x">–</span> <span class="NLM_lpage">676</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=669-676&issue=8&author=E.+Gregori-Puigjaneauthor=J.+Mestres&title=A+ligand-based+approach+to+mining+the+chemogenomic+space+of+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGregori-Puigjane%26aufirst%3DE.%26aulast%3DMestres%26aufirst%3DJ.%26atitle%3DA%2520ligand-based%2520approach%2520to%2520mining%2520the%2520chemogenomic%2520space%2520of%2520drugs%26jtitle%3DComb.%2520Chem.%2520High%2520Throughput%2520Screening%26date%3D2008%26volume%3D11%26issue%3D8%26spage%3D669%26epage%3D676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Cases, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestres, J.</span><span> </span><span class="NLM_article-title">A chemogenomic approach to drug discovery: focus on cardiovascular diseases</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x"> (</span><span class="NLM_issue">9/10</span><span class="NLM_x">) </span> <span class="NLM_fpage">479</span><span class="NLM_x">–</span> <span class="NLM_lpage">485</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=479-485&issue=9%2F10&author=M.+Casesauthor=J.+Mestres&title=A+chemogenomic+approach+to+drug+discovery%3A+focus+on+cardiovascular+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCases%26aufirst%3DM.%26aulast%3DMestres%26aufirst%3DJ.%26atitle%3DA%2520chemogenomic%2520approach%2520to%2520drug%2520discovery%253A%2520focus%2520on%2520cardiovascular%2520diseases%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26issue%3D9%252F10%26spage%3D479%26epage%3D485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Brianso, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrascosa, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oprea, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestres, J.</span><span> </span><span class="NLM_article-title">Cross-pharmacology analysis of G protein-coupled receptors</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">15</span><span class="NLM_x">) </span> <span class="NLM_fpage">1956</span><span class="NLM_x">–</span> <span class="NLM_lpage">1963</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.2174%2F156802611796391285" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVSmsLzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=1956-1963&issue=15&author=F.+Briansoauthor=M.+C.+Carrascosaauthor=T.+I.+Opreaauthor=J.+Mestres&title=Cross-pharmacology+analysis+of+G+protein-coupled+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Cross-pharmacology analysis of G protein-coupled receptors</span></div><div class="casAuthors">Brianso, Ferran; Carrascosa, Maria C.; Oprea, Tudor I.; Mestres, Jordi</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1956-1963</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The degree of applicability of chemogenomic approaches to protein families depends on the accuracy and completeness of pharmacol. data and the corresponding level of pharmacol. similarity obsd. among their protein members.  The recent public domain availability of pharmacol. data for thousands of small mols. on 204 G protein-coupled receptors (GPCRs) provides a firm basis for an in-depth cross-pharmacol. anal. of this superfamily.  The no. of protein targets included in the cross-pharmacol. profile of the different GPCRs changes significantly upon varying the ligand similarity and binding affinity criteria.  However, with the exception of muscarinic receptors, aminergic GPCRs distinguish themselves from the rest of the members in the family by their remarkably high levels of pharmacol. similarity among them.  Clusters of non-GPCR targets related by cross-pharmacol. with particular GPCRs are identified and the implications for unwanted side-effects, as well as for repurposing opportunities, discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcxMaSMU_YxLVg90H21EOLACvtfcHk0lijAyzIURxRMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVSmsLzO&md5=7805626c0844e84d16b56ed953823486</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.2174%2F156802611796391285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611796391285%26sid%3Dliteratum%253Aachs%26aulast%3DBrianso%26aufirst%3DF.%26aulast%3DCarrascosa%26aufirst%3DM.%2BC.%26aulast%3DOprea%26aufirst%3DT.%2BI.%26aulast%3DMestres%26aufirst%3DJ.%26atitle%3DCross-pharmacology%2520analysis%2520of%2520G%2520protein-coupled%2520receptors%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26issue%3D15%26spage%3D1956%26epage%3D1963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Mestres, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregori-Puigjane, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valverde, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sole, R.</span><span> </span><span class="NLM_article-title">V.The topology of drug-target interaction networks: Implicit dependence on drug properties and target families</span> <span class="citation_source-journal">Mol. BioSyst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1051</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1039%2Fb905821b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1MXps1Kksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=1051&issue=9&author=J.+Mestresauthor=E.+Gregori-Puigjaneauthor=S.+Valverdeauthor=R.+Sole&title=V.The+topology+of+drug-target+interaction+networks%3A+Implicit+dependence+on+drug+properties+and+target+families"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">The topology of drug-target interaction networks: Implicit dependence on drug properties and target families</span></div><div class="casAuthors">Mestres, Jordi; Gregori-Puigjane, Elisabet; Valverde, Sergi; Sole, Ricard V.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1051-1057</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-206X</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The availability of interaction data between small mol. drugs and protein targets has increased substantially in recent years.  Using seven different databases, we were able to assemble a total of 4767 unique interactions between 802 drugs and 480 targets, which means that on av. every drug is currently acknowledged to interact with 6 targets.  The application of network theory to the anal. of these data reveals an unexpectedly complex picture of drug-target interactions.  The results confirm that the topol. of drug-target networks depends implicitly on data completeness, drug properties, and target families.  The implications for drug discovery are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNAnnU4e6Jl7Vg90H21EOLACvtfcHk0lijAyzIURxRMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXps1Kksbo%253D&md5=a0999bf0521936fba03400554411e8d7</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1039%2Fb905821b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb905821b%26sid%3Dliteratum%253Aachs%26aulast%3DMestres%26aufirst%3DJ.%26aulast%3DGregori-Puigjane%26aufirst%3DE.%26aulast%3DValverde%26aufirst%3DS.%26aulast%3DSole%26aufirst%3DR.%26atitle%3DV.The%2520topology%2520of%2520drug-target%2520interaction%2520networks%253A%2520Implicit%2520dependence%2520on%2520drug%2520properties%2520and%2520target%2520families%26jtitle%3DMol.%2520BioSyst.%26date%3D2009%26volume%3D5%26issue%3D9%26spage%3D1051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Jalencas, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestres, J.</span><span> </span><span class="NLM_article-title">On the origins of drug polypharmacology</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">87</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=80-87&issue=1&author=X.+Jalencasauthor=J.+Mestres&title=On+the+origins+of+drug+polypharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJalencas%26aufirst%3DX.%26aulast%3DMestres%26aufirst%3DJ.%26atitle%3DOn%2520the%2520origins%2520of%2520drug%2520polypharmacology%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26issue%3D1%26spage%3D80%26epage%3D87" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Azzaoui, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faller, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitebread, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacoby, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, L.</span><span> </span><span class="NLM_article-title">Modeling promiscuity based on in vitro safety pharmacology profiling data</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">874</span><span class="NLM_x">–</span> <span class="NLM_lpage">880</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=874-880&issue=6&author=K.+Azzaouiauthor=J.+Hamonauthor=B.+Fallerauthor=S.+Whitebreadauthor=E.+Jacobyauthor=A.+Benderauthor=J.+L.+Jenkinsauthor=L.+Urban&title=Modeling+promiscuity+based+on+in+vitro+safety+pharmacology+profiling+data"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAzzaoui%26aufirst%3DK.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DFaller%26aufirst%3DB.%26aulast%3DWhitebread%26aufirst%3DS.%26aulast%3DJacoby%26aufirst%3DE.%26aulast%3DBender%26aufirst%3DA.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26aulast%3DUrban%26aufirst%3DL.%26atitle%3DModeling%2520promiscuity%2520based%2520on%2520in%2520vitro%2520safety%2520pharmacology%2520profiling%2520data%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26issue%3D6%26spage%3D874%26epage%3D880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Haupt, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daminelli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, M.</span><span> </span><span class="NLM_article-title">Drug promiscuity in PDB: protein binding site similarity is key</span> <span class="citation_source-journal">PLoS ONE</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">e65894</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e65894&issue=6&author=V.+J.+Hauptauthor=S.+Daminelliauthor=M.+Schroeder&title=Drug+promiscuity+in+PDB%3A+protein+binding+site+similarity+is+key"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHaupt%26aufirst%3DV.%2BJ.%26aulast%3DDaminelli%26aufirst%3DS.%26aulast%3DSchroeder%26aufirst%3DM.%26atitle%3DDrug%2520promiscuity%2520in%2520PDB%253A%2520protein%2520binding%2520site%2520similarity%2520is%2520key%26jtitle%3DPLoS%2520ONE%26date%3D2013%26volume%3D8%26issue%3D6%26spage%3De65894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Hughes, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeCrescenzo, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devraj, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellsworth, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fobian, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbs, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilles, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krieger-Burke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loesel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wager, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiteley, Y. Z.</span><span> </span><span class="NLM_article-title">Physiochemical drug properties associated with in vivo toxicological outcomes</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">4872</span><span class="NLM_x">–</span> <span class="NLM_lpage">4875</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1016%2Fj.bmcl.2008.07.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=18691886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsbjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4872-4875&issue=17&author=J.+D.+Hughesauthor=J.+Blaggauthor=D.+A.+Priceauthor=S.+Baileyauthor=G.+A.+DeCrescenzoauthor=R.+V.+Devrajauthor=E.+Ellsworthauthor=Y.+M.+Fobianauthor=M.+E.+Gibbsauthor=R.+W.+Gillesauthor=N.+Greeneauthor=E.+Huangauthor=T.+Krieger-Burkeauthor=J.+Loeselauthor=T.+Wagerauthor=Y.+Z.+Whiteley&title=Physiochemical+drug+properties+associated+with+in+vivo+toxicological+outcomes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Physiochemical drug properties associated with in vivo toxicological outcomes</span></div><div class="casAuthors">Hughes, Jason D.; Blagg, Julian; Price, David A.; Bailey, Simon; DeCrescenzo, Gary A.; Devraj, Rajesh V.; Ellsworth, Edmund; Fobian, Yvette M.; Gibbs, Michael E.; Gilles, Richard W.; Greene, Nigel; Huang, Enoch; Krieger-Burke, Teresa; Loesel, Jens; Wager, Travis; Whiteley, Larry; Zhang, Yao</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4872-4875</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Relationships between physicochem. drug properties and toxicity were inferred from a data set consisting of animal in vivo toleration (IVT) studies on 245 preclin. Pfizer compds.; an increased likelihood of toxic events was found for less polar, more lipophilic compds.  This trend held across a wide range of types of toxicity and across a broad swath of chem. space.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPMmGEpVF0mbVg90H21EOLACvtfcHk0liZrDuEXR2iig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsbjE&md5=80ea5ced359112a363f38b3545cd7646</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.07.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.07.071%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DJ.%2BD.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DDeCrescenzo%26aufirst%3DG.%2BA.%26aulast%3DDevraj%26aufirst%3DR.%2BV.%26aulast%3DEllsworth%26aufirst%3DE.%26aulast%3DFobian%26aufirst%3DY.%2BM.%26aulast%3DGibbs%26aufirst%3DM.%2BE.%26aulast%3DGilles%26aufirst%3DR.%2BW.%26aulast%3DGreene%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DE.%26aulast%3DKrieger-Burke%26aufirst%3DT.%26aulast%3DLoesel%26aufirst%3DJ.%26aulast%3DWager%26aufirst%3DT.%26aulast%3DWhiteley%26aufirst%3DY.%2BZ.%26atitle%3DPhysiochemical%2520drug%2520properties%2520associated%2520with%2520in%2520vivo%2520toxicological%2520outcomes%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26issue%3D17%26spage%3D4872%26epage%3D4875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Young, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, D. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luscombe, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, A. P.</span><span> </span><span class="NLM_article-title">Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">17–18</span><span class="NLM_x">) </span> <span class="NLM_fpage">822</span><span class="NLM_x">–</span> <span class="NLM_lpage">830</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1016%2Fj.drudis.2011.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=21704184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFCru7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=822-830&issue=17%E2%80%9318&author=R.+J.+Youngauthor=D.+V.+Greenauthor=C.+N.+Luscombeauthor=A.+P.+Hill&title=Getting+physical+in+drug+discovery+II%3A+the+impact+of+chromatographic+hydrophobicity+measurements+and+aromaticity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity</span></div><div class="casAuthors">Young, Robert J.; Green, Darren V. S.; Luscombe, Christopher N.; Hill, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">17/18</span>),
    <span class="NLM_cas:pages">822-830</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Here, we review the performance of chromatog. hydrophobicity measurements in a data set of 100 000 GlaxoSmithKline compds., demonstrating the advantages of the method over octanol-water partitioning and highlighting new insights for drug discovery.  The value of chromatog. measurements, vs. other hydrophobicity ests., was supported by improved relationships with soly., permeation, cytochrome P450s, intrinsic clearance, hERG binding and promiscuity.  We also obsd. marked differentiation of the relative influence of intrinsic and effective hydrophobicity.  The summing of hydrophobicity values plus arom. ring count [log D pH7.4 (or log P) + #Ar], indicated a wide relevance for simplistic property forecast indexes' in developability assays, clearly enhanced by chromatog. values; therefore establishing new foundations for enriching property-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmIJyWi-DBW7Vg90H21EOLACvtfcHk0liZrDuEXR2iig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFCru7vF&md5=22788603a45aa77537e8666433473d14</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DGreen%26aufirst%3DD.%2BV.%26aulast%3DLuscombe%26aufirst%3DC.%2BN.%26aulast%3DHill%26aufirst%3DA.%2BP.%26atitle%3DGetting%2520physical%2520in%2520drug%2520discovery%2520II%253A%2520the%2520impact%2520of%2520chromatographic%2520hydrophobicity%2520measurements%2520and%2520aromaticity%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26issue%3D17%25E2%2580%259318%26spage%3D822%26epage%3D830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Sturm, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desaphy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rognan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kellenberger, E.</span><span> </span><span class="NLM_article-title">Structural Insights into the Molecular Basis of the Ligand Promiscuity</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">2410</span><span class="NLM_x">–</span> <span class="NLM_lpage">2421</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci300196g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1GhurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=2410-2421&issue=9&author=N.+Sturmauthor=J.+Desaphyauthor=R.+J.+Quinnauthor=D.+Rognanauthor=E.+Kellenberger&title=Structural+Insights+into+the+Molecular+Basis+of+the+Ligand+Promiscuity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Insights into the Molecular Basis of the Ligand Promiscuity</span></div><div class="casAuthors">Sturm, Noe; Desaphy, Jeremy; Quinn, Ronald J.; Rognan, Didier; Kellenberger, Esther</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2410-2421</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Selectivity is a key factor in drug development.  In this paper, we questioned the Protein Data Bank to better understand the reasons for the promiscuity of bioactive compds.  We assembled a data set of >1000 pairs of three-dimensional structures of complexes between a "drug-like" ligand (as its physicochem. properties overlap that of approved drugs) and two distinct "druggable" protein targets (as their binding sites are likely to accommodate "drug-like" ligands).  Studying the similarity between the ligand-binding sites in the different targets revealed that the lack of selectivity of a ligand can be due (i) to the fact that Nature has created the same binding pocket in different proteins, which do not necessarily have otherwise sequence or fold similarity, or (ii) to specific characteristics of the ligand itself.  In particular, we demonstrated that many ligands can adapt to different protein environments by changing their conformation, by using different chem. moieties to anchor to different targets, or by adopting unusual extreme binding modes (e.g., only apolar contact between the ligand and the protein, even though polar groups are present on the ligand or at the protein surface).  Lastly, we provided new elements in support to the recent studies which suggest that the promiscuity of a ligand might be inferred from its mol. complexity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaq6HYzXDUl7Vg90H21EOLACvtfcHk0lhVRf4mQUM2OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1GhurbF&md5=808b3192a4110ec1bb26ddd41165d60d</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Fci300196g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci300196g%26sid%3Dliteratum%253Aachs%26aulast%3DSturm%26aufirst%3DN.%26aulast%3DDesaphy%26aufirst%3DJ.%26aulast%3DQuinn%26aufirst%3DR.%2BJ.%26aulast%3DRognan%26aufirst%3DD.%26aulast%3DKellenberger%26aufirst%3DE.%26atitle%3DStructural%2520Insights%2520into%2520the%2520Molecular%2520Basis%2520of%2520the%2520Ligand%2520Promiscuity%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2012%26volume%3D52%26issue%3D9%26spage%3D2410%26epage%3D2421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Lovering, F.</span><span> </span><span class="NLM_article-title">Escape from Flatland 2: complexity and promiscuity</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">515</span><span class="NLM_x">–</span> <span class="NLM_lpage">519</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=515-519&issue=3&author=F.+Lovering&title=Escape+from+Flatland+2%3A+complexity+and+promiscuity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26atitle%3DEscape%2520from%2520Flatland%25202%253A%2520complexity%2520and%2520promiscuity%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26issue%3D3%26spage%3D515%26epage%3D519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muresan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engkvist, O.</span><span> </span><span class="NLM_article-title">Investigation of the Relationship between Topology and Selectivity for Drug-like Molecules</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x"> (</span><span class="NLM_issue">21</span><span class="NLM_x">) </span> <span class="NLM_fpage">7709</span><span class="NLM_x">–</span> <span class="NLM_lpage">7714</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1008456" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7709-7714&issue=21&author=Y.+Yangauthor=H.+Chenauthor=I.+Nilssonauthor=S.+Muresanauthor=O.+Engkvist&title=Investigation+of+the+Relationship+between+Topology+and+Selectivity+for+Drug-like+Molecules"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fjm1008456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1008456%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DNilsson%26aufirst%3DI.%26aulast%3DMuresan%26aufirst%3DS.%26aulast%3DEngkvist%26aufirst%3DO.%26atitle%3DInvestigation%2520of%2520the%2520Relationship%2520between%2520Topology%2520and%2520Selectivity%2520for%2520Drug-like%2520Molecules%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D21%26spage%3D7709%26epage%3D7714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Hann, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, G.</span><span> </span><span class="NLM_article-title">Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery</span> <span class="citation_source-journal">J. Chem. Inf. Comp. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">856</span><span class="NLM_x">–</span> <span class="NLM_lpage">864</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci000403i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivFynt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2001&pages=856-864&issue=3&author=M.+M.+Hannauthor=A.+R.+Leachauthor=G.+Harper&title=Molecular+Complexity+and+Its+Impact+on+the+Probability+of+Finding+Leads+for+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery</span></div><div class="casAuthors">Hann, Michael M.; Leach, Andrew R.; Harper, Gavin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Computer Sciences</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">856-864</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">0095-2338</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Using a simple model of ligand-receptor interactions, the interactions between ligands and receptors of varying complexities are studied and the probabilities of binding calcd.  It is obsd. that as the systems become more complex the chance of observing a useful interaction for a randomly chosen ligand falls dramatically.  The implications of this for the design of combinatorial libraries is explored.  A large set of drug leads and optimized compds. is profiled using several different properties relevant to mol. recognition.  The changes obsd. for these properties during the drug optimization phase support the hypothesis that less complex mols. are more common starting points for the discovery of drugs.  An extreme example of the use of simple mols. for directed screening against thrombin is provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7ed40mt9qb7Vg90H21EOLACvtfcHk0lhVRf4mQUM2OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivFynt7w%253D&md5=e89e76c8fb83fc5012369ae30f20e6b7</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fci000403i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci000403i%26sid%3Dliteratum%253Aachs%26aulast%3DHann%26aufirst%3DM.%2BM.%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DHarper%26aufirst%3DG.%26atitle%3DMolecular%2520Complexity%2520and%2520Its%2520Impact%2520on%2520the%2520Probability%2520of%2520Finding%2520Leads%2520for%2520Drug%2520Discovery%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Comp.%2520Sci.%26date%3D2001%26volume%3D41%26issue%3D3%26spage%3D856%26epage%3D864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Leach, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hann, M. M.</span><span> </span><span class="NLM_article-title">Molecular complexity and fragment-based drug discovery: ten years on</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">489</span><span class="NLM_x">–</span> <span class="NLM_lpage">496</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1016%2Fj.cbpa.2011.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=21665521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvFCltrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=489-496&issue=4&author=A.+R.+Leachauthor=M.+M.+Hann&title=Molecular+complexity+and+fragment-based+drug+discovery%3A+ten+years+on"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular complexity and fragment-based drug discovery: ten years on</span></div><div class="casAuthors">Leach, Andrew R.; Hann, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">489-496</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We review the concept of mol. complexity in the context of the very simple model of mol. interactions that we introduced over 10 years ago.  A summary is presented of efforts to validate this simple model using screening data.  The relationship between the complexity model and the problem of sampling chem. space is discussed, together with the relevance of these theor. concepts to fragment-based drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNcMgTT6eLC7Vg90H21EOLACvtfcHk0lhVRf4mQUM2OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvFCltrg%253D&md5=19c2d65de80a8bab1059468828da6ce2</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2011.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2011.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DHann%26aufirst%3DM.%2BM.%26atitle%3DMolecular%2520complexity%2520and%2520fragment-based%2520drug%2520discovery%253A%2520ten%2520years%2520on%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D15%26issue%3D4%26spage%3D489%26epage%3D496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Andrews, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lloyd, E. J.</span><span> </span><span class="NLM_article-title">Molecular conformation and biological activity of central nervous system active drugs</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">393</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2Fmed.2610020404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADyaL38XmtVOmsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1982&pages=355-393&issue=4&author=P.+R.+Andrewsauthor=E.+J.+Lloyd&title=Molecular+conformation+and+biological+activity+of+central+nervous+system+active+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular conformation and biological activity of central nervous system active drugs</span></div><div class="casAuthors">Andrews, P. R.; Lloyd, E. J.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">355-93</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    </div><div class="casAbstract">A review with 135 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUsPpCqHa32bVg90H21EOLACvtfcHk0liXz3oBYoOpOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XmtVOmsro%253D&md5=d6bd57937e21326815b5ca8adc831247</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1002%2Fmed.2610020404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.2610020404%26sid%3Dliteratum%253Aachs%26aulast%3DAndrews%26aufirst%3DP.%2BR.%26aulast%3DLloyd%26aufirst%3DE.%2BJ.%26atitle%3DMolecular%2520conformation%2520and%2520biological%2520activity%2520of%2520central%2520nervous%2520system%2520active%2520drugs%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D1982%26volume%3D2%26issue%3D4%26spage%3D355%26epage%3D393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">LaBella, Frank, S.</span><span> </span><span class="NLM_article-title">Molecular basis for binding promiscuity of antagonist drugs</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">S1</span><span class="NLM_x">–</span> <span class="NLM_lpage">S8</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1991&pages=S1-S8&issue=Suppl&author=S.+LaBella%2C+Frank&title=Molecular+basis+for+binding+promiscuity+of+antagonist+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLaBella%252C%2BFrank%26aufirst%3DS.%26atitle%3DMolecular%2520basis%2520for%2520binding%2520promiscuity%2520of%2520antagonist%2520drugs%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1991%26volume%3D42%26issue%3DSuppl%26spage%3DS1%26epage%3DS8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Targeting cancer with small molecule kinase inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fnrc2559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=19104514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1yg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=28-39&issue=1&author=J.+Zhangauthor=P.+L.+Yangauthor=N.+S.+Gray&title=Targeting+cancer+with+small+molecule+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer with small molecule kinase inhibitors</span></div><div class="casAuthors">Zhang, Jianming; Yang, Priscilla L.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-39</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiol. constraints on growth and survival.  To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small mol. inhibitors for a host of other kinases that are implicated in cancer and other diseases.  Herein we discuss the current challenges in the field, such as designing selective inhibitors and developing strategies to overcome resistance mutations.  This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriSM3BN_uEz7Vg90H21EOLACvtfcHk0liXz3oBYoOpOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1yg&md5=35bc38f414cd21eef5e61ce181b580fb</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1038%2Fnrc2559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2559%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520cancer%2520with%2520small%2520molecule%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26issue%3D1%26spage%3D28%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Kirchner, S.</span><span> </span><span class="NLM_article-title">Kinases as Antitargets in Genotoxicity</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed., <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">63</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=63-81&author=S.+Kirchnerauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch4%26sid%3Dliteratum%253Aachs%26aulast%3DKirchner%26aufirst%3DS.%26atitle%3DKinases%2520as%2520Antitargets%2520in%2520Genotoxicity%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D63%26epage%3D81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Aronov, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McClain, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuver Moody, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murcko, M. A.</span><span> </span><span class="NLM_article-title">Kinase-likeness and Kinase-Privileged Fragments: Toward Virtual Polypharmacology</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">1214</span><span class="NLM_x">–</span> <span class="NLM_lpage">1222</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701021b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1214-1222&issue=5&author=A.+M.+Aronovauthor=B.+McClainauthor=C.+Stuver+Moodyauthor=M.+A.+Murcko&title=Kinase-likeness+and+Kinase-Privileged+Fragments%3A+Toward+Virtual+Polypharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Fjm701021b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701021b%26sid%3Dliteratum%253Aachs%26aulast%3DAronov%26aufirst%3DA.%2BM.%26aulast%3DMcClain%26aufirst%3DB.%26aulast%3DStuver%2BMoody%26aufirst%3DC.%26aulast%3DMurcko%26aufirst%3DM.%2BA.%26atitle%3DKinase-likeness%2520and%2520Kinase-Privileged%2520Fragments%253A%2520Toward%2520Virtual%2520Polypharmacology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D5%26spage%3D1214%26epage%3D1222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Brandt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, J.</span><span> </span><span class="NLM_article-title">Small kinase assay panels can provide a measure of selectivity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x"> (</span><span class="NLM_issue">20</span><span class="NLM_x">) </span> <span class="NLM_fpage">5861</span><span class="NLM_x">–</span> <span class="NLM_lpage">5863</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5861-5863&issue=20&author=P.+Brandtauthor=A.+J.+Jensenauthor=J.+Nilsson&title=Small+kinase+assay+panels+can+provide+a+measure+of+selectivity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrandt%26aufirst%3DP.%26aulast%3DJensen%26aufirst%3DA.%2BJ.%26aulast%3DNilsson%26aufirst%3DJ.%26atitle%3DSmall%2520kinase%2520assay%2520panels%2520can%2520provide%2520a%2520measure%2520of%2520selectivity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26issue%3D20%26spage%3D5861%26epage%3D5863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Supuran, C. T.</span><span> </span><span class="NLM_article-title">Carbonic Anhydrases: Off Targets, Add-on Activities, or Emerging Novel Targets?</span> In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed., <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">459</span><span class="NLM_x">–</span> <span class="NLM_lpage">491</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch23" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=459-491&author=C.+T.+Supuranauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch23%26sid%3Dliteratum%253Aachs%26aulast%3DSupuran%26aufirst%3DC.%2BT.%26atitle%3DCarbonic%2520Anhydrases%253A%2520Off%2520Targets%252C%2520Add-on%2520Activities%252C%2520or%2520Emerging%2520Novel%2520Targets%253F%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D459%26epage%3D491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Yadav, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patil, V. M.</span><span> </span><span class="NLM_article-title">Recent advances in studies on hydroxamates as matrix metalloproteinase inhibitors: a review</span> <span class="citation_source-journal">Curr.Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">1704</span><span class="NLM_x">–</span> <span class="NLM_lpage">1722</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.2174%2F092986711795471329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpslOiu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=1704-1722&issue=11&author=R.+K.+Yadavauthor=S.+P.+Guptaauthor=P.+K.+Sharmaauthor=V.+M.+Patil&title=Recent+advances+in+studies+on+hydroxamates+as+matrix+metalloproteinase+inhibitors%3A+a+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in studies on hydroxamates as matrix metalloproteinase inhibitors: a review</span></div><div class="casAuthors">Yadav, R. K.; Gupta, S. P.; Sharma, P. K.; Patil, V. M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1704-1722</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Matrix metalloproteinases (MMPs) are a large family of calcium-dependent zinc- contg. endopeptidases, which are responsible for the tissue remodeling and degrdn. of the extracellular matrix (ECM), including collagens, elastins, gelatin, matrix glycoproteins, and proteoglycan.  The inappropriate expression of these MMPs constitutes part of the pathogenic mechanism in several diseases, therefore they are subject to inhibition.  They can be inhibited by endogenous proteinase inhibitors such as 2-macroglobulin or by the family of tissue inhibitors of metalloproteinases (TIMPs), which are glycoproteins of mol. wt. 21-30 kDa, consisting of 184-194 amino acid residues.  Recently, many different classes of synthetic inhibitors have been developed in which the hydroxamic acidbased class of compds. (hydroxamates) have been most widely studied, as their hydroxamic acid group (CONHOH) enables them to act as a bidentate ligand with the zinc ion present in MMPs, leading to much stronger interaction with the receptor as compared to any other class of inhibitors.  The present review describes in detail the recent development on this class of MMP inihibitors.  Compds. like 12,17e, f, g and h, 45j, 45k, 50f, 62a, 63a, and 63b have been reported to be highly promising for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_CdMJAf2dWbVg90H21EOLACvtfcHk0lhrcprOLiA5Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpslOiu7c%253D&md5=a9a615faba9fca05433b6e2a452e2e56</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.2174%2F092986711795471329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711795471329%26sid%3Dliteratum%253Aachs%26aulast%3DYadav%26aufirst%3DR.%2BK.%26aulast%3DGupta%26aufirst%3DS.%2BP.%26aulast%3DSharma%26aufirst%3DP.%2BK.%26aulast%3DPatil%26aufirst%3DV.%2BM.%26atitle%3DRecent%2520advances%2520in%2520studies%2520on%2520hydroxamates%2520as%2520matrix%2520metalloproteinase%2520inhibitors%253A%2520a%2520review%26jtitle%3DCurr.Med.%2520Chem.%26date%3D2011%26volume%3D18%26issue%3D11%26spage%3D1704%26epage%3D1722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Lounkine, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keiser, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitebread, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikhailov, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doak, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cote, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, L.</span><span> </span><span class="NLM_article-title">Large-scale prediction and testing of drug activity on side-effect targets</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">486</span><span class="NLM_x"> (</span><span class="NLM_issue">7403</span><span class="NLM_x">) </span> <span class="NLM_fpage">361</span><span class="NLM_x">–</span> <span class="NLM_lpage">367</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fnature11159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=22722194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFyrtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=486&publication_year=2012&pages=361-367&issue=7403&author=E.+Lounkineauthor=M.+J.+Keiserauthor=S.+Whitebreadauthor=D.+Mikhailovauthor=J.+Hamonauthor=J.+L.+Jenkinsauthor=P.+Lavanauthor=E.+Weberauthor=A.+K.+Doakauthor=S.+Coteauthor=B.+K.+Shoichetauthor=L.+Urban&title=Large-scale+prediction+and+testing+of+drug+activity+on+side-effect+targets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Large-scale prediction and testing of drug activity on side-effect targets</span></div><div class="casAuthors">Lounkine, Eugen; Keiser, Michael J.; Whitebread, Steven; Mikhailov, Dmitri; Hamon, Jacques; Jenkins, Jeremy L.; Lavan, Paul; Weber, Eckhard; Doak, Allison K.; Cote, Serge; Shoichet, Brian K.; Urban, Laszlo</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">486</span>
        (<span class="NLM_cas:issue">7403</span>),
    <span class="NLM_cas:pages">361-367</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Discovering the unintended off-targets' that predict adverse drug reactions is daunting by empirical methods alone.  Drugs can act on several protein targets, some of which can be unrelated by conventional mol. metrics, and hundreds of proteins have been implicated in side effects.  Here we use a computational strategy to predict the activity of 656 marketed drugs on 73 unintended side-effect' targets.  Approx. half of the predictions were confirmed, either from proprietary databases unknown to the method or by new exptl. assays.  Affinities for these new off-targets ranged from 1 nM to 30 μM.  To explore relevance, we developed an assocn. metric to prioritize those new off-targets that explained side effects better than any known target of a given drug, creating a drug-target-adverse drug reaction network.  Among these new assocns. was the prediction that the abdominal pain side effect of the synthetic estrogen chlorotrianisene was mediated through its newly discovered inhibition of the enzyme cyclooxygenase-1.  The clin. relevance of this inhibition was borne out in whole human blood platelet aggregation assays.  This approach may have wide application to de-risking toxicol. liabilities in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5sVjfn4mgLLVg90H21EOLACvtfcHk0lhrcprOLiA5Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFyrtb0%253D&md5=9c133b839d9527818a27a5834e4dfe11</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1038%2Fnature11159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11159%26sid%3Dliteratum%253Aachs%26aulast%3DLounkine%26aufirst%3DE.%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DWhitebread%26aufirst%3DS.%26aulast%3DMikhailov%26aufirst%3DD.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26aulast%3DLavan%26aufirst%3DP.%26aulast%3DWeber%26aufirst%3DE.%26aulast%3DDoak%26aufirst%3DA.%2BK.%26aulast%3DCote%26aufirst%3DS.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DUrban%26aufirst%3DL.%26atitle%3DLarge-scale%2520prediction%2520and%2520testing%2520of%2520drug%2520activity%2520on%2520side-effect%2520targets%26jtitle%3DNature%26date%3D2012%26volume%3D486%26issue%3D7403%26spage%3D361%26epage%3D367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Keiser, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armbruster, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernsberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span> </span><span class="NLM_article-title">Relating protein pharmacology by ligand chemistry</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">197</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fnbt1284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=17287757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOrsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=197-206&issue=2&author=M.+J.+Keiserauthor=B.+L.+Rothauthor=B.+N.+Armbrusterauthor=P.+Ernsbergerauthor=J.+J.+Irwinauthor=B.+K.+Shoichet&title=Relating+protein+pharmacology+by+ligand+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Relating protein pharmacology by ligand chemistry</span></div><div class="casAuthors">Keiser, Michael J.; Roth, Bryan L.; Armbruster, Blaine N.; Ernsberger, Paul; Irwin, John J.; Shoichet, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">197-206</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The identification of protein function based on biol. information is an area of intense research.  Here the authors consider a complementary technique that quant. groups and relates proteins based on the chem. similarity of their ligands.  The authors began with 65,000 ligands annotated into sets for hundreds of drug targets.  The similarity score between each set was calcd. using ligand topol.  A statistical model was developed to rank the significance of the resulting similarity scores, which are expressed as a min. spanning tree to map the sets together.  Although these maps are connected solely by chem. similarity, biol. sensible clusters nevertheless emerged.  Links among unexpected targets also emerged, among them that methadone, emetine and loperamide (Imodium) may antagonize muscarinic M3, α2 adrenergic and neurokinin NK2 receptors, resp.  These predictions were subsequently confirmed exptl.  Relating receptors by ligand chem. organizes biol. to reveal unexpected relationships that may be assayed using the ligands themselves.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNKEMguhmluLVg90H21EOLACvtfcHk0lhrcprOLiA5Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOrsLo%253D&md5=1b7373d52563fca5fe1e893d85f70573</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1038%2Fnbt1284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1284%26sid%3Dliteratum%253Aachs%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DArmbruster%26aufirst%3DB.%2BN.%26aulast%3DErnsberger%26aufirst%3DP.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26atitle%3DRelating%2520protein%2520pharmacology%2520by%2520ligand%2520chemistry%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26issue%3D2%26spage%3D197%26epage%3D206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Keiser, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laggner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbas, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hufeisen, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuijer, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matos, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whaley, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glennon, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, K. L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, L. R.</span><span> </span><span class="NLM_article-title">Predicting new molecular targets for known drugs</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x"> (</span><span class="NLM_issue">7270</span><span class="NLM_x">) </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fnature08506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=19881490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlers7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=175-181&issue=7270&author=M.+J.+Keiserauthor=V.+Setolaauthor=J.+J.+Irwinauthor=C.+Laggnerauthor=A.+I.+Abbasauthor=S.+J.+Hufeisenauthor=N.+H.+Jensenauthor=M.+B.+Kuijerauthor=R.+C.+Matosauthor=T.+B.+Tranauthor=R.+Whaleyauthor=R.+A.+Glennonauthor=J.+Hertauthor=K.+L.+H.+Thomasauthor=D.+D.+Edwardsauthor=B.+K.+Shoichetauthor=L.+R.+Roth&title=Predicting+new+molecular+targets+for+known+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting new molecular targets for known drugs</span></div><div class="casAuthors">Keiser, Michael J.; Setola, Vincent; Irwin, John J.; Laggner, Christian; Abbas, Atheir I.; Hufeisen, Sandra J.; Jensen, Niels H.; Kuijer, Michael B.; Matos, Roberto C.; Tran, Thuy B.; Whaley, Ryan; Glennon, Richard A.; Hert, Jerome; Thomas, Kelan L. H.; Edwards, Douglas D.; Shoichet, Brian K.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7270</span>),
    <span class="NLM_cas:pages">175-181</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although drugs are intended to be selective, at least some bind to several physiol. targets, explaining side effects and efficacy.  Because many drug-target combinations exist, it would be useful to explore possible interactions computationally.  Here we compared 3665 US Food and Drug Administration (FDA)-approved and investigational drugs against hundreds of targets, defining each target by its ligands.  Chem. similarities between drugs and ligand sets predicted thousands of unanticipated assocns.  Thirty were tested exptl., including the antagonism of the β1 receptor by the transporter inhibitor Prozac, the inhibition of the 5-hydroxytryptamine (5-HT) transporter by the ion channel drug Vadilex, and antagonism of the histamine H4 receptor by the enzyme inhibitor Rescriptor.  Overall, 23 new drug-target assocns. were confirmed, five of which were potent (<100 nM).  The physiol. relevance of one, the drug N,N-dimethyltryptamine (DMT) on serotonergic receptors, was confirmed in a knockout mouse.  The chem. similarity approach is systematic and comprehensive, and may suggest side-effects and new indications for many drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozd-8cCXUskrVg90H21EOLACvtfcHk0lhrcprOLiA5Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlers7vO&md5=974e65f5d5b4dabde1a463c429215546</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1038%2Fnature08506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08506%26sid%3Dliteratum%253Aachs%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DLaggner%26aufirst%3DC.%26aulast%3DAbbas%26aufirst%3DA.%2BI.%26aulast%3DHufeisen%26aufirst%3DS.%2BJ.%26aulast%3DJensen%26aufirst%3DN.%2BH.%26aulast%3DKuijer%26aufirst%3DM.%2BB.%26aulast%3DMatos%26aufirst%3DR.%2BC.%26aulast%3DTran%26aufirst%3DT.%2BB.%26aulast%3DWhaley%26aufirst%3DR.%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26aulast%3DHert%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DK.%2BL.%2BH.%26aulast%3DEdwards%26aufirst%3DD.%2BD.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DRoth%26aufirst%3DL.%2BR.%26atitle%3DPredicting%2520new%2520molecular%2520targets%2520for%2520known%2520drugs%26jtitle%3DNature%26date%3D2009%26volume%3D462%26issue%3D7270%26spage%3D175%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Bender, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheiber, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azzaoui, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitebread, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, J. L.</span><span> </span><span class="NLM_article-title">Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">861</span><span class="NLM_x">–</span> <span class="NLM_lpage">873</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=861-873&issue=6&author=A.+Benderauthor=J.+Scheiberauthor=M.+Glickauthor=J.+W.+Daviesauthor=K.+Azzaouiauthor=J.+Hamonauthor=L.+Urbanauthor=S.+Whitebreadauthor=J.+L.+Jenkins&title=Analysis+of+pharmacology+data+and+the+prediction+of+adverse+drug+reactions+and+off-target+effects+from+chemical+structure"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DA.%26aulast%3DScheiber%26aufirst%3DJ.%26aulast%3DGlick%26aufirst%3DM.%26aulast%3DDavies%26aufirst%3DJ.%2BW.%26aulast%3DAzzaoui%26aufirst%3DK.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DUrban%26aufirst%3DL.%26aulast%3DWhitebread%26aufirst%3DS.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26atitle%3DAnalysis%2520of%2520pharmacology%2520data%2520and%2520the%2520prediction%2520of%2520adverse%2520drug%2520reactions%2520and%2520off-target%2520effects%2520from%2520chemical%2520structure%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26issue%3D6%26spage%3D861%26epage%3D873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">Perez-Nueno, V. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkatraman, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mavridis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ritchie, D. W.</span><span> </span><span class="NLM_article-title">Predicting drug promiscuity using spherical harmonic surface shape-based similarity comparisons</span> <span class="citation_source-journal">Open Conference Proc. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">129</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.2174%2F2210289201102010113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVShsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=113-129&author=V.+I.+Perez-Nuenoauthor=V.+Venkatramanauthor=L.+Mavridisauthor=D.+W.+Ritchie&title=Predicting+drug+promiscuity+using+spherical+harmonic+surface+shape-based+similarity+comparisons"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting drug promiscuity using spherical harmonic surface shape-based similarity comparisons</span></div><div class="casAuthors">Perez-Nueno, Violeta I.; Venkatraman, Vishwesh; Mavridis, Lazaros; Ritchie, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Open Conference Proceedings Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113-129</span>CODEN:
                <span class="NLM_cas:coden">OCPJC2</span>;
        ISSN:<span class="NLM_cas:issn">2210-2892</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Polypharmacol. is becoming an increasingly important aspect in drug design.  Pharmaceutical companies are discovering more and more cases in which multiple drugs bind to a given target (promiscuous targets) and in which a given drug binds to more than one target (promiscuous ligands).  These phenomena are clearly of great importance when considering drug side-effects.  In the last 4 years, more than 30 drugs have been tested against more than 40 novel secondary targets based on promiscuity predictions.  Current methods for predicting promiscuity typically aim to relate protein receptors according to their primary sequences, the similarity of their ligands, and more recently, the similarity of their ligand binding pockets.  Here, we present a spherical harmonic (SH) surface shape-based approach to predict rapidly promiscuous ligands and targets by comparing sets of SH ligand and protein shapes, resp.  We present details of our approach applied to a wide range of PDB complexes comprising ligands in a selected subset of the MDL Drug Data Report (MDDR) database which are distributed over 249 diverse pharmacol. targets.  The shape similarity of each ligand to each target's ligand set is quantified and used to predict promiscuity.  We also analyze the correlation between binding pocket and ligand shapes.  We compare our promiscuity predictions with exptl. activity values extd. from the BindingDB database.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXiXDlEVxlF7Vg90H21EOLACvtfcHk0linOFtQRGitYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVShsro%253D&md5=e1d2b8ece7f775cff0c9c0520fe1f06f</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.2174%2F2210289201102010113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F2210289201102010113%26sid%3Dliteratum%253Aachs%26aulast%3DPerez-Nueno%26aufirst%3DV.%2BI.%26aulast%3DVenkatraman%26aufirst%3DV.%26aulast%3DMavridis%26aufirst%3DL.%26aulast%3DRitchie%26aufirst%3DD.%2BW.%26atitle%3DPredicting%2520drug%2520promiscuity%2520using%2520spherical%2520harmonic%2520surface%2520shape-based%2520similarity%2520comparisons%26jtitle%3DOpen%2520Conference%2520Proc.%2520J.%26date%3D2011%26volume%3D2%26spage%3D113%26epage%3D129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Hopkins, A. L.</span><span> </span><span class="NLM_article-title">Drug discovery: Predicting promiscuity</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x"> (</span><span class="NLM_issue">7270</span><span class="NLM_x">) </span> <span class="NLM_fpage">167</span><span class="NLM_x">–</span> <span class="NLM_lpage">168</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=167-168&issue=7270&author=A.+L.+Hopkins&title=Drug+discovery%3A+Predicting+promiscuity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DDrug%2520discovery%253A%2520Predicting%2520promiscuity%26jtitle%3DNature%26date%3D2009%26volume%3D462%26issue%3D7270%26spage%3D167%26epage%3D168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Ekins, S.</span><span> </span><span class="NLM_article-title">Predicting undesirable drug interactions with promiscuous proteins in silico</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">276</span><span class="NLM_x">–</span> <span class="NLM_lpage">285</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=276-285&issue=6&author=S.+Ekins&title=Predicting+undesirable+drug+interactions+with+promiscuous+proteins+in+silico"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26atitle%3DPredicting%2520undesirable%2520drug%2520interactions%2520with%2520promiscuous%2520proteins%2520in%2520silico%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26issue%3D6%26spage%3D276%26epage%3D285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">Klabunde, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evers, A.</span><span> </span><span class="NLM_article-title">GPCR anti-target modeling: Pharmacophore models for biogenic amine binding GPCRs to avoid GPCR-mediated side-effects</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">876</span><span class="NLM_x">–</span> <span class="NLM_lpage">889</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=876-889&issue=5&author=T.+Klabundeauthor=A.+Evers&title=GPCR+anti-target+modeling%3A+Pharmacophore+models+for+biogenic+amine+binding+GPCRs+to+avoid+GPCR-mediated+side-effects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKlabunde%26aufirst%3DT.%26aulast%3DEvers%26aufirst%3DA.%26atitle%3DGPCR%2520anti-target%2520modeling%253A%2520Pharmacophore%2520models%2520for%2520biogenic%2520amine%2520binding%2520GPCRs%2520to%2520avoid%2520GPCR-mediated%2520side-effects%26jtitle%3DChemBioChem%26date%3D2005%26volume%3D6%26issue%3D5%26spage%3D876%26epage%3D889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">Zakharov, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagunin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filimonov, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poroikov, V. V.</span><span> </span><span class="NLM_article-title">Quantitative Prediction of Anti-target Interaction Profiles for Chemical Compounds</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">2378</span><span class="NLM_x">–</span> <span class="NLM_lpage">2385</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx300247r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=2378-2385&issue=11&author=A.+V.+Zakharovauthor=A.+A.+Laguninauthor=D.+A.+Filimonovauthor=V.+V.+Poroikov&title=Quantitative+Prediction+of+Anti-target+Interaction+Profiles+for+Chemical+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Ftx300247r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx300247r%26sid%3Dliteratum%253Aachs%26aulast%3DZakharov%26aufirst%3DA.%2BV.%26aulast%3DLagunin%26aufirst%3DA.%2BA.%26aulast%3DFilimonov%26aufirst%3DD.%2BA.%26aulast%3DPoroikov%26aufirst%3DV.%2BV.%26atitle%3DQuantitative%2520Prediction%2520of%2520Anti-target%2520Interaction%2520Profiles%2520for%2520Chemical%2520Compounds%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2012%26volume%3D25%26issue%3D11%26spage%3D2378%26epage%3D2385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group">Mestres, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregori-Puigjane, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valverde, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sole, R. V.</span><span> </span><span class="NLM_article-title">Data completeness-the Achilles heel of drug-target networks</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">983</span><span class="NLM_x">–</span> <span class="NLM_lpage">984</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=983-984&issue=9&author=J.+Mestresauthor=E.+Gregori-Puigjaneauthor=S.+Valverdeauthor=R.+V.+Sole&title=Data+completeness-the+Achilles+heel+of+drug-target+networks"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMestres%26aufirst%3DJ.%26aulast%3DGregori-Puigjane%26aufirst%3DE.%26aulast%3DValverde%26aufirst%3DS.%26aulast%3DSole%26aufirst%3DR.%2BV.%26atitle%3DData%2520completeness-the%2520Achilles%2520heel%2520of%2520drug-target%2520networks%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26issue%3D9%26spage%3D983%26epage%3D984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span> </span><span class="NLM_article-title">Compound promiscuity: what can we learn from current data?</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">13/14</span><span class="NLM_x">) </span> <span class="NLM_fpage">644</span><span class="NLM_x">–</span> <span class="NLM_lpage">650</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=644-650&issue=13%2F14&author=Y.+Huauthor=J.+Bajorath&title=Compound+promiscuity%3A+what+can+we+learn+from+current+data%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DY.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DCompound%2520promiscuity%253A%2520what%2520can%2520we%2520learn%2520from%2520current%2520data%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26issue%3D13%252F14%26spage%3D644%26epage%3D650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group">Paolini, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapland, R. H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Hoorn, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, A. L.</span><span> </span><span class="NLM_article-title">Global mapping of pharmacological space</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">805</span><span class="NLM_x">–</span> <span class="NLM_lpage">815</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=805-815&issue=7&author=G.+V.+Paoliniauthor=R.+H.+B.+Shaplandauthor=W.+P.+van+Hoornauthor=J.+S.+Masonauthor=A.+L.+Hopkins&title=Global+mapping+of+pharmacological+space"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPaolini%26aufirst%3DG.%2BV.%26aulast%3DShapland%26aufirst%3DR.%2BH.%2BB.%26aulast%3Dvan%2BHoorn%26aufirst%3DW.%2BP.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DGlobal%2520mapping%2520of%2520pharmacological%2520space%26jtitle%3DNat.%2520Biotechnol.%26date%3D2006%26volume%3D24%26issue%3D7%26spage%3D805%26epage%3D815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span> </span><span class="NLM_article-title">How Promiscuous Are Pharmaceutically Relevant Compounds? A Data-Driven Assessment</span> <span class="citation_source-journal">AAPS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">104</span><span class="NLM_x">–</span> <span class="NLM_lpage">111</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=104-111&issue=1&author=Y.+Huauthor=J.+Bajorath&title=How+Promiscuous+Are+Pharmaceutically+Relevant+Compounds%3F+A+Data-Driven+Assessment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DY.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DHow%2520Promiscuous%2520Are%2520Pharmaceutically%2520Relevant%2520Compounds%253F%2520A%2520Data-Driven%2520Assessment%26jtitle%3DAAPS%2520J.%26date%3D2013%26volume%3D15%26issue%3D1%26spage%3D104%26epage%3D111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span> </span><span class="NLM_article-title">What is the Likelihood of an Active Compound to Be Promiscuous? Systematic Assessment of Compound Promiscuity on the Basis of PubChem Confirmatory Bioassay Data</span> <span class="citation_source-journal">AAPS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">808</span><span class="NLM_x">–</span> <span class="NLM_lpage">815</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=808-815&issue=3&author=Y.+Huauthor=J.+Bajorath&title=What+is+the+Likelihood+of+an+Active+Compound+to+Be+Promiscuous%3F+Systematic+Assessment+of+Compound+Promiscuity+on+the+Basis+of+PubChem+Confirmatory+Bioassay+Data"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DY.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DWhat%2520is%2520the%2520Likelihood%2520of%2520an%2520Active%2520Compound%2520to%2520Be%2520Promiscuous%253F%2520Systematic%2520Assessment%2520of%2520Compound%2520Promiscuity%2520on%2520the%2520Basis%2520of%2520PubChem%2520Confirmatory%2520Bioassay%2520Data%26jtitle%3DAAPS%2520J.%26date%3D2013%26volume%3D15%26issue%3D3%26spage%3D808%26epage%3D815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group">Overington, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Lazikani, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, A. L.</span><span> </span><span class="NLM_article-title">How many drug targets are there?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">993</span><span class="NLM_x">–</span> <span class="NLM_lpage">996</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=993-996&issue=12&author=J.+P.+Overingtonauthor=B.+Al-Lazikaniauthor=A.+L.+Hopkins&title=How+many+drug+targets+are+there%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26aulast%3DAl-Lazikani%26aufirst%3DB.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DHow%2520many%2520drug%2520targets%2520are%2520there%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26issue%3D12%26spage%3D993%26epage%3D996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group">Garcia-Serna, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestres, J.</span><span> </span><span class="NLM_article-title">Chemical probes for biological systems</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">3/4</span><span class="NLM_x">) </span> <span class="NLM_fpage">99</span><span class="NLM_x">–</span> <span class="NLM_lpage">106</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=99-106&issue=3%2F4&author=R.+Garcia-Sernaauthor=J.+Mestres&title=Chemical+probes+for+biological+systems"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Serna%26aufirst%3DR.%26aulast%3DMestres%26aufirst%3DJ.%26atitle%3DChemical%2520probes%2520for%2520biological%2520systems%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26issue%3D3%252F4%26spage%3D99%26epage%3D106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group">Ruffolo, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feuerstein, G. Z.</span><span> </span><span class="NLM_article-title">Carvedilol case history: the discovery and development of the first β-blocker for the treatment of congestive heart failure</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">85</span><span class="NLM_x">–</span> <span class="NLM_lpage">89</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=85-89&issue=1&author=R.+R.+Ruffoloauthor=G.+Z.+Feuerstein&title=Carvedilol+case+history%3A+the+discovery+and+development+of+the+first+%CE%B2-blocker+for+the+treatment+of+congestive+heart+failure"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRuffolo%26aufirst%3DR.%2BR.%26aulast%3DFeuerstein%26aufirst%3DG.%2BZ.%26atitle%3DCarvedilol%2520case%2520history%253A%2520the%2520discovery%2520and%2520development%2520of%2520the%2520first%2520%25CE%25B2-blocker%2520for%2520the%2520treatment%2520of%2520congestive%2520heart%2520failure%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2006%26volume%3D1%26issue%3D1%26spage%3D85%26epage%3D89" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group">Carreira, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteiro, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goncalves, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Providencia, L. A.</span><span> </span><span class="NLM_article-title">Carvedilol: just another beta-blocker or a powerful cardioprotector?</span> <span class="citation_source-journal">Cardiovasc. Hematol. Disorders: Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">257</span><span class="NLM_x">–</span> <span class="NLM_lpage">266</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.2174%2F187152906779010746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1SmsrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=257-266&issue=4&author=R.+S.+Carreiraauthor=P.+Monteiroauthor=L.+M.+Goncalvesauthor=L.+A.+Providencia&title=Carvedilol%3A+just+another+beta-blocker+or+a+powerful+cardioprotector%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Carvedilol: just another beta-blocker or a powerful cardioprotector?</span></div><div class="casAuthors">Carreira, R. S.; Monteiro, P.; Goncalves, L. M.; Providencia, L. A.</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular & Hematological Disorders: Drug Targets</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">257-266</span>CODEN:
                <span class="NLM_cas:coden">CHDDBU</span>;
        ISSN:<span class="NLM_cas:issn">1871-529X</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Beta-blockers have been used to treat ischemic heart disease, due to neg. chronotropic and inotropic properties, thus inducing a decrease in myocardial consumption of oxygen and nutrients, allowing a better balance between nutritional needs and the supply provided by the coronary blood flow.  Recent developments in cell biol. allowed to understand that not all beta-blockers are equal, as their intracellular mechanisms of action can be very different.  This paper focuses on Carvedilol, a non-selective beta-blocker with alfa-blocker properties, currently used to treat hypertension, heart failure, and coronary artery disease.  Effects of Carvedilol on cardiac mitochondria, their relation to its antioxidant properties, and how these can improve cardiomyocyte resistance to aggression and cardiac function are discussed.  The authors begin by depicting the effect of Carvedilol on mitochondrial parameters, namely, oxidative phosphorylation, calcium homeostasis, and energy prodn.  Then they focus on the mitochondrial permeability transition (MPT) and how the antioxidant properties of Carvedilol can be used to minimize oxidative stress, a powerful inducer of MPT.  Carvedilol is also highlighted as an enzyme modulator, focusing on its importance to prevent doxorubicin (DOX) cardiotoxicity.  The mitochondrial-related mechanism of cardioprotection involving Carvedilol is also addressed, as the authors discuss some clin. pieces of evidence showing the importance of mechanisms previously depicted.  In conclusion, based upon its mol. mechanisms of action, Carvedilol seems to be an unique beta-blocker.  These unique characteristics can help understand the pos. impact of Carvedilol on the prognosis of patients with heart disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYA7M3Es-rYLVg90H21EOLACvtfcHk0lhI0oSFX968iA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1SmsrvK&md5=6346a3d8aff3ae3055a8bb9f437736a3</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.2174%2F187152906779010746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152906779010746%26sid%3Dliteratum%253Aachs%26aulast%3DCarreira%26aufirst%3DR.%2BS.%26aulast%3DMonteiro%26aufirst%3DP.%26aulast%3DGoncalves%26aufirst%3DL.%2BM.%26aulast%3DProvidencia%26aufirst%3DL.%2BA.%26atitle%3DCarvedilol%253A%2520just%2520another%2520beta-blocker%2520or%2520a%2520powerful%2520cardioprotector%253F%26jtitle%3DCardiovasc.%2520Hematol.%2520Disorders%253A%2520Drug%2520Targets%26date%3D2006%26volume%3D6%26issue%3D4%26spage%3D257%26epage%3D266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group">Fishback, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, R. R.</span><span> </span><span class="NLM_article-title">Sigma receptors: Potential targets for a new class of antidepressant drug</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">127</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">271</span><span class="NLM_x">–</span> <span class="NLM_lpage">282</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1016%2Fj.pharmthera.2010.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC3cXosV2htro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2010&pages=271-282&issue=3&author=J.+A.+Fishbackauthor=M.+J.+Robsonauthor=Y.-T.+Xuauthor=R.+R.+Matsumoto&title=Sigma+receptors%3A+Potential+targets+for+a+new+class+of+antidepressant+drug"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma receptors: Potential targets for a new class of antidepressant drug</span></div><div class="casAuthors">Fishback, James A.; Robson, Matthew J.; Xu, Yan-Tong; Matsumoto, Rae R.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">271-282</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Despite the widespread and devastating impact of depression on society, our current understanding of its pathogenesis is limited.  Likewise, existing treatments are inadequate, providing relief to only a subset of people suffering from depression.  The search for more effective antidepressant drugs includes the investigation of new mol. targets.  Among them, current data suggests that sigma receptors are involved in multiple processes effecting antidepressant-like actions in vivo and in vitro.  This review summarizes accumulated evidence supporting a role for sigma receptors in antidepressant effects and provides a conceptual framework for delineating their potential roles over the course of antidepressant treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLgoPQq-jsCbVg90H21EOLACvtfcHk0lhRd7ZmM647CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXosV2htro%253D&md5=8bc10680890e356f82ccd21b7885e9db</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2010.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2010.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DFishback%26aufirst%3DJ.%2BA.%26aulast%3DRobson%26aufirst%3DM.%2BJ.%26aulast%3DXu%26aufirst%3DY.-T.%26aulast%3DMatsumoto%26aufirst%3DR.%2BR.%26atitle%3DSigma%2520receptors%253A%2520Potential%2520targets%2520for%2520a%2520new%2520class%2520of%2520antidepressant%2520drug%26jtitle%3DPharmacol.%2520Ther.%26date%3D2010%26volume%3D127%26issue%3D3%26spage%3D271%26epage%3D282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group">Cobos, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Entrena, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nieto, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cendan, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">del Pozo, E.</span><span> </span><span class="NLM_article-title">Pharmacology and therapeutic potential of sigma1 receptor ligands</span> <span class="citation_source-journal">Curr. Neuropharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">344</span><span class="NLM_x">–</span> <span class="NLM_lpage">366</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.2174%2F157015908787386113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVSqu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=344-366&issue=4&author=E.+J.+Cobosauthor=J.+M.+Entrenaauthor=F.+R.+Nietoauthor=C.+M.+Cendanauthor=E.+del+Pozo&title=Pharmacology+and+therapeutic+potential+of+sigma1+receptor+ligands"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology and therapeutic potential of sigma1 receptor ligands</span></div><div class="casAuthors">Cobos, E. J.; Entrena, J. M.; Nieto, F. R.; Cendan, C. M.; del Pozo, E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Neuropharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">344-366</span>CODEN:
                <span class="NLM_cas:coden">CNUEAN</span>;
        ISSN:<span class="NLM_cas:issn">1875-6190</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Sigma (σ) receptors, initially described as a subtype of opioid receptors, are now considered unique receptors.  Pharmacol. studies have distinguished two types of σ receptors, termed σ1 and σ2.  Of these two subtypes, the σ1 receptor has been cloned in humans and rodents, and its amino acid sequence shows no homol. with other mammalian proteins.  Several psychoactive drugs show high to moderate affinity for σ1 receptors, including the antipsychotic haloperidol, the antidepressant drugs fluvoxamine and sertraline, and the psychostimulants cocaine and methamphetamine; in addn., the anticonvulsant drug phenytoin allosterically modulates σ1 receptors.  Certain neurosteroids are known to interact with σ1 receptors, and have been proposed to be their endogenous ligands.  These receptors are located in the plasma membrane and in subcellular membranes, particularly in the endoplasmic reticulum, where they play a modulatory role in intracellular Ca2+ signaling.  Sigma1 receptors also play a modulatory role in the activity of some ion channels and in several neurotransmitter systems, mainly in glutamatergic neurotransmission.  In accordance with their widespread modulatory role, σ1 receptor ligands have been proposed to be useful in several therapeutic fields such as amnesic and cognitive deficits, depression and anxiety, schizophrenia, analgesia, and against some effects of drugs of abuse (such as cocaine and methamphetamine).  In this review we provide an overview of the present knowledge of σ1 receptors, focusing on σ1 ligand neuropharmacol. and the role of σ1 receptors in behavioral animal studies, which have contributed greatly to the potential therapeutic applications of σ1 ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTkDMnDR6uN7Vg90H21EOLACvtfcHk0lhRd7ZmM647CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVSqu7w%253D&md5=37895c10c7ef1bb7077d0782f73d5776</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.2174%2F157015908787386113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157015908787386113%26sid%3Dliteratum%253Aachs%26aulast%3DCobos%26aufirst%3DE.%2BJ.%26aulast%3DEntrena%26aufirst%3DJ.%2BM.%26aulast%3DNieto%26aufirst%3DF.%2BR.%26aulast%3DCendan%26aufirst%3DC.%2BM.%26aulast%3Ddel%2BPozo%26aufirst%3DE.%26atitle%3DPharmacology%2520and%2520therapeutic%2520potential%2520of%2520sigma1%2520receptor%2520ligands%26jtitle%3DCurr.%2520Neuropharmacol.%26date%3D2008%26volume%3D6%26issue%3D4%26spage%3D344%26epage%3D366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group">Smith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, E. F.</span><span> </span><span class="NLM_article-title">Drug withdrawals and the lessons within</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">38</span><span class="NLM_x">–</span> <span class="NLM_lpage">45</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2006&pages=38-45&issue=1&author=D.+A.+Smithauthor=E.+F.+Schmid&title=Drug+withdrawals+and+the+lessons+within"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DSchmid%26aufirst%3DE.%2BF.%26atitle%3DDrug%2520withdrawals%2520and%2520the%2520lessons%2520within%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2006%26volume%3D9%26issue%3D1%26spage%3D38%26epage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group">Issa, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Bebber, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nidamarthy, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haas, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alldredge, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wachter, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bates, D. W.</span><span> </span><span class="NLM_article-title">Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends</span> <span class="citation_source-journal">Curr. Drug Safety</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">177</span><span class="NLM_x">–</span> <span class="NLM_lpage">185</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.2174%2F157488607781668855" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFGqtbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=177-185&issue=3&author=A.+M.+Issaauthor=K.+A.+Phillipsauthor=S.+Van+Bebberauthor=H.+G.+Nidamarthyauthor=K.+E.+Lasserauthor=J.+S.+Haasauthor=B.+K.+Alldredgeauthor=R.+M.+Wachterauthor=D.+W.+Bates&title=Drug+withdrawals+in+the+United+States%3A+a+systematic+review+of+the+evidence+and+analysis+of+trends"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends</span></div><div class="casAuthors">Issa, Amalia M.; Phillips, Kathryn A.; Van Bebber, Stephanie; Nidamarthy, Hima G.; Lasser, Karen E.; Haas, Jennifer S.; Alldredge, Brian K.; Wachter, Robert M.; Bates, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Safety</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">177-185</span>CODEN:
                <span class="NLM_cas:coden">CDSUBQ</span>;
        ISSN:<span class="NLM_cas:issn">1574-8863</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  There have been a no. of highly publicized safety-based drug withdrawals in the United States in recent years.  We conducted a review of drugs withdrawn since 1993 and examd. trends in drug withdrawals.  Our objective was to det. the frequency and characteristics of withdrawn drugs and trends since 1993, and to discuss the implications of the findings.  We found that a mean of 1.5 drugs per yr have been withdrawn since 1993, and that the no. of withdrawals has not increased over time.  However, some recent drug withdrawals have impacted large nos. of people.  The rate of withdrawals alone is not an adequate measure of the status of drug safety in the US, and there is a serious dearth of data that can be used to examine the impact of drug withdrawals.  Although drug withdrawals are an important issue to address, drug safety policies need to be developed within the broader context of drug safety and effectiveness.  A comprehensive approach will be needed to address the improvement of drug safety.  We propose improvements to the evidence base to increase drug safety and assess how new scientific evidence can be incorporated into drug safety efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoylL9cuj41PrVg90H21EOLACvtfcHk0lhRd7ZmM647CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFGqtbjI&md5=33dce2a8204f3c5f6bdcc3a90d133aa3</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.2174%2F157488607781668855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157488607781668855%26sid%3Dliteratum%253Aachs%26aulast%3DIssa%26aufirst%3DA.%2BM.%26aulast%3DPhillips%26aufirst%3DK.%2BA.%26aulast%3DVan%2BBebber%26aufirst%3DS.%26aulast%3DNidamarthy%26aufirst%3DH.%2BG.%26aulast%3DLasser%26aufirst%3DK.%2BE.%26aulast%3DHaas%26aufirst%3DJ.%2BS.%26aulast%3DAlldredge%26aufirst%3DB.%2BK.%26aulast%3DWachter%26aufirst%3DR.%2BM.%26aulast%3DBates%26aufirst%3DD.%2BW.%26atitle%3DDrug%2520withdrawals%2520in%2520the%2520United%2520States%253A%2520a%2520systematic%2520review%2520of%2520the%2520evidence%2520and%2520analysis%2520of%2520trends%26jtitle%3DCurr.%2520Drug%2520Safety%26date%3D2007%26volume%3D2%26issue%3D3%26spage%3D177%26epage%3D185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group">Schuster, D.; Laggner, C.; Langer, T.</span><span> </span><span class="NLM_article-title">Why drugs fail - a study on side-effects in new chemical entities</span>. In  <span class="citation_source-book">Antitargets</span>; <span class="NLM_contrib-group">Vaz, R. J.; Klabunde, T.</span>, Eds.; <span class="NLM_publisher-name">Wiley-VCH</span>: <span class="NLM_publisher-loc">Weinheim</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=3-22&author=D.+Schuster&author=C.+Laggner&author=T.+Langerauthor=R.+J.+Vaz&author=T.+Klabunde&title=Antitargets"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DSchuster%26aufirst%3DD.%26atitle%3DWhy%2520drugs%2520fail%2520-%2520a%2520study%2520on%2520side-effects%2520in%2520new%2520chemical%2520entities%26btitle%3DAntitargets%26aulast%3DVaz%26aufirst%3DR.%2BJ.%26pub%3DWiley-VCH%26date%3D2008%26spage%3D3%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group">Kalgutkar, A. S.; Dalvie, D.; Obach, R. S.; Smith, D. A.</span> <span class="citation_source-book">Reactive Drug Metabolites</span>; <span class="NLM_publisher-name">Wiley-VCH</span>: <span class="NLM_publisher-loc">Weinheim</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=A.+S.+Kalgutkar&author=D.+Dalvie&author=R.+S.+Obach&author=D.+A.+Smith&title=Reactive+Drug+Metabolites"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26btitle%3DReactive%2520Drug%2520Metabolites%26pub%3DWiley-VCH%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group">Stepan, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aleo, M. D.</span><span> </span><span class="NLM_article-title">Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: A perspective based on the critical examination of trends in the top 200 drugs marketed in the United States</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1345</span><span class="NLM_x">–</span> <span class="NLM_lpage">1410</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx200168d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1345-1410&issue=9&author=A.+F.+Stepanauthor=D.+P.+Walkerauthor=J.+Baumanauthor=D.+A.+Priceauthor=T.+A.+Baillieauthor=A.+S.+Kalgutkarauthor=M.+D.+Aleo&title=Structural+alert%2Freactive+metabolite+concept+as+applied+in+medicinal+chemistry+to+mitigate+the+risk+of+idiosyncratic+drug+toxicity%3A+A+perspective+based+on+the+critical+examination+of+trends+in+the+top+200+drugs+marketed+in+the+United+States"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Ftx200168d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx200168d%26sid%3Dliteratum%253Aachs%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DWalker%26aufirst%3DD.%2BP.%26aulast%3DBauman%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DAleo%26aufirst%3DM.%2BD.%26atitle%3DStructural%2520alert%252Freactive%2520metabolite%2520concept%2520as%2520applied%2520in%2520medicinal%2520chemistry%2520to%2520mitigate%2520the%2520risk%2520of%2520idiosyncratic%2520drug%2520toxicity%253A%2520A%2520perspective%2520based%2520on%2520the%2520critical%2520examination%2520of%2520trends%2520in%2520the%2520top%2520200%2520drugs%2520marketed%2520in%2520the%2520United%2520States%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26issue%3D9%26spage%3D1345%26epage%3D1410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group">Muthas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasselgren, C.</span><span> </span><span class="NLM_article-title">A critical assessment of modeling safety-related drug attrition</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1058</span><span class="NLM_x">–</span> <span class="NLM_lpage">1065</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1058-1065&issue=7&author=D.+Muthasauthor=S.+Boyerauthor=C.+Hasselgren&title=A+critical+assessment+of+modeling+safety-related+drug+attrition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMuthas%26aufirst%3DD.%26aulast%3DBoyer%26aufirst%3DS.%26aulast%3DHasselgren%26aufirst%3DC.%26atitle%3DA%2520critical%2520assessment%2520of%2520modeling%2520safety-related%2520drug%2520attrition%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26issue%3D7%26spage%3D1058%26epage%3D1065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group">Kroeze, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hufeisen, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popadak, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renock, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernsberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayathilake, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">H1-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and Atypical Antipsychotic Drugs</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">519</span><span class="NLM_x">–</span> <span class="NLM_lpage">526</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=519-526&issue=3&author=W.+K.+Kroezeauthor=S.+J.+Hufeisenauthor=B.+A.+Popadakauthor=S.+M.+Renockauthor=S.+Steinbergauthor=P.+Ernsbergerauthor=K.+Jayathilakeauthor=H.+Y.+Meltzerauthor=B.+L.+Roth&title=H1-Histamine+Receptor+Affinity+Predicts+Short-Term+Weight+Gain+for+Typical+and+Atypical+Antipsychotic+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26aulast%3DHufeisen%26aufirst%3DS.%2BJ.%26aulast%3DPopadak%26aufirst%3DB.%2BA.%26aulast%3DRenock%26aufirst%3DS.%2BM.%26aulast%3DSteinberg%26aufirst%3DS.%26aulast%3DErnsberger%26aufirst%3DP.%26aulast%3DJayathilake%26aufirst%3DK.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DH1-Histamine%2520Receptor%2520Affinity%2520Predicts%2520Short-Term%2520Weight%2520Gain%2520for%2520Typical%2520and%2520Atypical%2520Antipsychotic%2520Drugs%26jtitle%3DNeuropsychopharmacology%26date%3D2003%26volume%3D28%26issue%3D3%26spage%3D519%26epage%3D526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group">Michelsen, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, J. M.</span><span> </span><span class="NLM_article-title">Cardiovascular effects of antipsychotics</span> <span class="citation_source-journal">Expert Rev. Neurotherap.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">829</span><span class="NLM_x">–</span> <span class="NLM_lpage">839</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1586%2F14737175.7.7.829" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=829-839&issue=7&author=J.+W.+Michelsenauthor=J.+M.+Meyer&title=Cardiovascular+effects+of+antipsychotics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1586%2F14737175.7.7.829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737175.7.7.829%26sid%3Dliteratum%253Aachs%26aulast%3DMichelsen%26aufirst%3DJ.%2BW.%26aulast%3DMeyer%26aufirst%3DJ.%2BM.%26atitle%3DCardiovascular%2520effects%2520of%2520antipsychotics%26jtitle%3DExpert%2520Rev.%2520Neurotherap.%26date%3D2007%26volume%3D7%26issue%3D7%26spage%3D829%26epage%3D839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group">Gray, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">Developing selectively nonselective drugs for treating CNS disorders</span> <span class="citation_source-journal">Drug Discovery Today: Therapeutic Strategies</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">413</span><span class="NLM_x">–</span> <span class="NLM_lpage">419</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=413-419&issue=4&author=J.+A.+Grayauthor=B.+L.+Roth&title=Developing+selectively+nonselective+drugs+for+treating+CNS+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DJ.%2BA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DDeveloping%2520selectively%2520nonselective%2520drugs%2520for%2520treating%2520CNS%2520disorders%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Therapeutic%2520Strategies%26date%3D2006%26volume%3D3%26issue%3D4%26spage%3D413%26epage%3D419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group">Riemer, C.</span><span> </span><span class="NLM_article-title">Antipsychotics</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed.; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">343</span><span class="NLM_x">–</span> <span class="NLM_lpage">362</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch17" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=343-362&author=C.+Riemerauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch17%26sid%3Dliteratum%253Aachs%26aulast%3DRiemer%26aufirst%3DC.%26atitle%3DAntipsychotics%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D343%26epage%3D362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group">Miyamoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyake, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarskog, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleischhacker, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieberman, J. A.</span><span> </span><span class="NLM_article-title">Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">1206</span><span class="NLM_x">–</span> <span class="NLM_lpage">1227</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fmp.2012.47" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=22584864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslahtrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=1206-1227&issue=12&author=S.+Miyamotoauthor=N.+Miyakeauthor=L.+F.+Jarskogauthor=W.+W.+Fleischhackerauthor=J.+A.+Lieberman&title=Pharmacological+treatment+of+schizophrenia%3A+a+critical+review+of+the+pharmacology+and+clinical+effects+of+current+and+future+therapeutic+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents</span></div><div class="casAuthors">Miyamoto, S.; Miyake, N.; Jarskog, L. F.; Fleischhacker, W. W.; Lieberman, J. A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1206-1227</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since the introduction of chlorpromazine and throughout the development of the new-generation antipsychotic drugs (APDs) beginning with clozapine, the D2 receptor has been the target for the development of APDs.  Pharmacol. actions to reduce neurotransmission through the D2 receptor have been the only proven therapeutic mechanism for psychoses.  A no. of novel non-D2 mechanisms of action of APDs have been explored over the past 40 years but none has definitively been proven effective.  At the same time, the effectiveness of treatments and range of outcomes for patients are far from satisfactory.  The relative success of antipsychotics in treating pos. symptoms is limited by the fact that a substantial no. of patients are refractory to current medications and by their lack of efficacy for neg. and cognitive symptoms, which often det. the level of functional impairment.  In addn., while the newer antipsychotics produce fewer motor side effects, safety and tolerability concerns about wt. gain and endocrinopathies have emerged.  Consequently, there is an urgent need for more effective and better-tolerated antipsychotic agents, and to identify new mol. targets and develop mechanistically novel compds. that can address the various symptom dimensions of schizophrenia.  In recent years, a variety of new exptl. pharmacol. approaches have emerged, including compds. acting on targets other than the dopamine D2 receptor.  However, there is still an ongoing debate as to whether drugs selective for singe mol. targets (i.e., magic bullets') or drugs selectively non-selective for several mol. targets (i.e., magic shotguns', multifunctional drugs' or intramol. polypharmacy') will lead to more effective new medications for schizophrenia.  In this context, current and future drug development strategies can be seen to fall into three categories: (1) refinement of precedented mechanisms of action to provide drugs of comparable or superior efficacy and side-effect profiles to existing APDs; (2) development of novel (and presumably non-D2) mechanism APDs; (3) development of compds. to be used as adjuncts to APDs to augment efficacy by targeting specific symptom dimensions of schizophrenia and particularly those not responsive to traditional APD treatment.  In addn., efforts are being made to det. if the products of susceptibility genes in schizophrenia, identified by genetic linkage and assocn. studies, may be viable targets for drug development.  Finally, a focus on early detection and early intervention aimed at halting or reversing progressive pathophysiol. processes in schizophrenia has gained great influence.  This has encouraged future drug development and therapeutic strategies that are neuroprotective.  This article provides an update and crit. review of the pharmacol. and clin. profiles of current APDs and drugs acting on novel targets with potential to be therapeutic agents in the future.  Mol. Psychiatry (2012) 17, 1206-1227; doi:10.1038/mp.2012.47; published online 15 May 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8qXbq8buMvLVg90H21EOLACvtfcHk0ljgNZUicVj09g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslahtrbI&md5=f0240f40a88e012daaebd216efc438b1</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1038%2Fmp.2012.47&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmp.2012.47%26sid%3Dliteratum%253Aachs%26aulast%3DMiyamoto%26aufirst%3DS.%26aulast%3DMiyake%26aufirst%3DN.%26aulast%3DJarskog%26aufirst%3DL.%2BF.%26aulast%3DFleischhacker%26aufirst%3DW.%2BW.%26aulast%3DLieberman%26aufirst%3DJ.%2BA.%26atitle%3DPharmacological%2520treatment%2520of%2520schizophrenia%253A%2520a%2520critical%2520review%2520of%2520the%2520pharmacology%2520and%2520clinical%2520effects%2520of%2520current%2520and%2520future%2520therapeutic%2520agents%26jtitle%3DMol.%2520Psychiatry%26date%3D2012%26volume%3D17%26issue%3D12%26spage%3D1206%26epage%3D1227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group">Emsley, R.</span><span> </span><span class="NLM_article-title">Drugs in development for the treatment of schizophrenia</span> <span class="citation_source-journal">Expert Opin. Investig. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">1103</span><span class="NLM_x">–</span> <span class="NLM_lpage">1118</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=1103-1118&issue=8&author=R.+Emsley&title=Drugs+in+development+for+the+treatment+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DR.%26atitle%3DDrugs%2520in%2520development%2520for%2520the%2520treatment%2520of%2520schizophrenia%26jtitle%3DExpert%2520Opin.%2520Investig.%2520Drugs%26date%3D2009%26volume%3D18%26issue%3D8%26spage%3D1103%26epage%3D1118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group">Yadav, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbas, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrell, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sciaky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroeze, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piel, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keiser, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deneris, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingrich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">The Presynaptic Component of the Serotonergic System is Required for Clozapine’s Efficacy</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">638</span><span class="NLM_x">–</span> <span class="NLM_lpage">651</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2011&pages=638-651&issue=3&author=P.+N.+Yadavauthor=A.+I.+Abbasauthor=M.+S.+Farrellauthor=V.+Setolaauthor=N.+Sciakyauthor=X.-P.+Huangauthor=W.+K.+Kroezeauthor=L.+K.+Crawfordauthor=D.+A.+Pielauthor=M.+J.+Keiserauthor=J.+J.+Irwinauthor=B.+K.+Shoichetauthor=E.+S.+Denerisauthor=J.+Gingrichauthor=S.+G.+Beckauthor=B.+L.+Roth&title=The+Presynaptic+Component+of+the+Serotonergic+System+is+Required+for+Clozapine%E2%80%99s+Efficacy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYadav%26aufirst%3DP.%2BN.%26aulast%3DAbbas%26aufirst%3DA.%2BI.%26aulast%3DFarrell%26aufirst%3DM.%2BS.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DSciaky%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26aulast%3DCrawford%26aufirst%3DL.%2BK.%26aulast%3DPiel%26aufirst%3DD.%2BA.%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DDeneris%26aufirst%3DE.%2BS.%26aulast%3DGingrich%26aufirst%3DJ.%26aulast%3DBeck%26aufirst%3DS.%2BG.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DThe%2520Presynaptic%2520Component%2520of%2520the%2520Serotonergic%2520System%2520is%2520Required%2520for%2520Clozapine%25E2%2580%2599s%2520Efficacy%26jtitle%3DNeuropsychopharmacology%26date%3D2011%26volume%3D36%26issue%3D3%26spage%3D638%26epage%3D651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group">Boran, A. D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyengar, R.</span><span> </span><span class="NLM_article-title">Systems approaches to polypharmacology and drug discovery</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Devel.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">297</span><span class="NLM_x">–</span> <span class="NLM_lpage">309</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=20443163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFCqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=297-309&issue=3&author=A.+D.+W.+Boranauthor=R.+Iyengar&title=Systems+approaches+to+polypharmacology+and+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Systems approaches to polypharmacology and drug discovery</span></div><div class="casAuthors">Boran, Aislyn D. W.; Iyengar, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">297-309</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">2040-3437</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Systems biol. uses exptl. and computational approaches to characterize large sample populations systematically, process large datasets, examine and analyze regulatory networks, and model reactions to det. how components are joined to form functional systems.  Systems biol. technologies, data and knowledge are particularly useful in understanding disease processes and drug actions.  An important area of integration between systems biol. and drug discovery is the concept of polypharmacol.: the treatment of diseases by modulating more than one target.  Polypharmacol. for complex diseases is likely to involve multiple drugs acting on distinct targets that are part of a network regulating physiol. responses.  This review discusses the current state of the systems-level understanding of diseases and both the therapeutic and adverse mechanisms of drug actions.  Drug-target networks can be used to identify multiple targets and to det. suitable combinations of drug targets or drugs.  Thus, the discovery of new drug therapies for complex diseases may be greatly aided by systems biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7lrjWtBIXI7Vg90H21EOLACvtfcHk0ljgNZUicVj09g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFCqtrk%253D&md5=b26a44ecd76a605816e08985ff8a576f</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoran%26aufirst%3DA.%2BD.%2BW.%26aulast%3DIyengar%26aufirst%3DR.%26atitle%3DSystems%2520approaches%2520to%2520polypharmacology%2520and%2520drug%2520discovery%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Devel.%26date%3D2010%26volume%3D13%26issue%3D3%26spage%3D297%26epage%3D309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group">Barabasi, A.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oltvai, Z. N.</span><span> </span><span class="NLM_article-title">Network biology: Understanding the cell’s functional organization</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">427</span><span class="NLM_x"> (</span><span class="NLM_issue">6977</span><span class="NLM_x">) </span> <span class="NLM_fpage">839</span><span class="NLM_x">–</span> <span class="NLM_lpage">843</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=427&publication_year=2004&pages=839-843&issue=6977&author=A.-L.+Barabasiauthor=Z.+N.+Oltvai&title=Network+biology%3A+Understanding+the+cell%E2%80%99s+functional+organization"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBarabasi%26aufirst%3DA.-L.%26aulast%3DOltvai%26aufirst%3DZ.%2BN.%26atitle%3DNetwork%2520biology%253A%2520Understanding%2520the%2520cell%25E2%2580%2599s%2520functional%2520organization%26jtitle%3DNature%26date%3D2004%26volume%3D427%26issue%3D6977%26spage%3D839%26epage%3D843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group">Csermely, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agoston, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pongor, S.</span><span> </span><span class="NLM_article-title">The efficiency of multi-target drugs: the network approach might help drug design</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">178</span><span class="NLM_x">–</span> <span class="NLM_lpage">182</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2005&pages=178-182&issue=4&author=P.+Csermelyauthor=V.+Agostonauthor=S.+Pongor&title=The+efficiency+of+multi-target+drugs%3A+the+network+approach+might+help+drug+design"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCsermely%26aufirst%3DP.%26aulast%3DAgoston%26aufirst%3DV.%26aulast%3DPongor%26aufirst%3DS.%26atitle%3DThe%2520efficiency%2520of%2520multi-target%2520drugs%253A%2520the%2520network%2520approach%2520might%2520help%2520drug%2520design%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2005%26volume%3D26%26issue%3D4%26spage%3D178%26epage%3D182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group">Korcsmaros, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szalay, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovacs, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Csermely, P.</span><span> </span><span class="NLM_article-title">How to design multi-target drugs: target search options in cellular networks</span> <span class="citation_source-journal">Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">799</span><span class="NLM_x">–</span> <span class="NLM_lpage">808</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=799-808&issue=6&author=T.+Korcsmarosauthor=M.+S.+Szalayauthor=C.+Bodeauthor=I.+A.+Kovacsauthor=P.+Csermely&title=How+to+design+multi-target+drugs%3A+target+search+options+in+cellular+networks"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKorcsmaros%26aufirst%3DT.%26aulast%3DSzalay%26aufirst%3DM.%2BS.%26aulast%3DBode%26aufirst%3DC.%26aulast%3DKovacs%26aufirst%3DI.%2BA.%26aulast%3DCsermely%26aufirst%3DP.%26atitle%3DHow%2520to%2520design%2520multi-target%2520drugs%253A%2520target%2520search%2520options%2520in%2520cellular%2520networks%26jtitle%3DDrug%2520Discovery%26date%3D2007%26volume%3D2%26issue%3D6%26spage%3D799%26epage%3D808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group">Azmi, A. S.</span><span> </span><span class="NLM_article-title">Network pharmacology for cancer drug discovery: are we there yet?</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">939</span><span class="NLM_x">–</span> <span class="NLM_lpage">941</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.4155%2Ffmc.12.44" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvVOrsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=939-941&issue=8&author=A.+S.+Azmi&title=Network+pharmacology+for+cancer+drug+discovery%3A+are+we+there+yet%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Network pharmacology for cancer drug discovery: are we there yet?</span></div><div class="casAuthors">Azmi, Asfar S.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">939-941</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The emergence of network biol. has improved the knowledge of multi-pathway interactions in cancer and helped to make sense of drug-response signature datasets that collectively decode the complex mechanisms of drug action.  Network pharmacol. showed that promiscuity often engages a synergistic combination of appropriate high-value targets in cancer cells to develop treatment success.  In general, it holds promise to revolutionize the approach towards next-generation cancer drug design and development.  Thus, it certainly has the potential to modify the view of drug design and understanding mechanisms of action and, if used correctly, is predicted to significantly de-risk cancer drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-nEGlIwnic7Vg90H21EOLACvtfcHk0lhftsjETlnRdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvVOrsrc%253D&md5=b545e162e850a4ada587a447bf9b82b6</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.44&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.44%26sid%3Dliteratum%253Aachs%26aulast%3DAzmi%26aufirst%3DA.%2BS.%26atitle%3DNetwork%2520pharmacology%2520for%2520cancer%2520drug%2520discovery%253A%2520are%2520we%2520there%2520yet%253F%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2012%26volume%3D4%26issue%3D8%26spage%3D939%26epage%3D941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Targeting the cancer kinome through polypharmacology</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fnrc2787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=20094047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=130-137&issue=2&author=Z.+A.+Knightauthor=H.+Linauthor=K.+M.+Shokat&title=Targeting+the+cancer+kinome+through+polypharmacology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cancer kinome through polypharmacology</span></div><div class="casAuthors">Knight, Zachary A.; Lin, Henry; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-137</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Kinase inhibitors are the largest class of new cancer drugs.  However, it is already apparent that most tumors can escape from the inhibition of any single kinase.  If it is necessary to inhibit multiple kinases, how do we choose which ones.  In this Opinion article, we discuss some of the strategies that are currently being used to identify new therapeutic combinations of kinase targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkDv2FeeH58rVg90H21EOLACvtfcHk0lhftsjETlnRdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D&md5=9aaa314e54b43889e147a9f11ac77072</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1038%2Fnrc2787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2787%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DTargeting%2520the%2520cancer%2520kinome%2520through%2520polypharmacology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26issue%3D2%26spage%3D130%26epage%3D137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group">Faivre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sargent, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raymond, E.</span><span> </span><span class="NLM_article-title">Molecular basis for sunitinib efficacy and future clinical development</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">734</span><span class="NLM_x">–</span> <span class="NLM_lpage">745</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=734-745&issue=9&author=S.+Faivreauthor=G.+Demetriauthor=W.+Sargentauthor=E.+Raymond&title=Molecular+basis+for+sunitinib+efficacy+and+future+clinical+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFaivre%26aufirst%3DS.%26aulast%3DDemetri%26aufirst%3DG.%26aulast%3DSargent%26aufirst%3DW.%26aulast%3DRaymond%26aufirst%3DE.%26atitle%3DMolecular%2520basis%2520for%2520sunitinib%2520efficacy%2520and%2520future%2520clinical%2520development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26issue%3D9%26spage%3D734%26epage%3D745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group">Hampton, T.</span><span> </span><span class="NLM_article-title">“Promiscuous” anticancer drugs that hit multiple targets may thwart resistance</span> <span class="citation_source-journal">JAMA</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">292</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">419</span><span class="NLM_x">–</span> <span class="NLM_lpage">422</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=2004&pages=419-422&issue=4&author=T.+Hampton&title=%E2%80%9CPromiscuous%E2%80%9D+anticancer+drugs+that+hit+multiple+targets+may+thwart+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHampton%26aufirst%3DT.%26atitle%3D%25E2%2580%259CPromiscuous%25E2%2580%259D%2520anticancer%2520drugs%2520that%2520hit%2520multiple%2520targets%2520may%2520thwart%2520resistance%26jtitle%3DJAMA%26date%3D2004%26volume%3D292%26issue%3D4%26spage%3D419%26epage%3D422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group">Silver, L. L.</span><span> </span><span class="NLM_article-title">Polypharmacology as an Emerging Trend in Antibacterial Discovery</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed.; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">167</span><span class="NLM_x">–</span> <span class="NLM_lpage">202</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=167-202&author=L.+L.+Silverauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch9%26sid%3Dliteratum%253Aachs%26aulast%3DSilver%26aufirst%3DL.%2BL.%26atitle%3DPolypharmacology%2520as%2520an%2520Emerging%2520Trend%2520in%2520Antibacterial%2520Discovery%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D167%26epage%3D202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group">East, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silver, L. L.</span><span> </span><span class="NLM_article-title">Multitarget ligands in antibacterial research: progress and opportunities</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">143</span><span class="NLM_x">–</span> <span class="NLM_lpage">156</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=143-156&issue=2&author=S.+P.+Eastauthor=L.+L.+Silver&title=Multitarget+ligands+in+antibacterial+research%3A+progress+and+opportunities"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEast%26aufirst%3DS.%2BP.%26aulast%3DSilver%26aufirst%3DL.%2BL.%26atitle%3DMultitarget%2520ligands%2520in%2520antibacterial%2520research%253A%2520progress%2520and%2520opportunities%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2013%26volume%3D8%26issue%3D2%26spage%3D143%26epage%3D156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group">Broetz-Oesterhelt, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunner, N. A.</span><span> </span><span class="NLM_article-title">How many modes of action should an antibiotic have?</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">564</span><span class="NLM_x">–</span> <span class="NLM_lpage">573</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1016%2Fj.coph.2008.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlaqsLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=564-573&issue=5&author=H.+Broetz-Oesterheltauthor=N.+A.+Brunner&title=How+many+modes+of+action+should+an+antibiotic+have%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">How many modes of action should an antibiotic have?</span></div><div class="casAuthors">Broetz-Oesterhelt, Heike; Brunner, Nina A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">564-573</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  All antibiotics that have been successfully employed for decades as monotherapeutics in the treatment of bacterial infections rely on mechanisms of bacterial growth inhibition which are by far more complex than inhibition of a single enzyme.  Such successful antibiotics have in common that they address several targets in parallel and/or that their targets are encoded by multiple genes.  Such multiplicity of targets and of target genes has the advantage that the emergence of spontaneous target-related resistance is a comparatively slow process.  Recently registered antibiotics and novel antibiotics in development are discussed in the light of this promising concept of antibacterial polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp12RSKM_6SirVg90H21EOLACvtfcHk0lgv3xafOHa1dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlaqsLvP&md5=9bfd80d8766beb8f6212be6bf3407c2c</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2008.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2008.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DBroetz-Oesterhelt%26aufirst%3DH.%26aulast%3DBrunner%26aufirst%3DN.%2BA.%26atitle%3DHow%2520many%2520modes%2520of%2520action%2520should%2520an%2520antibiotic%2520have%253F%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2008%26volume%3D8%26issue%3D5%26spage%3D564%26epage%3D573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group">Bolognesi, M. L.</span><span> </span><span class="NLM_article-title">Multi-target-directed ligands as innovative tools to combat trypanosomatid diseases</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">22</span><span class="NLM_x">) </span> <span class="NLM_fpage">2824</span><span class="NLM_x">–</span> <span class="NLM_lpage">2833</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.2174%2F156802611798184391" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ehtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=2824-2833&issue=22&author=M.+L.+Bolognesi&title=Multi-target-directed+ligands+as+innovative+tools+to+combat+trypanosomatid+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target-directed ligands as innovative tools to combat trypanosomatid diseases</span></div><div class="casAuthors">Bolognesi, Maria Laura</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2824-2833</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Of the tropical diseases, trypanosomiases and leishmaniases should most concern the pharmaceutical community because of their high prevalence in developing countries and the lack of effective drug treatments.  Despite this, they have not historically received much attention in terms of investment and research effort, nor do they now.  In very recent years, thanks to the involvement of several nonprofit organizations, the chemotherapeutic options have expanded with the introduction of the first combination therapy.  The optimal efficacy and safety of nifurtimox-eflornithine combination against second-stage human African trypanosomiasis is an encouraging first step towards simpler and more affordable therapies.  Along the same line, I propose that single chem. entities able to modulate more than one target may prove more efficacious and tolerable than the available arsenal of drugs.  Herein, I discuss the pros and cons of this approach, together with examples taken from the recent literature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1kcKEh6X7xrVg90H21EOLACvtfcHk0lgv3xafOHa1dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ehtbg%253D&md5=8c6ae7cf628d2b7888a7e9fb833b3a62</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.2174%2F156802611798184391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611798184391%26sid%3Dliteratum%253Aachs%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DMulti-target-directed%2520ligands%2520as%2520innovative%2520tools%2520to%2520combat%2520trypanosomatid%2520diseases%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26issue%3D22%26spage%3D2824%26epage%3D2833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group">Espinoza-Fonseca, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trujillo-Ferrara, J. G.</span><span> </span><span class="NLM_article-title">Toward a rational design of selective multi-trypanosomatid inhibitors: A computational docking study</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">24</span><span class="NLM_x">) </span> <span class="NLM_fpage">6288</span><span class="NLM_x">–</span> <span class="NLM_lpage">6292</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=6288-6292&issue=24&author=L.+M.+Espinoza-Fonsecaauthor=J.+G.+Trujillo-Ferrara&title=Toward+a+rational+design+of+selective+multi-trypanosomatid+inhibitors%3A+A+computational+docking+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEspinoza-Fonseca%26aufirst%3DL.%2BM.%26aulast%3DTrujillo-Ferrara%26aufirst%3DJ.%2BG.%26atitle%3DToward%2520a%2520rational%2520design%2520of%2520selective%2520multi-trypanosomatid%2520inhibitors%253A%2520A%2520computational%2520docking%2520study%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26issue%3D24%26spage%3D6288%26epage%3D6292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolognesi, M. L.</span><span> </span><span class="NLM_article-title">Neglected Tropical Diseases: Multi-Target-Directed Ligands in the Search for Novel Lead Candidates against Trypanosoma and Leishmania</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">7339</span><span class="NLM_x">–</span> <span class="NLM_lpage">7359</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9004835" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7339-7359&author=A.+Cavalliauthor=M.+L.+Bolognesi&title=Neglected+Tropical+Diseases%3A+Multi-Target-Directed+Ligands+in+the+Search+for+Novel+Lead+Candidates+against+Trypanosoma+and+Leishmania"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1021%2Fjm9004835&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9004835%26sid%3Dliteratum%253Aachs%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DNeglected%2520Tropical%2520Diseases%253A%2520Multi-Target-Directed%2520Ligands%2520in%2520the%2520Search%2520for%2520Novel%2520Lead%2520Candidates%2520against%2520Trypanosoma%2520and%2520Leishmania%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7339%26epage%3D7359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group">Aminake, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahajan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hans, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesner, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Kock, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grobler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirschner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rethwilm, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pradel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chibale, K.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of hybrid drugs for a potential HIV/AIDS-malaria combination therapy</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">5277</span><span class="NLM_x">–</span> <span class="NLM_lpage">5289</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=5277-5289&issue=17&author=M.+N.+Aminakeauthor=A.+Mahajanauthor=V.+Kumarauthor=R.+Hansauthor=L.+Wiesnerauthor=D.+Taylorauthor=C.+de+Kockauthor=A.+Groblerauthor=P.+J.+Smithauthor=M.+Kirschnerauthor=A.+Rethwilmauthor=G.+Pradelauthor=K.+Chibale&title=Synthesis+and+evaluation+of+hybrid+drugs+for+a+potential+HIV%2FAIDS-malaria+combination+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAminake%26aufirst%3DM.%2BN.%26aulast%3DMahajan%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DHans%26aufirst%3DR.%26aulast%3DWiesner%26aufirst%3DL.%26aulast%3DTaylor%26aufirst%3DD.%26aulast%3Dde%2BKock%26aufirst%3DC.%26aulast%3DGrobler%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DP.%2BJ.%26aulast%3DKirschner%26aufirst%3DM.%26aulast%3DRethwilm%26aufirst%3DA.%26aulast%3DPradel%26aufirst%3DG.%26aulast%3DChibale%26aufirst%3DK.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520hybrid%2520drugs%2520for%2520a%2520potential%2520HIV%252FAIDS-malaria%2520combination%2520therapy%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26issue%3D17%26spage%3D5277%26epage%3D5289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group">Millan, Mark, J.</span><span> </span><span class="NLM_article-title">Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">135</span><span class="NLM_x">–</span> <span class="NLM_lpage">370</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1016%2Fj.pharmthera.2005.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtFCqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2006&pages=135-370&issue=2&author=J.+Millan%2C+Mark&title=Multi-target+strategies+for+the+improved+treatment+of+depressive+states%3A+Conceptual+foundations+and+neuronal+substrates%2C+drug+discovery+and+therapeutic+application"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application</span></div><div class="casAuthors">Millan, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">135-370</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Major depression is a debilitating and recurrent disorder with a substantial lifetime risk and a high social cost.  Depressed patients generally display co-morbid symptoms, and depression frequently accompanies other serious disorders.  Currently available drugs display limited efficacy and a pronounced delay to onset of action, and all provoke distressing side effects.  Cloning of the human genome has fuelled expectations that symptomatic treatment may soon become more rapid and effective, and that depressive states may ultimately be "prevented" or "cured".  In pursuing these objectives, in particular for genome-derived, non-monoaminergic targets, "specificity" of drug actions is often emphasized.  That is, priority is afforded to agents that interact exclusively with a single site hypothesized as critically involved in the pathogenesis and/or control of depression.  Certain highly selective drugs may prove effective, and they remain indispensable in the exptl. (and clin.) evaluation of the significance of novel mechanisms.  However, by analogy to other multifactorial disorders, "multi-target" agents may be better adapted to the improved treatment of depressive states.  Support for this contention is garnered from a broad palette of observations, ranging from mechanisms of action of adjunctive drug combinations and electroconvulsive therapy to "network theory" anal. of the etiol. and management of depressive states.  The review also outlines opportunities to be exploited, and challenges to be addressed, in the discovery and characterization of drugs recognizing multiple targets.  Finally, a diversity of multi-target strategies is proposed for the more efficacious and rapid control of core and co-morbid symptoms of depression, together with improved tolerance relative to currently available agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxf3nCB4E-O7Vg90H21EOLACvtfcHk0lg7jepuEPlzWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtFCqtr4%253D&md5=dbca7f1b7bba52c69d9c6b95eea01d69</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2005.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2005.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DMillan%252C%2BMark%26aufirst%3DJ.%26atitle%3DMulti-target%2520strategies%2520for%2520the%2520improved%2520treatment%2520of%2520depressive%2520states%253A%2520Conceptual%2520foundations%2520and%2520neuronal%2520substrates%252C%2520drug%2520discovery%2520and%2520therapeutic%2520application%26jtitle%3DPharmacol.%2520Ther.%26date%3D2006%26volume%3D110%26issue%3D2%26spage%3D135%26epage%3D370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group">Millan, Mark, J.</span><span> </span><span class="NLM_article-title">Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs</span> <span class="citation_source-journal">Neurotherapeutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">53</span><span class="NLM_x">–</span> <span class="NLM_lpage">77</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=53-77&issue=1&author=J.+Millan%2C+Mark&title=Dual-+and+triple-acting+agents+for+treating+core+and+co-morbid+symptoms+of+major+depression%3A+novel+concepts%2C+new+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMillan%252C%2BMark%26aufirst%3DJ.%26atitle%3DDual-%2520and%2520triple-acting%2520agents%2520for%2520treating%2520core%2520and%2520co-morbid%2520symptoms%2520of%2520major%2520depression%253A%2520novel%2520concepts%252C%2520new%2520drugs%26jtitle%3DNeurotherapeutics%26date%3D2009%26volume%3D6%26issue%3D1%26spage%3D53%26epage%3D77" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group">Connolly, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thase, M. E.</span><span> </span><span class="NLM_article-title">Emerging drugs for major depressive disorder</span> <span class="citation_source-journal">Expert Opin. Emerging Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">105</span><span class="NLM_x">–</span> <span class="NLM_lpage">126</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1517%2F14728214.2012.660146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC38XksVOktrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=105-126&issue=1&author=K.+R.+Connollyauthor=M.+E.+Thase&title=Emerging+drugs+for+major+depressive+disorder"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging drugs for major depressive disorder</span></div><div class="casAuthors">Connolly, Kevin Ryan; Thase, Michael E.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Emerging Drugs</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">105-126</span>CODEN:
                <span class="NLM_cas:coden">EOEDA3</span>;
        ISSN:<span class="NLM_cas:issn">1472-8214</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Major depressive disorder (MDD) remains a major public health concern, and one that continues to suffer an incompletely-met need for effective and acceptable treatments. The development of antidepressants, to date,has focused primarily on increasing monoamine neurotransmission with increasing efficacy while minimizing adverse effects. Medications currently recommended as 'first-line' are far more tolerable than the older medications they replaced, but as many as 70% of patients continue to suffer significant depressive symptoms after treatment with one of these agents, and as many as 50% will discontinue a trial due to issues with acceptability. This review will summarize antidepressants that have recently entered the market as well as those still in development to help characterize the current state of antidepressant development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplUBvx97MRkrVg90H21EOLACvtfcHk0lg7jepuEPlzWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksVOktrs%253D&md5=deb3b11ec5798d8d979542ef01b1d5db</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1517%2F14728214.2012.660146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728214.2012.660146%26sid%3Dliteratum%253Aachs%26aulast%3DConnolly%26aufirst%3DK.%2BR.%26aulast%3DThase%26aufirst%3DM.%2BE.%26atitle%3DEmerging%2520drugs%2520for%2520major%2520depressive%2520disorder%26jtitle%3DExpert%2520Opin.%2520Emerging%2520Drugs%26date%3D2012%26volume%3D17%26issue%3D1%26spage%3D105%26epage%3D126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group">Shahid, M.</span><span> </span><span class="NLM_article-title">Clinical Need and Rationale for Multi-Target Drugs in Psychiatry</span>. In  <span class="citation_source-book">Designing Multi-Target Drugs</span>; <span class="NLM_contrib-group">Morphy, J. R.; Harris, C. J.</span>, Eds.; <span class="NLM_publisher-name">RSC Publishing</span>: <span class="NLM_publisher-loc">Cambridge</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">14</span><span class="NLM_x">–</span> <span class="NLM_lpage">31</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1039%2F9781849734912-00014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=14-31&author=M.+Shahidauthor=J.+R.+Morphy&author=C.+J.+Harris&title=Designing+Multi-Target+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1039%2F9781849734912-00014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1039%252F9781849734912-00014%26sid%3Dliteratum%253Aachs%26aulast%3DShahid%26aufirst%3DM.%26atitle%3DClinical%2520Need%2520and%2520Rationale%2520for%2520Multi-Target%2520Drugs%2520in%2520Psychiatry%26btitle%3DDesigning%2520Multi-Target%2520Drugs%26aulast%3DMorphy%26aufirst%3DJ.%2BR.%26pub%3DRSC%2520Publishing%26date%3D2012%26spage%3D14%26epage%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelton, R. C.</span><span> </span><span class="NLM_article-title">Review of Pharmacological Treatment in Mood Disorders and Future Directions for Drug Development</span> <span class="citation_source-journal">Neuropsychopharmacology.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">77</span><span class="NLM_x">–</span> <span class="NLM_lpage">101</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2012&pages=77-101&issue=1&author=X.+Liauthor=M.+A.+Fryeauthor=R.+C.+Shelton&title=Review+of+Pharmacological+Treatment+in+Mood+Disorders+and+Future+Directions+for+Drug+Development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DFrye%26aufirst%3DM.%2BA.%26aulast%3DShelton%26aufirst%3DR.%2BC.%26atitle%3DReview%2520of%2520Pharmacological%2520Treatment%2520in%2520Mood%2520Disorders%2520and%2520Future%2520Directions%2520for%2520Drug%2520Development%26jtitle%3DNeuropsychopharmacology.%26date%3D2012%26volume%3D37%26issue%3D1%26spage%3D77%26epage%3D101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group">Cavalli, A.; Bolognesi, M. L.</span><span> </span><span class="NLM_article-title">Multitargeted Drugs for Treatment of Alzheimer’s Disease</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed.; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">458</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch22" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=441-458&author=A.+Cavalli&author=M.+L.+Bolognesiauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch22%26sid%3Dliteratum%253Aachs%26aulast%3DCavalli%26aufirst%3DA.%26atitle%3DMultitargeted%2520Drugs%2520for%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D441%26epage%3D458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group">Van der Schyf, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geldenhuys, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amit, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avramovich, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridkin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinreb, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Am, O. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sagi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youdim, M. B. H.</span><span> </span><span class="NLM_article-title">Novel multifunctional anti-alzheimer drugs with various CNS neurotransmitter targets and neuroprotective moieties</span> <span class="citation_source-journal">Curr. Alzheimer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">522</span><span class="NLM_x">–</span> <span class="NLM_lpage">536</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.2174%2F156720507783018226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisVGruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&pages=522-536&issue=5&author=C.+J.+Van+der+Schyfauthor=S.+Mandelauthor=W.+J.+Geldenhuysauthor=T.+Amitauthor=Y.+Avramovichauthor=H.+Zhengauthor=M.+Fridkinauthor=S.+Galauthor=O.+Weinrebauthor=O.+B.+Amauthor=Y.+Sagiauthor=M.+B.+H.+Youdim&title=Novel+multifunctional+anti-alzheimer+drugs+with+various+CNS+neurotransmitter+targets+and+neuroprotective+moieties"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Novel multifunctional anti-alzheimer drugs with various CNS neurotransmitter targets and neuroprotective moieties</span></div><div class="casAuthors">Van der Schyf, Cornelis J.; Mandel, Silvia; Geldenhuys, Werner J.; Amit, Tamar; Avramovich, Yael; Zheng, Hailin; Fridkin, Mati; Gal, Shunit; Weinreb, Orly; Am, Orit Bar; Sagi, Yotam; Youdim, Moussa B. H.</div><div class="citationInfo"><span class="NLM_cas:title">Current Alzheimer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">522-536</span>CODEN:
                <span class="NLM_cas:coden">CARUBY</span>;
        ISSN:<span class="NLM_cas:issn">1567-2050</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Traditionally, drug design programs are focused on optimizing the specificity of lead compds. against a carefully selected drug target.  Disappointingly, this approach to discover a "magic bullet" drug has not met with the expected success for CNS disorders.  Transcriptomics and proteomic profiling of neurodegenerative diseases have indicated that they are poly-etiol. in origin and that the processes leading to neuronal death are multifactorial.  An emerging concept is the design of drug ligands that modulate multiple drug targets identified for a particular disease.  In this review we explore some examples of multifunctional drugs which may be useful in the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFYARzHINRR7Vg90H21EOLACvtfcHk0lhuT4zqdJHI4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisVGruw%253D%253D&md5=d4e893f60f8657b7f762147366dbdedb</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.2174%2F156720507783018226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156720507783018226%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bder%2BSchyf%26aufirst%3DC.%2BJ.%26aulast%3DMandel%26aufirst%3DS.%26aulast%3DGeldenhuys%26aufirst%3DW.%2BJ.%26aulast%3DAmit%26aufirst%3DT.%26aulast%3DAvramovich%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DH.%26aulast%3DFridkin%26aufirst%3DM.%26aulast%3DGal%26aufirst%3DS.%26aulast%3DWeinreb%26aufirst%3DO.%26aulast%3DAm%26aufirst%3DO.%2BB.%26aulast%3DSagi%26aufirst%3DY.%26aulast%3DYoudim%26aufirst%3DM.%2BB.%2BH.%26atitle%3DNovel%2520multifunctional%2520anti-alzheimer%2520drugs%2520with%2520various%2520CNS%2520neurotransmitter%2520targets%2520and%2520neuroprotective%2520moieties%26jtitle%3DCurr.%2520Alzheimer%2520Res.%26date%3D2007%26volume%3D4%26issue%3D5%26spage%3D522%26epage%3D536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolognesi, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minarini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tumiatti, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Recanatini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melchiorre, C.</span><span> </span><span class="NLM_article-title">Multi-target-Directed Ligands to Combat Neurodegenerative Diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">347</span><span class="NLM_x">–</span> <span class="NLM_lpage">372</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm7009364" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsl2qsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=347-372&issue=3&author=A.+Cavalliauthor=M.+L.+Bolognesiauthor=A.+Minariniauthor=M.+Rosiniauthor=V.+Tumiattiauthor=M.+Recanatiniauthor=C.+Melchiorre&title=Multi-target-Directed+Ligands+to+Combat+Neurodegenerative+Diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target-Directed Ligands to Combat Neurodegenerative Diseases</span></div><div class="casAuthors">Cavalli, Andrea; Bolognesi, Maria Laura; Minarini, Anna; Rosini, Michela; Tumiatti, Vincenzo; Recanatini, Maurizio; Melchiorre, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">347-372</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The authors review the investigations reported in the past decade that illustrate the ability of medicinal chemists to design multi-target-directed ligands (MTDLs) to confront neurodegenerative diseases.  The authors briefly illustrate the multifactorial nature of these diseases before discussing the possible development of MTDLs in light of the known mol. bases of the main neurodegenerative pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYY0I0UHEir7Vg90H21EOLACvtfcHk0lhuT4zqdJHI4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsl2qsbk%253D&md5=c682235151489316d043cf97f78e56f3</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1021%2Fjm7009364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7009364%26sid%3Dliteratum%253Aachs%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DMinarini%26aufirst%3DA.%26aulast%3DRosini%26aufirst%3DM.%26aulast%3DTumiatti%26aufirst%3DV.%26aulast%3DRecanatini%26aufirst%3DM.%26aulast%3DMelchiorre%26aufirst%3DC.%26atitle%3DMulti-target-Directed%2520Ligands%2520to%2520Combat%2520Neurodegenerative%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D3%26spage%3D347%26epage%3D372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group">Bajda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzior, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ignasik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malawska, B.</span><span> </span><span class="NLM_article-title">Multi-target-directed ligands in Alzheimer’s disease treatment</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">32</span><span class="NLM_x">) </span> <span class="NLM_fpage">4949</span><span class="NLM_x">–</span> <span class="NLM_lpage">4975</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.2174%2F092986711797535245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVOrtL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=4949-4975&issue=32&author=M.+Bajdaauthor=N.+Guziorauthor=M.+Ignasikauthor=B.+Malawska&title=Multi-target-directed+ligands+in+Alzheimer%E2%80%99s+disease+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target-directed ligands in Alzheimer's disease treatment</span></div><div class="casAuthors">Bajda, M.; Guzior, N.; Ignasik, M.; Malawska, B.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">4949-4975</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Among the various drug discovery methods, a very promising modern approach consists in designing multi-target-directed ligands (MTDLs).  This methodol. has been specifically developed for treatment of disorders with complex pathol. mechanisms.  One such disorder is Alzheimer's disease (AD), currently the most common multifactorial neurodegenerative disease.  AD is related to increased levels of the amyloid β peptide (Aβ) and the hyperphosphorylated tau protein, along with loss of neurons and synapses.  Moreover, there is some evidence pointing to the role of oxidative stress, metal ion deregulation, inflammation and cell cycle regulatory failure in its pathogenesis.  There are many attractive targets for the development of anti-AD drugs, and the multi-factor nature of this disease calls for multi-target-directed compds. which can be beneficial for AD treatment.  This review presents the discovery of dual- and multi-acting anti-AD drug candidates, focusing on the novel design strategy and the compds. it yields - particularly hybrids obtained by linking structurally active moieties interacting with different targets.  The first group of compds. includes cholinesterase inhibitors acting as dual binding site inhibitors and/or inhibitors with addnl. properties.  These compds. are characterized by increased potency against acetylcholinesterase (AChE) and Aβ plaque formation with addnl. properties such as antioxidant activity, neuroprotective, and metal-complexing property, voltage-dependent calcium channel antagonistic activity, inhibitory activity against glutamate-induced excitotoxicity, histamine H3 receptor antagonism, cannabinoid CB1 receptor antagonism and β-secretase (BACE1) inhibition.  A novel class of compds. represents the combination of dual BACE1 inhibitors with metal chelators, and dual modulators of γ-secretase with peroxisome proliferator-activated receptor γ (PPARγ).  We have reviewed the latest reports (2008-2011) presenting new multi-target-directed compds. in Alzheimer's disease treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZHSluHvxy4bVg90H21EOLACvtfcHk0lhuT4zqdJHI4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVOrtL3F&md5=c8f35f849c399d43c90570f71ca10e13</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.2174%2F092986711797535245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711797535245%26sid%3Dliteratum%253Aachs%26aulast%3DBajda%26aufirst%3DM.%26aulast%3DGuzior%26aufirst%3DN.%26aulast%3DIgnasik%26aufirst%3DM.%26aulast%3DMalawska%26aufirst%3DB.%26atitle%3DMulti-target-directed%2520ligands%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520treatment%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26issue%3D32%26spage%3D4949%26epage%3D4975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group">Bianchi, M. T.; Chuang, K.</span><span> </span><span class="NLM_article-title">A Magic Shotgun Perspective on Anticonvulsant Mechanisms</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed.; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">225</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch10" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=203-225&author=M.+T.+Bianchi&author=K.+Chuangauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch10%26sid%3Dliteratum%253Aachs%26aulast%3DBianchi%26aufirst%3DM.%2BT.%26atitle%3DA%2520Magic%2520Shotgun%2520Perspective%2520on%2520Anticonvulsant%2520Mechanisms%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D203%26epage%3D225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group">Daull, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeng, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battistini, B.</span><span> </span><span class="NLM_article-title">Towards Triple Vasopeptidase Inhibitors for the Treatment of Cardiovascular Diseases</span> <span class="citation_source-journal">J. Cardiovasc. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">247</span><span class="NLM_x">–</span> <span class="NLM_lpage">256</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=247-256&issue=3&author=P.+Daullauthor=A.+Y.+Jengauthor=B.+Battistini&title=Towards+Triple+Vasopeptidase+Inhibitors+for+the+Treatment+of+Cardiovascular+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDaull%26aufirst%3DP.%26aulast%3DJeng%26aufirst%3DA.%2BY.%26aulast%3DBattistini%26aufirst%3DB.%26atitle%3DTowards%2520Triple%2520Vasopeptidase%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Cardiovascular%2520Diseases%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D2007%26volume%3D50%26issue%3D3%26spage%3D247%26epage%3D256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group">Calhoun, D. A.</span><span> </span><span class="NLM_article-title">Use of single-pill combination therapy in the evolving paradigm of hypertension management</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">1869</span><span class="NLM_x">–</span> <span class="NLM_lpage">1874</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1517%2F14656560902980210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1MXoslaqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=1869-1874&issue=12&author=D.+A.+Calhoun&title=Use+of+single-pill+combination+therapy+in+the+evolving+paradigm+of+hypertension+management"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Use of single-pill combination therapy in the evolving paradigm of hypertension management</span></div><div class="casAuthors">Calhoun, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1869-1874</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The use of antihypertensive therapy is an evolving paradigm.  Although blood pressure (BP) control rates remain low, there have been improvements that may be attributable in part to a recent shift in clin. guidelines that recognizes that most patients will require multiple drugs to reach BP goals and encourages clinicians to use combination therapy as first-line treatment in selected patients.  Single-pill combinations of two complementary antihypertensive medications offer benefits beyond those of sep. administration of the individual component agents, providing a simpler medication regimen that is effective and well tolerated while enhancing patient adherence to therapy.  In the future, there may be single-pill combinations of three antihypertensive drugs to further enhance BP control rates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql2DUwqQH0UbVg90H21EOLACvtfcHk0ljNol7k63BkCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXoslaqtb8%253D&md5=2d9c158e32d0db555dddef9c1316988f</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1517%2F14656560902980210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656560902980210%26sid%3Dliteratum%253Aachs%26aulast%3DCalhoun%26aufirst%3DD.%2BA.%26atitle%3DUse%2520of%2520single-pill%2520combination%2520therapy%2520in%2520the%2520evolving%2520paradigm%2520of%2520hypertension%2520management%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2009%26volume%3D10%26issue%3D12%26spage%3D1869%26epage%3D1874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group">Milnes, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madge, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. W.</span><span> </span><span class="NLM_article-title">New pharmacological approaches to atrial fibrillation</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">13–14</span><span class="NLM_x">) </span> <span class="NLM_fpage">654</span><span class="NLM_x">–</span> <span class="NLM_lpage">659</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=654-659&issue=13%E2%80%9314&author=J.+T.+Milnesauthor=D.+J.+Madgeauthor=J.+W.+Ford&title=New+pharmacological+approaches+to+atrial+fibrillation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMilnes%26aufirst%3DJ.%2BT.%26aulast%3DMadge%26aufirst%3DD.%2BJ.%26aulast%3DFord%26aufirst%3DJ.%2BW.%26atitle%3DNew%2520pharmacological%2520approaches%2520to%2520atrial%2520fibrillation%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26issue%3D13%25E2%2580%259314%26spage%3D654%26epage%3D659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group">Dobrev, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlsson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nattel, S.</span><span> </span><span class="NLM_article-title">Novel molecular targets for atrial fibrillation therapy</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">275</span><span class="NLM_x">–</span> <span class="NLM_lpage">291</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=275-291&issue=4&author=D.+Dobrevauthor=L.+Carlssonauthor=S.+Nattel&title=Novel+molecular+targets+for+atrial+fibrillation+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDobrev%26aufirst%3DD.%26aulast%3DCarlsson%26aufirst%3DL.%26aulast%3DNattel%26aufirst%3DS.%26atitle%3DNovel%2520molecular%2520targets%2520for%2520atrial%2520fibrillation%2520therapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26issue%3D4%26spage%3D275%26epage%3D291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group">Krishnamoorthy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lip, G. Y. H.</span><span> </span><span class="NLM_article-title">Novel antiarrhythmic drugs in atrial fibrillation: focus on tedisamil</span> <span class="citation_source-journal">Expert Opin. Investig. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">1191</span><span class="NLM_x">–</span> <span class="NLM_lpage">1196</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=1191-1196&issue=8&author=S.+Krishnamoorthyauthor=G.+Y.+H.+Lip&title=Novel+antiarrhythmic+drugs+in+atrial+fibrillation%3A+focus+on+tedisamil"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKrishnamoorthy%26aufirst%3DS.%26aulast%3DLip%26aufirst%3DG.%2BY.%2BH.%26atitle%3DNovel%2520antiarrhythmic%2520drugs%2520in%2520atrial%2520fibrillation%253A%2520focus%2520on%2520tedisamil%26jtitle%3DExpert%2520Opin.%2520Investig.%2520Drugs%26date%3D2009%26volume%3D18%26issue%3D8%26spage%3D1191%26epage%3D1196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group">Sabroe, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calverley, P. M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dower, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whyte, M. K. B.</span><span> </span><span class="NLM_article-title">Pathological networking: a new approach to understanding COPD</span> <span class="citation_source-journal">Thorax</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">733</span><span class="NLM_x">–</span> <span class="NLM_lpage">738</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2007&pages=733-738&issue=8&author=I.+Sabroeauthor=L.+C.+Parkerauthor=P.+M.+A.+Calverleyauthor=S.+K.+Dowerauthor=M.+K.+B.+Whyte&title=Pathological+networking%3A+a+new+approach+to+understanding+COPD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSabroe%26aufirst%3DI.%26aulast%3DParker%26aufirst%3DL.%2BC.%26aulast%3DCalverley%26aufirst%3DP.%2BM.%2BA.%26aulast%3DDower%26aufirst%3DS.%2BK.%26aulast%3DWhyte%26aufirst%3DM.%2BK.%2BB.%26atitle%3DPathological%2520networking%253A%2520a%2520new%2520approach%2520to%2520understanding%2520COPD%26jtitle%3DThorax%26date%3D2007%26volume%3D62%26issue%3D8%26spage%3D733%26epage%3D738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basu, A.</span><span> </span><span class="NLM_article-title">Network medicine in drug design: implications for neuroinflammation</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">11–12</span><span class="NLM_x">) </span> <span class="NLM_fpage">600</span><span class="NLM_x">–</span> <span class="NLM_lpage">607</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=600-607&issue=11%E2%80%9312&author=S.+Ghoshauthor=A.+Basu&title=Network+medicine+in+drug+design%3A+implications+for+neuroinflammation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DBasu%26aufirst%3DA.%26atitle%3DNetwork%2520medicine%2520in%2520drug%2520design%253A%2520implications%2520for%2520neuroinflammation%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26issue%3D11%25E2%2580%259312%26spage%3D600%26epage%3D607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group">Albrecht, W.; Laufer, S.</span><span> </span><span class="NLM_article-title">Therapeutic Potential of Small Molecules Modulating the Cyclooxygenase-5-lipoxygenase Pathway</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed.; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">383</span><span class="NLM_x">–</span> <span class="NLM_lpage">408</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch19" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=383-408&author=W.+Albrecht&author=S.+Lauferauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch19%26sid%3Dliteratum%253Aachs%26aulast%3DAlbrecht%26aufirst%3DW.%26atitle%3DTherapeutic%2520Potential%2520of%2520Small%2520Molecules%2520Modulating%2520the%2520Cyclooxygenase-5-lipoxygenase%2520Pathway%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D383%26epage%3D408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group">Borisy, A. A.; Zimmermann, G. R.; Lehar, J.</span><span> </span><span class="NLM_article-title">Multicomponent Therapeutics</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed.; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">315</span><span class="NLM_x">–</span> <span class="NLM_lpage">321</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch15" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=315-321&author=A.+A.+Borisy&author=G.+R.+Zimmermann&author=J.+Leharauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch15%26sid%3Dliteratum%253Aachs%26aulast%3DBorisy%26aufirst%3DA.%2BA.%26atitle%3DMulticomponent%2520Therapeutics%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D315%26epage%3D321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group">Keith, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borisy, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stockwell, B. R.</span><span> </span><span class="NLM_article-title">Innovation: Multicomponent therapeutics for networked systems</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">71</span><span class="NLM_x">–</span> <span class="NLM_lpage">78</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=71-78&issue=1&author=C.+T.+Keithauthor=A.+A.+Borisyauthor=B.+R.+Stockwell&title=Innovation%3A+Multicomponent+therapeutics+for+networked+systems"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKeith%26aufirst%3DC.%2BT.%26aulast%3DBorisy%26aufirst%3DA.%2BA.%26aulast%3DStockwell%26aufirst%3DB.%2BR.%26atitle%3DInnovation%253A%2520Multicomponent%2520therapeutics%2520for%2520networked%2520systems%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26issue%3D1%26spage%3D71%26epage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group">Tzschentke, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christoph, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koegel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiene, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennies, H.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Englberger, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haurand, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jahnel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cremers, T. I. F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friderichs, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vry, J.</span><span> </span><span class="NLM_article-title">(−)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel μ-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties</span> <span class="citation_source-journal">J. Pharmacol. Exp. Therap.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">323</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">265</span><span class="NLM_x">–</span> <span class="NLM_lpage">276</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1124%2Fjpet.107.126052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFahsb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=2007&pages=265-276&issue=1&author=T.+M.+Tzschentkeauthor=T.+Christophauthor=B.+Koegelauthor=K.+Schieneauthor=H.-H.+Henniesauthor=W.+Englbergerauthor=M.+Haurandauthor=U.+Jahnelauthor=T.+I.+F.+H.+Cremersauthor=E.+Friderichsauthor=J.+De+Vry&title=%28%E2%88%92%29-%281R%2C2R%29-3-%283-Dimethylamino-1-ethyl-2-methyl-propyl%29-phenol+hydrochloride+%28tapentadol+HCl%29%3A+a+novel+%CE%BC-opioid+receptor+agonist%2Fnorepinephrine+reuptake+inhibitor+with+broad-spectrum+analgesic+properties"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">(-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel μ-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties</span></div><div class="casAuthors">Tzschentke, Thomas M.; Christoph, Thomas; Koegel, Babette; Schiene, Klaus; Hennies, Hagen-Heinrich; Englberger, Werner; Haurand, Michael; Jahnel, Ulrich; Cremers, Thomas I. F. H.; Friderichs, Elmar; De Vry, Jean</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">265-276</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">(-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl) is a novel μ-opioid receptor (MOR) agonist (Ki = 0.1 μM; relative efficacy compared with morphine 88% in a [35S]guanosine 5'-3-O-(thio)triphosphate binding assay) and NE reuptake inhibitor (Ki = 0.5 μM for synaptosomal reuptake inhibition).  In vivo intracerebral microdialysis showed that tapentadol, in contrast to morphine, produces large increases in extracellular levels of NE (+450% at 10 mg/kg i.p.).  Tapentadol exhibited analgesic effects in a wide range of animal models of acute and chronic pain [hot plate, tail-flick, writhing, Randall-Selitto, mustard oil colitis, chronic constriction injury (CCI), and spinal nerve ligation (SNL)], with ED50 values ranging from 8.2 to 13 mg/kg after i.p. administration in rats.  Despite a 50-fold lower binding affinity to MOR, the analgesic potency of tapentadol was only two to three times lower than that of morphine, suggesting that the dual mode of action of tapentadol may result in an opiate-sparing effect.  A role of NE in the analgesic efficacy of tapentadol was directly demonstrated in the SNL model, where the analgesic effect of tapentadol was strongly reduced by the α2-adrenoceptor antagonist yohimbine but only moderately attenuated by the MOR antagonist naloxone, whereas the opposite was seen for morphine.  Tolerance development to the analgesic effect of tapentadol in the CCI model was twice as slow as that of morphine.  It is suggested that the broad analgesic profile of tapentadol and its relative resistance to tolerance development may be due to a dual mode of action consisting of both MOR activation and NE reuptake inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEuKmQM4JgvrVg90H21EOLACvtfcHk0ljSIQOWJUhvLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFahsb7P&md5=b2e196297096bac7c057f0e4a8d90bfb</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.126052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.126052%26sid%3Dliteratum%253Aachs%26aulast%3DTzschentke%26aufirst%3DT.%2BM.%26aulast%3DChristoph%26aufirst%3DT.%26aulast%3DKoegel%26aufirst%3DB.%26aulast%3DSchiene%26aufirst%3DK.%26aulast%3DHennies%26aufirst%3DH.-H.%26aulast%3DEnglberger%26aufirst%3DW.%26aulast%3DHaurand%26aufirst%3DM.%26aulast%3DJahnel%26aufirst%3DU.%26aulast%3DCremers%26aufirst%3DT.%2BI.%2BF.%2BH.%26aulast%3DFriderichs%26aufirst%3DE.%26aulast%3DDe%2BVry%26aufirst%3DJ.%26atitle%3D%2528%25E2%2588%2592%2529-%25281R%252C2R%2529-3-%25283-Dimethylamino-1-ethyl-2-methyl-propyl%2529-phenol%2520hydrochloride%2520%2528tapentadol%2520HCl%2529%253A%2520a%2520novel%2520%25CE%25BC-opioid%2520receptor%2520agonist%252Fnorepinephrine%2520reuptake%2520inhibitor%2520with%2520broad-spectrum%2520analgesic%2520properties%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Therap.%26date%3D2007%26volume%3D323%26issue%3D1%26spage%3D265%26epage%3D276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group">Khanna, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khanna, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furst, D. E.</span><span> </span><span class="NLM_article-title">COX-2 controversy: where are we and where do we go from here?</span> <span class="citation_source-journal">Inflammopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">395</span><span class="NLM_x">–</span> <span class="NLM_lpage">402</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=395-402&issue=4&author=D.+Khannaauthor=P.+P.+Khannaauthor=D.+E.+Furst&title=COX-2+controversy%3A+where+are+we+and+where+do+we+go+from+here%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKhanna%26aufirst%3DD.%26aulast%3DKhanna%26aufirst%3DP.%2BP.%26aulast%3DFurst%26aufirst%3DD.%2BE.%26atitle%3DCOX-2%2520controversy%253A%2520where%2520are%2520we%2520and%2520where%2520do%2520we%2520go%2520from%2520here%253F%26jtitle%3DInflammopharmacology%26date%3D2005%26volume%3D13%26issue%3D4%26spage%3D395%26epage%3D402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group">Jooste, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emala, C. W.</span><span> </span><span class="NLM_article-title">Rapacuronium Preferentially Antagonizes the Function of M2 versus M3Muscarinic Receptors in Guinea Pig Airway Smooth Muscle</span> <span class="citation_source-journal">Anesthesiology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=117-124&issue=1&author=E.+Joosteauthor=Y.+Zhangauthor=C.+W.+Emala&title=Rapacuronium+Preferentially+Antagonizes+the+Function+of+M2+versus+M3Muscarinic+Receptors+in+Guinea+Pig+Airway+Smooth+Muscle"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJooste%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DEmala%26aufirst%3DC.%2BW.%26atitle%3DRapacuronium%2520Preferentially%2520Antagonizes%2520the%2520Function%2520of%2520M2%2520versus%2520M3Muscarinic%2520Receptors%2520in%2520Guinea%2520Pig%2520Airway%2520Smooth%2520Muscle%26jtitle%3DAnesthesiology%26date%3D2005%26volume%3D102%26issue%3D1%26spage%3D117%26epage%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group">Hou, V. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirshman, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emala, C. W.</span><span> </span><span class="NLM_article-title">Neuromuscular relaxants as antagonists for M2 and M3 muscarinic receptors</span> <span class="citation_source-journal">Anesthesiology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">744</span><span class="NLM_x">–</span> <span class="NLM_lpage">750</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1998&pages=744-750&issue=3&author=V.+Y.+Houauthor=C.+A.+Hirshmanauthor=C.+W.+Emala&title=Neuromuscular+relaxants+as+antagonists+for+M2+and+M3+muscarinic+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHou%26aufirst%3DV.%2BY.%26aulast%3DHirshman%26aufirst%3DC.%2BA.%26aulast%3DEmala%26aufirst%3DC.%2BW.%26atitle%3DNeuromuscular%2520relaxants%2520as%2520antagonists%2520for%2520M2%2520and%2520M3%2520muscarinic%2520receptors%26jtitle%3DAnesthesiology%26date%3D1998%26volume%3D88%26issue%3D3%26spage%3D744%26epage%3D750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group">Martin, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salmen, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmatier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gintant, G. A.</span><span> </span><span class="NLM_article-title">The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block</span> <span class="citation_source-journal">J. Cardiovasc. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">369</span><span class="NLM_x">–</span> <span class="NLM_lpage">379</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2004&pages=369-379&issue=3&author=R.+L.+Martinauthor=J.+S.+McDermottauthor=H.+J.+Salmenauthor=J.+Palmatierauthor=B.+F.+Coxauthor=G.+A.+Gintant&title=The+utility+of+hERG+and+repolarization+assays+in+evaluating+delayed+cardiac+repolarization%3A+influence+of+multi-channel+block"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DR.%2BL.%26aulast%3DMcDermott%26aufirst%3DJ.%2BS.%26aulast%3DSalmen%26aufirst%3DH.%2BJ.%26aulast%3DPalmatier%26aufirst%3DJ.%26aulast%3DCox%26aufirst%3DB.%2BF.%26aulast%3DGintant%26aufirst%3DG.%2BA.%26atitle%3DThe%2520utility%2520of%2520hERG%2520and%2520repolarization%2520assays%2520in%2520evaluating%2520delayed%2520cardiac%2520repolarization%253A%2520influence%2520of%2520multi-channel%2520block%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D2004%26volume%3D43%26issue%3D3%26spage%3D369%26epage%3D379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group">Sala, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coppa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappucciati, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brambilla, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">d’Allio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caverzasi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barale, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Ferrari, G. M.</span><span> </span><span class="NLM_article-title">Antidepressants: their effects on cardiac channels, QT prolongation and Torsade de Pointes</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">256</span><span class="NLM_x">–</span> <span class="NLM_lpage">263</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=256-263&issue=3&author=M.+Salaauthor=F.+Coppaauthor=C.+Cappucciatiauthor=P.+Brambillaauthor=G.+d%E2%80%99Allioauthor=E.+Caverzasiauthor=F.+Baraleauthor=G.+M.+De+Ferrari&title=Antidepressants%3A+their+effects+on+cardiac+channels%2C+QT+prolongation+and+Torsade+de+Pointes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSala%26aufirst%3DM.%26aulast%3DCoppa%26aufirst%3DF.%26aulast%3DCappucciati%26aufirst%3DC.%26aulast%3DBrambilla%26aufirst%3DP.%26aulast%3Dd%25E2%2580%2599Allio%26aufirst%3DG.%26aulast%3DCaverzasi%26aufirst%3DE.%26aulast%3DBarale%26aufirst%3DF.%26aulast%3DDe%2BFerrari%26aufirst%3DG.%2BM.%26atitle%3DAntidepressants%253A%2520their%2520effects%2520on%2520cardiac%2520channels%252C%2520QT%2520prolongation%2520and%2520Torsade%2520de%2520Pointes%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2006%26volume%3D7%26issue%3D3%26spage%3D256%26epage%3D263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group">Tobinick, E. L.</span><span> </span><span class="NLM_article-title">The value of drug repositioning in the current pharmaceutical market</span> <span class="citation_source-journal">Drug News Perspect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">119</span><span class="NLM_x">–</span> <span class="NLM_lpage">125</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1358%2Fdnp.2009.22.2.1343228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A280%3ADC%252BD1M3kt1anuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=119-125&issue=2&author=E.+L.+Tobinick&title=The+value+of+drug+repositioning+in+the+current+pharmaceutical+market"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">The value of drug repositioning in the current pharmaceutical market</span></div><div class="casAuthors">Tobinick Edward L</div><div class="citationInfo"><span class="NLM_cas:title">Drug news & perspectives</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">119-25</span>
        ISSN:<span class="NLM_cas:issn">0214-0934</span>.
    </div><div class="casAbstract">Drug repositioning is the process of developing new indications for existing drugs or biologics.  Increasing interest in drug repositioning has occurred due to sustained high failure rates and costs involved in attempts to bring new drugs to market.  It has been estimated that it may cost more than USD 800 million to develop a new drug de novo.  In addition, due to regulatory requirements regarding safety, efficacy and quality, the time required to develop a new drug de novo has been estimated to be 10 to 17 years.  De novo drug discovery has failed to efficiently supply pharmaceutical company pipelines.  A rational approach to drug repositioning may include a cross-disciplinary focus on the elucidation of the mechanisms of disease, allowing matching of disease pathways with appropriately targeted therapeutic agents.  Repurposed drugs or biologics have the advantage of decreased development costs and decreased time to launch due to previously collected pharmacokinetic, toxicology and safety data.  For these reasons, repurposing should be a primary strategy in drug discovery for every broadly focused, research-based pharmaceutical company.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRHCgc-C0DhQZagfuraLLzSfW6udTcc2eb8Q8iiliiP9bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M3kt1anuw%253D%253D&md5=d55a5f23cb69258c0f06189e2c4d9011</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1358%2Fdnp.2009.22.2.1343228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdnp.2009.22.2.1343228%26sid%3Dliteratum%253Aachs%26aulast%3DTobinick%26aufirst%3DE.%2BL.%26atitle%3DThe%2520value%2520of%2520drug%2520repositioning%2520in%2520the%2520current%2520pharmaceutical%2520market%26jtitle%3DDrug%2520News%2520Perspect.%26date%3D2009%26volume%3D22%26issue%3D2%26spage%3D119%26epage%3D125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group">Ashburn, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thor, K. B.</span><span> </span><span class="NLM_article-title">Drug repositioning: identifying and developing new uses for existing drugs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">673</span><span class="NLM_x">–</span> <span class="NLM_lpage">683</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fnrd1468" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=15286734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVOhtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=673-683&issue=8&author=T.+T.+Ashburnauthor=K.+B.+Thor&title=Drug+repositioning%3A+identifying+and+developing+new+uses+for+existing+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Drug repositioning: identifying and developing new uses for existing drugs</span></div><div class="casAuthors">Ashburn, Ted T.; Thor, Karl B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">673-683</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Biopharmaceutical companies attempting to increase productivity through novel discovery technologies have fallen short of achieving the desired results.  Repositioning existing drugs for new indications could deliver the productivity increases that the industry needs while shifting the locus of prodn. to biotechnol. companies.  More and more companies are scanning the existing pharmacopeia for repositioning candidates, and the no. of repositioning success stories is increasing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLkWl3DnePhrVg90H21EOLACvtfcHk0lgp9pBRLF1AVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVOhtL8%253D&md5=0145c02423ab81ace6e3b3d92585cccc</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1038%2Fnrd1468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1468%26sid%3Dliteratum%253Aachs%26aulast%3DAshburn%26aufirst%3DT.%2BT.%26aulast%3DThor%26aufirst%3DK.%2BB.%26atitle%3DDrug%2520repositioning%253A%2520identifying%2520and%2520developing%2520new%2520uses%2520for%2520existing%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26issue%3D8%26spage%3D673%26epage%3D683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group">Oprea, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauman, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">G. Bologa, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buranda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chigaev, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarvik, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gresham, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haynes, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hjelle, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hromas, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackenzie, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simons, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smagley, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strouse, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surviladze, Z.</span><span> </span><span class="NLM_article-title">Drug repurposing from an academic perspective</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">3–4</span><span class="NLM_x">) </span> <span class="NLM_fpage">61</span><span class="NLM_x">–</span> <span class="NLM_lpage">69</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=61-69&issue=3%E2%80%934&author=T.+I.+Opreaauthor=J.+E.+Baumanauthor=C.+G.+G.+Bologaauthor=T.+Burandaauthor=A.+Chigaevauthor=B.+S.+Edwardsauthor=J.+W.+Jarvikauthor=H.+D.+Greshamauthor=M.+K.+Haynesauthor=B.+Hjelleauthor=R.+Hromasauthor=L.+Hudsonauthor=D.+A.+Mackenzieauthor=C.+Y.+Mullerauthor=J.+C.+Reedauthor=P.+C.+Simonsauthor=Y.+Smagleyauthor=J.+Strouseauthor=Z.+Surviladze&title=Drug+repurposing+from+an+academic+perspective"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOprea%26aufirst%3DT.%2BI.%26aulast%3DBauman%26aufirst%3DJ.%2BE.%26aulast%3DG.%2BBologa%26aufirst%3DC.%2BG.%26aulast%3DBuranda%26aufirst%3DT.%26aulast%3DChigaev%26aufirst%3DA.%26aulast%3DEdwards%26aufirst%3DB.%2BS.%26aulast%3DJarvik%26aufirst%3DJ.%2BW.%26aulast%3DGresham%26aufirst%3DH.%2BD.%26aulast%3DHaynes%26aufirst%3DM.%2BK.%26aulast%3DHjelle%26aufirst%3DB.%26aulast%3DHromas%26aufirst%3DR.%26aulast%3DHudson%26aufirst%3DL.%26aulast%3DMackenzie%26aufirst%3DD.%2BA.%26aulast%3DMuller%26aufirst%3DC.%2BY.%26aulast%3DReed%26aufirst%3DJ.%2BC.%26aulast%3DSimons%26aufirst%3DP.%2BC.%26aulast%3DSmagley%26aufirst%3DY.%26aulast%3DStrouse%26aufirst%3DJ.%26aulast%3DSurviladze%26aufirst%3DZ.%26atitle%3DDrug%2520repurposing%2520from%2520an%2520academic%2520perspective%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D8%26issue%3D3%25E2%2580%25934%26spage%3D61%26epage%3D69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group">Hansen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, C.</span><span> </span><span class="NLM_article-title">A Novel Hypothesis for Thalidomide-Induced Limb Teratogenesis: Redox Misregulation of the NF-κB Pathway</span> <span class="citation_source-journal">Antiox. Redox Signal</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">14</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1089%2F152308604771978291" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=1-14&issue=1&author=J.+M.+Hansenauthor=C.+Harris&title=A+Novel+Hypothesis+for+Thalidomide-Induced+Limb+Teratogenesis%3A+Redox+Misregulation+of+the+NF-%CE%BAB+Pathway"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1089%2F152308604771978291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252F152308604771978291%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DJ.%2BM.%26aulast%3DHarris%26aufirst%3DC.%26atitle%3DA%2520Novel%2520Hypothesis%2520for%2520Thalidomide-Induced%2520Limb%2520Teratogenesis%253A%2520Redox%2520Misregulation%2520of%2520the%2520NF-%25CE%25BAB%2520Pathway%26jtitle%3DAntiox.%2520Redox%2520Signal%26date%3D2004%26volume%3D6%26issue%3D1%26spage%3D1%26epage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group">Meierhofer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunzendorfer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiedermann, C. J.</span><span> </span><span class="NLM_article-title">Theoretical basis for the activity of thalidomide</span> <span class="citation_source-journal">BioDrugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">681</span><span class="NLM_x">–</span> <span class="NLM_lpage">703</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2001&pages=681-703&issue=10&author=C.+Meierhoferauthor=S.+Dunzendorferauthor=C.+J.+Wiedermann&title=Theoretical+basis+for+the+activity+of+thalidomide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeierhofer%26aufirst%3DC.%26aulast%3DDunzendorfer%26aufirst%3DS.%26aulast%3DWiedermann%26aufirst%3DC.%2BJ.%26atitle%3DTheoretical%2520basis%2520for%2520the%2520activity%2520of%2520thalidomide%26jtitle%3DBioDrugs%26date%3D2001%26volume%3D15%26issue%3D10%26spage%3D681%26epage%3D703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group">Holzgrabe, U.</span><span> </span><span class="NLM_article-title">An old drug as a carcinostatic. The new career of thalidomide</span> <span class="citation_source-journal">Pharm. Z.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">446</span><span class="NLM_x">–</span> <span class="NLM_lpage">449</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2007&pages=446-449&issue=6&author=U.+Holzgrabe&title=An+old+drug+as+a+carcinostatic.+The+new+career+of+thalidomide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHolzgrabe%26aufirst%3DU.%26atitle%3DAn%2520old%2520drug%2520as%2520a%2520carcinostatic.%2520The%2520new%2520career%2520of%2520thalidomide%26jtitle%3DPharm.%2520Z.%26date%3D2007%26volume%3D36%26issue%3D6%26spage%3D446%26epage%3D449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group">Manley, P. W.; Zimmermann, J.</span><span> </span><span class="NLM_article-title">Drug Research Leading to Imatinib and Beyond to Nilotinib</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed.; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">409</span><span class="NLM_x">–</span> <span class="NLM_lpage">421</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch20" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=409-421&author=P.+W.+Manley&author=J.+Zimmermannauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch20&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch20%26sid%3Dliteratum%253Aachs%26aulast%3DManley%26aufirst%3DP.%2BW.%26atitle%3DDrug%2520Research%2520Leading%2520to%2520Imatinib%2520and%2520Beyond%2520to%2520Nilotinib%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D409%26epage%3D421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matter, A.</span><span> </span><span class="NLM_article-title">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">493</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=493-502&issue=7&author=R.+Capdevilleauthor=E.+Buchdungerauthor=J.+Zimmermannauthor=A.+Matter&title=Glivec+%28STI571%2C+imatinib%29%2C+a+rationally+developed%2C+targeted+anticancer+drug"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DMatter%26aufirst%3DA.%26atitle%3DGlivec%2520%2528STI571%252C%2520imatinib%2529%252C%2520a%2520rationally%2520developed%252C%2520targeted%2520anticancer%2520drug%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26issue%3D7%26spage%3D493%26epage%3D502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group">Hirota, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isozaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishiguro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurata, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tunio, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuzawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanakura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinomura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitamura, Y.</span><span> </span><span class="NLM_article-title">Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x"> (</span><span class="NLM_issue">5350</span><span class="NLM_x">) </span> <span class="NLM_fpage">577</span><span class="NLM_x">–</span> <span class="NLM_lpage">580</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=1998&pages=577-580&issue=5350&author=S.+Hirotaauthor=K.+Isozakiauthor=Y.+Moriyamaauthor=K.+Hashimotoauthor=T.+Nishidaauthor=S.+Ishiguroauthor=K.+Kawanoauthor=M.+Hanadaauthor=A.+Kurataauthor=M.+Takedaauthor=G.+M.+Tunioauthor=Y.+Matsuzawaauthor=Y.+Kanakuraauthor=Y.+Shinomuraauthor=Y.+Kitamura&title=Gain-of-function+mutations+of+c-kit+in+human+gastrointestinal+stromal+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHirota%26aufirst%3DS.%26aulast%3DIsozaki%26aufirst%3DK.%26aulast%3DMoriyama%26aufirst%3DY.%26aulast%3DHashimoto%26aufirst%3DK.%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DIshiguro%26aufirst%3DS.%26aulast%3DKawano%26aufirst%3DK.%26aulast%3DHanada%26aufirst%3DM.%26aulast%3DKurata%26aufirst%3DA.%26aulast%3DTakeda%26aufirst%3DM.%26aulast%3DTunio%26aufirst%3DG.%2BM.%26aulast%3DMatsuzawa%26aufirst%3DY.%26aulast%3DKanakura%26aufirst%3DY.%26aulast%3DShinomura%26aufirst%3DY.%26aulast%3DKitamura%26aufirst%3DY.%26atitle%3DGain-of-function%2520mutations%2520of%2520c-kit%2520in%2520human%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DScience%26date%3D1998%26volume%3D279%26issue%3D5350%26spage%3D577%26epage%3D580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group">Delbaldo, C.; Colichi, C.; Sablin, M.-P.; Dreyer, C.; Billemont, B.; Faivre, S.; Raymond, E.</span><span> </span><span class="NLM_article-title">Discovery of Sunitinib as a Multitarget Treatment of Cancer</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed.; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">325</span><span class="NLM_x">–</span> <span class="NLM_lpage">342</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=325-342&author=C.+Delbaldo&author=C.+Colichi&author=M.-P.+Sablin&author=C.+Dreyer&author=B.+Billemont&author=S.+Faivre&author=E.+Raymondauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDelbaldo%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520Sunitinib%2520as%2520a%2520Multitarget%2520Treatment%2520of%2520Cancer%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D325%26epage%3D342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group">Wilhelm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowinger, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simantov, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelley, S.</span><span> </span><span class="NLM_article-title">Discovery and development of sorafenib: a multikinase inhibitor for treating cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">835</span><span class="NLM_x">–</span> <span class="NLM_lpage">844</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=835-844&issue=10&author=S.+Wilhelmauthor=C.+Carterauthor=M.+Lynchauthor=T.+Lowingerauthor=J.+Dumasauthor=R.+A.+Smithauthor=B.+Schwartzauthor=R.+Simantovauthor=S.+Kelley&title=Discovery+and+development+of+sorafenib%3A+a+multikinase+inhibitor+for+treating+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DS.%26aulast%3DCarter%26aufirst%3DC.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DLowinger%26aufirst%3DT.%26aulast%3DDumas%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DR.%2BA.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DSimantov%26aufirst%3DR.%26aulast%3DKelley%26aufirst%3DS.%26atitle%3DDiscovery%2520and%2520development%2520of%2520sorafenib%253A%2520a%2520multikinase%2520inhibitor%2520for%2520treating%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26issue%3D10%26spage%3D835%26epage%3D844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group">Meyer, U.</span><span> </span><span class="NLM_article-title">The history of antihistamines</span> <span class="citation_source-journal">Pharm.  Z.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">86</span><span class="NLM_x">–</span> <span class="NLM_lpage">91</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2004&pages=86-91&issue=2&author=U.+Meyer&title=The+history+of+antihistamines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DU.%26atitle%3DThe%2520history%2520of%2520antihistamines%26jtitle%3DPharm.%2520%2520Z.%26date%3D2004%26volume%3D33%26issue%3D2%26spage%3D86%26epage%3D91" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group">Sneader, W.</span><span> </span><span class="NLM_article-title">The 50th anniversary of chlorpromazine</span> <span class="citation_source-journal">Drug News Perspect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">466</span><span class="NLM_x">–</span> <span class="NLM_lpage">471</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1358%2Fdnp.2002.15.7.840082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD38XptlShsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2002&pages=466-471&issue=7&author=W.+Sneader&title=The+50th+anniversary+of+chlorpromazine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">The 50th anniversary of chlorpromazine</span></div><div class="casAuthors">Sneader, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Drug News & Perspectives</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">466-471</span>CODEN:
                <span class="NLM_cas:coden">DNPEED</span>;
        ISSN:<span class="NLM_cas:issn">0214-0934</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A historical account of the origins of the work that led to the marketing of chlorpromazine is presented.  The marketing of chlorpromazine 50 yr ago can be traced back to investigations carried out in 1891 by the father of chemotherapy, Paul Ehrlich.  Ehrlich's studies on possible antimalarial effects of methylene blue prompted other studies with antimalarials, including phenothiazine analogs of the dye.  Henri Laborit's search to find a drug that would be of value in preventing the traumatic consequences of shock caused circulatory collapse during surgery led him to discover the important effects that antihistamines, particularly promethazine, had on the central nervous system.  Investigations of centrally acting phenothiazines suitable to Laborit's requirements, with more sedating properties, eventually led to the development of chloropromazine and its use as an antipsychotic drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkieGcMTylvbVg90H21EOLACvtfcHk0lgbLCyhKLEb4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptlShsb0%253D&md5=895d09277b6bf74e3235e6eeaed90066</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1358%2Fdnp.2002.15.7.840082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdnp.2002.15.7.840082%26sid%3Dliteratum%253Aachs%26aulast%3DSneader%26aufirst%3DW.%26atitle%3DThe%252050th%2520anniversary%2520of%2520chlorpromazine%26jtitle%3DDrug%2520News%2520Perspect.%26date%3D2002%26volume%3D15%26issue%3D7%26spage%3D466%26epage%3D471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group">Lopez-Munoz, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alamo, C.</span><span> </span><span class="NLM_article-title">Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">14</span><span class="NLM_x">) </span> <span class="NLM_fpage">1563</span><span class="NLM_x">–</span> <span class="NLM_lpage">1586</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.2174%2F138161209788168001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtValtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=1563-1586&issue=14&author=F.+Lopez-Munozauthor=C.+Alamo&title=Monoaminergic+neurotransmission%3A+the+history+of+the+discovery+of+antidepressants+from+1950s+until+today"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today</span></div><div class="casAuthors">Lopez-Munoz, Francisco; Alamo, Cecilio</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1563-1586</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The 1950s saw the clin. introduction of the first two specifically antidepressant drugs: iproniazid, a monoamine-oxidase inhibitor that had been used in the treatment of tuberculosis, and imipramine, the first drug in the tricyclic antidepressant family.  Iproniazid and imipramine made two fundamental contributions to the development of psychiatry: one of a social-health nature, consisting in an authentic change in the psychiatric care of depressive patients; and the other of a purely pharmacol. nature, since these agents have constituted an indispensable research tool for neurobiol. and psychopharmacol., permitting, among other things, the postulation of the first etiopathogenic hypotheses of depressive disorders.  The clin. introduction of fluoxetine, a selective serotonin reuptake, inhibitor, in the late 1980s, once again revolutionized therapy for depression, opening the way for new families of antidepressants.  The present work reviews, from a historical perspective, the entire process that led to the discovery of these drugs, as well as their contribution to the development of the neuro-scientific disciplines.  However, all of these antidepressants, like the rest of those currently available for clin. practice, share the same action mechanism, which involves the modulation of monoaminergic neurotransmission at a synaptic level, so that the future of antidepressant therapy would seem to revolve around the search for extraneuronal non-aminergic mechanisms or mechanisms that modulate the intraneuronal biochem. pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtkMPhW4WjILVg90H21EOLACvtfcHk0lgbLCyhKLEb4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtValtrc%253D&md5=e9f791ce372daa3bd12893356f89c715</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.2174%2F138161209788168001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161209788168001%26sid%3Dliteratum%253Aachs%26aulast%3DLopez-Munoz%26aufirst%3DF.%26aulast%3DAlamo%26aufirst%3DC.%26atitle%3DMonoaminergic%2520neurotransmission%253A%2520the%2520history%2520of%2520the%2520discovery%2520of%2520antidepressants%2520from%25201950s%2520until%2520today%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2009%26volume%3D15%26issue%3D14%26spage%3D1563%26epage%3D1586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group">Creese, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burt, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, S. H.</span><span> </span><span class="NLM_article-title">Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">192</span><span class="NLM_x"> (</span><span class="NLM_issue">4238</span><span class="NLM_x">) </span> <span class="NLM_fpage">481</span><span class="NLM_x">–</span> <span class="NLM_lpage">483</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=1976&pages=481-483&issue=4238&author=I.+Creeseauthor=D.+R.+Burtauthor=S.+H.+Snyder&title=Dopamine+receptor+binding+predicts+clinical+and+pharmacological+potencies+of+antischizophrenic+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCreese%26aufirst%3DI.%26aulast%3DBurt%26aufirst%3DD.%2BR.%26aulast%3DSnyder%26aufirst%3DS.%2BH.%26atitle%3DDopamine%2520receptor%2520binding%2520predicts%2520clinical%2520and%2520pharmacological%2520potencies%2520of%2520antischizophrenic%2520drugs%26jtitle%3DScience%26date%3D1976%26volume%3D192%26issue%3D4238%26spage%3D481%26epage%3D483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group">Seeman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chau-Wong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.</span><span> </span><span class="NLM_article-title">Antipsychotic drug doses and neuroleptic/dopamine receptors</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">261</span><span class="NLM_x"> (</span><span class="NLM_issue">5562</span><span class="NLM_x">) </span> <span class="NLM_fpage">717</span><span class="NLM_x">–</span> <span class="NLM_lpage">719</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=261&publication_year=1976&pages=717-719&issue=5562&author=P.+Seemanauthor=T.+Leeauthor=M.+Chau-Wongauthor=K.+Wong&title=Antipsychotic+drug+doses+and+neuroleptic%2Fdopamine+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSeeman%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DChau-Wong%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.%26atitle%3DAntipsychotic%2520drug%2520doses%2520and%2520neuroleptic%252Fdopamine%2520receptors%26jtitle%3DNature%26date%3D1976%26volume%3D261%26issue%3D5562%26spage%3D717%26epage%3D719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group">Glowinski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Axelrod, J.</span><span> </span><span class="NLM_article-title">Inhibition of uptake of tritiated noradrenaline in the intact rat brain by imipramine and structurally related compounds</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1964</span><span class="NLM_x">, </span> <span class="NLM_volume">204</span><span class="NLM_x"> (</span><span class="NLM_issue">4965</span><span class="NLM_x">) </span> <span class="NLM_fpage">1318</span><span class="NLM_x">–</span> <span class="NLM_lpage">1319</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=1964&pages=1318-1319&issue=4965&author=J.+Glowinskiauthor=J.+Axelrod&title=Inhibition+of+uptake+of+tritiated+noradrenaline+in+the+intact+rat+brain+by+imipramine+and+structurally+related+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGlowinski%26aufirst%3DJ.%26aulast%3DAxelrod%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520uptake%2520of%2520tritiated%2520noradrenaline%2520in%2520the%2520intact%2520rat%2520brain%2520by%2520imipramine%2520and%2520structurally%2520related%2520compounds%26jtitle%3DNature%26date%3D1964%26volume%3D204%26issue%3D4965%26spage%3D1318%26epage%3D1319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="note"><p class="first last">No generic name could be found for compound <b>1</b>. Today, Loranil is a trade name of the antihistamine, loratidine, which is an entirely different drug.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group">Meyer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuhmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedrich, C.</span><span> </span><span class="NLM_article-title">Chance and calculated development! The history of oral antidiabetics</span> <span class="citation_source-journal">Pharm. Z.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">242</span><span class="NLM_x">–</span> <span class="NLM_lpage">250</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2002&pages=242-250&issue=3&author=U.+Meyerauthor=A.+Schuhmannauthor=C.+Friedrich&title=Chance+and+calculated+development%21+The+history+of+oral+antidiabetics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DU.%26aulast%3DSchuhmann%26aufirst%3DA.%26aulast%3DFriedrich%26aufirst%3DC.%26atitle%3DChance%2520and%2520calculated%2520development%2521%2520The%2520history%2520of%2520oral%2520antidiabetics%26jtitle%3DPharm.%2520Z.%26date%3D2002%26volume%3D31%26issue%3D3%26spage%3D242%26epage%3D250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group">Sneader, W.</span> <span class="citation_source-book">Drug Discovery – A History</span>; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Chichester</span>,<span class="NLM_x"> </span><span class="NLM_year">2005</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">392</span><span class="NLM_x">–</span> <span class="NLM_lpage">393</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F0470015535" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&pages=392-393&author=W.+Sneader&title=Drug+Discovery+%E2%80%93+A+History"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1002%2F0470015535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F0470015535%26sid%3Dliteratum%253Aachs%26aulast%3DSneader%26aufirst%3DW.%26btitle%3DDrug%2520Discovery%2520%25E2%2580%2593%2520A%2520History%26pub%3DWiley%26date%3D2005%26spage%3D392%26epage%3D393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group">Langer, T.; Wermuth, C.-G.</span><span> </span><span class="NLM_article-title">Selective Optimization of Side Activities (SOSA): A Promising Way for Drug Discovery</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed.; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">227</span><span class="NLM_x">–</span> <span class="NLM_lpage">243</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch11" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=227-243&author=T.+Langer&author=C.-G.+Wermuthauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch11%26sid%3Dliteratum%253Aachs%26aulast%3DLanger%26aufirst%3DT.%26atitle%3DSelective%2520Optimization%2520of%2520Side%2520Activities%2520%2528SOSA%2529%253A%2520A%2520Promising%2520Way%2520for%2520Drug%2520Discovery%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D227%26epage%3D243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group">Wermuth, C. G.</span><span> </span><span class="NLM_article-title">Selective optimization of side activities: the SOSA approach</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">3 & 4</span><span class="NLM_x">) </span> <span class="NLM_fpage">160</span><span class="NLM_x">–</span> <span class="NLM_lpage">164</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2006&pages=160-164&issue=3+%26+4&author=C.+G.+Wermuth&title=Selective+optimization+of+side+activities%3A+the+SOSA+approach"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWermuth%26aufirst%3DC.%2BG.%26atitle%3DSelective%2520optimization%2520of%2520side%2520activities%253A%2520the%2520SOSA%2520approach%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2006%26volume%3D11%26issue%3D3%2520%2526%25204%26spage%3D160%26epage%3D164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group">Wermuth, C. G.</span><span> </span><span class="NLM_article-title">Selective Optimization of Side Activities: Another Way for Drug Discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">1303</span><span class="NLM_x">–</span> <span class="NLM_lpage">1314</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm030480f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1303-1314&issue=6&author=C.+G.+Wermuth&title=Selective+Optimization+of+Side+Activities%3A+Another+Way+for+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1021%2Fjm030480f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030480f%26sid%3Dliteratum%253Aachs%26aulast%3DWermuth%26aufirst%3DC.%2BG.%26atitle%3DSelective%2520Optimization%2520of%2520Side%2520Activities%253A%2520Another%2520Way%2520for%2520Drug%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26issue%3D6%26spage%3D1303%26epage%3D1314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group">Morphy, J. R.</span><span> </span><span class="NLM_article-title">The Challenges of Multi-Target Lead Optimization</span>. In  <span class="citation_source-book">Designing Multi-Target Drugs</span>; <span class="NLM_contrib-group">Morphy, J. R.; Harris, C. J.</span>, Eds.; <span class="NLM_publisher-name">RSC Publishing</span>: <span class="NLM_publisher-loc">Cambridge</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">141</span><span class="NLM_x">–</span> <span class="NLM_lpage">154</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1039%2F9781849734912-00141" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=141-154&author=J.+R.+Morphyauthor=J.+R.+Morphy&author=C.+J.+Harris&title=Designing+Multi-Target+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1039%2F9781849734912-00141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1039%252F9781849734912-00141%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520Challenges%2520of%2520Multi-Target%2520Lead%2520Optimization%26btitle%3DDesigning%2520Multi-Target%2520Drugs%26aulast%3DMorphy%26aufirst%3DJ.%2BR.%26pub%3DRSC%2520Publishing%26date%3D2012%26spage%3D141%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group">Marchand, C.</span><span> </span><span class="NLM_article-title">The elvitegravir Quad pill: the first once-daily dual-target anti-HIV tablet</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">901</span><span class="NLM_x">–</span> <span class="NLM_lpage">904</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=901-904&issue=7&author=C.+Marchand&title=The+elvitegravir+Quad+pill%3A+the+first+once-daily+dual-target+anti-HIV+tablet"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarchand%26aufirst%3DC.%26atitle%3DThe%2520elvitegravir%2520Quad%2520pill%253A%2520the%2520first%2520once-daily%2520dual-target%2520anti-HIV%2520tablet%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2012%26volume%3D21%26issue%3D7%26spage%3D901%26epage%3D904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group">Monzon, J. G.; Dancey, J.</span><span> </span><span class="NLM_article-title">Combination Agents Versus Multi-Targeted Agents – Pros and Cons</span>. In  <span class="citation_source-book">Designing Multi-Target Drugs</span>; <span class="NLM_contrib-group">Morphy, J. R.; Harris, C. J.</span>, Eds.; <span class="NLM_publisher-name">RSC Publishing</span>: <span class="NLM_publisher-loc">Cambridge</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">155</span><span class="NLM_x">–</span> <span class="NLM_lpage">175</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1039%2F9781849734912-00155" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=155-175&author=J.+G.+Monzon&author=J.+Danceyauthor=J.+R.+Morphy&author=C.+J.+Harris&title=Designing+Multi-Target+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1039%2F9781849734912-00155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1039%252F9781849734912-00155%26sid%3Dliteratum%253Aachs%26aulast%3DMonzon%26aufirst%3DJ.%2BG.%26atitle%3DCombination%2520Agents%2520Versus%2520Multi-Targeted%2520Agents%2520%25E2%2580%2593%2520Pros%2520and%2520Cons%26btitle%3DDesigning%2520Multi-Target%2520Drugs%26aulast%3DMorphy%26aufirst%3DJ.%2BR.%26pub%3DRSC%2520Publishing%26date%3D2012%26spage%3D155%26epage%3D175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group">Bolognesi, M. L.</span><span> </span><span class="NLM_article-title">Polypharmacology in a single drug: multitarget drugs</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x"> (</span><span class="NLM_issue">13</span><span class="NLM_x">) </span> <span class="NLM_fpage">1639</span><span class="NLM_x">–</span> <span class="NLM_lpage">1645</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.2174%2F0929867311320130004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=23410164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotl2jtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1639-1645&issue=13&author=M.+L.+Bolognesi&title=Polypharmacology+in+a+single+drug%3A+multitarget+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology in a single drug: multitarget drugs</span></div><div class="casAuthors">Bolognesi, M. L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1639-1645</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Polypharmacol. offers a model for the way drug discovery must evolve to develop therapies most suited to treating currently incurable diseases.  It is driven by a worldwide demand for safer, more effective, and affordable medicines against the most complex diseases, and by the failures of modern drug discovery to provide these.  Polypharmacol. can involve combinations and/or multitarget drugs (MTD).  Although not mutually exclusive, my premise is that MTDs have inherent advantages over combinations.  This review article focuses on MTDs from a medicinal chem. perspective.  I will explore their use in current clin. practice, their likely application in the future, and the challenges to be overcome to achieve this goal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeSnmeFeRpMrVg90H21EOLACvtfcHk0liacXDmR3lqlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotl2jtLk%253D&md5=0e69395566711e018db8a61b1ae0f56e</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.2174%2F0929867311320130004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867311320130004%26sid%3Dliteratum%253Aachs%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DPolypharmacology%2520in%2520a%2520single%2520drug%253A%2520multitarget%2520drugs%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26issue%3D13%26spage%3D1639%26epage%3D1645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group">Morphy, R.</span><span> </span><span class="NLM_article-title">Selective Multitargeted Drugs</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed.; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">247</span><span class="NLM_x">–</span> <span class="NLM_lpage">262</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=247-262&author=R.+Morphyauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26atitle%3DSelective%2520Multitargeted%2520Drugs%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D247%26epage%3D262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group">Morphy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">Designing multiple ligands - medicinal chemistry strategies and challenges</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">587</span><span class="NLM_x">–</span> <span class="NLM_lpage">600</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.2174%2F138161209787315594" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=19199984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvVSns70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=587-600&issue=6&author=R.+Morphyauthor=Z.+Rankovic&title=Designing+multiple+ligands+-+medicinal+chemistry+strategies+and+challenges"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Designing multiple ligands - medicinal chemistry strategies and challenges</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">587-600</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  It has been widely recognized over the recent years that parallel modulation of multiple biol. targets can be beneficial for treatment of diseases with complex etiologies such as cancer asthma, and psychiatric disease.  In this article, current strategies for the generation of ligands with a specific multi-target profile (designed multiple ligands or DMLs) are described and a no. of illustrative example are given.  Designing multiple ligands is frequently a challenging endeavor for medicinal chemists, with the need to appropriately balance affinity for 2 or more targets while obtaining physicochem. and pharmacokinetic properties that are consistent with the administration of an oral drug.  Given that the properties of DMLs are influenced to a large extent by the proteomic superfamily to which the targets belong and the lead generation strategy that is pursued, an early assessment of the feasibility of any given DML project is essential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUo6NjoK5D-LVg90H21EOLACvtfcHk0liacXDmR3lqlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvVSns70%253D&md5=fa34039be6e9c3b489f530fc74fd0346</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.2174%2F138161209787315594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161209787315594%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigning%2520multiple%2520ligands%2520-%2520medicinal%2520chemistry%2520strategies%2520and%2520challenges%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2009%26volume%3D15%26issue%3D6%26spage%3D587%26epage%3D600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group">Allan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cambridge, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hardy, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Follenfant, M. J.</span><span> </span><span class="NLM_article-title">BW A575C, a chemically novel agent with angiotensin converting enzyme inhibitor and β-adrenoceptorblocking properties</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">609</span><span class="NLM_x">–</span> <span class="NLM_lpage">615</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1111%2Fj.1476-5381.1987.tb11212.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADyaL2sXhvVylu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1987&pages=609-615&author=G.+Allanauthor=D.+Cambridgeauthor=G.+W.+Hardyauthor=M.+J.+Follenfant&title=BW+A575C%2C+a+chemically+novel+agent+with+angiotensin+converting+enzyme+inhibitor+and+%CE%B2-adrenoceptorblocking+properties"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">BW A575C, a chemically novel agent with angiotensin-converting enzyme-inhibitor and β-adrenoceptor-blocking properties</span></div><div class="casAuthors">Allan, G.; Cambridge, D.; Hardy, G. W.; Follenfant, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">609-15</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    </div><div class="casAbstract">BW A575C (I)  [103221-88-1] is a chem. novel agent which exhibits in a single mol. both angiotensin converting enzyme (ACE)  [9015-82-1] inhibition and β-adrenoceptor-blocking properties.  BW A575C produced a competitive blockade of heart rate responses to isoprenaline in a guinea-pig right atrial prepn.  BW A575C inhibited a partially purified prepn. of ACE obtained from rabbit lung.  I.v. administration of BW A575C to the pithed rat inhibited, in a dose-dependent fashion, both angiotensin I-induced pressor responses and isoprenaline-induced tachycardia.  Dose-ratios obtained from such studies demonstrated that, in this prepn., BW A575C was approx. 100 times more active as an ACE inhibitor than as a β-adrenoceptor blocking agent.  I.v. administration of BW A575C (1 mg/kg) to the conscious rat inhibited angiotensin I-induced pressor responses, being approx. equipotent to enalapril and 10 times more potent than captopril.  At the same dose, BW A575C had a similar duration of action as an ACE inhibitor to enalapril.  I.v. administration of BW A575C (1 mg/kg) to either conscious dogs or rats inhibited both angiotensin I-induced pressor responses and isoprenaline-induced heart rate responses.  Dose-ratios obtained from such studies demonstrated that in these species, BW A575C was 2-10 times more active as an ACE inhibitor than as a β-adrenoceptor blocking agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIubMbW41qXrVg90H21EOLACvtfcHk0liacXDmR3lqlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXhvVylu7s%253D&md5=4e8b54bc3031daf1c4dadc35aa6af979</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1987.tb11212.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1987.tb11212.x%26sid%3Dliteratum%253Aachs%26aulast%3DAllan%26aufirst%3DG.%26aulast%3DCambridge%26aufirst%3DD.%26aulast%3DHardy%26aufirst%3DG.%2BW.%26aulast%3DFollenfant%26aufirst%3DM.%2BJ.%26atitle%3DBW%2520A575C%252C%2520a%2520chemically%2520novel%2520agent%2520with%2520angiotensin%2520converting%2520enzyme%2520inhibitor%2520and%2520%25CE%25B2-adrenoceptorblocking%2520properties%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1987%26volume%3D90%26spage%3D609%26epage%3D615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group">Morphy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">From magic bullets to designed multiple ligands</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">15</span><span class="NLM_x">) </span> <span class="NLM_fpage">641</span><span class="NLM_x">–</span> <span class="NLM_lpage">651</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1016%2FS1359-6446%2804%2903163-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=15279847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=641-651&issue=15&author=R.+Morphyauthor=C.+Kayauthor=Z.+Rankovic&title=From+magic+bullets+to+designed+multiple+ligands"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">From magic bullets to designed multiple ligands</span></div><div class="casAuthors">Morphy, Richard; Kay, Corinne; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">641-651</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  A major trend in medicinal chem. in the coming years will be the rational design of ligands that are capable of modulating multiple disease-relevant targets in a specific manner.  Increasingly, it is being recognized that a balanced modulation of several targets can provide a superior therapeutic effect and side effect profile compared to the action of a selective ligand.  Rational approaches in which structural features from selective ligands are combined have produced designed multiple ligands that span a wide variety of targets and target classes.  A key challenge in the design of multiple ligands is attaining a balanced activity at each target of interest while simultaneously achieving a wider selectivity and a suitable pharmacokinetic profile.  An anal. of literature examples reveals trends and insights that might help medicinal chemists discover the next generation of these types of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcsGpfzZok5rVg90H21EOLACvtfcHk0lg05aKQMso1EQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D&md5=cd2491baad707043dbee4f59ccad9e1d</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903163-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903163-0%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DKay%26aufirst%3DC.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFrom%2520magic%2520bullets%2520to%2520designed%2520multiple%2520ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26issue%3D15%26spage%3D641%26epage%3D651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group">Morphy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">Designed Multiple Ligands</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x"> (</span><span class="NLM_issue">21</span><span class="NLM_x">) </span> <span class="NLM_fpage">6523</span><span class="NLM_x">–</span> <span class="NLM_lpage">6543</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&issue=21&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+Multiple+Ligands"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520Multiple%2520Ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D21%26spage%3D6523%26epage%3D6543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group">Besnard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruda, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abecassis, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguiz, R. M</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norval, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sassano, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simeons, F. R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stojanovski, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidah, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Constam, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bickerton, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetsel, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, I. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, A. L.</span><span> </span><span class="NLM_article-title">Automated design of ligands to polypharmacological profiles</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">492</span><span class="NLM_x"> (</span><span class="NLM_issue">7428</span><span class="NLM_x">) </span> <span class="NLM_fpage">215</span><span class="NLM_x">–</span> <span class="NLM_lpage">220</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fnature11691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=23235874" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=492&publication_year=2012&pages=215-220&issue=7428&author=J.+Besnardauthor=G.+F.+Rudaauthor=V.+Setolaauthor=K.+Abecassisauthor=R.+M+Rodriguizauthor=X.-P.+Huangauthor=S.+Norvalauthor=M.+F.+Sassanoauthor=I.+Shinauthor=L.+A.+Websterauthor=F.+R.+C.+Simeonsauthor=L.+Stojanovskiauthor=A.+Pratauthor=N.+G.+Seidahauthor=D.+B.+Constamauthor=G.+R.+Bickertonauthor=K.+D.+Readauthor=W.+C.+Wetselauthor=I.+H.+Gilbertauthor=B.+L.+Rothauthor=A.+L.+Hopkins&title=Automated+design+of+ligands+to+polypharmacological+profiles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1038%2Fnature11691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11691%26sid%3Dliteratum%253Aachs%26aulast%3DBesnard%26aufirst%3DJ.%26aulast%3DRuda%26aufirst%3DG.%2BF.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DAbecassis%26aufirst%3DK.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DNorval%26aufirst%3DS.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DShin%26aufirst%3DI.%26aulast%3DWebster%26aufirst%3DL.%2BA.%26aulast%3DSimeons%26aufirst%3DF.%2BR.%2BC.%26aulast%3DStojanovski%26aufirst%3DL.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DSeidah%26aufirst%3DN.%2BG.%26aulast%3DConstam%26aufirst%3DD.%2BB.%26aulast%3DBickerton%26aufirst%3DG.%2BR.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DAutomated%2520design%2520of%2520ligands%2520to%2520polypharmacological%2520profiles%26jtitle%3DNature%26date%3D2012%26volume%3D492%26issue%3D7428%26spage%3D215%26epage%3D220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group">Day, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottaway, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelfanov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smiley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gidda, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Findeisen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruemmer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drucker, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaudhary, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holland, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hembree, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abplanalp, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruehl, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirchner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockie, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nogueiras, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfluger, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Tilve, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMarchi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tschöp, M. H.</span><span> </span><span class="NLM_article-title">A new glucagon and GLP-1 co-agonist eliminates obesity in rodents</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">749</span><span class="NLM_x">–</span> <span class="NLM_lpage">757</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fnchembio.209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=19597507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosFWhsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=749-757&issue=10&author=J.+W.+Dayauthor=N.+Ottawayauthor=J.+T.+Pattersonauthor=V.+Gelfanovauthor=D.+Smileyauthor=J.+Giddaauthor=H.+Findeisenauthor=D.+Bruemmerauthor=D.+J.+Druckerauthor=N.+Chaudharyauthor=J.+Hollandauthor=J.+Hembreeauthor=W.+Abplanalpauthor=E.+Grantauthor=J.+Ruehlauthor=H.+Wilsonauthor=H.+Kirchnerauthor=S.+H.+Lockieauthor=S.+Hofmannauthor=S.+C.+Woodsauthor=R.+Nogueirasauthor=P.+T.+Pflugerauthor=D.+Perez-Tilveauthor=R.+DiMarchiauthor=M.+H.+Tsch%C3%B6p&title=A+new+glucagon+and+GLP-1+co-agonist+eliminates+obesity+in+rodents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">A new glucagon and GLP-1 co-agonist eliminates obesity in rodents</span></div><div class="casAuthors">Day, Jonathan W.; Ottaway, Nickki; Patterson, James T.; Gelfanov, Vasily; Smiley, David; Gidda, Jas; Findeisen, Hannes; Bruemmer, Dennis; Drucker, Daniel J.; Chaudhary, Nilika; Holland, Jenna; Hembree, Jazzminn; Abplanalp, William; Grant, Erin; Ruehl, Jennifer; Wilson, Hilary; Kirchner, Henriette; Lockie, Sarah Haas; Hofmann, Susanna; Woods, Stephen C.; Nogueiras, Ruben; Pfluger, Paul T.; Perez-Tilve, Diego; DiMarchi, Richard; Tschoep, Matthias H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">749-757</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We report the efficacy of a new peptide with agonism at the glucagon and GLP-1 receptors that has potent, sustained satiation-inducing and lipolytic effects.  Selective chem. modification to glucagon resulted in a loss of specificity, with minimal change to inherent activity.  The structural basis for the co-agonism appears to be a combination of local positional interactions and a change in secondary structure.  Two co-agonist peptides differing from each other only in their level of glucagon receptor agonism were studied in rodent obesity models.  Administration of PEGylated peptides once per wk normalized adiposity and glucose tolerance in diet-induced obese mice.  Redn. of body wt. was achieved by a loss of body fat resulting from decreased food intake and increased energy expenditure.  These preclin. studies indicate that when full GLP-1 agonism is augmented with an appropriate degree of glucagon receptor activation, body fat redn. can be substantially enhanced without any overt adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4K1-_eVTTKbVg90H21EOLACvtfcHk0lhcALziqGOimg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosFWhsLk%253D&md5=74b57672bfd375dd4d073624a25eab9b</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.209%26sid%3Dliteratum%253Aachs%26aulast%3DDay%26aufirst%3DJ.%2BW.%26aulast%3DOttaway%26aufirst%3DN.%26aulast%3DPatterson%26aufirst%3DJ.%2BT.%26aulast%3DGelfanov%26aufirst%3DV.%26aulast%3DSmiley%26aufirst%3DD.%26aulast%3DGidda%26aufirst%3DJ.%26aulast%3DFindeisen%26aufirst%3DH.%26aulast%3DBruemmer%26aufirst%3DD.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DChaudhary%26aufirst%3DN.%26aulast%3DHolland%26aufirst%3DJ.%26aulast%3DHembree%26aufirst%3DJ.%26aulast%3DAbplanalp%26aufirst%3DW.%26aulast%3DGrant%26aufirst%3DE.%26aulast%3DRuehl%26aufirst%3DJ.%26aulast%3DWilson%26aufirst%3DH.%26aulast%3DKirchner%26aufirst%3DH.%26aulast%3DLockie%26aufirst%3DS.%2BH.%26aulast%3DHofmann%26aufirst%3DS.%26aulast%3DWoods%26aufirst%3DS.%2BC.%26aulast%3DNogueiras%26aufirst%3DR.%26aulast%3DPfluger%26aufirst%3DP.%2BT.%26aulast%3DPerez-Tilve%26aufirst%3DD.%26aulast%3DDiMarchi%26aufirst%3DR.%26aulast%3DTsch%25C3%25B6p%26aufirst%3DM.%2BH.%26atitle%3DA%2520new%2520glucagon%2520and%2520GLP-1%2520co-agonist%2520eliminates%2520obesity%2520in%2520rodents%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D5%26issue%3D10%26spage%3D749%26epage%3D757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group">Fosgerau, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jessen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lind Tolborg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterlund, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaeffer Larsen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolsted, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brorson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jelsing, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skovlund Ryge Neerup, T.</span><span> </span><span class="NLM_article-title">The novel GLP-1-gastrin dual agonist, ZP3022, increases β-cell mass and prevents diabetes in db/db mice</span> <span class="citation_source-journal">Diabetes, Obesity Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">62</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1111%2Fj.1463-1326.2012.01676.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCksLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=62-71&issue=1&author=K.+Fosgerauauthor=L.+Jessenauthor=J.+Lind+Tolborgauthor=T.+Osterlundauthor=K.+Schaeffer+Larsenauthor=K.+Rolstedauthor=M.+Brorsonauthor=J.+Jelsingauthor=T.+Skovlund+Ryge+Neerup&title=The+novel+GLP-1-gastrin+dual+agonist%2C+ZP3022%2C+increases+%CE%B2-cell+mass+and+prevents+diabetes+in+db%2Fdb+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">The novel GLP-1-gastrin dual agonist, ZP3022, increases β-cell mass and prevents diabetes in db/db mice</span></div><div class="casAuthors">Fosgerau, K.; Jessen, L.; Lind Tolborg, J.; Osterlund, T.; Schaeffer Larsen, K.; Rolsted, K.; Brorson, M.; Jelsing, J.; Skovlund Ryge Neerup, T.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">62-71</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aim : Diabetes is characterized by β-cell deficiency, and therefore restoration of β-cell function has been suggested as a potential therapy.  We hypothesized that a novel glucagon-like peptide-1 (GLP-1)-gastrin dual agonist, ZP3022, improves glycemic control via improvement of β-cell status in db/db mice..  Methods : Diabetic mice were studied following short- or long-term treatment with either the GLP-1-gastrin dual agonist or the com. available GLP-1 agonists (exendin-4 and liraglutide).  The effects on glycemic control were addressed by repeated glucose tolerance tests and/or measurements of HbA1c levels, and pancreatic islet and β-cell masses were detd. by stereol.Results : ZP3022 and the pure GLP-1 agonists improved glycemic control after both short- and long-term treatment compared with vehicle.  Interestingly, the effect was sustainable only in mice treated with ZP3022.  Stereol. data displayed a dose-dependent increase of β-cell mass (p < 0.05) following treatment with ZP3022, whereas no significant effect of liraglutide was obsd. (β-cell mass: vehicle 3.7 ± 0.2 mg; liraglutide (30 nmol/kg) 3.4 ± 0.5 mg; ZP3022 (30 nmol/kg) 4.3 ± 0.4 mg and ZP3022 (100 nmol/kg) 5.2 ± 0.4 mg).Conclusion : The novel GLP-1-gastrin dual agonist, ZP3022, improved glycemic control in db/db mice, and pancreatic islet and β-cell mass increased significantly following treatment with ZP3022 compared with vehicle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8ta9zMqxjlbVg90H21EOLACvtfcHk0lhcALziqGOimg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCksLrE&md5=cc432fa85f778937f2c2113f189b8aa4</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1111%2Fj.1463-1326.2012.01676.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1463-1326.2012.01676.x%26sid%3Dliteratum%253Aachs%26aulast%3DFosgerau%26aufirst%3DK.%26aulast%3DJessen%26aufirst%3DL.%26aulast%3DLind%2BTolborg%26aufirst%3DJ.%26aulast%3DOsterlund%26aufirst%3DT.%26aulast%3DSchaeffer%2BLarsen%26aufirst%3DK.%26aulast%3DRolsted%26aufirst%3DK.%26aulast%3DBrorson%26aufirst%3DM.%26aulast%3DJelsing%26aufirst%3DJ.%26aulast%3DSkovlund%2BRyge%2BNeerup%26aufirst%3DT.%26atitle%3DThe%2520novel%2520GLP-1-gastrin%2520dual%2520agonist%252C%2520ZP3022%252C%2520increases%2520%25CE%25B2-cell%2520mass%2520and%2520prevents%2520diabetes%2520in%2520db%252Fdb%2520mice%26jtitle%3DDiabetes%252C%2520Obesity%2520Metab.%26date%3D2013%26volume%3D15%26issue%3D1%26spage%3D62%26epage%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group">Atkinson, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bromidge, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duxon, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaster, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadley, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammond, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middlemiss, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">North, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, G. W.</span><span> </span><span class="NLM_article-title">3,4-Dihydro-2H-benzoxazinones are 5-HT1A receptor antagonists with potent 5-HT reuptake inhibitory activity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">737</span><span class="NLM_x">–</span> <span class="NLM_lpage">741</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=737-741&issue=3&author=P.+J.+Atkinsonauthor=S.+M.+Bromidgeauthor=M.+S.+Duxonauthor=L.+M.+Gasterauthor=M.+S.+Hadleyauthor=B.+Hammondauthor=C.+N.+Johnsonauthor=D.+N.+Middlemissauthor=S.+E.+Northauthor=G.+W.+Price&title=3%2C4-Dihydro-2H-benzoxazinones+are+5-HT1A+receptor+antagonists+with+potent+5-HT+reuptake+inhibitory+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAtkinson%26aufirst%3DP.%2BJ.%26aulast%3DBromidge%26aufirst%3DS.%2BM.%26aulast%3DDuxon%26aufirst%3DM.%2BS.%26aulast%3DGaster%26aufirst%3DL.%2BM.%26aulast%3DHadley%26aufirst%3DM.%2BS.%26aulast%3DHammond%26aufirst%3DB.%26aulast%3DJohnson%26aufirst%3DC.%2BN.%26aulast%3DMiddlemiss%26aufirst%3DD.%2BN.%26aulast%3DNorth%26aufirst%3DS.%2BE.%26aulast%3DPrice%26aufirst%3DG.%2BW.%26atitle%3D3%252C4-Dihydro-2H-benzoxazinones%2520are%25205-HT1A%2520receptor%2520antagonists%2520with%2520potent%25205-HT%2520reuptake%2520inhibitory%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26issue%3D3%26spage%3D737%26epage%3D741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group">Chen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wild, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guha, R.</span><span> </span><span class="NLM_article-title">PubChem as a Source of Polypharmacology</span> <span class="citation_source-journal">J. Chem. Inf. Mod.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">2044</span><span class="NLM_x">–</span> <span class="NLM_lpage">2055</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci9001876" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVGjtbrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=2044-2055&issue=9&author=B.+Chenauthor=D.+Wildauthor=R.+Guha&title=PubChem+as+a+Source+of+Polypharmacology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">PubChem as a Source of Polypharmacology</span></div><div class="casAuthors">Chen, Bin; Wild, David; Guha, Rajarshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2044-2055</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polypharmacol. provides a new way to address the issue of high attrition rates arising from lack of efficacy and toxicity.  However, the development of polypharmacol. is hampered by the incomplete SAR data and limited resources for validating target combinations.  The PubChem bioassay collection, reporting the activity of compds. in multiple assays, allows us to study polypharmacol. behavior in the PubChem collection via cross-assay anal.  In this paper, we developed a network representation of the assay collection and then applied a bipartite mapping between this network and various biol. networks (i.e., PPI, pathway) as well as artificial networks (i.e., drug-target network).  Mapping to a drug-target network allows us to prioritize new selective compds., while mapping to other biol. networks enable us to observe interesting target pairs and their assocd. compds. in the context of biol. systems.  Our results indicate this approach could be a useful way to investigate polypharmacol. in the PubChem bioassay collection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRZbl2jMrHtrVg90H21EOLACvtfcHk0lj3nU92HQ5lAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVGjtbrK&md5=76b5e8c8aa3e71a6c17b702db6988548</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1021%2Fci9001876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci9001876%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DB.%26aulast%3DWild%26aufirst%3DD.%26aulast%3DGuha%26aufirst%3DR.%26atitle%3DPubChem%2520as%2520a%2520Source%2520of%2520Polypharmacology%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Mod.%26date%3D2009%26volume%3D49%26issue%3D9%26spage%3D2044%26epage%3D2055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group">Artis, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehra, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perreault, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erbe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krupka, H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">England, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, J.</span><span> </span><span class="NLM_article-title">Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">262</span><span class="NLM_x">–</span> <span class="NLM_lpage">267</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=262-267&issue=1&author=D.+R.+Artisauthor=J.+J.+Linauthor=C.+Zhangauthor=W.+Wangauthor=U.+Mehraauthor=M.+Perreaultauthor=D.+Erbeauthor=H.+I.+Krupkaauthor=B.+P.+Englandauthor=J.+Arnold&title=Scaffold-based+discovery+of+indeglitazar%2C+a+PPAR+pan-active+anti-diabetic+agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DLin%26aufirst%3DJ.%2BJ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DMehra%26aufirst%3DU.%26aulast%3DPerreault%26aufirst%3DM.%26aulast%3DErbe%26aufirst%3DD.%26aulast%3DKrupka%26aufirst%3DH.%2BI.%26aulast%3DEngland%26aufirst%3DB.%2BP.%26aulast%3DArnold%26aufirst%3DJ.%26atitle%3DScaffold-based%2520discovery%2520of%2520indeglitazar%252C%2520a%2520PPAR%2520pan-active%2520anti-diabetic%2520agent%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26issue%3D1%26spage%3D262%26epage%3D267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group">Horst, J. A.; Laurenzi, A.; Bernard, B.; Samudrala, R.</span><span> </span><span class="NLM_article-title">Computational Multitarget Drug Discovery</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed.; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">263</span><span class="NLM_x">–</span> <span class="NLM_lpage">301</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch13" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=263-301&author=J.+A.+Horst&author=A.+Laurenzi&author=B.+Bernard&author=R.+Samudralaauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch13%26sid%3Dliteratum%253Aachs%26aulast%3DHorst%26aufirst%3DJ.%2BA.%26atitle%3DComputational%2520Multitarget%2520Drug%2520Discovery%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D263%26epage%3D301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group">Jenwitheesuk, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horst, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivas, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Voorhis, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samudrala, R.</span><span> </span><span class="NLM_article-title">Novel paradigms for drug discovery: computational multitarget screening</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">62</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=62-71&issue=2&author=E.+Jenwitheesukauthor=J.+A.+Horstauthor=K.+L.+Rivasauthor=W.+C.+Van+Voorhisauthor=R.+Samudrala&title=Novel+paradigms+for+drug+discovery%3A+computational+multitarget+screening"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJenwitheesuk%26aufirst%3DE.%26aulast%3DHorst%26aufirst%3DJ.%2BA.%26aulast%3DRivas%26aufirst%3DK.%2BL.%26aulast%3DVan%2BVoorhis%26aufirst%3DW.%2BC.%26aulast%3DSamudrala%26aufirst%3DR.%26atitle%3DNovel%2520paradigms%2520for%2520drug%2520discovery%253A%2520computational%2520multitarget%2520screening%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2008%26volume%3D29%26issue%3D2%26spage%3D62%26epage%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group">Carrieri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Nueno, V. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lentini, Gi.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ritchie, D. W.</span><span> </span><span class="NLM_article-title">Recent Trends And Future Prospects In Computational GPCR Drug Discovery: From Virtual Screening To Polypharmacology</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1069</span><span class="NLM_x">–</span> <span class="NLM_lpage">1097</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.2174%2F15680266113139990028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Wns7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=1069-1097&issue=9&author=A.+Carrieriauthor=V.+I.+Perez-Nuenoauthor=Gi.+Lentiniauthor=D.+W.+Ritchie&title=Recent+Trends+And+Future+Prospects+In+Computational+GPCR+Drug+Discovery%3A+From+Virtual+Screening+To+Polypharmacology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Trends and Future Prospects in Computational GPCR Drug Discovery: From Virtual Screening to Polypharmacology</span></div><div class="casAuthors">Carrieri, Antonio; Perez-Nueno, Violeta I.; Lentini, Giovanni; Ritchie, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1069-1097</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Extending virtual screening approaches to deal with multi-target drug design and polypharmacol. is an increasingly important aspect in drug design.  In light of this, the concept of accessible chem. space and its exploration should be reviewed.  The great advantages of re-using drugs with safe pharmacol. profiles with favorable pharmacokinetic properties highlights drug repositioning as a valid alternative to rational drug design, massive drug development efforts, and high-throughput screening, esp. when supported by in silico techniques.  Here, we discuss some of the advantages of multi-target approaches, and we review some significant examples of their application in the last decade to that well known class of pharmaceutical targets, the G-protein coupled receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXMiMDWYHyo7Vg90H21EOLACvtfcHk0lj3nU92HQ5lAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Wns7zK&md5=d651022fd90928c68e331199e10319c3</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.2174%2F15680266113139990028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F15680266113139990028%26sid%3Dliteratum%253Aachs%26aulast%3DCarrieri%26aufirst%3DA.%26aulast%3DPerez-Nueno%26aufirst%3DV.%2BI.%26aulast%3DLentini%26aufirst%3DGi.%26aulast%3DRitchie%26aufirst%3DD.%2BW.%26atitle%3DRecent%2520Trends%2520And%2520Future%2520Prospects%2520In%2520Computational%2520GPCR%2520Drug%2520Discovery%253A%2520From%2520Virtual%2520Screening%2520To%2520Polypharmacology%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26issue%3D9%26spage%3D1069%26epage%3D1097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group">Wei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, L.</span><span> </span><span class="NLM_article-title">Discovery of Multitarget Inhibitors by Combining Molecular Docking with Common Pharmacophore Matching</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x"> (</span><span class="NLM_issue">24</span><span class="NLM_x">) </span> <span class="NLM_fpage">7882</span><span class="NLM_x">–</span> <span class="NLM_lpage">7888</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8010096" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVKlu7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7882-7888&issue=24&author=D.+Weiauthor=X.+Jiangauthor=L.+Zhouauthor=J.+Chenauthor=Z.+Chenauthor=C.+Heauthor=K.+Yangauthor=Y.+Liuauthor=J.+Peiauthor=L.+Lai&title=Discovery+of+Multitarget+Inhibitors+by+Combining+Molecular+Docking+with+Common+Pharmacophore+Matching"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Multitarget Inhibitors by Combining Molecular Docking with Common Pharmacophore Matching</span></div><div class="casAuthors">Wei, Dengguo; Jiang, Xiaolu; Zhou, Lu; Chen, Jing; Chen, Zheng; He, Chong; Yang, Kun; Liu, Ying; Pei, Jianfeng; Lai, Luhua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7882-7888</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multitarget drugs have been to be found effective in controlling complex diseases.  However, how to design multitarget drugs presents a great challenge. We have developed a computer-assisted strategy to screen for multitarget inhibitors using a combination of mol. docking and common pharmacophore matching.  This strategy was successfully applied to screen for dual-target inhibitors against both the human leukotriene A4 hydrolase (LTA4H-h) and the human nonpancreatic secretory phospholipase A2 (hnps-PLA2).  Three compds. screened from the chem. database MDL Available Chem. Directory were found to inhibit these two enzymes at the 10 μM level.  Moreover, one synthetic compd. matching the common pharmacophores inhibits LTA4H-h and hnps-PLA2 with IC50 values of 35 nM and 7.3 μM, resp.  The common pharmacophore model can also be used to search small mol. databases or collections of existing inhibitors, as well as to guide combinatorial library design to search for ideal multitarget inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJgzU8gGUcMrVg90H21EOLACvtfcHk0lgREnNBCCosXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVKlu7nK&md5=0039b1caccc0518b554a20ed1e2e42c9</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1021%2Fjm8010096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8010096%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DD.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DPei%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520Multitarget%2520Inhibitors%2520by%2520Combining%2520Molecular%2520Docking%2520with%2520Common%2520Pharmacophore%2520Matching%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D24%26spage%3D7882%26epage%3D7888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group">Hoffmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metternich, R.</span><span> </span><span class="NLM_article-title">The Future of Medicinal Chemistry</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x"> (</span><span class="NLM_issue">35</span><span class="NLM_x">) </span> <span class="NLM_fpage">8670</span><span class="NLM_x">–</span> <span class="NLM_lpage">8671</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=8670-8671&issue=35&author=T.+Hoffmannauthor=R.+Metternich&title=The+Future+of+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHoffmann%26aufirst%3DT.%26aulast%3DMetternich%26aufirst%3DR.%26atitle%3DThe%2520Future%2520of%2520Medicinal%2520Chemistry%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2012%26volume%3D51%26issue%3D35%26spage%3D8670%26epage%3D8671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group">Swinney, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anthony, J.</span><span> </span><span class="NLM_article-title">How were new medicines discovered?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">507</span><span class="NLM_x">–</span> <span class="NLM_lpage">519</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=507-519&issue=7&author=D.+C.+Swinneyauthor=J.+Anthony&title=How+were+new+medicines+discovered%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSwinney%26aufirst%3DD.%2BC.%26aulast%3DAnthony%26aufirst%3DJ.%26atitle%3DHow%2520were%2520new%2520medicines%2520discovered%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26issue%3D7%26spage%3D507%26epage%3D519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group">Dar, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cagan, R. L.</span><span> </span><span class="NLM_article-title">Chemical genetic discovery of targets and antitargets for cancer polypharmacology</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">486</span><span class="NLM_x"> (</span><span class="NLM_issue">7401</span><span class="NLM_x">) </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">84</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=486&publication_year=2012&pages=80-84&issue=7401&author=A.+C.+Darauthor=T.+K.+Dasauthor=K.+M.+Shokatauthor=R.+L.+Cagan&title=Chemical+genetic+discovery+of+targets+and+antitargets+for+cancer+polypharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDar%26aufirst%3DA.%2BC.%26aulast%3DDas%26aufirst%3DT.%2BK.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DCagan%26aufirst%3DR.%2BL.%26atitle%3DChemical%2520genetic%2520discovery%2520of%2520targets%2520and%2520antitargets%2520for%2520cancer%2520polypharmacology%26jtitle%3DNature%26date%3D2012%26volume%3D486%26issue%3D7401%26spage%3D80%26epage%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group">Pang, M.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, D. H.</span><span> </span><span class="NLM_article-title">A series of case studies: practical methodology for identifying antinociceptive multi-target drugs</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">9–10</span><span class="NLM_x">) </span> <span class="NLM_fpage">425</span><span class="NLM_x">–</span> <span class="NLM_lpage">434</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=425-434&issue=9%E2%80%9310&author=M.-H.+Pangauthor=Y.+Kimauthor=K.+W.+Jungauthor=S.+Choauthor=D.+H.+Lee&title=A+series+of+case+studies%3A+practical+methodology+for+identifying+antinociceptive+multi-target+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPang%26aufirst%3DM.-H.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DJung%26aufirst%3DK.%2BW.%26aulast%3DCho%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DD.%2BH.%26atitle%3DA%2520series%2520of%2520case%2520studies%253A%2520practical%2520methodology%2520for%2520identifying%2520antinociceptive%2520multi-target%2520drugs%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26issue%3D9%25E2%2580%259310%26spage%3D425%26epage%3D434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':[],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 268 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Francesca Alessandra Ambrosio, Adriana Coricello, Giosuè Costa, Antonio Lupia, Mariachiara Micaelli, Nicoletta Marchesi, Federico Sala, Alessia Pascale, Daniela Rossi, Francesca Vasile, Stefano Alcaro, <span class="NLM_string-name hlFld-ContribAuthor">Simona Collina</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Compounds Targeting HuD. Another Brick in the Wall of Neurodegenerative Disease Treatment. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (14)
                                     , 9989-10000. <a href="https://doi.org/10.1021/acs.jmedchem.1c00191" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00191</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00191%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252BCompounds%252BTargeting%252BHuD.%252BAnother%252BBrick%252Bin%252Bthe%252BWall%252Bof%252BNeurodegenerative%252BDisease%252BTreatment%26aulast%3DAmbrosio%26aufirst%3DFrancesca%2BAlessandra%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D01022021%26date%3D05072021%26volume%3D64%26issue%3D14%26spage%3D9989%26epage%3D10000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaopeng Peng, Jingxuan Chen, Ling Li, Zhiqiang Sun, Jin Liu, Yichang Ren, Junli Huang, <span class="NLM_string-name hlFld-ContribAuthor">Jianjun Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 8447-8473. <a href="https://doi.org/10.1021/acs.jmedchem.1c00413" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00413</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00413%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DEfficient%252BSynthesis%252Band%252BBioevaluation%252Bof%252BNovel%252BDual%252BTubulin%25252FHistone%252BDeacetylase%252B3%252BInhibitors%252Bas%252BPotential%252BAnticancer%252BAgents%26aulast%3DPeng%26aufirst%3DXiaopeng%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D08032021%26date%3D07062021%26volume%3D64%26issue%3D12%26spage%3D8447%26epage%3D8473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Stefanie Hagenow, Anna Affini, Elsa Y. Pioli, Sonja Hinz, Yan Zhao, Gregory Porras, Vigneshwaran Namasivayam, Christa E. Müller, Jian-Sheng Lin, Erwan Bezard, <span class="NLM_string-name hlFld-ContribAuthor">Holger Stark</span>. </span><span class="cited-content_cbyCitation_article-title">Adenosine A2AR/A1R Antagonists Enabling Additional H3R Antagonism for the Treatment of Parkinson’s Disease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 8246-8262. <a href="https://doi.org/10.1021/acs.jmedchem.0c00914" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00914</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00914%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAdenosine%252BA2AR%25252FA1R%252BAntagonists%252BEnabling%252BAdditional%252BH3R%252BAntagonism%252Bfor%252Bthe%252BTreatment%252Bof%252BParkinson%2525E2%252580%252599s%252BDisease%26aulast%3DHagenow%26aufirst%3DStefanie%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D25012021%26date%3D09062021%26volume%3D64%26issue%3D12%26spage%3D8246%26epage%3D8262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kalpana Tilekar, Jessica D. Hess, Neha Upadhyay, Alessandra Lo Bianco, Markus Schweipert, Antonio Laghezza, Fulvio Loiodice, Franz-Josef Meyer-Almes, Renato J. Aguilera, Antonio Lavecchia, <span class="NLM_string-name hlFld-ContribAuthor">Ramaa C S</span>. </span><span class="cited-content_cbyCitation_article-title">Thiazolidinedione “Magic Bullets” Simultaneously Targeting PPARγ and HDACs: Design, Synthesis, and Investigations of their In Vitro and In Vivo Antitumor Effects. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (10)
                                     , 6949-6971. <a href="https://doi.org/10.1021/acs.jmedchem.1c00491" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00491</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00491%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThiazolidinedione%252B%2525E2%252580%25259CMagic%252BBullets%2525E2%252580%25259D%252BSimultaneously%252BTargeting%252BPPAR%2525CE%2525B3%252Band%252BHDACs%25253A%252BDesign%25252C%252BSynthesis%25252C%252Band%252BInvestigations%252Bof%252Btheir%252BIn%252BVitro%252Band%252BIn%252BVivo%252BAntitumor%252BEffects%26aulast%3DTilekar%26aufirst%3DKalpana%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D18032021%26date%3D18052021%26volume%3D64%26issue%3D10%26spage%3D6949%26epage%3D6971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Angela De Simone, Vincenzo Tumiatti, Vincenza Andrisano, <span class="NLM_string-name hlFld-ContribAuthor">Andrea Milelli</span>. </span><span class="cited-content_cbyCitation_article-title">Glycogen Synthase Kinase 3β: A New Gold Rush in Anti-Alzheimer’s Disease Multitarget Drug Discovery?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (1)
                                     , 26-41. <a href="https://doi.org/10.1021/acs.jmedchem.0c00931" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00931</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00931%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DGlycogen%252BSynthase%252BKinase%252B3%2525CE%2525B2%25253A%252BA%252BNew%252BGold%252BRush%252Bin%252BAnti-Alzheimer%2525E2%252580%252599s%252BDisease%252BMultitarget%252BDrug%252BDiscovery%25253F%26aulast%3DDe%2BSimone%26aufirst%3DAngela%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D01062020%26date%3D21122020%26volume%3D64%26issue%3D1%26spage%3D26%26epage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Christian Feldmann, Dimitar Yonchev, Dagmar Stumpfe, <span class="NLM_string-name hlFld-ContribAuthor">Jürgen Bajorath</span>. </span><span class="cited-content_cbyCitation_article-title">Systematic Data Analysis and Diagnostic Machine Learning Reveal Differences between Compounds with Single- and Multitarget Activity. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2020,</strong> <em>17 </em>
                                    (12)
                                     , 4652-4666. <a href="https://doi.org/10.1021/acs.molpharmaceut.0c00901" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.0c00901</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.0c00901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.0c00901%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DSystematic%252BData%252BAnalysis%252Band%252BDiagnostic%252BMachine%252BLearning%252BReveal%252BDifferences%252Bbetween%252BCompounds%252Bwith%252BSingle-%252Band%252BMultitarget%252BActivity%26aulast%3DFeldmann%26aufirst%3DChristian%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D04092020%26date%3D23102020%26date%3D02102020%26date%3D05112020%26volume%3D17%26issue%3D12%26spage%3D4652%26epage%3D4666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Falgun Shah, <span class="NLM_string-name hlFld-ContribAuthor">Ian M. Bell</span>. </span><span class="cited-content_cbyCitation_article-title">Cutaneous Adverse Events Caused by Sulfonamide-Containing Drugs: Reality or Perception?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (14)
                                     , 7447-7457. <a href="https://doi.org/10.1021/acs.jmedchem.9b01932" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01932</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01932&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01932%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCutaneous%252BAdverse%252BEvents%252BCaused%252Bby%252BSulfonamide-Containing%252BDrugs%25253A%252BReality%252Bor%252BPerception%25253F%26aulast%3DShah%26aufirst%3DFalgun%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D22112019%26date%3D24022020%26volume%3D63%26issue%3D14%26spage%3D7447%26epage%3D7457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dean G. Brown, Graham F. Smith, <span class="NLM_string-name hlFld-ContribAuthor">Heike J. Wobst</span>. </span><span class="cited-content_cbyCitation_article-title">Promiscuity of in Vitro Secondary Pharmacology Assays and Implications for Lead Optimization Strategies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (12)
                                     , 6251-6275. <a href="https://doi.org/10.1021/acs.jmedchem.9b01625" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01625</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01625%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPromiscuity%252Bof%252Bin%252BVitro%252BSecondary%252BPharmacology%252BAssays%252Band%252BImplications%252Bfor%252BLead%252BOptimization%252BStrategies%26aulast%3DBrown%26aufirst%3DDean%2BG.%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D30092019%26date%3D26112019%26date%3D12112019%26volume%3D63%26issue%3D12%26spage%3D6251%26epage%3D6275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Guiyan Han, Na Liu, Chenglan Li, Jie Tu, Zhuang Li, <span class="NLM_string-name hlFld-ContribAuthor">Chunquan Sheng</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Fungal Lanosterol 14α-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (10)
                                     , 5341-5359. <a href="https://doi.org/10.1021/acs.jmedchem.0c00102" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00102</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00102%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BFungal%252BLanosterol%252B14%2525CE%2525B1-Demethylase%252B%252528CYP51%252529%25252FHistone%252BDeacetylase%252BDual%252BInhibitors%252Bto%252BTreat%252BAzole-Resistant%252BCandidiasis%26aulast%3DHan%26aufirst%3DGuiyan%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D04022020%26date%3D09052020%26date%3D29042020%26volume%3D63%26issue%3D10%26spage%3D5341%26epage%3D5359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Luca Pinzi, <span class="NLM_string-name hlFld-ContribAuthor">Giulio Rastelli</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Target Associations for Polypharmacology from Analysis of Crystallographic Ligands of the Protein Data Bank. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2020,</strong> <em>60 </em>
                                    (1)
                                     , 372-390. <a href="https://doi.org/10.1021/acs.jcim.9b00821" title="DOI URL">https://doi.org/10.1021/acs.jcim.9b00821</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.9b00821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.9b00821%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DIdentification%252Bof%252BTarget%252BAssociations%252Bfor%252BPolypharmacology%252Bfrom%252BAnalysis%252Bof%252BCrystallographic%252BLigands%252Bof%252Bthe%252BProtein%252BData%252BBank%26aulast%3DPinzi%26aufirst%3DLuca%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D20092019%26date%3D19122019%26date%3D04122019%26volume%3D60%26issue%3D1%26spage%3D372%26epage%3D390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Junwei Wang, Hui Li, Guangchao He, Zhaoxing Chu, Kewen Peng, Yiran Ge, Qihua Zhu, <span class="NLM_string-name hlFld-ContribAuthor">Yungen Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Dual Poly(ADP-ribose)polymerase and Phosphoinositide 3-Kinase Inhibitors as a Promising Strategy for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (1)
                                     , 122-139. <a href="https://doi.org/10.1021/acs.jmedchem.9b00622" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00622</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00622%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BDual%252BPoly%252528ADP-ribose%252529polymerase%252Band%252BPhosphoinositide%252B3-Kinase%252BInhibitors%252Bas%252Ba%252BPromising%252BStrategy%252Bfor%252BCancer%252BTherapy%26aulast%3DWang%26aufirst%3DJunwei%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D11042019%26date%3D27122019%26date%3D17122019%26volume%3D63%26issue%3D1%26spage%3D122%26epage%3D139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kehui Zhang, Fangfang Lai, Songwen Lin, Ming Ji, Jingbo Zhang, Yan Zhang, Jing Jin, Rong Fu, Deyu Wu, Hua Tian, Nina Xue, Li Sheng, Xiaowen Zou, Yan Li, Xiaoguang Chen, <span class="NLM_string-name hlFld-ContribAuthor">Heng Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (15)
                                     , 6992-7014. <a href="https://doi.org/10.1021/acs.jmedchem.9b00390" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00390</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00390%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252B4-Methyl%252BQuinazoline%252BDerivatives%252Bas%252BAnticancer%252BAgents%252BSimultaneously%252BTargeting%252BPhosphoinositide%252B3-Kinases%252Band%252BHistone%252BDeacetylases%26aulast%3DZhang%26aufirst%3DKehui%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D03032019%26date%3D29052019%26date%3D22052019%26volume%3D62%26issue%3D15%26spage%3D6992%26epage%3D7014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Hana Kostrhunova, Juraj Zajac, Vojtech Novohradsky, Jana Kasparkova, Jaroslav Malina, Janice R. Aldrich-Wright, Emanuele Petruzzella, Roman Sirota, Dan Gibson, <span class="NLM_string-name hlFld-ContribAuthor">Viktor Brabec</span>. </span><span class="cited-content_cbyCitation_article-title">A Subset of New Platinum Antitumor Agents Kills Cells by a Multimodal Mechanism of Action Also Involving Changes in the Organization of the Microtubule Cytoskeleton. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (10)
                                     , 5176-5190. <a href="https://doi.org/10.1021/acs.jmedchem.9b00489" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00489</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00489%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BSubset%252Bof%252BNew%252BPlatinum%252BAntitumor%252BAgents%252BKills%252BCells%252Bby%252Ba%252BMultimodal%252BMechanism%252Bof%252BAction%252BAlso%252BInvolving%252BChanges%252Bin%252Bthe%252BOrganization%252Bof%252Bthe%252BMicrotubule%252BCytoskeleton%26aulast%3DKostrhunova%26aufirst%3DHana%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D20032019%26date%3D09052019%26date%3D28042019%26volume%3D62%26issue%3D10%26spage%3D5176%26epage%3D5190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xuewu Liang, Jie Zang, Xiaoyang Li, Shuai Tang, Min Huang, Meiyu Geng, C. James Chou, Chunpu Li, Yichun Cao, Wenfang Xu, Hong Liu, <span class="NLM_string-name hlFld-ContribAuthor">Yingjie Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (8)
                                     , 3898-3923. <a href="https://doi.org/10.1021/acs.jmedchem.8b01597" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01597</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01597%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BJanus%252BKinase%252B%252528JAK%252529%252Band%252BHistone%252BDeacetylase%252B%252528HDAC%252529%252BDual%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BHematological%252BMalignancies%26aulast%3DLiang%26aufirst%3DXuewu%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D14102018%26date%3D03042019%26date%3D22032019%26volume%3D62%26issue%3D8%26spage%3D3898%26epage%3D3923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Syed Muhammad Usama, Bosheng Zhao, <span class="NLM_string-name hlFld-ContribAuthor">Kevin Burgess</span>. </span><span class="cited-content_cbyCitation_article-title">A Near-IR Fluorescent Dasatinib Derivative That Localizes in Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2019,</strong> <em>30 </em>
                                    (4)
                                     , 1175-1181. <a href="https://doi.org/10.1021/acs.bioconjchem.9b00118" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.9b00118</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.9b00118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.9b00118%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DA%252BNear-IR%252BFluorescent%252BDasatinib%252BDerivative%252BThat%252BLocalizes%252Bin%252BCancer%252BCells%26aulast%3DUsama%26aufirst%3DSyed%2BMuhammad%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D12022019%26date%3D19032019%26date%3D01042019%26volume%3D30%26issue%3D4%26spage%3D1175%26epage%3D1181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Conrad Stork, Ya Chen, Martin Šícho, <span class="NLM_string-name hlFld-ContribAuthor">Johannes Kirchmair</span>. </span><span class="cited-content_cbyCitation_article-title">Hit Dexter 2.0: Machine-Learning Models for the Prediction of Frequent Hitters. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2019,</strong> <em>59 </em>
                                    (3)
                                     , 1030-1043. <a href="https://doi.org/10.1021/acs.jcim.8b00677" title="DOI URL">https://doi.org/10.1021/acs.jcim.8b00677</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.8b00677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.8b00677%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DHit%252BDexter%252B2.0%25253A%252BMachine-Learning%252BModels%252Bfor%252Bthe%252BPrediction%252Bof%252BFrequent%252BHitters%26aulast%3DStork%26aufirst%3DConrad%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D01102018%26date%3D25012019%26date%3D09012019%26volume%3D59%26issue%3D3%26spage%3D1030%26epage%3D1043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ellen Watts, David Heidenreich, Elizabeth Tucker, Monika Raab, Klaus Strebhardt, Louis Chesler, Stefan Knapp, Benjamin Bellenie, <span class="NLM_string-name hlFld-ContribAuthor">Swen Hoelder</span>. </span><span class="cited-content_cbyCitation_article-title">Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (5)
                                     , 2618-2637. <a href="https://doi.org/10.1021/acs.jmedchem.8b01947" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01947</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01947%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesigning%252BDual%252BInhibitors%252Bof%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%252Band%252BBromodomain-4%252B%252528BRD4%252529%252Bby%252BTuning%252BKinase%252BSelectivity%26aulast%3DWatts%26aufirst%3DEllen%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D13122018%26date%3D21022019%26volume%3D62%26issue%3D5%26spage%3D2618%26epage%3D2637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Erik Gilberg, <span class="NLM_string-name hlFld-ContribAuthor">Jürgen Bajorath</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Progress in Structure-Based Evaluation of Compound Promiscuity. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2019,</strong> <em>4 </em>
                                    (2)
                                     , 2758-2765. <a href="https://doi.org/10.1021/acsomega.8b03639" title="DOI URL">https://doi.org/10.1021/acsomega.8b03639</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.8b03639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.8b03639%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DRecent%252BProgress%252Bin%252BStructure-Based%252BEvaluation%252Bof%252BCompound%252BPromiscuity%26aulast%3DGilberg%26aufirst%3DErik%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D27122018%26date%3D29012019%26volume%3D4%26issue%3D2%26spage%3D2758%26epage%3D2765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ewgenij Proschak, Holger Stark, <span class="NLM_string-name hlFld-ContribAuthor">Daniel Merk</span>. </span><span class="cited-content_cbyCitation_article-title">Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (2)
                                     , 420-444. <a href="https://doi.org/10.1021/acs.jmedchem.8b00760" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00760</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00760%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPolypharmacology%252Bby%252BDesign%25253A%252BA%252BMedicinal%252BChemist%2525E2%252580%252599s%252BPerspective%252Bon%252BMultitargeting%252BCompounds%26aulast%3DProschak%26aufirst%3DEwgenij%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D11052018%26date%3D03082018%26date%3D23072018%26volume%3D62%26issue%3D2%26spage%3D420%26epage%3D444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Hassan Al-Ali, Ginamarie Debevec, Radleigh G. Santos, Richard A. Houghten, Jennifer C. Davis, Adel Nefzi, Vance P. Lemmon, John L. Bixby, <span class="NLM_string-name hlFld-ContribAuthor">Marc A. Giulianotti</span>. </span><span class="cited-content_cbyCitation_article-title">Scaffold Ranking and Positional Scanning Identify Novel Neurite Outgrowth Promoters with Nanomolar Potency. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (10)
                                     , 1057-1062. <a href="https://doi.org/10.1021/acsmedchemlett.8b00425" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00425</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00425%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DScaffold%252BRanking%252Band%252BPositional%252BScanning%252BIdentify%252BNovel%252BNeurite%252BOutgrowth%252BPromoters%252Bwith%252BNanomolar%252BPotency%26aulast%3DAl-Ali%26aufirst%3DHassan%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D17092018%26date%3D24092018%26date%3D01102018%26date%3D24092018%26volume%3D9%26issue%3D10%26spage%3D1057%26epage%3D1062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Koilpitchai Sivamuthuraman, <span class="NLM_string-name hlFld-ContribAuthor">Venkitasamy Kesavan</span>. </span><span class="cited-content_cbyCitation_article-title">Stereodivergent Synthesis of 3-Aminooxindole Derivatives Containing Vicinal Tetrasubstituted Stereocenters via the Mannich Reaction. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>83 </em>
                                    (16)
                                     , 8936-8952. <a href="https://doi.org/10.1021/acs.joc.8b01020" title="DOI URL">https://doi.org/10.1021/acs.joc.8b01020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b01020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b01020%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DStereodivergent%252BSynthesis%252Bof%252B3-Aminooxindole%252BDerivatives%252BContaining%252BVicinal%252BTetrasubstituted%252BStereocenters%252Bvia%252Bthe%252BMannich%252BReaction%26aulast%3DSivamuthuraman%26aufirst%3DKoilpitchai%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D05052018%26date%3D23072018%26date%3D02072018%26volume%3D83%26issue%3D16%26spage%3D8936%26epage%3D8952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yahui Huang, Guoqiang Dong, Huanqiu Li, Na Liu, Wannian Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Chunquan Sheng</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (14)
                                     , 6056-6074. <a href="https://doi.org/10.1021/acs.jmedchem.8b00393" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00393</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00393%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BJanus%252BKinase%252B2%252B%252528JAK2%252529%252Band%252BHistone%252BDeacetylase%252B%252528HDAC%252529%252BDual%252BInhibitors%252Bas%252Ba%252BNovel%252BStrategy%252Bfor%252Bthe%252BCombinational%252BTreatment%252Bof%252BLeukemia%252Band%252BInvasive%252BFungal%252BInfections%26aulast%3DHuang%26aufirst%3DYahui%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D10032018%26date%3D14072018%26date%3D25062018%26volume%3D61%26issue%3D14%26spage%3D6056%26epage%3D6074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jie Zang, Xuewu Liang, Yongxue Huang, Yuping Jia, Xiaoyang Li, Wenfang Xu, C. James Chou, <span class="NLM_string-name hlFld-ContribAuthor">Yingjie Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (12)
                                     , 5304-5322. <a href="https://doi.org/10.1021/acs.jmedchem.8b00384" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00384</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00384%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BPazopanib-Based%252BHDAC%252Band%252BVEGFR%252BDual%252BInhibitors%252BTargeting%252BCancer%252BEpigenetics%252Band%252BAngiogenesis%252BSimultaneously%26aulast%3DZang%26aufirst%3DJie%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D09032018%26date%3D07062018%26date%3D22052018%26volume%3D61%26issue%3D12%26spage%3D5304%26epage%3D5322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kai Wang, Li Bao, Nan Zhou, Jinjin Zhang, Mingfang Liao, Zhongyong Zheng, Yujing Wang, Chang Liu, Jun Wang, Lifeng Wang, Wenzhao Wang, ShuangJiang Liu, <span class="NLM_string-name hlFld-ContribAuthor">Hongwei Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Modification of Natural Product Ganomycin I Leading to Discovery of a α-Glucosidase and HMG-CoA Reductase Dual Inhibitor Improving Obesity and Metabolic Dysfunction in Vivo. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (8)
                                     , 3609-3625. <a href="https://doi.org/10.1021/acs.jmedchem.8b00107" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00107</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00107%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructural%252BModification%252Bof%252BNatural%252BProduct%252BGanomycin%252BI%252BLeading%252Bto%252BDiscovery%252Bof%252Ba%252B%2525CE%2525B1-Glucosidase%252Band%252BHMG-CoA%252BReductase%252BDual%252BInhibitor%252BImproving%252BObesity%252Band%252BMetabolic%252BDysfunction%252Bin%252BVivo%26aulast%3DWang%26aufirst%3DKai%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D22012018%26date%3D13042018%26date%3D10042018%26volume%3D61%26issue%3D8%26spage%3D3609%26epage%3D3625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kun Fang, Guoqiang Dong, Yu Li, Shipeng He, Ying Wu, Shanchao Wu, Wei Wang, <span class="NLM_string-name hlFld-ContribAuthor">Chunquan Sheng</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (4)
                                     , 312-317. <a href="https://doi.org/10.1021/acsmedchemlett.7b00487" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.7b00487</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.7b00487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.7b00487%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BNovel%252BIndoleamine%252B2%25252C3-Dioxygenase%252B1%252B%252528IDO1%252529%252Band%252BHistone%252BDeacetylase%252B%252528HDAC%252529%252BDual%252BInhibitors%26aulast%3DFang%26aufirst%3DKun%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D26112017%26date%3D26032018%26date%3D02042018%26date%3D26032018%26volume%3D9%26issue%3D4%26spage%3D312%26epage%3D317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei  Chen</span>, <span class="hlFld-ContribAuthor ">Guoqiang  Dong</span>, <span class="hlFld-ContribAuthor ">Ying  Wu</span>, <span class="hlFld-ContribAuthor ">Wannian  Zhang</span>, <span class="hlFld-ContribAuthor ">Chaoyu  Miao</span>, and <span class="hlFld-ContribAuthor ">Chunquan  Sheng</span>  . </span><span class="cited-content_cbyCitation_article-title">Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (1)
                                     , 34-38. <a href="https://doi.org/10.1021/acsmedchemlett.7b00414" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.7b00414</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.7b00414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.7b00414%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDual%252BNAMPT%25252FHDAC%252BInhibitors%252Bas%252Ba%252BNew%252BStrategy%252Bfor%252BMultitargeting%252BAntitumor%252BDrug%252BDiscovery%26aulast%3DChen%26aufirst%3DWei%26date%3D2018%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D10102017%26date%3D14122017%26date%3D19122017%26date%3D11012018%26date%3D14122017%26volume%3D9%26issue%3D1%26spage%3D34%26epage%3D38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shrawan R.  Chavan</span>, <span class="hlFld-ContribAuthor ">Kishor S.  Gavale</span>, <span class="hlFld-ContribAuthor ">Ayesha  Khan</span>, <span class="hlFld-ContribAuthor ">Rakesh  Joshi</span>, <span class="hlFld-ContribAuthor ">Navanath  Kumbhar</span>, <span class="hlFld-ContribAuthor ">Debamitra  Chakravarty</span>, and <span class="hlFld-ContribAuthor ">Dilip D.  Dhavale</span>  . </span><span class="cited-content_cbyCitation_article-title">Iminosugars Spiro-Linked with Morpholine-Fused 1,2,3-Triazole: Synthesis, Conformational Analysis, Glycosidase Inhibitory Activity, Antifungal Assay, and Docking Studies. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2017,</strong> <em>2 </em>
                                    (10)
                                     , 7203-7218. <a href="https://doi.org/10.1021/acsomega.7b01299" title="DOI URL">https://doi.org/10.1021/acsomega.7b01299</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.7b01299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.7b01299%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DIminosugars%252BSpiro-Linked%252Bwith%252BMorpholine-Fused%252B1%25252C2%25252C3-Triazole%25253A%252BSynthesis%25252C%252BConformational%252BAnalysis%25252C%252BGlycosidase%252BInhibitory%252BActivity%25252C%252BAntifungal%252BAssay%25252C%252Band%252BDocking%252BStudies%26aulast%3DChavan%26aufirst%3DShrawan%2BR.%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D04092017%26date%3D13102017%26date%3D31102017%26volume%3D2%26issue%3D10%26spage%3D7203%26epage%3D7218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guoqiang  Dong</span>, <span class="hlFld-ContribAuthor ">Wei  Chen</span>, <span class="hlFld-ContribAuthor ">Xia  Wang</span>, <span class="hlFld-ContribAuthor ">Xinglin  Yang</span>, <span class="hlFld-ContribAuthor ">Tianying  Xu</span>, <span class="hlFld-ContribAuthor ">Pei  Wang</span>, <span class="hlFld-ContribAuthor ">Wannian  Zhang</span>, <span class="hlFld-ContribAuthor ">Yu  Rao</span>, <span class="hlFld-ContribAuthor ">Chaoyu  Miao</span>, and <span class="hlFld-ContribAuthor ">Chunquan  Sheng</span>  . </span><span class="cited-content_cbyCitation_article-title">Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (19)
                                     , 7965-7983. <a href="https://doi.org/10.1021/acs.jmedchem.7b00467" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00467</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00467%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall%252BMolecule%252BInhibitors%252BSimultaneously%252BTargeting%252BCancer%252BMetabolism%252Band%252BEpigenetics%25253A%252BDiscovery%252Bof%252BNovel%252BNicotinamide%252BPhosphoribosyltransferase%252B%252528NAMPT%252529%252Band%252BHistone%252BDeacetylase%252B%252528HDAC%252529%252BDual%252BInhibitors%26aulast%3DDong%26aufirst%3DGuoqiang%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D27032017%26date%3D21092017%26date%3D12102017%26date%3D08092017%26volume%3D60%26issue%3D19%26spage%3D7965%26epage%3D7983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jurema  Schmidt</span>, <span class="hlFld-ContribAuthor ">Marco  Rotter</span>, <span class="hlFld-ContribAuthor ">Tim  Weiser</span>, <span class="hlFld-ContribAuthor ">Sandra  Wittmann</span>, <span class="hlFld-ContribAuthor ">Lilia  Weizel</span>, <span class="hlFld-ContribAuthor ">Astrid  Kaiser</span>, <span class="hlFld-ContribAuthor ">Jan  Heering</span>, <span class="hlFld-ContribAuthor ">Tamara  Goebel</span>, <span class="hlFld-ContribAuthor ">Carlo  Angioni</span>, <span class="hlFld-ContribAuthor ">Mario  Wurglics</span>, <span class="hlFld-ContribAuthor ">Alexander  Paulke</span>, <span class="hlFld-ContribAuthor ">Gerd  Geisslinger</span>, <span class="hlFld-ContribAuthor ">Astrid  Kahnt</span>, <span class="hlFld-ContribAuthor ">Dieter  Steinhilber</span>, <span class="hlFld-ContribAuthor ">Ewgenij  Proschak</span>, and <span class="hlFld-ContribAuthor ">Daniel  Merk</span>  . </span><span class="cited-content_cbyCitation_article-title">A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (18)
                                     , 7703-7724. <a href="https://doi.org/10.1021/acs.jmedchem.7b00398" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00398</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00398%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BDual%252BModulator%252Bof%252BFarnesoid%252BX%252BReceptor%252Band%252BSoluble%252BEpoxide%252BHydrolase%252BTo%252BCounter%252BNonalcoholic%252BSteatohepatitis%26aulast%3DSchmidt%26aufirst%3DJurema%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D14032017%26date%3D08092017%26date%3D28092017%26date%3D28082017%26volume%3D60%26issue%3D18%26spage%3D7703%26epage%3D7724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fiona M.  Deane</span>, <span class="hlFld-ContribAuthor ">Andrew J. S.  Lin</span>, <span class="hlFld-ContribAuthor ">Peter G.  Hains</span>, <span class="hlFld-ContribAuthor ">Sarah L.  Pilgrim</span>, <span class="hlFld-ContribAuthor ">Phillip J.  Robinson</span>, and <span class="hlFld-ContribAuthor ">Adam  McCluskey</span>  . </span><span class="cited-content_cbyCitation_article-title">FD5180, a Novel Protein Kinase Affinity Probe, and the Effect of Bead Loading on Protein Kinase Identification. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2017,</strong> <em>2 </em>
                                    (7)
                                     , 3828-3838. <a href="https://doi.org/10.1021/acsomega.7b00020" title="DOI URL">https://doi.org/10.1021/acsomega.7b00020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.7b00020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.7b00020%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DFD5180%25252C%252Ba%252BNovel%252BProtein%252BKinase%252BAffinity%252BProbe%25252C%252Band%252Bthe%252BEffect%252Bof%252BBead%252BLoading%252Bon%252BProtein%252BKinase%252BIdentification%26aulast%3DDeane%26aufirst%3DFiona%2BM.%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D09012017%26date%3D12062017%26date%3D31072017%26volume%3D2%26issue%3D7%26spage%3D3828%26epage%3D3838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ewgenij  Proschak</span>, <span class="hlFld-ContribAuthor ">Pascal  Heitel</span>, <span class="hlFld-ContribAuthor ">Lena  Kalinowsky</span>, and <span class="hlFld-ContribAuthor ">Daniel  Merk</span>  . </span><span class="cited-content_cbyCitation_article-title">Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (13)
                                     , 5235-5266. <a href="https://doi.org/10.1021/acs.jmedchem.6b01287" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01287</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01287%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DOpportunities%252Band%252BChallenges%252Bfor%252BFatty%252BAcid%252BMimetics%252Bin%252BDrug%252BDiscovery%26aulast%3DProschak%26aufirst%3DEwgenij%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D25082016%26date%3D27032017%26date%3D13072017%26date%3D02032017%26volume%3D60%26issue%3D13%26spage%3D5235%26epage%3D5266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David  Schaller</span>, <span class="hlFld-ContribAuthor ">Stefanie  Hagenow</span>, <span class="hlFld-ContribAuthor ">Gina  Alpert</span>, <span class="hlFld-ContribAuthor ">Alexandra  Naß</span>, <span class="hlFld-ContribAuthor ">Robert  Schulz</span>, <span class="hlFld-ContribAuthor ">Marcel  Bermudez</span>, <span class="hlFld-ContribAuthor ">Holger  Stark</span>, and <span class="hlFld-ContribAuthor ">Gerhard  Wolber</span>  . </span><span class="cited-content_cbyCitation_article-title">Systematic Data Mining Reveals Synergistic H3R/MCHR1 Ligands. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>8 </em>
                                    (6)
                                     , 648-653. <a href="https://doi.org/10.1021/acsmedchemlett.7b00118" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.7b00118</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.7b00118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.7b00118%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSystematic%252BData%252BMining%252BReveals%252BSynergistic%252BH3R%25252FMCHR1%252BLigands%26aulast%3DSchaller%26aufirst%3DDavid%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D18032017%26date%3D04052017%26date%3D08052017%26date%3D08062017%26date%3D04052017%26volume%3D8%26issue%3D6%26spage%3D648%26epage%3D653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simon  Krautwald</span> and <span class="hlFld-ContribAuthor ">Erick M.  Carreira</span>  . </span><span class="cited-content_cbyCitation_article-title">Stereodivergence in Asymmetric Catalysis. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2017,</strong> <em>139 </em>
                                    (16)
                                     , 5627-5639. <a href="https://doi.org/10.1021/jacs.6b13340" title="DOI URL">https://doi.org/10.1021/jacs.6b13340</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.6b13340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.6b13340%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DStereodivergence%252Bin%252BAsymmetric%252BCatalysis%26aulast%3DKrautwald%26aufirst%3DSimon%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D29122016%26date%3D12042017%26date%3D26042017%26date%3D06042017%26volume%3D139%26issue%3D16%26spage%3D5627%26epage%3D5639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Inès  Rasolohery</span>, <span class="hlFld-ContribAuthor ">Gautier  Moroy</span>, and <span class="hlFld-ContribAuthor ">Frédéric  Guyon</span>  . </span><span class="cited-content_cbyCitation_article-title">PatchSearch: A Fast Computational Method for Off-Target Detection. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2017,</strong> <em>57 </em>
                                    (4)
                                     , 769-777. <a href="https://doi.org/10.1021/acs.jcim.6b00529" title="DOI URL">https://doi.org/10.1021/acs.jcim.6b00529</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.6b00529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.6b00529%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DPatchSearch%25253A%252BA%252BFast%252BComputational%252BMethod%252Bfor%252BOff-Target%252BDetection%26aulast%3DRasolohery%26aufirst%3DIn%25C3%25A8s%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D05092016%26date%3D24032017%26date%3D24042017%26date%3D10032017%26volume%3D57%26issue%3D4%26spage%3D769%26epage%3D777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Weilin  Zhang</span>, <span class="hlFld-ContribAuthor ">Jianfeng  Pei</span>, and <span class="hlFld-ContribAuthor ">Luhua  Lai</span>  . </span><span class="cited-content_cbyCitation_article-title">Computational Multitarget Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2017,</strong> <em>57 </em>
                                    (3)
                                     , 403-412. <a href="https://doi.org/10.1021/acs.jcim.6b00491" title="DOI URL">https://doi.org/10.1021/acs.jcim.6b00491</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.6b00491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.6b00491%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DComputational%252BMultitarget%252BDrug%252BDesign%26aulast%3DZhang%26aufirst%3DWeilin%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D19082016%26date%3D23022017%26date%3D27032017%26date%3D06022017%26volume%3D57%26issue%3D3%26spage%3D403%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alessio  De Simone</span>, <span class="hlFld-ContribAuthor ">Debora  Russo</span>, <span class="hlFld-ContribAuthor ">Gian Filippo  Ruda</span>, <span class="hlFld-ContribAuthor ">Alessandra  Micoli</span>, <span class="hlFld-ContribAuthor ">Mariarosaria  Ferraro</span>, <span class="hlFld-ContribAuthor ">Rita Maria Concetta  Di Martino</span>, <span class="hlFld-ContribAuthor ">Giuliana  Ottonello</span>, <span class="hlFld-ContribAuthor ">Maria  Summa</span>, <span class="hlFld-ContribAuthor ">Andrea  Armirotti</span>, <span class="hlFld-ContribAuthor ">Tiziano  Bandiera</span>, <span class="hlFld-ContribAuthor ">Andrea  Cavalli</span>, and <span class="hlFld-ContribAuthor ">Giovanni  Bottegoni</span>  . </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, Structure–Activity Relationship Studies, and Three-Dimensional Quantitative Structure–Activity Relationship (3D-QSAR) Modeling of a Series of O-Biphenyl Carbamates as Dual Modulators of Dopamine D3 Receptor and Fatty Acid Amide Hydrolase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (6)
                                     , 2287-2304. <a href="https://doi.org/10.1021/acs.jmedchem.6b01578" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01578</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01578%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252BStructure%2525E2%252580%252593Activity%252BRelationship%252BStudies%25252C%252Band%252BThree-Dimensional%252BQuantitative%252BStructure%2525E2%252580%252593Activity%252BRelationship%252B%2525283D-QSAR%252529%252BModeling%252Bof%252Ba%252BSeries%252Bof%252BO-Biphenyl%252BCarbamates%252Bas%252BDual%252BModulators%252Bof%252BDopamine%252BD3%252BReceptor%252Band%252BFatty%252BAcid%252BAmide%252BHydrolase%26aulast%3DDe%2BSimone%26aufirst%3DAlessio%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D24102016%26date%3D02032017%26date%3D23032017%26date%3D09022017%26volume%3D60%26issue%3D6%26spage%3D2287%26epage%3D2304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ross  McGuire</span>, <span class="hlFld-ContribAuthor ">Stefan  Verhoeven</span>, <span class="hlFld-ContribAuthor ">Márton  Vass</span>, <span class="hlFld-ContribAuthor ">Gerrit  Vriend</span>, <span class="hlFld-ContribAuthor ">Iwan J. P.  de Esch</span>, <span class="hlFld-ContribAuthor ">Scott J.  Lusher</span>, <span class="hlFld-ContribAuthor ">Rob  Leurs</span>, <span class="hlFld-ContribAuthor ">Lars  Ridder</span>, <span class="hlFld-ContribAuthor ">Albert J.  Kooistra</span>, <span class="hlFld-ContribAuthor ">Tina  Ritschel</span>, and <span class="hlFld-ContribAuthor ">Chris  de Graaf</span>  . </span><span class="cited-content_cbyCitation_article-title">3D-e-Chem-VM: Structural Cheminformatics Research Infrastructure in a Freely Available Virtual Machine. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2017,</strong> <em>57 </em>
                                    (2)
                                     , 115-121. <a href="https://doi.org/10.1021/acs.jcim.6b00686" title="DOI URL">https://doi.org/10.1021/acs.jcim.6b00686</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.6b00686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.6b00686%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3D3D-e-Chem-VM%25253A%252BStructural%252BCheminformatics%252BResearch%252BInfrastructure%252Bin%252Ba%252BFreely%252BAvailable%252BVirtual%252BMachine%26aulast%3DMcGuire%26aufirst%3DRoss%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D16112016%26date%3D14022017%26date%3D27022017%26date%3D26012017%26volume%3D57%26issue%3D2%26spage%3D115%26epage%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matteo  Aldeghi</span>, <span class="hlFld-ContribAuthor ">Alexander  Heifetz</span>, <span class="hlFld-ContribAuthor ">Michael J.  Bodkin</span>, <span class="hlFld-ContribAuthor ">Stefan  Knapp</span>, and <span class="hlFld-ContribAuthor ">Philip C.  Biggin</span>  . </span><span class="cited-content_cbyCitation_article-title">Predictions of Ligand Selectivity from Absolute Binding Free Energy Calculations. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2017,</strong> <em>139 </em>
                                    (2)
                                     , 946-957. <a href="https://doi.org/10.1021/jacs.6b11467" title="DOI URL">https://doi.org/10.1021/jacs.6b11467</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.6b11467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.6b11467%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DPredictions%252Bof%252BLigand%252BSelectivity%252Bfrom%252BAbsolute%252BBinding%252BFree%252BEnergy%252BCalculations%26aulast%3DAldeghi%26aufirst%3DMatteo%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D04112016%26date%3D09012017%26date%3D18012017%26date%3D23122016%26volume%3D139%26issue%3D2%26spage%3D946%26epage%3D957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthew D.  Cheeseman</span>, <span class="hlFld-ContribAuthor ">Nicola E. A.  Chessum</span>, <span class="hlFld-ContribAuthor ">Carl S.  Rye</span>, <span class="hlFld-ContribAuthor ">A. Elisa  Pasqua</span>, <span class="hlFld-ContribAuthor ">Michael J.  Tucker</span>, <span class="hlFld-ContribAuthor ">Birgit  Wilding</span>, <span class="hlFld-ContribAuthor ">Lindsay E.  Evans</span>, <span class="hlFld-ContribAuthor ">Susan  Lepri</span>, <span class="hlFld-ContribAuthor ">Meirion  Richards</span>, <span class="hlFld-ContribAuthor ">Swee Y.  Sharp</span>, <span class="hlFld-ContribAuthor ">Salyha  Ali</span>, <span class="hlFld-ContribAuthor ">Martin  Rowlands</span>, <span class="hlFld-ContribAuthor ">Lisa  O’Fee</span>, <span class="hlFld-ContribAuthor ">Asadh  Miah</span>, <span class="hlFld-ContribAuthor ">Angela  Hayes</span>, <span class="hlFld-ContribAuthor ">Alan T.  Henley</span>, <span class="hlFld-ContribAuthor ">Marissa  Powers</span>, <span class="hlFld-ContribAuthor ">Robert  te Poele</span>, <span class="hlFld-ContribAuthor ">Emmanuel  De Billy</span>, <span class="hlFld-ContribAuthor ">Loredana  Pellegrino</span>, <span class="hlFld-ContribAuthor ">Florence  Raynaud</span>, <span class="hlFld-ContribAuthor ">Rosemary  Burke</span>, <span class="hlFld-ContribAuthor ">Rob L. M.  van Montfort</span>, <span class="hlFld-ContribAuthor ">Suzanne A.  Eccles</span>, <span class="hlFld-ContribAuthor ">Paul  Workman</span>, and <span class="hlFld-ContribAuthor ">Keith  Jones</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (1)
                                     , 180-201. <a href="https://doi.org/10.1021/acs.jmedchem.6b01055" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01055</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01055%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BChemical%252BProbe%252BBisamide%252B%252528CCT251236%252529%25253A%252BAn%252BOrally%252BBioavailable%252BEfficacious%252BPirin%252BLigand%252Bfrom%252Ba%252BHeat%252BShock%252BTranscription%252BFactor%252B1%252B%252528HSF1%252529%252BPhenotypic%252BScreen%26aulast%3DCheeseman%26aufirst%3DMatthew%2BD.%26date%3D2017%26date%3D2016%26date%3D2016%26date%3D15072016%26date%3D22122016%26date%3D12012017%26date%3D23112016%26volume%3D60%26issue%3D1%26spage%3D180%26epage%3D201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luke R.  Odell</span>, <span class="hlFld-ContribAuthor ">Mohammed K.  Abdel-Hamid</span>, <span class="hlFld-ContribAuthor ">Timothy A.  Hill</span>, <span class="hlFld-ContribAuthor ">Ngoc  Chau</span>, <span class="hlFld-ContribAuthor ">Kelly A.  Young</span>, <span class="hlFld-ContribAuthor ">Fiona M.  Deane</span>, <span class="hlFld-ContribAuthor ">Jennette A.  Sakoff</span>, <span class="hlFld-ContribAuthor ">Sofia  Andersson</span>, <span class="hlFld-ContribAuthor ">James A.  Daniel</span>, <span class="hlFld-ContribAuthor ">Phillip J.  Robinson</span>, and <span class="hlFld-ContribAuthor ">Adam  McCluskey</span>  . </span><span class="cited-content_cbyCitation_article-title">Pyrimidine-Based Inhibitors of Dynamin I GTPase Activity: Competitive Inhibition at the Pleckstrin Homology Domain. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (1)
                                     , 349-361. <a href="https://doi.org/10.1021/acs.jmedchem.6b01422" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01422</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01422%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPyrimidine-Based%252BInhibitors%252Bof%252BDynamin%252BI%252BGTPase%252BActivity%25253A%252BCompetitive%252BInhibition%252Bat%252Bthe%252BPleckstrin%252BHomology%252BDomain%26aulast%3DOdell%26aufirst%3DLuke%2BR.%26date%3D2017%26date%3D2016%26date%3D2016%26date%3D26092016%26date%3D20122016%26date%3D12012017%26date%3D07122016%26volume%3D60%26issue%3D1%26spage%3D349%26epage%3D361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chi B.  Vu</span>, <span class="hlFld-ContribAuthor ">Robert J.  Bridges</span>, <span class="hlFld-ContribAuthor ">Cecilia  Pena-Rasgado</span>, <span class="hlFld-ContribAuthor ">Antonio E.  Lacerda</span>, <span class="hlFld-ContribAuthor ">Curtis  Bordwell</span>, <span class="hlFld-ContribAuthor ">Abby  Sewell</span>, <span class="hlFld-ContribAuthor ">Andrew J.  Nichols</span>, <span class="hlFld-ContribAuthor ">Sachin  Chandran</span>, <span class="hlFld-ContribAuthor ">Pallavi  Lonkar</span>, <span class="hlFld-ContribAuthor ">Dominic  Picarella</span>, <span class="hlFld-ContribAuthor ">Amal  Ting</span>, <span class="hlFld-ContribAuthor ">Allison  Wensley</span>, <span class="hlFld-ContribAuthor ">Maisy  Yeager</span>, and <span class="hlFld-ContribAuthor ">Feng  Liu</span>  . </span><span class="cited-content_cbyCitation_article-title">Fatty Acid Cysteamine Conjugates as Novel and Potent Autophagy Activators That Enhance the Correction of Misfolded F508del-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (1)
                                     , 458-473. <a href="https://doi.org/10.1021/acs.jmedchem.6b01539" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01539</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01539%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFatty%252BAcid%252BCysteamine%252BConjugates%252Bas%252BNovel%252Band%252BPotent%252BAutophagy%252BActivators%252BThat%252BEnhance%252Bthe%252BCorrection%252Bof%252BMisfolded%252BF508del-Cystic%252BFibrosis%252BTransmembrane%252BConductance%252BRegulator%252B%252528CFTR%252529%26aulast%3DVu%26aufirst%3DChi%2BB.%26date%3D2017%26date%3D2016%26date%3D2016%26date%3D18102016%26date%3D23122016%26date%3D12012017%26date%3D15122016%26volume%3D60%26issue%3D1%26spage%3D458%26epage%3D473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alvaro  Cortes Cabrera</span>, <span class="hlFld-ContribAuthor ">Daniel  Lucena-Agell</span>, <span class="hlFld-ContribAuthor ">Mariano  Redondo-Horcajo</span>, <span class="hlFld-ContribAuthor ">Isabel  Barasoain</span>, <span class="hlFld-ContribAuthor ">José Fernando  Díaz</span>, <span class="hlFld-ContribAuthor ">Bernhard  Fasching</span>, and <span class="hlFld-ContribAuthor ">Paula M.  Petrone</span>  . </span><span class="cited-content_cbyCitation_article-title">Aggregated Compound Biological Signatures Facilitate Phenotypic Drug Discovery and Target Elucidation. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2016,</strong> <em>11 </em>
                                    (11)
                                     , 3024-3034. <a href="https://doi.org/10.1021/acschembio.6b00358" title="DOI URL">https://doi.org/10.1021/acschembio.6b00358</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.6b00358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.6b00358%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DAggregated%252BCompound%252BBiological%252BSignatures%252BFacilitate%252BPhenotypic%252BDrug%252BDiscovery%252Band%252BTarget%252BElucidation%26aulast%3DCortes%2BCabrera%26aufirst%3DAlvaro%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D25042016%26date%3D26082016%26date%3D14092016%26date%3D18112016%26date%3D26082016%26volume%3D11%26issue%3D11%26spage%3D3024%26epage%3D3034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luca  Carlino</span> and <span class="hlFld-ContribAuthor ">Giulio  Rastelli</span>  . </span><span class="cited-content_cbyCitation_article-title">Dual Kinase-Bromodomain Inhibitors in Anticancer Drug Discovery: A Structural and Pharmacological Perspective. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (20)
                                     , 9305-9320. <a href="https://doi.org/10.1021/acs.jmedchem.6b00438" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00438</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00438%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDual%252BKinase-Bromodomain%252BInhibitors%252Bin%252BAnticancer%252BDrug%252BDiscovery%25253A%252BA%252BStructural%252Band%252BPharmacological%252BPerspective%26aulast%3DCarlino%26aufirst%3DLuca%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D24032016%26date%3D07092016%26date%3D27102016%26date%3D25082016%26volume%3D59%26issue%3D20%26spage%3D9305%26epage%3D9320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paul  Czodrowski</span> and <span class="hlFld-ContribAuthor ">Wolf-Guido  Bolick</span>  . </span><span class="cited-content_cbyCitation_article-title">OCEAN: Optimized Cross rEActivity estimatioN. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2016,</strong> <em>56 </em>
                                    (10)
                                     , 2013-2023. <a href="https://doi.org/10.1021/acs.jcim.6b00067" title="DOI URL">https://doi.org/10.1021/acs.jcim.6b00067</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.6b00067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.6b00067%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DOCEAN%25253A%252BOptimized%252BCross%252BrEActivity%252BestimatioN%26aulast%3DCzodrowski%26aufirst%3DPaul%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D11022016%26date%3D26092016%26date%3D24102016%26volume%3D56%26issue%3D10%26spage%3D2013%26epage%3D2023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eugene Guorong  Yang</span>, <span class="hlFld-ContribAuthor ">Nurulhuda  Mustafa</span>, <span class="hlFld-ContribAuthor ">Eng Chong  Tan</span>, <span class="hlFld-ContribAuthor ">Anders  Poulsen</span>, <span class="hlFld-ContribAuthor ">Pondy Murugappan  Ramanujulu</span>, <span class="hlFld-ContribAuthor ">Wee Joo  Chng</span>, <span class="hlFld-ContribAuthor ">Jeffrey J. Y.  Yen</span>, and <span class="hlFld-ContribAuthor ">Brian W.  Dymock</span>  . </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (18)
                                     , 8233-8262. <a href="https://doi.org/10.1021/acs.jmedchem.6b00157" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00157</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00157%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BJanus%252BKinase%252B2%252B%252528JAK2%252529%252Band%252BHistone%252BDeacetlyase%252B%252528HDAC%252529%252BBispecific%252BInhibitors%252BBased%252Bon%252BPacritinib%252Band%252BEvidence%252Bof%252BDual%252BPathway%252BInhibition%252Bin%252BHematological%252BCell%252BLines%26aulast%3DYang%26aufirst%3DEugene%2BGuorong%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D03022016%26date%3D08092016%26date%3D22092016%26date%3D19082016%26volume%3D59%26issue%3D18%26spage%3D8233%26epage%3D8262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bruce E.  Maryanoff</span>  . </span><span class="cited-content_cbyCitation_article-title">Phenotypic Assessment and the Discovery of Topiramate. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>7 </em>
                                    (7)
                                     , 662-665. <a href="https://doi.org/10.1021/acsmedchemlett.6b00176" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.6b00176</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.6b00176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.6b00176%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DPhenotypic%252BAssessment%252Band%252Bthe%252BDiscovery%252Bof%252BTopiramate%26aulast%3DMaryanoff%26aufirst%3DBruce%2BE.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D27042016%26date%3D13062016%26date%3D01072016%26date%3D14072016%26date%3D13062016%26volume%3D7%26issue%3D7%26spage%3D662%26epage%3D665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xia  Wang</span>, <span class="hlFld-ContribAuthor ">Chenxu  Pan</span>, <span class="hlFld-ContribAuthor ">Jiayu  Gong</span>, <span class="hlFld-ContribAuthor ">Xiaofeng  Liu</span>, and <span class="hlFld-ContribAuthor ">Honglin  Li</span>  . </span><span class="cited-content_cbyCitation_article-title">Enhancing the Enrichment of Pharmacophore-Based Target Prediction for the Polypharmacological Profiles of Drugs. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2016,</strong> <em>56 </em>
                                    (6)
                                     , 1175-1183. <a href="https://doi.org/10.1021/acs.jcim.5b00690" title="DOI URL">https://doi.org/10.1021/acs.jcim.5b00690</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.5b00690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.5b00690%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DEnhancing%252Bthe%252BEnrichment%252Bof%252BPharmacophore-Based%252BTarget%252BPrediction%252Bfor%252Bthe%252BPolypharmacological%252BProfiles%252Bof%252BDrugs%26aulast%3DWang%26aufirst%3DXia%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D17112015%26date%3D31052016%26date%3D27062016%26date%3D17052016%26volume%3D56%26issue%3D6%26spage%3D1175%26epage%3D1183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Craig  Fraser</span>, <span class="hlFld-ContribAuthor ">John C.  Dawson</span>, <span class="hlFld-ContribAuthor ">Reece  Dowling</span>, <span class="hlFld-ContribAuthor ">Douglas R.  Houston</span>, <span class="hlFld-ContribAuthor ">Jason T.  Weiss</span>, <span class="hlFld-ContribAuthor ">Alison F.  Munro</span>, <span class="hlFld-ContribAuthor ">Morwenna  Muir</span>, <span class="hlFld-ContribAuthor ">Lea  Harrington</span>, <span class="hlFld-ContribAuthor ">Scott P.  Webster</span>, <span class="hlFld-ContribAuthor ">Margaret C.  Frame</span>, <span class="hlFld-ContribAuthor ">Valerie G.  Brunton</span>, <span class="hlFld-ContribAuthor ">E. Elizabeth  Patton</span>, <span class="hlFld-ContribAuthor ">Neil O.  Carragher</span>, and <span class="hlFld-ContribAuthor ">Asier  Unciti-Broceta</span>  . </span><span class="cited-content_cbyCitation_article-title">Rapid Discovery and Structure–Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (10)
                                     , 4697-4710. <a href="https://doi.org/10.1021/acs.jmedchem.6b00065" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00065</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00065%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRapid%252BDiscovery%252Band%252BStructure%2525E2%252580%252593Activity%252BRelationships%252Bof%252BPyrazolopyrimidines%252BThat%252BPotently%252BSuppress%252BBreast%252BCancer%252BCell%252BGrowth%252Bvia%252BSRC%252BKinase%252BInhibition%252Bwith%252BExceptional%252BSelectivity%252Bover%252BABL%252BKinase%26aulast%3DFraser%26aufirst%3DCraig%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D14012016%26date%3D04052016%26date%3D26052016%26date%3D26042016%26volume%3D59%26issue%3D10%26spage%3D4697%26epage%3D4710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nikita  Remez</span>, <span class="hlFld-ContribAuthor ">Ricard  Garcia-Serna</span>, <span class="hlFld-ContribAuthor ">David  Vidal</span>, and <span class="hlFld-ContribAuthor ">Jordi  Mestres</span>  . </span><span class="cited-content_cbyCitation_article-title">The In Vitro Pharmacological Profile of Drugs as a Proxy Indicator of Potential In Vivo Organ Toxicities. </span><span class="cited-content_cbyCitation_journal-name">Chemical Research in Toxicology</span><span> <strong>2016,</strong> <em>29 </em>
                                    (4)
                                     , 637-648. <a href="https://doi.org/10.1021/acs.chemrestox.5b00470" title="DOI URL">https://doi.org/10.1021/acs.chemrestox.5b00470</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrestox.5b00470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrestox.5b00470%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Research%2520in%2520Toxicology%26atitle%3DThe%252BIn%252BVitro%252BPharmacological%252BProfile%252Bof%252BDrugs%252Bas%252Ba%252BProxy%252BIndicator%252Bof%252BPotential%252BIn%252BVivo%252BOrgan%252BToxicities%26aulast%3DRemez%26aufirst%3DNikita%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D16112015%26date%3D16032016%26date%3D18042016%26date%3D08032016%26volume%3D29%26issue%3D4%26spage%3D637%26epage%3D648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chi B.  Vu</span>, <span class="hlFld-ContribAuthor ">Jean E.  Bemis</span>, <span class="hlFld-ContribAuthor ">Ericka  Benson</span>, <span class="hlFld-ContribAuthor ">Pradeep  Bista</span>, <span class="hlFld-ContribAuthor ">David  Carney</span>, <span class="hlFld-ContribAuthor ">Richard  Fahrner</span>, <span class="hlFld-ContribAuthor ">Diana  Lee</span>, <span class="hlFld-ContribAuthor ">Feng  Liu</span>, <span class="hlFld-ContribAuthor ">Pallavi  Lonkar</span>, <span class="hlFld-ContribAuthor ">Jill C.  Milne</span>, <span class="hlFld-ContribAuthor ">Andrew J.  Nichols</span>, <span class="hlFld-ContribAuthor ">Dominic  Picarella</span>, <span class="hlFld-ContribAuthor ">Adam  Shoelson</span>, <span class="hlFld-ContribAuthor ">Jesse  Smith</span>, <span class="hlFld-ContribAuthor ">Amal  Ting</span>, <span class="hlFld-ContribAuthor ">Allison  Wensley</span>, <span class="hlFld-ContribAuthor ">Maisy  Yeager</span>, <span class="hlFld-ContribAuthor ">Michael  Zimmer</span>, and <span class="hlFld-ContribAuthor ">Michael R.  Jirousek</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis and Characterization of Fatty Acid Conjugates of Niacin and Salicylic Acid. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (3)
                                     , 1217-1231. <a href="https://doi.org/10.1021/acs.jmedchem.5b01961" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01961</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01961%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252BCharacterization%252Bof%252BFatty%252BAcid%252BConjugates%252Bof%252BNiacin%252Band%252BSalicylic%252BAcid%26aulast%3DVu%26aufirst%3DChi%2BB.%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D18122015%26date%3D01022016%26date%3D11022016%26date%3D19012016%26volume%3D59%26issue%3D3%26spage%3D1217%26epage%3D1231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">René  Blöcher</span>, <span class="hlFld-ContribAuthor ">Christina  Lamers</span>, <span class="hlFld-ContribAuthor ">Sandra K.  Wittmann</span>, <span class="hlFld-ContribAuthor ">Daniel  Merk</span>, <span class="hlFld-ContribAuthor ">Markus  Hartmann</span>, <span class="hlFld-ContribAuthor ">Lilia  Weizel</span>, <span class="hlFld-ContribAuthor ">Olaf  Diehl</span>, <span class="hlFld-ContribAuthor ">Astrid  Brüggerhoff</span>, <span class="hlFld-ContribAuthor ">Marcel  Boß</span>, <span class="hlFld-ContribAuthor ">Astrid  Kaiser</span>, <span class="hlFld-ContribAuthor ">Tim  Schader</span>, <span class="hlFld-ContribAuthor ">Tamara  Göbel</span>, <span class="hlFld-ContribAuthor ">Manuel  Grundmann</span>, <span class="hlFld-ContribAuthor ">Carlo  Angioni</span>, <span class="hlFld-ContribAuthor ">Jan  Heering</span>, <span class="hlFld-ContribAuthor ">Gerd  Geisslinger</span>, <span class="hlFld-ContribAuthor ">Mario  Wurglics</span>, <span class="hlFld-ContribAuthor ">Evi  Kostenis</span>, <span class="hlFld-ContribAuthor ">Bernhard  Brüne</span>, <span class="hlFld-ContribAuthor ">Dieter  Steinhilber</span>, <span class="hlFld-ContribAuthor ">Manfred  Schubert-Zsilavecz</span>, <span class="hlFld-ContribAuthor ">Astrid S.  Kahnt</span>, and <span class="hlFld-ContribAuthor ">Ewgenij  Proschak</span>  . </span><span class="cited-content_cbyCitation_article-title">N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor γ Modulators. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (1)
                                     , 61-81. <a href="https://doi.org/10.1021/acs.jmedchem.5b01239" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01239</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01239%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DN-Benzylbenzamides%25253A%252BA%252BNovel%252BMerged%252BScaffold%252Bfor%252BOrally%252BAvailable%252BDual%252BSoluble%252BEpoxide%252BHydrolase%25252FPeroxisome%252BProliferator-Activated%252BReceptor%252B%2525CE%2525B3%252BModulators%26aulast%3DBl%25C3%25B6cher%26aufirst%3DRen%25C3%25A9%26date%3D2016%26date%3D2015%26date%3D2015%26date%3D02042015%26date%3D25122015%26date%3D14012016%26date%3D23112015%26volume%3D59%26issue%3D1%26spage%3D61%26epage%3D81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor "> Ye    Hu </span><span class="hlFld-ContribAuthor "> Jürgen    Bajorath </span>. </span><span class="cited-content_cbyCitation_article-title">Exploring Molecular Promiscuity from a Ligand and Target Perspective. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 19-34. <a href="https://doi.org/10.1021/bk-2016-1222.ch003" title="DOI URL">https://doi.org/10.1021/bk-2016-1222.ch003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/bk-2016-1222.ch003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fbk-2016-1222.ch003%26sid%3Dliteratum%253Aachs%26atitle%3DExploring%252BMolecular%252BPromiscuity%252Bfrom%252Ba%252BLigand%252Band%252BTarget%252BPerspective%26aulast%3DHu%26aufirst%3DYe%26date%3D2016%26date%3D2016%26spage%3D19%26epage%3D34%26atitle%3DFrontiers%252Bin%252BMolecular%252BDesign%252Band%252BChemical%252BInformation%252BScience%252B-%252BHerman%252BSkolnik%252BAward%252BSymposium%252B2015%25253A%252BJ%2525C3%2525BCrgen%252BBajorath%26aulast%3DBienstock%26aufirst%3DRachelle%2BJ.%26date%3D2016%26date%3D2016%26volume%3D1222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor "> Gerald    Maggiora </span><span class="hlFld-ContribAuthor "> Vijay    Gokhale </span>. </span><span class="cited-content_cbyCitation_article-title">Non-Specificity of Drug-Target Interactions – Consequences for Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 91-142. <a href="https://doi.org/10.1021/bk-2016-1222.ch007" title="DOI URL">https://doi.org/10.1021/bk-2016-1222.ch007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/bk-2016-1222.ch007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fbk-2016-1222.ch007%26sid%3Dliteratum%253Aachs%26atitle%3DNon-Specificity%252Bof%252BDrug-Target%252BInteractions%252B%2525E2%252580%252593%252BConsequences%252Bfor%252BDrug%252BDiscovery%26aulast%3DMaggiora%26aufirst%3DGerald%26date%3D2016%26date%3D2016%26spage%3D91%26epage%3D142%26atitle%3DFrontiers%252Bin%252BMolecular%252BDesign%252Band%252BChemical%252BInformation%252BScience%252B-%252BHerman%252BSkolnik%252BAward%252BSymposium%252B2015%25253A%252BJ%2525C3%2525BCrgen%252BBajorath%26aulast%3DBienstock%26aufirst%3DRachelle%2BJ.%26date%3D2016%26date%3D2016%26volume%3D1222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ricard  Garcia-Serna</span>, <span class="hlFld-ContribAuthor ">David  Vidal</span>, <span class="hlFld-ContribAuthor ">Nikita  Remez</span>, and <span class="hlFld-ContribAuthor ">Jordi  Mestres</span>  . </span><span class="cited-content_cbyCitation_article-title">Large-Scale Predictive Drug Safety: From Structural Alerts to Biological Mechanisms. </span><span class="cited-content_cbyCitation_journal-name">Chemical Research in Toxicology</span><span> <strong>2015,</strong> <em>28 </em>
                                    (10)
                                     , 1875-1887. <a href="https://doi.org/10.1021/acs.chemrestox.5b00260" title="DOI URL">https://doi.org/10.1021/acs.chemrestox.5b00260</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrestox.5b00260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrestox.5b00260%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Research%2520in%2520Toxicology%26atitle%3DLarge-Scale%252BPredictive%252BDrug%252BSafety%25253A%252BFrom%252BStructural%252BAlerts%252Bto%252BBiological%252BMechanisms%26aulast%3DGarcia-Serna%26aufirst%3DRicard%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D19062015%26date%3D21092015%26date%3D19102015%26date%3D11092015%26volume%3D28%26issue%3D10%26spage%3D1875%26epage%3D1887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hassan  Al-Ali</span>, <span class="hlFld-ContribAuthor ">Do-Hun  Lee</span>, <span class="hlFld-ContribAuthor ">Matt C.  Danzi</span>, <span class="hlFld-ContribAuthor ">Houssam  Nassif</span>, <span class="hlFld-ContribAuthor ">Prson  Gautam</span>, <span class="hlFld-ContribAuthor ">Krister  Wennerberg</span>, <span class="hlFld-ContribAuthor ">Bill  Zuercher</span>, <span class="hlFld-ContribAuthor ">David H.  Drewry</span>, <span class="hlFld-ContribAuthor ">Jae K.  Lee</span>, <span class="hlFld-ContribAuthor ">Vance P.  Lemmon</span>, and <span class="hlFld-ContribAuthor ">John L.  Bixby</span>  . </span><span class="cited-content_cbyCitation_article-title">Rational Polypharmacology: Systematically Identifying and Engaging Multiple Drug Targets To Promote Axon Growth. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2015,</strong> <em>10 </em>
                                    (8)
                                     , 1939-1951. <a href="https://doi.org/10.1021/acschembio.5b00289" title="DOI URL">https://doi.org/10.1021/acschembio.5b00289</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.5b00289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.5b00289%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DRational%252BPolypharmacology%25253A%252BSystematically%252BIdentifying%252Band%252BEngaging%252BMultiple%252BDrug%252BTargets%252BTo%252BPromote%252BAxon%252BGrowth%26aulast%3DAl-Ali%26aufirst%3DHassan%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D22042015%26date%3D09062015%26date%3D24062015%26date%3D21082015%26date%3D09062015%26volume%3D10%26issue%3D8%26spage%3D1939%26epage%3D1951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lijia  Chen</span>, <span class="hlFld-ContribAuthor ">Jeremy L.  Yap</span>, <span class="hlFld-ContribAuthor ">Makoto  Yoshioka</span>, <span class="hlFld-ContribAuthor ">Maryanna E.  Lanning</span>, <span class="hlFld-ContribAuthor ">Rachel N.  Fountain</span>, <span class="hlFld-ContribAuthor ">Mithun  Raje</span>, <span class="hlFld-ContribAuthor ">Jacob A.  Scheenstra</span>, <span class="hlFld-ContribAuthor ">Jeffrey W.  Strovel</span>, and <span class="hlFld-ContribAuthor ">Steven  Fletcher</span>  . </span><span class="cited-content_cbyCitation_article-title">BRD4 Structure–Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>6 </em>
                                    (7)
                                     , 764-769. <a href="https://doi.org/10.1021/acsmedchemlett.5b00084" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.5b00084</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.5b00084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.5b00084%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DBRD4%252BStructure%2525E2%252580%252593Activity%252BRelationships%252Bof%252BDual%252BPLK1%252BKinase%25252FBRD4%252BBromodomain%252BInhibitor%252BBI-2536%26aulast%3DChen%26aufirst%3DLijia%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D18022015%26date%3D17052015%26date%3D02062015%26date%3D09072015%26date%3D18052015%26volume%3D6%26issue%3D7%26spage%3D764%26epage%3D769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew  Anighoro</span>, <span class="hlFld-ContribAuthor ">Dagmar  Stumpfe</span>, <span class="hlFld-ContribAuthor ">Kathrin  Heikamp</span>, <span class="hlFld-ContribAuthor ">Kristin  Beebe</span>, <span class="hlFld-ContribAuthor ">Leonard M.  Neckers</span>, <span class="hlFld-ContribAuthor ">Jürgen  Bajorath</span>, and <span class="hlFld-ContribAuthor ">Giulio  Rastelli</span>  . </span><span class="cited-content_cbyCitation_article-title">Computational Polypharmacology Analysis of the Heat Shock Protein 90 Interactome. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2015,</strong> <em>55 </em>
                                    (3)
                                     , 676-686. <a href="https://doi.org/10.1021/ci5006959" title="DOI URL">https://doi.org/10.1021/ci5006959</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ci5006959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fci5006959%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DComputational%252BPolypharmacology%252BAnalysis%252Bof%252Bthe%252BHeat%252BShock%252BProtein%252B90%252BInteractome%26aulast%3DAnighoro%26aufirst%3DAndrew%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D21112014%26date%3D23022015%26date%3D23032015%26date%3D16022015%26volume%3D55%26issue%3D3%26spage%3D676%26epage%3D686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shipeng  He</span>, <span class="hlFld-ContribAuthor ">Guoqiang  Dong</span>, <span class="hlFld-ContribAuthor ">Zhibin  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Chen</span>, <span class="hlFld-ContribAuthor ">Yahui  Huang</span>, <span class="hlFld-ContribAuthor ">Zhengang  Li</span>, <span class="hlFld-ContribAuthor ">Yan  Jiang</span>, <span class="hlFld-ContribAuthor ">Na  Liu</span>, <span class="hlFld-ContribAuthor ">Jianzhong  Yao</span>, <span class="hlFld-ContribAuthor ">Zhenyuan  Miao</span>, <span class="hlFld-ContribAuthor ">Wannian  Zhang</span>, and <span class="hlFld-ContribAuthor ">Chunquan  Sheng</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>6 </em>
                                    (3)
                                     , 239-243. <a href="https://doi.org/10.1021/ml500327q" title="DOI URL">https://doi.org/10.1021/ml500327q</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml500327q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml500327q%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BNovel%252BMultiacting%252BTopoisomerase%252BI%25252FII%252Band%252BHistone%252BDeacetylase%252BInhibitors%26aulast%3DHe%26aufirst%3DShipeng%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D05082014%26date%3D14012015%26date%3D20012015%26date%3D12032015%26date%3D14012015%26volume%3D6%26issue%3D3%26spage%3D239%26epage%3D243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ye  Hu</span> and <span class="hlFld-ContribAuthor ">Jürgen  Bajorath</span>  . </span><span class="cited-content_cbyCitation_article-title">Influence of Search Parameters and Criteria on Compound Selection, Promiscuity, and Pan Assay Interference Characteristics. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2014,</strong> <em>54 </em>
                                    (11)
                                     , 3056-3066. <a href="https://doi.org/10.1021/ci5005509" title="DOI URL">https://doi.org/10.1021/ci5005509</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ci5005509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fci5005509%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DInfluence%252Bof%252BSearch%252BParameters%252Band%252BCriteria%252Bon%252BCompound%252BSelection%25252C%252BPromiscuity%25252C%252Band%252BPan%252BAssay%252BInterference%252BCharacteristics%26aulast%3DHu%26aufirst%3DYe%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D04082014%26date%3D31102014%26date%3D24112014%26date%3D20102014%26volume%3D54%26issue%3D11%26spage%3D3056%26epage%3D3066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eugenie  Nepovimova</span>, <span class="hlFld-ContribAuthor ">Elisa  Uliassi</span>, <span class="hlFld-ContribAuthor ">Jan  Korabecny</span>, <span class="hlFld-ContribAuthor ">Luis Emiliano  Peña-Altamira</span>, <span class="hlFld-ContribAuthor ">Sarah  Samez</span>, <span class="hlFld-ContribAuthor ">Alessandro  Pesaresi</span>, <span class="hlFld-ContribAuthor ">Gregory E.  Garcia</span>, <span class="hlFld-ContribAuthor ">Manuela  Bartolini</span>, <span class="hlFld-ContribAuthor ">Vincenza  Andrisano</span>, <span class="hlFld-ContribAuthor ">Christian  Bergamini</span>, <span class="hlFld-ContribAuthor ">Romana  Fato</span>, <span class="hlFld-ContribAuthor ">Doriano  Lamba</span>, <span class="hlFld-ContribAuthor ">Marinella  Roberti</span>, <span class="hlFld-ContribAuthor ">Kamil  Kuca</span>, <span class="hlFld-ContribAuthor ">Barbara  Monti</span>, and <span class="hlFld-ContribAuthor ">Maria Laura  Bolognesi</span>  . </span><span class="cited-content_cbyCitation_article-title">Multitarget Drug Design Strategy: Quinone–Tacrine Hybrids Designed To Block Amyloid-β Aggregation and To Exert Anticholinesterase and Antioxidant Effects. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (20)
                                     , 8576-8589. <a href="https://doi.org/10.1021/jm5010804" title="DOI URL">https://doi.org/10.1021/jm5010804</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm5010804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm5010804%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMultitarget%252BDrug%252BDesign%252BStrategy%25253A%252BQuinone%2525E2%252580%252593Tacrine%252BHybrids%252BDesigned%252BTo%252BBlock%252BAmyloid-%2525CE%2525B2%252BAggregation%252Band%252BTo%252BExert%252BAnticholinesterase%252Band%252BAntioxidant%252BEffects%26aulast%3DNepovimova%26aufirst%3DEugenie%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D17072014%26date%3D10102014%26date%3D23102014%26date%3D26092014%26volume%3D57%26issue%3D20%26spage%3D8576%26epage%3D8589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew  Anighoro</span>, <span class="hlFld-ContribAuthor ">Jürgen  Bajorath</span>, and <span class="hlFld-ContribAuthor ">Giulio  Rastelli</span>  . </span><span class="cited-content_cbyCitation_article-title">Polypharmacology: Challenges and Opportunities in Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (19)
                                     , 7874-7887. <a href="https://doi.org/10.1021/jm5006463" title="DOI URL">https://doi.org/10.1021/jm5006463</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm5006463%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPolypharmacology%25253A%252BChallenges%252Band%252BOpportunities%252Bin%252BDrug%252BDiscovery%26aulast%3DAnighoro%26aufirst%3DAndrew%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D25042014%26date%3D25062014%26date%3D09102014%26date%3D19062014%26volume%3D57%26issue%3D19%26spage%3D7874%26epage%3D7887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elisa  Giacomini</span>, <span class="hlFld-ContribAuthor ">Angela  Nebbioso</span>, <span class="hlFld-ContribAuthor ">Alfonso  Ciotta</span>, <span class="hlFld-ContribAuthor ">Cristina  Ianni</span>, <span class="hlFld-ContribAuthor ">Federico  Falchi</span>, <span class="hlFld-ContribAuthor ">Marinella  Roberti</span>, <span class="hlFld-ContribAuthor ">Manlio  Tolomeo</span>, <span class="hlFld-ContribAuthor ">Stefania  Grimaudo</span>, <span class="hlFld-ContribAuthor ">Antonietta Di  Cristina</span>, <span class="hlFld-ContribAuthor ">Rosaria Maria  Pipitone</span>, <span class="hlFld-ContribAuthor ">Lucia  Altucci</span>, and <span class="hlFld-ContribAuthor ">Maurizio  Recanatini</span>  . </span><span class="cited-content_cbyCitation_article-title">Novel Antiproliferative Chimeric Compounds with Marked Histone Deacetylase Inhibitory Activity. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2014,</strong> <em>5 </em>
                                    (9)
                                     , 973-978. <a href="https://doi.org/10.1021/ml5000959" title="DOI URL">https://doi.org/10.1021/ml5000959</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml5000959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml5000959%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DNovel%252BAntiproliferative%252BChimeric%252BCompounds%252Bwith%252BMarked%252BHistone%252BDeacetylase%252BInhibitory%252BActivity%26aulast%3DGiacomini%26aufirst%3DElisa%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D04032014%26date%3D07072014%26date%3D16072014%26date%3D11092014%26date%3D08072014%26volume%3D5%26issue%3D9%26spage%3D973%26epage%3D978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alban  Lepailleur</span>, <span class="hlFld-ContribAuthor ">Thomas  Freret</span>, <span class="hlFld-ContribAuthor ">Stéphane  Lemaître</span>, <span class="hlFld-ContribAuthor ">Michel  Boulouard</span>, <span class="hlFld-ContribAuthor ">François  Dauphin</span>, <span class="hlFld-ContribAuthor ">Antoine  Hinschberger</span>, <span class="hlFld-ContribAuthor ">Fabienne  Dulin</span>, <span class="hlFld-ContribAuthor ">Aurélien  Lesnard</span>, <span class="hlFld-ContribAuthor ">Ronan  Bureau</span>, and <span class="hlFld-ContribAuthor ">Sylvain  Rault</span>  . </span><span class="cited-content_cbyCitation_article-title">Dual Histamine H3R/Serotonin 5-HT4R Ligands with Antiamnesic Properties: Pharmacophore-Based Virtual Screening and Polypharmacology. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2014,</strong> <em>54 </em>
                                    (6)
                                     , 1773-1784. <a href="https://doi.org/10.1021/ci500157n" title="DOI URL">https://doi.org/10.1021/ci500157n</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ci500157n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fci500157n%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DDual%252BHistamine%252BH3R%25252FSerotonin%252B5-HT4R%252BLigands%252Bwith%252BAntiamnesic%252BProperties%25253A%252BPharmacophore-Based%252BVirtual%252BScreening%252Band%252BPolypharmacology%26aulast%3DLepailleur%26aufirst%3DAlban%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D12032014%26date%3D10062014%26date%3D23062014%26date%3D23052014%26volume%3D54%26issue%3D6%26spage%3D1773%26epage%3D1784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin  Liu</span>, <span class="hlFld-ContribAuthor ">Ye  Zhang</span>, <span class="hlFld-ContribAuthor ">Lucas D.  Ward</span>, <span class="hlFld-ContribAuthor ">Qinghong  Yan</span>, <span class="hlFld-ContribAuthor ">Tanggis  Bohnuud</span>, <span class="hlFld-ContribAuthor ">Rocio  Hernandez</span>, <span class="hlFld-ContribAuthor ">Socheata  Lao</span>, <span class="hlFld-ContribAuthor ">Jing  Yuan</span>, <span class="hlFld-ContribAuthor ">Fan  Fan</span>. </span><span class="cited-content_cbyCitation_article-title">A proteomic platform to identify off-target proteins associated with therapeutic modalities that induce protein degradation or gene silencing. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-021-95354-3" title="DOI URL">https://doi.org/10.1038/s41598-021-95354-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-021-95354-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-021-95354-3%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DA%252Bproteomic%252Bplatform%252Bto%252Bidentify%252Boff-target%252Bproteins%252Bassociated%252Bwith%252Btherapeutic%252Bmodalities%252Bthat%252Binduce%252Bprotein%252Bdegradation%252Bor%252Bgene%252Bsilencing%26aulast%3DLiu%26aufirst%3DXin%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefanie  Kampen</span>, <span class="hlFld-ContribAuthor ">Duc  Duy Vo</span>, <span class="hlFld-ContribAuthor ">Xiaoqun  Zhang</span>, <span class="hlFld-ContribAuthor ">Nicolas  Panel</span>, <span class="hlFld-ContribAuthor ">Yunting  Yang</span>, <span class="hlFld-ContribAuthor ">Mariama  Jaiteh</span>, <span class="hlFld-ContribAuthor ">Pierre  Matricon</span>, <span class="hlFld-ContribAuthor ">Per  Svenningsson</span>, <span class="hlFld-ContribAuthor ">Jose  Brea</span>, <span class="hlFld-ContribAuthor ">Maria Isabel  Loza</span>, <span class="hlFld-ContribAuthor ">Jan  Kihlberg</span>, <span class="hlFld-ContribAuthor ">Jens  Carlsson</span>. </span><span class="cited-content_cbyCitation_article-title">Structure‐Guided Design of G‐Protein‐Coupled Receptor Polypharmacology. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2021,</strong> <em>60 </em>
                                    (33)
                                     , 18022-18030. <a href="https://doi.org/10.1002/anie.202101478" title="DOI URL">https://doi.org/10.1002/anie.202101478</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.202101478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.202101478%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DStructure%2525E2%252580%252590Guided%252BDesign%252Bof%252BG%2525E2%252580%252590Protein%2525E2%252580%252590Coupled%252BReceptor%252BPolypharmacology%26aulast%3DKampen%26aufirst%3DStefanie%26date%3D2021%26date%3D2021%26volume%3D60%26issue%3D33%26spage%3D18022%26epage%3D18030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefanie  Kampen</span>, <span class="hlFld-ContribAuthor ">Duc  Duy Vo</span>, <span class="hlFld-ContribAuthor ">Xiaoqun  Zhang</span>, <span class="hlFld-ContribAuthor ">Nicolas  Panel</span>, <span class="hlFld-ContribAuthor ">Yunting  Yang</span>, <span class="hlFld-ContribAuthor ">Mariama  Jaiteh</span>, <span class="hlFld-ContribAuthor ">Pierre  Matricon</span>, <span class="hlFld-ContribAuthor ">Per  Svenningsson</span>, <span class="hlFld-ContribAuthor ">Jose  Brea</span>, <span class="hlFld-ContribAuthor ">Maria Isabel  Loza</span>, <span class="hlFld-ContribAuthor ">Jan  Kihlberg</span>, <span class="hlFld-ContribAuthor ">Jens  Carlsson</span>. </span><span class="cited-content_cbyCitation_article-title">Structure‐Guided Design of G‐Protein‐Coupled Receptor Polypharmacology. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2021,</strong> <em>133 </em>
                                    (33)
                                     , 18170-18178. <a href="https://doi.org/10.1002/ange.202101478" title="DOI URL">https://doi.org/10.1002/ange.202101478</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.202101478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.202101478%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DStructure%2525E2%252580%252590Guided%252BDesign%252Bof%252BG%2525E2%252580%252590Protein%2525E2%252580%252590Coupled%252BReceptor%252BPolypharmacology%26aulast%3DKampen%26aufirst%3DStefanie%26date%3D2021%26date%3D2021%26volume%3D133%26issue%3D33%26spage%3D18170%26epage%3D18178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Toi  Kobayashi</span>, <span class="hlFld-ContribAuthor ">Takumi  Yasuno</span>, <span class="hlFld-ContribAuthor ">Kyoko  Takahashi</span>, <span class="hlFld-ContribAuthor ">Shigeo  Nakamura</span>, <span class="hlFld-ContribAuthor ">Tadahiko  Mashino</span>, <span class="hlFld-ContribAuthor ">Tomoyuki  Ohe</span>. </span><span class="cited-content_cbyCitation_article-title">Novel pyridinium-type fullerene derivatives as multitargeting inhibitors of HIV-1 reverse transcriptase, HIV-1 protease, and HCV NS5B polymerase. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>32 </em>, 128267. <a href="https://doi.org/10.1016/j.bmcl.2021.128267" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.128267</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.128267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.128267%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DNovel%252Bpyridinium-type%252Bfullerene%252Bderivatives%252Bas%252Bmultitargeting%252Binhibitors%252Bof%252BHIV-1%252Breverse%252Btranscriptase%25252C%252BHIV-1%252Bprotease%25252C%252Band%252BHCV%252BNS5B%252Bpolymerase%26aulast%3DKobayashi%26aufirst%3DToi%26date%3D2021%26volume%3D32%26spage%3D128267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dagmar  Stumpfe</span>, <span class="hlFld-ContribAuthor ">Alexander  Hoch</span>, <span class="hlFld-ContribAuthor ">Jürgen  Bajorath</span>. </span><span class="cited-content_cbyCitation_article-title">Introducing the metacore concept for multi-target ligand design. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (4)
                                     , 628-635. <a href="https://doi.org/10.1039/D1MD00056J" title="DOI URL">https://doi.org/10.1039/D1MD00056J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1MD00056J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1MD00056J%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DIntroducing%252Bthe%252Bmetacore%252Bconcept%252Bfor%252Bmulti-target%252Bligand%252Bdesign%26aulast%3DStumpfe%26aufirst%3DDagmar%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D4%26spage%3D628%26epage%3D635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yue  Ma</span>, <span class="hlFld-ContribAuthor ">Estrella  Frutos-Beltrán</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Luis  Menéndez-Arias</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses. </span><span class="cited-content_cbyCitation_journal-name">Chemical Society Reviews</span><span> <strong>2021,</strong> <em>50 </em>
                                    (7)
                                     , 4514-4540. <a href="https://doi.org/10.1039/D0CS01084G" title="DOI URL">https://doi.org/10.1039/D0CS01084G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0CS01084G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0CS01084G%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Society%2520Reviews%26atitle%3DMedicinal%252Bchemistry%252Bstrategies%252Bfor%252Bdiscovering%252Bantivirals%252Beffective%252Bagainst%252Bdrug-resistant%252Bviruses%26aulast%3DMa%26aufirst%3DYue%26date%3D2021%26date%3D2021%26volume%3D50%26issue%3D7%26spage%3D4514%26epage%3D4540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lauren M.  Slosky</span>, <span class="hlFld-ContribAuthor ">Marc G.  Caron</span>, <span class="hlFld-ContribAuthor ">Lawrence S.  Barak</span>. </span><span class="cited-content_cbyCitation_article-title">Biased Allosteric Modulators: New Frontiers in GPCR Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">Trends in Pharmacological Sciences</span><span> <strong>2021,</strong> <em>42 </em>
                                    (4)
                                     , 283-299. <a href="https://doi.org/10.1016/j.tips.2020.12.005" title="DOI URL">https://doi.org/10.1016/j.tips.2020.12.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tips.2020.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tips.2020.12.005%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Pharmacological%2520Sciences%26atitle%3DBiased%252BAllosteric%252BModulators%25253A%252BNew%252BFrontiers%252Bin%252BGPCR%252BDrug%252BDiscovery%26aulast%3DSlosky%26aufirst%3DLauren%2BM.%26date%3D2021%26volume%3D42%26issue%3D4%26spage%3D283%26epage%3D299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">H.  Pavan Kumar</span>, <span class="hlFld-ContribAuthor ">H. K.  Kumara</span>, <span class="hlFld-ContribAuthor ">R.  Suhas</span>, <span class="hlFld-ContribAuthor ">D.  Channe Gowda</span>. </span><span class="cited-content_cbyCitation_article-title">Multitarget‐directed therapeutics: (Urea/thiourea)
              2
              derivatives of diverse heterocyclic‐Lys conjugates. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2021,</strong> <em>36 </em><a href="https://doi.org/10.1002/ardp.202000468" title="DOI URL">https://doi.org/10.1002/ardp.202000468</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.202000468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.202000468%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DMultitarget%2525E2%252580%252590directed%252Btherapeutics%25253A%252B%252528Urea%25252Fthiourea%252529%252B2%252Bderivatives%252Bof%252Bdiverse%252Bheterocyclic%2525E2%252580%252590Lys%252Bconjugates%26aulast%3DPavan%2BKumar%26aufirst%3DH.%26date%3D2021%26date%3D2021%26volume%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel A.  Rodrigues</span>, <span class="hlFld-ContribAuthor ">Pedro S. M.  Pinheiro</span>, <span class="hlFld-ContribAuthor ">Carlos A. M.  Fraga</span>. </span><span class="cited-content_cbyCitation_article-title">Multitarget Inhibition of Histone Deacetylase (HDAC) and Phosphatidylinositol‐3‐kinase (PI3K): Current and Future Prospects. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>16 </em>
                                    (3)
                                     , 448-457. <a href="https://doi.org/10.1002/cmdc.202000643" title="DOI URL">https://doi.org/10.1002/cmdc.202000643</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000643%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DMultitarget%252BInhibition%252Bof%252BHistone%252BDeacetylase%252B%252528HDAC%252529%252Band%252BPhosphatidylinositol%2525E2%252580%2525903%2525E2%252580%252590kinase%252B%252528PI3K%252529%25253A%252BCurrent%252Band%252BFuture%252BProspects%26aulast%3DRodrigues%26aufirst%3DDaniel%2BA.%26date%3D2021%26date%3D2020%26volume%3D16%26issue%3D3%26spage%3D448%26epage%3D457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jichao  Sun</span>, <span class="hlFld-ContribAuthor ">Nayana  Prabhu</span>, <span class="hlFld-ContribAuthor ">Jun  Tang</span>, <span class="hlFld-ContribAuthor ">Fan  Yang</span>, <span class="hlFld-ContribAuthor ">Lin  Jia</span>, <span class="hlFld-ContribAuthor ">Jinan  Guo</span>, <span class="hlFld-ContribAuthor ">Kefeng  Xiao</span>, <span class="hlFld-ContribAuthor ">Wai Leong  Tam</span>, <span class="hlFld-ContribAuthor ">Pär  Nordlund</span>, <span class="hlFld-ContribAuthor ">Lingyun  Dai</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in proteome‐wide label‐free target deconvolution for bioactive small molecules. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2021,</strong> <em>72 </em><a href="https://doi.org/10.1002/med.21788" title="DOI URL">https://doi.org/10.1002/med.21788</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21788%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DRecent%252Badvances%252Bin%252Bproteome%2525E2%252580%252590wide%252Blabel%2525E2%252580%252590free%252Btarget%252Bdeconvolution%252Bfor%252Bbioactive%252Bsmall%252Bmolecules%26aulast%3DSun%26aufirst%3DJichao%26date%3D2021%26date%3D2021%26volume%3D72" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claudia  Albertini</span>, <span class="hlFld-ContribAuthor ">Marina  Naldi</span>, <span class="hlFld-ContribAuthor ">Sabrina  Petralla</span>, <span class="hlFld-ContribAuthor ">Silvia  Strocchi</span>, <span class="hlFld-ContribAuthor ">Daniela  Grifoni</span>, <span class="hlFld-ContribAuthor ">Barbara  Monti</span>, <span class="hlFld-ContribAuthor ">Manuela  Bartolini</span>, <span class="hlFld-ContribAuthor ">Maria Laura  Bolognesi</span>. </span><span class="cited-content_cbyCitation_article-title">From Combinations to Single-Molecule Polypharmacology—Cromolyn-Ibuprofen Conjugates for Alzheimer’s Disease. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (4)
                                     , 1112. <a href="https://doi.org/10.3390/molecules26041112" title="DOI URL">https://doi.org/10.3390/molecules26041112</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26041112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26041112%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DFrom%252BCombinations%252Bto%252BSingle-Molecule%252BPolypharmacology%2525E2%252580%252594Cromolyn-Ibuprofen%252BConjugates%252Bfor%252BAlzheimer%2525E2%252580%252599s%252BDisease%26aulast%3DAlbertini%26aufirst%3DClaudia%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D4%26spage%3D1112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wanheng  Zhang</span>, <span class="hlFld-ContribAuthor ">Kuojun  Zhang</span>, <span class="hlFld-ContribAuthor ">Yiwu  Yao</span>, <span class="hlFld-ContribAuthor ">Yunyao  Liu</span>, <span class="hlFld-ContribAuthor ">Yong  Ni</span>, <span class="hlFld-ContribAuthor ">Chenzhong  Liao</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Yatao  Qiu</span>, <span class="hlFld-ContribAuthor ">Dexiang  Wang</span>, <span class="hlFld-ContribAuthor ">Dong  Chen</span>, <span class="hlFld-ContribAuthor ">Lei  Qiang</span>, <span class="hlFld-ContribAuthor ">Zheng  Li</span>, <span class="hlFld-ContribAuthor ">Sheng  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>211 </em>, 113022. <a href="https://doi.org/10.1016/j.ejmech.2020.113022" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113022</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113022%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDual%252Bnicotinamide%252Bphosphoribosyltransferase%252Band%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Bcancer%26aulast%3DZhang%26aufirst%3DWanheng%26date%3D2021%26volume%3D211%26spage%3D113022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Patricia  Saenz-Méndez</span>. </span><span class="cited-content_cbyCitation_article-title">Multi-Target Drugs as Master Keys to Complex Diseases: Inverse Docking Strategies and Opportunities. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 295-311. <a href="https://doi.org/10.1016/B978-0-12-822312-3.00005-9" title="DOI URL">https://doi.org/10.1016/B978-0-12-822312-3.00005-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-822312-3.00005-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-822312-3.00005-9%26sid%3Dliteratum%253Aachs%26atitle%3DMulti-Target%252BDrugs%252Bas%252BMaster%252BKeys%252Bto%252BComplex%252BDiseases%25253A%252BInverse%252BDocking%252BStrategies%252Band%252BOpportunities%26aulast%3DSaenz-M%25C3%25A9ndez%26aufirst%3DPatricia%26date%3D2021%26spage%3D295%26epage%3D311%26pub%3DElsevier%26atitle%3DMolecular%252BDocking%252Bfor%252BComputer-Aided%252BDrug%252BDesign%26date%3D2021%26volume%3D52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joyce Villa Verde Bastos  Borba</span>, <span class="hlFld-ContribAuthor ">Arthur Carvalho  Silva</span>, <span class="hlFld-ContribAuthor ">Marilia Nunes Nascimento  Lima</span>, <span class="hlFld-ContribAuthor ">Sabrina Silva  Mendonca</span>, <span class="hlFld-ContribAuthor ">Nicholas  Furnham</span>, <span class="hlFld-ContribAuthor ">Fabio Trindade Maranhão  Costa</span>, <span class="hlFld-ContribAuthor ">Carolina Horta  Andrade</span>. </span><span class="cited-content_cbyCitation_article-title">Chemogenomics and bioinformatics approaches for prioritizing kinases as drug targets for neglected tropical diseases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 187-223. <a href="https://doi.org/10.1016/bs.apcsb.2020.10.006" title="DOI URL">https://doi.org/10.1016/bs.apcsb.2020.10.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.apcsb.2020.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.apcsb.2020.10.006%26sid%3Dliteratum%253Aachs%26atitle%3DChemogenomics%252Band%252Bbioinformatics%252Bapproaches%252Bfor%252Bprioritizing%252Bkinases%252Bas%252Bdrug%252Btargets%252Bfor%252Bneglected%252Btropical%252Bdiseases%26aulast%3DBorba%26aufirst%3DJoyce%2BVilla%2BVerde%2BBastos%26date%3D2021%26spage%3D187%26epage%3D223%26pub%3DElsevier%26atitle%3DProtein%252BKinases%252Bin%252BDrug%252BDiscovery%26date%3D2021%26volume%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Takumi  Yasuno</span>, <span class="hlFld-ContribAuthor ">Tomoyuki  Ohe</span>, <span class="hlFld-ContribAuthor ">Hiroki  Kataoka</span>, <span class="hlFld-ContribAuthor ">Kosho  Hashimoto</span>, <span class="hlFld-ContribAuthor ">Yumiko  Ishikawa</span>, <span class="hlFld-ContribAuthor ">Keigo  Furukawa</span>, <span class="hlFld-ContribAuthor ">Yasuhiro  Tateishi</span>, <span class="hlFld-ContribAuthor ">Toi  Kobayashi</span>, <span class="hlFld-ContribAuthor ">Kyoko  Takahashi</span>, <span class="hlFld-ContribAuthor ">Shigeo  Nakamura</span>, <span class="hlFld-ContribAuthor ">Tadahiko  Mashino</span>. </span><span class="cited-content_cbyCitation_article-title">Fullerene derivatives as dual inhibitors of HIV-1 reverse transcriptase and protease. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>31 </em>, 127675. <a href="https://doi.org/10.1016/j.bmcl.2020.127675" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127675%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DFullerene%252Bderivatives%252Bas%252Bdual%252Binhibitors%252Bof%252BHIV-1%252Breverse%252Btranscriptase%252Band%252Bprotease%26aulast%3DYasuno%26aufirst%3DTakumi%26date%3D2021%26volume%3D31%26spage%3D127675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John  Bremner</span>. </span><span class="cited-content_cbyCitation_article-title">Antibacterials. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-20. <a href="https://doi.org/10.1007/978-981-16-0999-2_1" title="DOI URL">https://doi.org/10.1007/978-981-16-0999-2_1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-981-16-0999-2_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-981-16-0999-2_1%26sid%3Dliteratum%253Aachs%26atitle%3DAntibacterials%26aulast%3DBremner%26aufirst%3DJohn%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D20%26pub%3DSpringer%2520Singapore%26atitle%3DMultiple%252BAction-Based%252BDesign%252BApproaches%252Bto%252BAntibacterials%26aulast%3DBremner%26aufirst%3DJohn%26date%3D2021%26volume%3D74" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Suresh  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Protein–Protein Interaction Network for the Identification of New Targets Against Novel Coronavirus. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1007/7653_2020_62" title="DOI URL">https://doi.org/10.1007/7653_2020_62</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7653_2020_62&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7653_2020_62%26sid%3Dliteratum%253Aachs%26atitle%3DProtein%2525E2%252580%252593Protein%252BInteraction%252BNetwork%252Bfor%252Bthe%252BIdentification%252Bof%252BNew%252BTargets%252BAgainst%252BNovel%252BCoronavirus%26aulast%3DKumar%26aufirst%3DSuresh%26date%3D2021%26date%3D2021%26pub%3DSpringer%2520US%26date%3D2021%26date%3D2021%26volume%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">, <span class="hlFld-ContribAuthor ">Anna  Pasieka</span>, , <span class="hlFld-ContribAuthor ">Dawid  Panek</span>, , <span class="hlFld-ContribAuthor ">Barbara  Malawska</span>, . </span><span class="cited-content_cbyCitation_article-title">Multifunctional Ligand Approach: Search for Effective Therapy Against Alzheimer’s Disease. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 181-203. <a href="https://doi.org/10.36255/exonpublications.alzheimersdisease.2020.ch11" title="DOI URL">https://doi.org/10.36255/exonpublications.alzheimersdisease.2020.ch11</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.36255/exonpublications.alzheimersdisease.2020.ch11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.36255%2Fexonpublications.alzheimersdisease.2020.ch11%26sid%3Dliteratum%253Aachs%26atitle%3DMultifunctional%252BLigand%252BApproach%25253A%252BSearch%252Bfor%252BEffective%252BTherapy%252BAgainst%252BAlzheimer%2525E2%252580%252599s%252BDisease%26aulast%3DPasieka%26aufirst%3DAnna%26date%3D2020%26date%3D2020%26spage%3D181%26epage%3D203%26pub%3DExon%2520Publications%26atitle%3DAlzheimer%2525E2%252580%252599s%252BDisease%25253A%252BDrug%252BDiscovery%26aulast%3DHuang%26aufirst%3DXudong%26date%3D2020%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuhong  Dong</span>, <span class="hlFld-ContribAuthor ">Hao  Hu</span>, <span class="hlFld-ContribAuthor ">Yuwei  Sun</span>, <span class="hlFld-ContribAuthor ">Mingze  Qin</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>, <span class="hlFld-ContribAuthor ">Yunlei  Hou</span>, <span class="hlFld-ContribAuthor ">Yanfang  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel c-Met/HDAC dual inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (23)
                                     , 127610. <a href="https://doi.org/10.1016/j.bmcl.2020.127610" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127610</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127610%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bc-Met%25252FHDAC%252Bdual%252Binhibitors%26aulast%3DDong%26aufirst%3DYuhong%26date%3D2020%26volume%3D30%26issue%3D23%26spage%3D127610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zoe  Sessions</span>, <span class="hlFld-ContribAuthor ">Norberto  Sánchez-Cruz</span>, <span class="hlFld-ContribAuthor ">Fernando D.  Prieto-Martínez</span>, <span class="hlFld-ContribAuthor ">Vinicius M.  Alves</span>, <span class="hlFld-ContribAuthor ">Hudson P.  Santos</span>, <span class="hlFld-ContribAuthor ">Eugene  Muratov</span>, <span class="hlFld-ContribAuthor ">Alexander  Tropsha</span>, <span class="hlFld-ContribAuthor ">José L.  Medina-Franco</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress on cheminformatics approaches to epigenetic drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2020,</strong> <em>25 </em>
                                    (12)
                                     , 2268-2276. <a href="https://doi.org/10.1016/j.drudis.2020.09.021" title="DOI URL">https://doi.org/10.1016/j.drudis.2020.09.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2020.09.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2020.09.021%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DRecent%252Bprogress%252Bon%252Bcheminformatics%252Bapproaches%252Bto%252Bepigenetic%252Bdrug%252Bdiscovery%26aulast%3DSessions%26aufirst%3DZoe%26date%3D2020%26volume%3D25%26issue%3D12%26spage%3D2268%26epage%3D2276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Albert A.  Antolin</span>, <span class="hlFld-ContribAuthor ">Malaka  Ameratunga</span>, <span class="hlFld-ContribAuthor ">Udai  Banerji</span>, <span class="hlFld-ContribAuthor ">Paul A.  Clarke</span>, <span class="hlFld-ContribAuthor ">Paul  Workman</span>, <span class="hlFld-ContribAuthor ">Bissan  Al-Lazikani</span>. </span><span class="cited-content_cbyCitation_article-title">The kinase polypharmacology landscape of clinical PARP inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2020,</strong> <em>10 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-020-59074-4" title="DOI URL">https://doi.org/10.1038/s41598-020-59074-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-020-59074-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-020-59074-4%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DThe%252Bkinase%252Bpolypharmacology%252Blandscape%252Bof%252Bclinical%252BPARP%252Binhibitors%26aulast%3DAntolin%26aufirst%3DAlbert%2BA.%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kerri A.  Ball</span>, <span class="hlFld-ContribAuthor ">Kristofor J.  Webb</span>, <span class="hlFld-ContribAuthor ">Stephen J.  Coleman</span>, <span class="hlFld-ContribAuthor ">Kira A.  Cozzolino</span>, <span class="hlFld-ContribAuthor ">Jeremy  Jacobsen</span>, <span class="hlFld-ContribAuthor ">Kevin R.  Jones</span>, <span class="hlFld-ContribAuthor ">Michael H. B.  Stowell</span>, <span class="hlFld-ContribAuthor ">William M.  Old</span>. </span><span class="cited-content_cbyCitation_article-title">An isothermal shift assay for proteome scale drug-target identification. </span><span class="cited-content_cbyCitation_journal-name">Communications Biology</span><span> <strong>2020,</strong> <em>3 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s42003-020-0795-6" title="DOI URL">https://doi.org/10.1038/s42003-020-0795-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s42003-020-0795-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs42003-020-0795-6%26sid%3Dliteratum%253Aachs%26jtitle%3DCommunications%2520Biology%26atitle%3DAn%252Bisothermal%252Bshift%252Bassay%252Bfor%252Bproteome%252Bscale%252Bdrug-target%252Bidentification%26aulast%3DBall%26aufirst%3DKerri%2BA.%26date%3D2020%26date%3D2020%26volume%3D3%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marcus J. G.W.  Ladds</span>, <span class="hlFld-ContribAuthor ">Gergana  Popova</span>, <span class="hlFld-ContribAuthor ">Andrés  Pastor-Fernández</span>, <span class="hlFld-ContribAuthor ">Srinivasaraghavan  Kannan</span>, <span class="hlFld-ContribAuthor ">Ingeborg M.M.  van Leeuwen</span>, <span class="hlFld-ContribAuthor ">Maria  Håkansson</span>, <span class="hlFld-ContribAuthor ">Björn  Walse</span>, <span class="hlFld-ContribAuthor ">Fredrik  Tholander</span>, <span class="hlFld-ContribAuthor ">Ravi  Bhatia</span>, <span class="hlFld-ContribAuthor ">Chandra S.  Verma</span>, <span class="hlFld-ContribAuthor ">David P.  Lane</span>, <span class="hlFld-ContribAuthor ">Sonia  Laín</span>. </span><span class="cited-content_cbyCitation_article-title">Exploitation of dihydroorotate dehydrogenase (DHODH) and p53 activation as therapeutic targets: A case study in polypharmacology. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biological Chemistry</span><span> <strong>2020,</strong> <em>295 </em>
                                    (52)
                                     , 17935-17949. <a href="https://doi.org/10.1074/jbc.RA119.012056" title="DOI URL">https://doi.org/10.1074/jbc.RA119.012056</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1074/jbc.RA119.012056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1074%2Fjbc.RA119.012056%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biological%2520Chemistry%26atitle%3DExploitation%252Bof%252Bdihydroorotate%252Bdehydrogenase%252B%252528DHODH%252529%252Band%252Bp53%252Bactivation%252Bas%252Btherapeutic%252Btargets%25253A%252BA%252Bcase%252Bstudy%252Bin%252Bpolypharmacology%26aulast%3DLadds%26aufirst%3DMarcus%2BJ.%2BG.W.%26date%3D2020%26volume%3D295%26issue%3D52%26spage%3D17935%26epage%3D17949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laeeq  Ahmed</span>, <span class="hlFld-ContribAuthor ">Hiba  Alogheli</span>, <span class="hlFld-ContribAuthor ">Staffan Arvidsson  McShane</span>, <span class="hlFld-ContribAuthor ">Jonathan  Alvarsson</span>, <span class="hlFld-ContribAuthor ">Arvid  Berg</span>, <span class="hlFld-ContribAuthor ">Anders  Larsson</span>, <span class="hlFld-ContribAuthor ">Wesley  Schaal</span>, <span class="hlFld-ContribAuthor ">Erwin  Laure</span>, <span class="hlFld-ContribAuthor ">Ola  Spjuth</span>. </span><span class="cited-content_cbyCitation_article-title">Predicting target profiles with confidence as a service using docking scores. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cheminformatics</span><span> <strong>2020,</strong> <em>12 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13321-020-00464-1" title="DOI URL">https://doi.org/10.1186/s13321-020-00464-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13321-020-00464-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13321-020-00464-1%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cheminformatics%26atitle%3DPredicting%252Btarget%252Bprofiles%252Bwith%252Bconfidence%252Bas%252Ba%252Bservice%252Busing%252Bdocking%252Bscores%26aulast%3DAhmed%26aufirst%3DLaeeq%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jameela  Banu</span>. </span><span class="cited-content_cbyCitation_article-title">Nutritional Interventions: Diet Modifications, Nutritional Supplements, Complementary and Alternative Medicine. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,<a href="https://doi.org/10.5772/intechopen.94645" title="DOI URL">https://doi.org/10.5772/intechopen.94645</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5772/intechopen.94645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5772%2Fintechopen.94645%26sid%3Dliteratum%253Aachs%26atitle%3DNutritional%252BInterventions%25253A%252BDiet%252BModifications%25252C%252BNutritional%252BSupplements%25252C%252BComplementary%252Band%252BAlternative%252BMedicine%26aulast%3DBanu%26aufirst%3DJameela%26date%3D2020%26date%3D2020%26pub%3DIntechOpen%26atitle%3DType%252B2%252BDiabetes%252B%25255BWorking%252BTitle%25255D%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel A.  Rodrigues</span>, <span class="hlFld-ContribAuthor ">Pedro de S. M.  Pinheiro</span>, <span class="hlFld-ContribAuthor ">Fernanda S.  Sagrillo</span>, <span class="hlFld-ContribAuthor ">Maria L.  Bolognesi</span>, <span class="hlFld-ContribAuthor ">Carlos A. M.  Fraga</span>. </span><span class="cited-content_cbyCitation_article-title">Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2020,</strong> <em>40 </em>
                                    (6)
                                     , 2177-2211. <a href="https://doi.org/10.1002/med.21701" title="DOI URL">https://doi.org/10.1002/med.21701</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21701%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DHistone%252Bdeacetylases%252Bas%252Btargets%252Bfor%252Bthe%252Btreatment%252Bof%252Bneurodegenerative%252Bdisorders%25253A%252BChallenges%252Band%252Bfuture%252Bopportunities%26aulast%3DRodrigues%26aufirst%3DDaniel%2BA.%26date%3D2020%26date%3D2020%26volume%3D40%26issue%3D6%26spage%3D2177%26epage%3D2211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael  González-Durruthy</span>, <span class="hlFld-ContribAuthor ">Riccardo  Concu</span>, <span class="hlFld-ContribAuthor ">Laura F. Osmari  Vendrame</span>, <span class="hlFld-ContribAuthor ">Ivana  Zanella</span>, <span class="hlFld-ContribAuthor ">Juan M.  Ruso</span>, <span class="hlFld-ContribAuthor ">M. Natália D. S.  Cordeiro</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Beta-Blocker Drug–Drug Interactions with Fibrinogen Blood Plasma Protein: A Computational and Experimental Study. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (22)
                                     , 5425. <a href="https://doi.org/10.3390/molecules25225425" title="DOI URL">https://doi.org/10.3390/molecules25225425</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25225425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25225425%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DTargeting%252BBeta-Blocker%252BDrug%2525E2%252580%252593Drug%252BInteractions%252Bwith%252BFibrinogen%252BBlood%252BPlasma%252BProtein%25253A%252BA%252BComputational%252Band%252BExperimental%252BStudy%26aulast%3DGonz%25C3%25A1lez-Durruthy%26aufirst%3DMichael%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D22%26spage%3D5425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joshua P.  Smalley</span>, <span class="hlFld-ContribAuthor ">Shaun M.  Cowley</span>, <span class="hlFld-ContribAuthor ">James T.  Hodgkinson</span>. </span><span class="cited-content_cbyCitation_article-title">Bifunctional HDAC Therapeutics: One Drug to Rule Them All?. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (19)
                                     , 4394. <a href="https://doi.org/10.3390/molecules25194394" title="DOI URL">https://doi.org/10.3390/molecules25194394</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25194394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25194394%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DBifunctional%252BHDAC%252BTherapeutics%25253A%252BOne%252BDrug%252Bto%252BRule%252BThem%252BAll%25253F%26aulast%3DSmalley%26aufirst%3DJoshua%2BP.%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D19%26spage%3D4394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pascal  Mayer</span>, . </span><span class="cited-content_cbyCitation_article-title">Modelling bioactivities of combinations of whole extracts of edibles with a simplified theoretical framework reveals the statistical role of molecular diversity and system complexity in their mode of action and their nearly certain safety. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2020,</strong> <em>15 </em>
                                    (9)
                                     , e0239841. <a href="https://doi.org/10.1371/journal.pone.0239841" title="DOI URL">https://doi.org/10.1371/journal.pone.0239841</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0239841&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0239841%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DModelling%252Bbioactivities%252Bof%252Bcombinations%252Bof%252Bwhole%252Bextracts%252Bof%252Bedibles%252Bwith%252Ba%252Bsimplified%252Btheoretical%252Bframework%252Breveals%252Bthe%252Bstatistical%252Brole%252Bof%252Bmolecular%252Bdiversity%252Band%252Bsystem%252Bcomplexity%252Bin%252Btheir%252Bmode%252Bof%252Baction%252Band%252Btheir%252Bnearly%252Bcertain%252Bsafety%26aulast%3DMayer%26aufirst%3DPascal%26date%3D2020%26date%3D2020%26volume%3D15%26issue%3D9%26spage%3De0239841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Krishnankutty Chandrika  Sivakumar</span>, <span class="hlFld-ContribAuthor ">Jin  Haixiao</span>, <span class="hlFld-ContribAuthor ">C. Benjamin  Naman</span>, <span class="hlFld-ContribAuthor ">T. P.  Sajeevan</span>. </span><span class="cited-content_cbyCitation_article-title">Prospects of
              multitarget
              drug designing strategies by linking molecular docking and molecular dynamics to explore the
              protein–ligand
              recognition process. </span><span class="cited-content_cbyCitation_journal-name">Drug Development Research</span><span> <strong>2020,</strong> <em>81 </em>
                                    (6)
                                     , 685-699. <a href="https://doi.org/10.1002/ddr.21673" title="DOI URL">https://doi.org/10.1002/ddr.21673</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ddr.21673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fddr.21673%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Development%2520Research%26atitle%3DProspects%252Bof%252Bmultitarget%252Bdrug%252Bdesigning%252Bstrategies%252Bby%252Blinking%252Bmolecular%252Bdocking%252Band%252Bmolecular%252Bdynamics%252Bto%252Bexplore%252Bthe%252Bprotein%2525E2%252580%252593ligand%252Brecognition%252Bprocess%26aulast%3DSivakumar%26aufirst%3DKrishnankutty%2BChandrika%26date%3D2020%26date%3D2020%26volume%3D81%26issue%3D6%26spage%3D685%26epage%3D699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S.  Hjorth</span>, <span class="hlFld-ContribAuthor ">S.  Waters</span>, <span class="hlFld-ContribAuthor ">N.  Waters</span>, <span class="hlFld-ContribAuthor ">J.  Tedroff</span>, <span class="hlFld-ContribAuthor ">P.  Svensson</span>, <span class="hlFld-ContribAuthor ">A.  Fagerberg</span>, <span class="hlFld-ContribAuthor ">M.  Edling</span>, <span class="hlFld-ContribAuthor ">B.  Svanberg</span>, <span class="hlFld-ContribAuthor ">E.  Ljung</span>, <span class="hlFld-ContribAuthor ">J.  Gunnergren</span>, <span class="hlFld-ContribAuthor ">S.L.  McLean</span>, <span class="hlFld-ContribAuthor ">B.  Grayson</span>, <span class="hlFld-ContribAuthor ">N.F.  Idris</span>, <span class="hlFld-ContribAuthor ">J.C.  Neill</span>, <span class="hlFld-ContribAuthor ">C.  Sonesson</span>. </span><span class="cited-content_cbyCitation_article-title">(3
              S
              )‐3‐(2,3‐difluorophenyl)‐3‐methoxypyrrolidine (IRL752) —a Novel Cortical-Preferring Catecholamine Transmission- and Cognition-Promoting Agent. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacology and Experimental Therapeutics</span><span> <strong>2020,</strong> <em>374 </em>
                                    (3)
                                     , 404-419. <a href="https://doi.org/10.1124/jpet.120.000037" title="DOI URL">https://doi.org/10.1124/jpet.120.000037</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/jpet.120.000037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fjpet.120.000037%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacology%2520and%2520Experimental%2520Therapeutics%26atitle%3D%2525283%252BS%252B%252529%2525E2%252580%2525903%2525E2%252580%252590%2525282%25252C3%2525E2%252580%252590difluorophenyl%252529%2525E2%252580%2525903%2525E2%252580%252590methoxypyrrolidine%252B%252528IRL752%252529%252B%2525E2%252580%252594a%252BNovel%252BCortical-Preferring%252BCatecholamine%252BTransmission-%252Band%252BCognition-Promoting%252BAgent%26aulast%3DHjorth%26aufirst%3DS.%26date%3D2020%26date%3D2020%26volume%3D374%26issue%3D3%26spage%3D404%26epage%3D419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhiwei  Li</span>, <span class="hlFld-ContribAuthor ">Le  Xu</span>, <span class="hlFld-ContribAuthor ">Liangyu  Zhu</span>, <span class="hlFld-ContribAuthor ">Yanfang  Zhao</span>, <span class="hlFld-ContribAuthor ">Tao  Hu</span>, <span class="hlFld-ContribAuthor ">Bixi  Yin</span>, <span class="hlFld-ContribAuthor ">Yajing  Liu</span>, <span class="hlFld-ContribAuthor ">Yunlei  Hou</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel pteridinone derivatives possessing a hydrazone moiety as potent PLK1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (16)
                                     , 127329. <a href="https://doi.org/10.1016/j.bmcl.2020.127329" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127329</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127329%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bpteridinone%252Bderivatives%252Bpossessing%252Ba%252Bhydrazone%252Bmoiety%252Bas%252Bpotent%252BPLK1%252Binhibitors%26aulast%3DLi%26aufirst%3DZhiwei%26date%3D2020%26volume%3D30%26issue%3D16%26spage%3D127329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joshua  Pottel</span>, <span class="hlFld-ContribAuthor ">Duncan  Armstrong</span>, <span class="hlFld-ContribAuthor ">Ling  Zou</span>, <span class="hlFld-ContribAuthor ">Alexander  Fekete</span>, <span class="hlFld-ContribAuthor ">Xi-Ping  Huang</span>, <span class="hlFld-ContribAuthor ">Hayarpi  Torosyan</span>, <span class="hlFld-ContribAuthor ">Dallas  Bednarczyk</span>, <span class="hlFld-ContribAuthor ">Steven  Whitebread</span>, <span class="hlFld-ContribAuthor ">Barun  Bhhatarai</span>, <span class="hlFld-ContribAuthor ">Guiqing  Liang</span>, <span class="hlFld-ContribAuthor ">Hong  Jin</span>, <span class="hlFld-ContribAuthor ">S. Nassir  Ghaemi</span>, <span class="hlFld-ContribAuthor ">Samuel  Slocum</span>, <span class="hlFld-ContribAuthor ">Katalin V.  Lukacs</span>, <span class="hlFld-ContribAuthor ">John J.  Irwin</span>, <span class="hlFld-ContribAuthor ">Ellen L.  Berg</span>, <span class="hlFld-ContribAuthor ">Kathleen M.  Giacomini</span>, <span class="hlFld-ContribAuthor ">Bryan L.  Roth</span>, <span class="hlFld-ContribAuthor ">Brian K.  Shoichet</span>, <span class="hlFld-ContribAuthor ">Laszlo  Urban</span>. </span><span class="cited-content_cbyCitation_article-title">The activities of drug inactive ingredients
                                                  on biological targets. </span><span class="cited-content_cbyCitation_journal-name">Science</span><span> <strong>2020,</strong> <em>369 </em>
                                    (6502)
                                     , 403-413. <a href="https://doi.org/10.1126/science.aaz9906" title="DOI URL">https://doi.org/10.1126/science.aaz9906</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1126/science.aaz9906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1126%2Fscience.aaz9906%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%26atitle%3DThe%252Bactivities%252Bof%252Bdrug%252Binactive%252Bingredients%252Bon%252Bbiological%252Btargets%26aulast%3DPottel%26aufirst%3DJoshua%26date%3D2020%26date%3D2020%26volume%3D369%26issue%3D6502%26spage%3D403%26epage%3D413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vijay  Kumar</span>, <span class="hlFld-ContribAuthor ">Bhupinder  Kumar</span>, <span class="hlFld-ContribAuthor ">Ashish  Ranjan Dwivedi</span>, <span class="hlFld-ContribAuthor ">Devashish  Mehta</span>, <span class="hlFld-ContribAuthor ">Naveen  Kumar</span>, <span class="hlFld-ContribAuthor ">Beenu  Bajaj</span>, <span class="hlFld-ContribAuthor ">Tania  Arora</span>, <span class="hlFld-ContribAuthor ">Vikash  Prashar</span>, <span class="hlFld-ContribAuthor ">Jyoti  Parkash</span>, <span class="hlFld-ContribAuthor ">Vinod  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Evaluation of
              O
              ‐Pentyne Substituted Diphenylpyrimidines as Monoamine Oxidase and Acetylcholinesterase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2020,</strong> <em>5 </em>
                                    (27)
                                     , 8021-8032. <a href="https://doi.org/10.1002/slct.202002425" title="DOI URL">https://doi.org/10.1002/slct.202002425</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.202002425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.202002425%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BEvaluation%252Bof%252BO%252B%2525E2%252580%252590Pentyne%252BSubstituted%252BDiphenylpyrimidines%252Bas%252BMonoamine%252BOxidase%252Band%252BAcetylcholinesterase%252BInhibitors%26aulast%3DKumar%26aufirst%3DVijay%26date%3D2020%26date%3D2020%26volume%3D5%26issue%3D27%26spage%3D8021%26epage%3D8032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yahui  Huang</span>, <span class="hlFld-ContribAuthor ">Shuqiang  Chen</span>, <span class="hlFld-ContribAuthor ">Shanchao  Wu</span>, <span class="hlFld-ContribAuthor ">Guoqiang  Dong</span>, <span class="hlFld-ContribAuthor ">Chunquan  Sheng</span>. </span><span class="cited-content_cbyCitation_article-title">Evodiamine-inspired dual inhibitors of histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) with potent antitumor activity. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2020,</strong> <em>10 </em>
                                    (7)
                                     , 1294-1308. <a href="https://doi.org/10.1016/j.apsb.2019.11.011" title="DOI URL">https://doi.org/10.1016/j.apsb.2019.11.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2019.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2019.11.011%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DEvodiamine-inspired%252Bdual%252Binhibitors%252Bof%252Bhistone%252Bdeacetylase%252B1%252B%252528HDAC1%252529%252Band%252Btopoisomerase%252B2%252B%252528TOP2%252529%252Bwith%252Bpotent%252Bantitumor%252Bactivity%26aulast%3DHuang%26aufirst%3DYahui%26date%3D2020%26volume%3D10%26issue%3D7%26spage%3D1294%26epage%3D1308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claudia  Albertini</span>, <span class="hlFld-ContribAuthor ">Alessandra  Salerno</span>, <span class="hlFld-ContribAuthor ">Pedro  Sena Murteira Pinheiro</span>, <span class="hlFld-ContribAuthor ">Maria L.  Bolognesi</span>. </span><span class="cited-content_cbyCitation_article-title">From combinations to multitarget‐directed ligands: A continuum in Alzheimer's disease polypharmacology. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2020,</strong> <em>10 </em><a href="https://doi.org/10.1002/med.21699" title="DOI URL">https://doi.org/10.1002/med.21699</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21699%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DFrom%252Bcombinations%252Bto%252Bmultitarget%2525E2%252580%252590directed%252Bligands%25253A%252BA%252Bcontinuum%252Bin%252BAlzheimer%252527s%252Bdisease%252Bpolypharmacology%26aulast%3DAlbertini%26aufirst%3DClaudia%26date%3D2020%26date%3D2020%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christian  Feldmann</span>, <span class="hlFld-ContribAuthor ">Jürgen  Bajorath</span>. </span><span class="cited-content_cbyCitation_article-title">X-ray Structure-Based Chemoinformatic Analysis Identifies Promiscuous Ligands Binding to Proteins from Different Classes with Varying Shapes. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (11)
                                     , 3782. <a href="https://doi.org/10.3390/ijms21113782" title="DOI URL">https://doi.org/10.3390/ijms21113782</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21113782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21113782%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DX-ray%252BStructure-Based%252BChemoinformatic%252BAnalysis%252BIdentifies%252BPromiscuous%252BLigands%252BBinding%252Bto%252BProteins%252Bfrom%252BDifferent%252BClasses%252Bwith%252BVarying%252BShapes%26aulast%3DFeldmann%26aufirst%3DChristian%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D11%26spage%3D3782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div><a href="#" data-source="/pb/widgets/cited-by?doi=10.1021%2Fjm400856t&amp;widgetId=9cf770f4-a9a2-46e0-bd29-3da15bcf4ae0&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2013.56.issue-22%3Barticle%3Aarticle%3A10.1021%2Fjm400856t%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text&amp;citedByCount=268&amp;pagesCount=3&amp;pageNumber=2" title="Load more citations" class="button_primary float-right cited-by__see-more mb-5"><i aria-hidden="”true”" class="icon-angle-double-down"></i><span>Load more citations</span></a></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_null" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/medium/jm-2013-00856t_0011.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400856t&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/medium/jm-2013-00856t_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0003.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Dependence of pharmacological promiscuity (hit rate) on ionization state and lipophilicity in the BioPrint data set. The majority of promiscuous compounds are bases, which carry a positive charge under assay conditions. Compounds with a ClogP > 2 tend to be more promiscuous. The “hit rate” of a compound is the percentage of targets, to which this compound binds with sub-micromolar affinity (cytochrome P450 [CYP] enzymes are excluded). For instance, the topmost blue data point represents a compound, which “hits” 19% of the BioPrint targets (25 out of 132). Reproduced with permission from <i>Drug Discovery Today</i><b>2012</b>, <i>17</i>(7–8), 325–335. Copyright 2012 Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400856t&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/medium/jm-2013-00856t_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0004.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Dependence of pharmacological promiscuity (off-target hits) on the lipophilicity of marketed beta-blockers. Lipophilic beta-blockers tend to be more promiscuous. “Off-target hits” denote the number of submicromolar hits in a safety screening panel of 129 targets (BioPrint data set excluding β-adrenergic receptors and CYP enzymes). Number-labeled data points represent, in order of increasing ClogP: atenolol (1), sotalol (2), nadolol (3), timolol (4), carteolol (5), metoprolol (6), pindolol (7), acebutolol (8), esmolol (9), bisoprolol (10), celiprolol (11), oxprenolol (12), levobunolol (13), betaxolol (14), labetalol (15), alprenolol (16).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400856t&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/medium/jm-2013-00856t_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0001.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. The “Heteroaryl-NH-aryl” Motif Is Predictive of Kinase Activity<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400856t&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/medium/jm-2013-00856t_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0005.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Mechanistic reasons for drug withdrawals since 1980. Withdrawn drugs were classified by the presumed mechanism of their main adverse effects: (a) hERG blockade: astemizole, cisapride, grepafloxacin, levomethadyl, terfenadine, terodiline, thioridazine; (b) serotonin 5-HT<sub>2B</sub> receptor agonism: benfluorex, dexfenfluramine, fenfluramine, pergolide; (c) muscarinic M<sub>2</sub> receptor antagonism: rapacuronium; (d) CYP interaction: mibefradil; (e) therapeutic-target related: alosetron, cerivastatin, encainide, etretinate, flosequinan, hydromorphone extended-release (Palladone), methaqualone, phenylpropanolamine, rimonabant, rofecoxib, rosiglitazone, valdecoxib; (f) reactive metabolite formation, bile salt export pump (BSEP) inhibition, or mitochondrial toxicity: alpidem, amineptine, benoxaprofen, benzbromarone, bromfenac, chlormezanone, levamisole, lumiracoxib, nefazodone, nomifensine, pemoline, phenacetin, remoxipiride, sitaxentan, suprofen, temafloxacin, ticrynafen, tolcapone, tolrestat, troglitazone, trovafloxacin, ximelagatran, zimelidine, zomepirac; (g) unknown: gatifloxacin, sibutramine (likely therapeutic target related), tegaserod.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400856t&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/medium/jm-2013-00856t_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0006.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Tumors and their surrounding tissue exchange growth factors and cytokines and thereby stimulate angiogenesis and tumor growth. The receptor kinases of these growth factors are targets of multikinase inhibiting anticancer drugs. (Reproduced with permission from <i>Polypharmacology in Drug Discovery</i>; Peters, J.-U., Ed.; Wiley, New York, 2012; the picture is courtesy of Annalisa Petrelli, University of Turin).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400856t&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Chart 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/medium/jm-2013-00856t_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0002.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 2. Recently Approved, Polypharmacological Drugs for Different Indications and Target Classes</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400856t&amp;id=cht2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/medium/jm-2013-00856t_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0007.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Experimentation with early, polypharmacological antihistamines led to the discovery of antipsychotics and antidepressants.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400856t&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/medium/jm-2013-00856t_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0008.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Sulfonylurea antidiabetics were derived from antibiotics with hypoglycemic side-effects.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400856t&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/medium/jm-2013-00856t_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0009.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. The connection of two dissimilar pharmacophores led to the dual-target antihypertensive <b>2</b> with a high molecular weight.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400856t&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/medium/jm-2013-00856t_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0010.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. The antipsychotic ziprasidone was discovered by merging serotonin and dopamine receptor pharmacophores.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm400856t/production/images/large/jm-2013-00856t_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400856t&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i24">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70444" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70444" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 198 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Rothman, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumann, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauser, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hufeisen, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x"> (</span><span class="NLM_issue">23</span><span class="NLM_x">) </span> <span class="NLM_fpage">2836</span><span class="NLM_x">–</span> <span class="NLM_lpage">2841</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2000&pages=2836-2841&issue=23&author=R.+B.+Rothmanauthor=M.+H.+Baumannauthor=J.+E.+Savageauthor=L.+Rauserauthor=A.+McBrideauthor=S.+J.+Hufeisenauthor=B.+L.+Roth&title=Evidence+for+possible+involvement+of+5-HT2B+receptors+in+the+cardiac+valvulopathy+associated+with+fenfluramine+and+other+serotonergic+medications"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRothman%26aufirst%3DR.%2BB.%26aulast%3DBaumann%26aufirst%3DM.%2BH.%26aulast%3DSavage%26aufirst%3DJ.%2BE.%26aulast%3DRauser%26aufirst%3DL.%26aulast%3DMcBride%26aufirst%3DA.%26aulast%3DHufeisen%26aufirst%3DS.%2BJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DEvidence%2520for%2520possible%2520involvement%2520of%25205-HT2B%2520receptors%2520in%2520the%2520cardiac%2520valvulopathy%2520associated%2520with%2520fenfluramine%2520and%2520other%2520serotonergic%2520medications%26jtitle%3DCirculation%26date%3D2000%26volume%3D102%26issue%3D23%26spage%3D2836%26epage%3D2841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Connolly, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crary, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mcgoon, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hensrud, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaff, H. V.</span><span> </span><span class="NLM_article-title">Valvular heart disease associated with fenfluramine-phentermine</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">337</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">581</span><span class="NLM_x">–</span> <span class="NLM_lpage">588</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1056%2FNEJM199708283370901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADyaK2sXmtVGntLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=337&publication_year=1997&pages=581-588&issue=9&author=H.+M.+Connollyauthor=J.+L.+Craryauthor=M.+D.+Mcgoonauthor=D.+D.+Hensrudauthor=B.+S.+Edwardsauthor=W.+D.+Edwardsauthor=H.+V.+Schaff&title=Valvular+heart+disease+associated+with+fenfluramine-phentermine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Valvular heart disease associated with fenfluramine-phentermine</span></div><div class="casAuthors">Connolly, Heidi M.; Crary, Jack L.; Mcgoon, Michael D.; Hensrud, Donald D.; Edwards, Brooks S.; Edwards, William D.; Schaff, Hartzell V.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">337</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">581-588</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Fenfluramine and phentermine have been individually approved as anorectic agents by the Food and Drug Administration (FDA).  When used in combination the drugs may be just as effective as either drug alone, with the added advantages of the need for lower doses of each agent and perhaps fewer side effects.  Although the combination has not been approved by the FDA, in 1996 the total no. of prescriptions in the United States for fenfluramine and phentermine exceeded 18 million.  We identified valvular heart disease in 24 women treated with fenfluramine-phentermine who had no history of cardiac disease.  The women presented with cardiovascular symptoms or a heart murmur.  As increasing nos. of these patients with similar clin. features were identified, there appeared to be an assocn. between these features and fenfluramine-phentermine therapy.  Twenty-four women (mean [±SD] age, 44±8 yr) were evaluated 12.3±7.1 mo after the initiation of fenfluramine-phentermine therapy.  Echocardiog. demonstrated unusual valvular morphol. and regurgitation in all patients.  Both right-side and left-sided heart values were involved.  Eight women also had newly documented pulmonary hypertension.  To date, cardiac surgical intervention has been required in five patients.  The heart valves had a glistening white appearance.  Histopathol. findings included plaque-like encasement of the leaflets and chordal structures with intact valve architecture.  The histopathol. features were identical to those seen in carcinoid or ergotamine-induced valve disease.  These cases arouse concern that fenfluramine-phentermine therapy may be assocd. with valvular heart disease.  Candidates for fenfluramine-phentermine therapy should be informed about serious potential adverse effects, including pulmonary hypertension and valvular heart disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAXd7m-oabsLVg90H21EOLACvtfcHk0lizJ3LcrPyhLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmtVGntLc%253D&md5=f206b00f5881d0d50b2d710ea41f44fe</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJM199708283370901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199708283370901%26sid%3Dliteratum%253Aachs%26aulast%3DConnolly%26aufirst%3DH.%2BM.%26aulast%3DCrary%26aufirst%3DJ.%2BL.%26aulast%3DMcgoon%26aufirst%3DM.%2BD.%26aulast%3DHensrud%26aufirst%3DD.%2BD.%26aulast%3DEdwards%26aufirst%3DB.%2BS.%26aulast%3DEdwards%26aufirst%3DW.%2BD.%26aulast%3DSchaff%26aufirst%3DH.%2BV.%26atitle%3DValvular%2520heart%2520disease%2520associated%2520with%2520fenfluramine-phentermine%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1997%26volume%3D337%26issue%3D9%26spage%3D581%26epage%3D588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Hutcheson, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merryman, W. D.</span><span> </span><span class="NLM_article-title">Serotonin receptors and heart valve disease-It was meant 2B</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">146</span><span class="NLM_x">–</span> <span class="NLM_lpage">157</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1016%2Fj.pharmthera.2011.03.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFaksLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2011&pages=146-157&issue=2&author=J.+D.+Hutchesonauthor=V.+Setolaauthor=B.+L.+Rothauthor=W.+D.+Merryman&title=Serotonin+receptors+and+heart+valve+disease-It+was+meant+2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin receptors and heart valve disease-It was meant 2B</span></div><div class="casAuthors">Hutcheson, Joshua D.; Setola, Vincent; Roth, Bryan L.; Merryman, W. David</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">146-157</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Carcinoid heart disease was one of the first valvular pathologies studied in mol. detail, and early research identified serotonin produced by oncogenic enterochromaffin cells as the likely culprit in causing changes in heart valve tissue.  Researchers and physicians in the mid-1960s noted a connection between the use of several ergot-derived medications with structures similar to serotonin and the development of heart valve pathologies similar to those obsd. in carcinoid patients.  The exact serotonergic target that mediated valvular pathogenesis remained a mystery for many years until similar cases were reported in patients using the popular diet drug Fen-Phen in the late 1990s.  The Fen-Phen episode sparked renewed interest in serotonin-mediated valve disease, and studies led to the identification of the 5-HT2B receptor as the likely mol. target leading to heart valve tissue fibrosis.  Subsequent studies have identified numerous other activators of the 5-HT2B receptor, and consequently, the use of many of these mols. has been linked to heart valve disease.  Herein, we: review the mol. properties of the 5-HT2B receptor including factors that differentiate the 5-HT2B receptor from other 5-HT receptor subtypes, discuss the studies that led to the identification of the 5-HT2B receptor as the mediator of heart valve disease, present current efforts to identify potential valvulopathogens by screening for 5-HT2B receptor activity, and speculate on potential therapeutic benefits of 5-HT2B receptor targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4R8A9Ia-r3LVg90H21EOLACvtfcHk0lizJ3LcrPyhLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFaksLnO&md5=b97c1992208a501b1959c2f48f3ca9cd</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2011.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2011.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DHutcheson%26aufirst%3DJ.%2BD.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DMerryman%26aufirst%3DW.%2BD.%26atitle%3DSerotonin%2520receptors%2520and%2520heart%2520valve%2520disease-It%2520was%2520meant%25202B%26jtitle%3DPharmacol.%2520Ther.%26date%3D2011%26volume%3D132%26issue%3D2%26spage%3D146%26epage%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Whitebread, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bojanic, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, L.</span><span> </span><span class="NLM_article-title">In vitro safety pharmacology profiling: an essential tool for successful drug development</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">21</span><span class="NLM_x">) </span> <span class="NLM_fpage">1421</span><span class="NLM_x">–</span> <span class="NLM_lpage">1433</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=1421-1433&issue=21&author=S.+Whitebreadauthor=J.+Hamonauthor=D.+Bojanicauthor=L.+Urban&title=In+vitro+safety+pharmacology+profiling%3A+an+essential+tool+for+successful+drug+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWhitebread%26aufirst%3DS.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DBojanic%26aufirst%3DD.%26aulast%3DUrban%26aufirst%3DL.%26atitle%3DIn%2520vitro%2520safety%2520pharmacology%2520profiling%253A%2520an%2520essential%2520tool%2520for%2520successful%2520drug%2520development%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2005%26volume%3D10%26issue%3D21%26spage%3D1421%26epage%3D1433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Hopkins, A. L.</span><span> </span><span class="NLM_article-title">Network pharmacology: the next paradigm in drug discovery</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">682</span><span class="NLM_x">–</span> <span class="NLM_lpage">690</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fnchembio.118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=18936753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=682-690&issue=11&author=A.+L.+Hopkins&title=Network+pharmacology%3A+the+next+paradigm+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Network pharmacology: the next paradigm in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">682-690</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The dominant paradigm in drug discovery is the concept of designing maximally selective ligands to act on individual drug targets.  However, many effective drugs act via modulation of multiple proteins rather than single targets.  Advances in systems biol. are revealing a phenotypic robustness and a network structure that strongly suggests that exquisitely selective compds., compared with multi-target drugs, may exhibit lower than desired clin. efficacy.  This new appreciation of the role of polypharmacol. has significant implications for tackling the two major sources of attrition in drug development, efficacy and toxicity.  Integrating network biol. and polypharmacol. holds the promise of expanding the current opportunity space for druggable targets.  However, the rational design of polypharmacol. faces considerable challenges in the need for new methods to validate target combinations and optimize multiple structure-activity relationships while maintaining drug-like properties.  Advances in these areas are creating the foundation of the next paradigm in drug discovery: network pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqHy4FqkK-h7Vg90H21EOLACvtfcHk0lj-RsGwOKvPTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK&md5=03b8be3ddbcab7dc65afd17df7ee8395</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.118%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DNetwork%2520pharmacology%253A%2520the%2520next%2520paradigm%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26issue%3D11%26spage%3D682%26epage%3D690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Gleeson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hersey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montanari, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overington, J.</span><span> </span><span class="NLM_article-title">Probing the links between in vitro potency, ADMET and physicochemical parameters</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">197</span><span class="NLM_x">–</span> <span class="NLM_lpage">208</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fnrd3367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=21358739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFemsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=197-208&issue=3&author=M.+P.+Gleesonauthor=A.+Herseyauthor=D.+Montanariauthor=J.+Overington&title=Probing+the+links+between+in+vitro+potency%2C+ADMET+and+physicochemical+parameters"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Probing the links between in vitro potency, ADMET and physicochemical parameters</span></div><div class="casAuthors">Gleeson, M. Paul; Hersey, Anne; Montanari, Dino; Overington, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">197-208</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  A common underlying assumption in current drug discovery strategies is that compds. with higher in vitro potency at their target(s) have greater potential to translate into successful, low-dose therapeutics.  This has led to the development of screening cascades with in vitro potency embedded as an early filter.  However, this approach is beginning to be questioned, given the bias in physicochem. properties that it can introduce early in lead generation and optimization, which is due to the often diametrically opposed relationship between physicochem. parameters assocd. with high in vitro potency and those assocd. with desirable absorption, distribution, metab., excretion and toxicity (ADMET) characteristics.  Here, we describe analyses that probe these issues further using the ChEMBL database, which includes more than 500,000 drug discovery and marketed oral drug compds.  Key findings include: first, that oral drugs seldom possess nanomolar potency (50 nM on av.); second, that many oral drugs have considerable off-target activity; and third, that in vitro potency does not correlate strongly with the therapeutic dose.  These findings suggest that the perceived benefit of high in vitro potency may be negated by poorer ADMET properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovOslFSgIkUbVg90H21EOLACvtfcHk0lj-RsGwOKvPTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFemsr8%253D&md5=e275044516e9b0245b71c9603477ef74</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrd3367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3367%26sid%3Dliteratum%253Aachs%26aulast%3DGleeson%26aufirst%3DM.%2BP.%26aulast%3DHersey%26aufirst%3DA.%26aulast%3DMontanari%26aufirst%3DD.%26aulast%3DOverington%26aufirst%3DJ.%26atitle%3DProbing%2520the%2520links%2520between%2520in%2520vitro%2520potency%252C%2520ADMET%2520and%2520physicochemical%2520parameters%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26issue%3D3%26spage%3D197%26epage%3D208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Ainsworth, C.</span><span> </span><span class="NLM_article-title">Networking for new drugs</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">1166</span><span class="NLM_x">–</span> <span class="NLM_lpage">1168</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fnm1011-1166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht12iu7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=1166-1168&issue=10&author=C.+Ainsworth&title=Networking+for+new+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Networking for new drugs</span></div><div class="casAuthors">Ainsworth, Claire</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1166-1168</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Many of today's most celebrated drugs are designed to hit only one biol. target with great precision.  But a novel clin. trial aims to turn this idea on its head by using 'network pharmacol.' to more effectively tackle a common neurol. disorder affecting limb movement.  Claire Ainsworth looks into how medicine's proverbial 'magic bullet' might soon give way to a more sophisticated arsenal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP6ub5TqNMc7Vg90H21EOLACvtfcHk0lj-RsGwOKvPTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht12iu7vF&md5=ee8ad6c3bccc296c49d55398ce2d5eb7</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnm1011-1166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1011-1166%26sid%3Dliteratum%253Aachs%26aulast%3DAinsworth%26aufirst%3DC.%26atitle%3DNetworking%2520for%2520new%2520drugs%26jtitle%3DNat.%2520Med.%26date%3D2011%26volume%3D17%26issue%3D10%26spage%3D1166%26epage%3D1168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Mencher, Simon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Long, G.</span><span> </span><span class="NLM_article-title">Promiscuous drugs compared to selective drugs (promiscuity can be a virtue)</span> <span class="citation_source-journal">BMC Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">3</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1186%2F1472-6904-5-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A280%3ADC%252BD2M3ktVartA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=3&issue=1&author=K.+Mencher%2C+Simonauthor=G.+Wang%2C+Long&title=Promiscuous+drugs+compared+to+selective+drugs+%28promiscuity+can+be+a+virtue%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Promiscuous drugs compared to selective drugs (promiscuity can be a virtue)</span></div><div class="casAuthors">Mencher Simon K; Wang Long G</div><div class="citationInfo"><span class="NLM_cas:title">BMC clinical pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The word selectivity describes a drug's ability to affect a particular cell population in preference to others.  As part of the current state of art in the search for new therapeutic agents, the property of selectivity is a mode of action thought to have a high degree of desirability.  Consequently there is a growing activity in this area of research.  Selectivity is generally a worthy property in a drug because a drug having high selectivity may have a dramatic effect when there is a single agent that can be targeted against the appropriate molecular-driver involved in the pathogenesis of a disease.  An example is chronic myeloid leukemia (CML).  CML has a specific chromosomal abnormality, the Philadelphia chromosome, that results in a single gene that produces an abnormal protein.  DISCUSSION:  There is a burgeoning understanding of the cellular mechanisms that control the etiology and pathogeneses of diseases.  This understanding both enables and motivates the development of drugs that induce a specific action in a selected cell population; i.e., a targeted treatment.  Consequently, drugs that can target distinct molecular targets involved in pathologic/pathogenetic processes, or signal-transduction pathways, are being developed.  However, in most cases, diseases involve multiple abnormalities.  A disease may be associated with more than one dysfunctional protein and these may be out-of-balance with each other.  Likewise a drug might strongly target a protein that shares a similar active domain with other proteins.  A drug may also target pleiotropic cytokines, or other proteins that have multi-physiological functions.  In this way multiple normal cellular pathways can be simultaneously influenced.  Long term experience with drugs supposedly designed for only a single target, but which unavoidably involve other functional effects, is uncovering the fact that molecular targeting is not medically flawless.  SUMMARY:  We contend that an ideal drug may be one whose efficacy is based not on the inhibition of a single target, but rather on the rebalancing of the several proteins or events, that contribute to the etiology, pathogeneses, and progression of diseases, i.e., in effect a promiscuous drug.  Ideally, if this could be done at minimum drug concentration, side effects could be minimized.  Corollaries to this argument are that the growing fervor for researching truly selective drugs may be imprudent when considering the totality of responses; and that the expensive screening techniques used to discover these, may be both medically and financially inefficient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQc3Gp004wjH9yzdcP07UmufW6udTcc2eZDnpEu3npdRrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M3ktVartA%253D%253D&md5=bfc2421479ee2f2169efd58bdc0238ec</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1186%2F1472-6904-5-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1472-6904-5-3%26sid%3Dliteratum%253Aachs%26aulast%3DMencher%252C%2BSimon%26aufirst%3DK.%26aulast%3DWang%252C%2BLong%26aufirst%3DG.%26atitle%3DPromiscuous%2520drugs%2520compared%2520to%2520selective%2520drugs%2520%2528promiscuity%2520can%2520be%2520a%2520virtue%2529%26jtitle%3DBMC%2520Clin.%2520Pharmacol.%26date%3D2005%26volume%3D5%26issue%3D1%26spage%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Hopkins, A. L.</span><span> </span><span class="NLM_article-title">The Case for Polypharmacology</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed.; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=1-6&author=A.+L.+Hopkinsauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DThe%2520Case%2520for%2520Polypharmacology%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D1%26epage%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Abbenante, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reid, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairlie, D. P.</span><span> </span><span class="NLM_article-title">‘Clean’ or ‘Dirty’ - Just How Selective Do Drugs Need To Be?</span> <span class="citation_source-journal">Aust. J. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">654</span><span class="NLM_x">–</span> <span class="NLM_lpage">660</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2008&pages=654-660&issue=9&author=G.+Abbenanteauthor=R.+C.+Reidauthor=D.+P.+Fairlie&title=%E2%80%98Clean%E2%80%99+or+%E2%80%98Dirty%E2%80%99+-+Just+How+Selective+Do+Drugs+Need+To+Be%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAbbenante%26aufirst%3DG.%26aulast%3DReid%26aufirst%3DR.%2BC.%26aulast%3DFairlie%26aufirst%3DD.%2BP.%26atitle%3D%25E2%2580%2598Clean%25E2%2580%2599%2520or%2520%25E2%2580%2598Dirty%25E2%2580%2599%2520-%2520Just%2520How%2520Selective%2520Do%2520Drugs%2520Need%2520To%2520Be%253F%26jtitle%3DAust.%2520J.%2520Chem.%26date%3D2008%26volume%3D61%26issue%3D9%26spage%3D654%26epage%3D660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Korcsmaros, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szalay, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovacs, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Csermely, P.</span><span> </span><span class="NLM_article-title">How to design multi-target drugs: target search options in cellular networks</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">799</span><span class="NLM_x">–</span> <span class="NLM_lpage">808</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=799-808&issue=6&author=T.+Korcsmarosauthor=M.+S.+Szalayauthor=C.+Bodeauthor=I.+A.+Kovacsauthor=P.+Csermely&title=How+to+design+multi-target+drugs%3A+target+search+options+in+cellular+networks"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKorcsmaros%26aufirst%3DT.%26aulast%3DSzalay%26aufirst%3DM.%2BS.%26aulast%3DBode%26aufirst%3DC.%26aulast%3DKovacs%26aufirst%3DI.%2BA.%26aulast%3DCsermely%26aufirst%3DP.%26atitle%3DHow%2520to%2520design%2520multi-target%2520drugs%253A%2520target%2520search%2520options%2520in%2520cellular%2520networks%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2007%26volume%3D2%26issue%3D6%26spage%3D799%26epage%3D808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Reddy, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span> </span><span class="NLM_article-title">Polypharmacology: drug discovery for the future</span> <span class="citation_source-journal">Expert Rev. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">47</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1586%2Fecp.12.74" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=23272792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntlei" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=41-47&issue=1&author=A.+S.+Reddyauthor=S.+Zhang&title=Polypharmacology%3A+drug+discovery+for+the+future"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: drug discovery for the future</span></div><div class="casAuthors">Reddy, A. Srinivas; Zhang, Shuxing</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-47</span>CODEN:
                <span class="NLM_cas:coden">ERCPAG</span>;
        ISSN:<span class="NLM_cas:issn">1751-2433</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  In recent years, even with remarkable scientific advancements and a significant increase of global research and development spending, drugs are frequently withdrawn from markets.  This is primarily due to their side effects or toxicities.  Drug mols. often interact with multiple targets, coined as polypharmacol., and the unintended drug-target interactions could cause side effects.  Polypharmacol. remains one of the major challenges in drug development, and it opens novel avenues to rationally design the next generation of more effective, but less toxic, therapeutic agents.  This review outlines the latest progress and challenges in polypharmacol. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh9arBzCHL27Vg90H21EOLACvtfcHk0lh7BbfePvQy0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntlei&md5=651b742d7e8254d8f4ef00f225dfa39e</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1586%2Fecp.12.74&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fecp.12.74%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DA.%2BS.%26aulast%3DZhang%26aufirst%3DS.%26atitle%3DPolypharmacology%253A%2520drug%2520discovery%2520for%2520the%2520future%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D6%26issue%3D1%26spage%3D41%26epage%3D47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Sams-Dodd, F.</span><span> </span><span class="NLM_article-title">Target-based drug discovery: is something wrong?</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">139</span><span class="NLM_x">–</span> <span class="NLM_lpage">147</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=139-147&issue=2&author=F.+Sams-Dodd&title=Target-based+drug+discovery%3A+is+something+wrong%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSams-Dodd%26aufirst%3DF.%26atitle%3DTarget-based%2520drug%2520discovery%253A%2520is%2520something%2520wrong%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2005%26volume%3D10%26issue%3D2%26spage%3D139%26epage%3D147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Hornberg, J. J.</span><span> </span><span class="NLM_article-title">Simple Drugs Do Not Cure Complex Diseases: The Need for Multi-Targeted Drugs</span>. In  <span class="citation_source-book">Designing Multi-Target Drugs</span>; <span class="NLM_contrib-group">Morphy, J. R.; Harris, C. J.</span>, Eds.; <span class="NLM_publisher-name">RSC Publishing</span>: <span class="NLM_publisher-loc">Cambridge</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">13</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1039%2F9781849734912-00001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=1-13&author=J.+J.+Hornbergauthor=J.+R.+Morphy&author=C.+J.+Harris&title=Designing+Multi-Target+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1039%2F9781849734912-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1039%252F9781849734912-00001%26sid%3Dliteratum%253Aachs%26aulast%3DHornberg%26aufirst%3DJ.%2BJ.%26atitle%3DSimple%2520Drugs%2520Do%2520Not%2520Cure%2520Complex%2520Diseases%253A%2520The%2520Need%2520for%2520Multi-Targeted%2520Drugs%26btitle%3DDesigning%2520Multi-Target%2520Drugs%26aulast%3DMorphy%26aufirst%3DJ.%2BR.%26pub%3DRSC%2520Publishing%26date%3D2012%26spage%3D1%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Petrelli, A.</span><span> </span><span class="NLM_article-title">Polypharmacological Kinase Inhibitors: New Hopes for Cancer Therapy</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed., <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">149</span><span class="NLM_x">–</span> <span class="NLM_lpage">165</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=149-165&author=A.+Petrelliauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch8%26sid%3Dliteratum%253Aachs%26aulast%3DPetrelli%26aufirst%3DA.%26atitle%3DPolypharmacological%2520Kinase%2520Inhibitors%253A%2520New%2520Hopes%2520for%2520Cancer%2520Therapy%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D149%26epage%3D165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Kroeze, W. K.; Roth, B. L.</span><span> </span><span class="NLM_article-title">Polypharmacological Drugs: Magic Shotguns for Psychiatric Diseases</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed., <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">135</span><span class="NLM_x">–</span> <span class="NLM_lpage">148</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=135-148&author=W.+K.+Kroeze&author=B.+L.+Rothauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch7%26sid%3Dliteratum%253Aachs%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26atitle%3DPolypharmacological%2520Drugs%253A%2520Magic%2520Shotguns%2520for%2520Psychiatric%2520Diseases%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D135%26epage%3D148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheffler, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroeze, W. K.</span><span> </span><span class="NLM_article-title">Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">353</span><span class="NLM_x">–</span> <span class="NLM_lpage">359</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fnrd1346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=15060530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=353-359&issue=4&author=B.+L.+Rothauthor=D.+J.+Shefflerauthor=W.+K.+Kroeze&title=Magic+shotguns+versus+magic+bullets%3A+selectively+non-selective+drugs+for+mood+disorders+and+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia</span></div><div class="casAuthors">Roth, Bryan L.; Sheffler, Douglas J.; Kroeze, Wesley K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">353-359</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Most common central nervous system disorders - such as depression, bipolar disorder, and schizophrenia - seem to be polygenic in origin, and the most effective medications have exceedingly complex pharmacologies.  Attempts to develop more effective treatments for diseases such as schizophrenia and depression by discovering drugs selective for single mol. targets (i.e., 'magic bullets') have, not surprisingly, been largely unsuccessful.  Here the authors propose that designing selectively non-selective drugs (i.e., 'magic shotguns') that interact with several mol. targets will lead to new and more effective medications for a variety of central nervous system disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnSsuUXzmbirVg90H21EOLACvtfcHk0lhj7jpYERV8aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D&md5=77196583acccca65457fec7a67218463</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnrd1346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1346%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DSheffler%26aufirst%3DD.%2BJ.%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26atitle%3DMagic%2520shotguns%2520versus%2520magic%2520bullets%253A%2520selectively%2520non-selective%2520drugs%2520for%2520mood%2520disorders%2520and%2520schizophrenia%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26issue%3D4%26spage%3D353%26epage%3D359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Hopkins, A. L.</span><span> </span><span class="NLM_article-title">Network pharmacology</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">1110</span><span class="NLM_x">–</span> <span class="NLM_lpage">1111</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fnbt1007-1110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=17921993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFagt7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=1110-1111&issue=10&author=A.+L.+Hopkins&title=Network+pharmacology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Network pharmacology</span></div><div class="casAuthors">Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1110-1111</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Network biol. illuminates our understanding of drug action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBLPM5MyYqHbVg90H21EOLACvtfcHk0lhj7jpYERV8aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFagt7vO&md5=7d88f8f8d6b6e76017475bc59a314e4c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnbt1007-1110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1007-1110%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DNetwork%2520pharmacology%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26issue%3D10%26spage%3D1110%26epage%3D1111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Vaz, R. J.; Klabunde, T.</span>, Eds.  <span class="citation_source-book">Antitargets</span>; <span class="NLM_publisher-name">Wiley-VCH</span>: <span class="NLM_publisher-loc">Weinheim</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9783527621460" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=R.+J.+Vaz&author=T.+Klabunde&title=Antitargets"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2F9783527621460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527621460%26sid%3Dliteratum%253Aachs%26aulast%3DVaz%26aufirst%3DR.%2BJ.%26btitle%3DAntitargets%26pub%3DWiley-VCH%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Urban, L.; Whitebread, S.; Hamon, J.; Mikhailov, D.; Azzaoui, K.</span><span> </span><span class="NLM_article-title">Screening for Safety-Relevant Off-Target Activities</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed., <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">46</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=15-46&author=L.+Urban&author=S.+Whitebread&author=J.+Hamon&author=D.+Mikhailov&author=K.+Azzaouiauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch2%26sid%3Dliteratum%253Aachs%26aulast%3DUrban%26aufirst%3DL.%26atitle%3DScreening%2520for%2520Safety-Relevant%2520Off-Target%2520Activities%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D15%26epage%3D46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Olson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Betton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolaja, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lilly, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanders, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sipes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bracken, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Deun, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heller, A.</span><span> </span><span class="NLM_article-title">Concordance of the Toxicity of Pharmaceuticals in Humans and in Animals</span> <span class="citation_source-journal">Regul. Toxicol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">56</span><span class="NLM_x">–</span> <span class="NLM_lpage">67</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1006%2Frtph.2000.1399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=11029269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntF2gu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2000&pages=56-67&issue=1&author=H.+Olsonauthor=G.+Bettonauthor=D.+Robinsonauthor=K.+Thomasauthor=A.+Monroauthor=G.+Kolajaauthor=P.+Lillyauthor=J.+Sandersauthor=G.+Sipesauthor=W.+Brackenauthor=M.+Doratoauthor=K.+Van+Deunauthor=P.+Smithauthor=B.+Bergerauthor=A.+Heller&title=Concordance+of+the+Toxicity+of+Pharmaceuticals+in+Humans+and+in+Animals"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Concordance of the Toxicity of Pharmaceuticals in Humans and in Animals</span></div><div class="casAuthors">Olson, Harry; Betton, Graham; Robinson, Denise; Thomas, Karluss; Monro, Alastair; Kolaja, Gerald; Lilly, Patrick; Sanders, James; Sipes, Glenn; Bracken, William; Dorato, Michael; Van Deun, Koen; Smith, Peter; Berger, Bruce; Heller, Allen</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory Toxicology and Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-67</span>CODEN:
                <span class="NLM_cas:coden">RTOPDW</span>;
        ISSN:<span class="NLM_cas:issn">0273-2300</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review is given with 29 refs. on the results of a multinational pharmaceutical company survey and the outcome of an International Life Sciences Institute (ILSI) Workshop (Apr. 1999), which served to better understand concordance of the toxicity of pharmaceuticals obsd. in humans with that obsd. in exptl. animals.  The Workshop included representatives from academia, the multinational pharmaceutical industry, and international regulatory scientists.  The main aim of this project was to examine the strengths and weaknesses of animal studies to predict human toxicity (HT).  The database was developed from a survey which covered only those compds. where HTs were identified during clin. development of new pharmaceuticals, detg. whether animal toxicity studies identified concordant target organ toxicities in humans.  Data collected included codified compds., therapeutic category, the HT organ system affected, and the species and duration of studies in which the corresponding HT was either 1st identified or not obsd.  This survey includes input from 12 pharmaceutical companies with data compiled from 150 compds. with 221 HT events reported.  Multiple HTs were reported in 47 cases.  The results showed the true pos. HT concordance rate of 71% for rodent and nonrodent species, with nonrodents alone being predictive for 63% of HTs and rodents alone for 43%.  The highest incidence of overall concordance was seen in hematol., gastrointestinal, and cardiovascular HTs, and the least was seen in cutaneous HT.  Where animal models, in 1 or more species, identified concordant HT, 94% were 1st obsd. in studies of 1 mo or less in duration.  These survey results support the value of in vivo toxicol. studies to predict for many significant HTs assocd. with pharmaceuticals and have helped to identify HT categories that may benefit from improved methods.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEmD_XsaoSaLVg90H21EOLACvtfcHk0lhj7jpYERV8aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntF2gu7k%253D&md5=8555af1a059d6e3811ade843d77e5f04</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1006%2Frtph.2000.1399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Frtph.2000.1399%26sid%3Dliteratum%253Aachs%26aulast%3DOlson%26aufirst%3DH.%26aulast%3DBetton%26aufirst%3DG.%26aulast%3DRobinson%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DK.%26aulast%3DMonro%26aufirst%3DA.%26aulast%3DKolaja%26aufirst%3DG.%26aulast%3DLilly%26aufirst%3DP.%26aulast%3DSanders%26aufirst%3DJ.%26aulast%3DSipes%26aufirst%3DG.%26aulast%3DBracken%26aufirst%3DW.%26aulast%3DDorato%26aufirst%3DM.%26aulast%3DVan%2BDeun%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DBerger%26aufirst%3DB.%26aulast%3DHeller%26aufirst%3DA.%26atitle%3DConcordance%2520of%2520the%2520Toxicity%2520of%2520Pharmaceuticals%2520in%2520Humans%2520and%2520in%2520Animals%26jtitle%3DRegul.%2520Toxicol.%2520Pharmacol.%26date%3D2000%26volume%3D32%26issue%3D1%26spage%3D56%26epage%3D67" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Zbinden, G.</span><span> </span><span class="NLM_article-title">Predictive value of animal studies in toxicology</span> <span class="citation_source-journal">Regul. Toxicol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">167</span><span class="NLM_x">–</span> <span class="NLM_lpage">77</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1016%2F0273-2300%2891%2990004-F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A280%3ADyaK387mvFajug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1991&pages=167-77&issue=2&author=G.+Zbinden&title=Predictive+value+of+animal+studies+in+toxicology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Predictive value of animal studies in toxicology</span></div><div class="casAuthors">Zbinden G</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory toxicology and pharmacology : RTP</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-77</span>
        ISSN:<span class="NLM_cas:issn">0273-2300</span>.
    </div><div class="casAbstract">The three main purposes of experimental toxicology are (1) determination of the toxicological spectrum in selected laboratory animal species; (2) extrapolation to other species and prediction of adverse effects in man; and (3) determination of safe levels of exposure.  Toxicology has reached a satisfactory level of performance in identifying toxicity in animals, and experimental techniques are now available to characterize the toxicological potential of chemical substances in great detail.  In many instances, extrapolation of toxicological findings in animals to man is possible.  It must also be admitted that toxicological studies have, at times, failed to predict human toxicity.  In many cases, this can be explained by biological differences between animals and man.  A particularly difficult problem is the "low incidence responses" that occur only in especially sensitive individuals.  They represent a challenge that can be met only be a determined research effort.  Failure to predict toxic responses in man is sometimes also brought about by the toxicologists' own faults.  It is essential, therefore, that we analyze the errors committed in the past and continuously evaluate and improve our performance.  Society's demand for specific safe levels of exposure is difficult to meet.  After a long period of confusion and confrontation, toxicology appears to be on the road to a truly science-based methodology for risk assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5nu87lg_jKdK0qsdY6Nc1fW6udTcc2eYh2V7EWM6jx7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK387mvFajug%253D%253D&md5=ae8e3eb02c49588188e26275208e9560</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2F0273-2300%2891%2990004-F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0273-2300%252891%252990004-F%26sid%3Dliteratum%253Aachs%26aulast%3DZbinden%26aufirst%3DG.%26atitle%3DPredictive%2520value%2520of%2520animal%2520studies%2520in%2520toxicology%26jtitle%3DRegul.%2520Toxicol.%2520Pharmacol.%26date%3D1991%26volume%3D14%26issue%3D2%26spage%3D167%26epage%3D77" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Kaczorowski, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bode, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, U. A.</span><span> </span><span class="NLM_article-title">The importance of being profiled: improving drug candidate safety and efficacy using ion channel profiling</span> <span class="citation_source-journal">Front. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">78</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.3389%2Ffphar.2011.00078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC38Xis1agsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=78&author=G.+J.+Kaczorowskiauthor=M.+L.+Garciaauthor=J.+Bodeauthor=S.+D.+Hessauthor=U.+A.+Patel&title=The+importance+of+being+profiled%3A+improving+drug+candidate+safety+and+efficacy+using+ion+channel+profiling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The importance of being profiled: improving drug candidate safety and efficacy using ion channel profiling</span></div><div class="casAuthors">Kaczorowski, Gregory J.; Garcia, Maria L.; Bode, Jacob; Hess, Stephen D.; Patel, Umesh A.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology of Ion Channels and Channelopathies</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">Dec.</span>),
    <span class="NLM_cas:pages">78</span>CODEN:
                <span class="NLM_cas:coden">FPICA4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Profiling of putative lead compds. against a representative panel of relevant enzymes, receptors, ion channels, and transporters is a pragmatic approach to establish a preliminary view of potential issues that might later hamper development.  An early idea of which off-target activities must be minimized can save valuable time and money during the preclin. lead optimization phase if pivotal questions are asked beyond the usual profiling at hERG.  The best data for crit. evaluation of activity at ion channels is obtained using functional assays, since binding assays cannot detect all interactions and do not provide information on whether the interaction is that of an agonist, antagonist, or allosteric modulator.  For ion channels present in human cardiac muscle, depending on the required throughput, manual-, or automated-patch-clamp methodologies can be easily used to evaluate compds. individually to accurately reveal any potential liabilities.  The issue of expanding screening capacity against a cardiac panel has recently been addressed by developing a series of robust, high-throughput, cell-based counter-screening assays employing fluorescence-based readouts.  Similar assay development approaches can be used to configure panels of efficacy assays that can be used to assess selectivity within a family of related ion channels, such as Nav1.X channels.  This overview discusses the benefits of in vitro assays, specific decision points where profiling can be of immediate benefit, and highlights the development and validation of patch-clamp and fluorescence-based profiling assays for ion channel (for examples of fluorescence-based assays, and for high-throughput patch-clamp assays).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobRRFIISqLOLVg90H21EOLACvtfcHk0lh9ZL3M1Fdz1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xis1agsQ%253D%253D&md5=05f5ac4dd973d3509de02a7c2f1e2f74</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2011.00078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2011.00078%26sid%3Dliteratum%253Aachs%26aulast%3DKaczorowski%26aufirst%3DG.%2BJ.%26aulast%3DGarcia%26aufirst%3DM.%2BL.%26aulast%3DBode%26aufirst%3DJ.%26aulast%3DHess%26aufirst%3DS.%2BD.%26aulast%3DPatel%26aufirst%3DU.%2BA.%26atitle%3DThe%2520importance%2520of%2520being%2520profiled%253A%2520improving%2520drug%2520candidate%2520safety%2520and%2520efficacy%2520using%2520ion%2520channel%2520profiling%26jtitle%3DFront.%2520Pharmacol.%26date%3D2011%26volume%3D2%26spage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><a href="http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7A/Step4/S7A_Guideline.pdf" class="extLink">http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7A/Step4/S7A_Guideline.pdf</a></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=http%3A%2F%2Fwww.ich.org%2Ffileadmin%2FPublic_Web_Site%2FICH_Products%2FGuidelines%2FSafety%2FS7A%2FStep4%2FS7A_Guideline.pdf"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Pugsley, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Authier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtis, M. J.</span><span> </span><span class="NLM_article-title">Principles of Safety Pharmacology</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">154</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1382</span><span class="NLM_x">–</span> <span class="NLM_lpage">1399</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fbjp.2008.280" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=18604233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVajsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2008&pages=1382-1399&issue=7&author=M.+K.+Pugsleyauthor=S.+Authierauthor=M.+J.+Curtis&title=Principles+of+Safety+Pharmacology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Principles of Safety Pharmacology</span></div><div class="casAuthors">Pugsley, M. K.; Authier, S.; Curtis, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1382-1399</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Safety Pharmacol. is a rapidly developing discipline that uses the basic principles of pharmacol. in a regulatory-driven process to generate data to inform risk/benefit assessment.  The aim of Safety Pharmacol. is to characterize the pharmacodynamic/pharmacokinetic (PK/PD) relationship of a drug's adverse effects using continuously evolving methodol.  Unlike toxicol., Safety Pharmacol. includes within its remit a regulatory requirement to predict the risk of rare lethal events.  This gives Safety Pharmacol. its unique character.  The key issues for Safety Pharmacol. are detection of an adverse effect liability, projection of the data into safety margin calcn. and finally clin. safety monitoring.  This article sets out to explain the drivers for Safety Pharmacol. so that the wider pharmacol. community is better placed to understand the discipline.  It concludes with a summary of principles that may help inform future resoln. of unmet needs (esp. establishing model validation for accurate risk assessment).  Subsequent articles in this issue of the journal address specific aspects of Safety Pharmacol. to explore the issues of model choice, the burden of proof and to highlight areas of intensive activity such as testing for drug-induced rare event liability, and the challenge of testing the safety of so-called biologics (antibodies, gene therapy and so on).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpicQ5MbtK_VbVg90H21EOLACvtfcHk0lgDy4EZWZxwUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVajsLg%253D&md5=4636b0d84dc4b1bd2166e34ddcdf7a1a</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fbjp.2008.280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjp.2008.280%26sid%3Dliteratum%253Aachs%26aulast%3DPugsley%26aufirst%3DM.%2BK.%26aulast%3DAuthier%26aufirst%3DS.%26aulast%3DCurtis%26aufirst%3DM.%2BJ.%26atitle%3DPrinciples%2520of%2520Safety%2520Pharmacology%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D154%26issue%3D7%26spage%3D1382%26epage%3D1399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Kola, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landis, J.</span><span> </span><span class="NLM_article-title">Can the pharmaceutical industry reduce attrition rates?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">711</span><span class="NLM_x">–</span> <span class="NLM_lpage">716</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=711-716&issue=8&author=I.+Kolaauthor=J.+Landis&title=Can+the+pharmaceutical+industry+reduce+attrition+rates%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKola%26aufirst%3DI.%26aulast%3DLandis%26aufirst%3DJ.%26atitle%3DCan%2520the%2520pharmaceutical%2520industry%2520reduce%2520attrition%2520rates%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26issue%3D8%26spage%3D711%26epage%3D716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Muthas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyer, S.</span><span> </span><span class="NLM_article-title">Exploiting Pharmacological Similarity to Identify Safety Concerns - Listen to What the Data Tells You</span> <span class="citation_source-journal">Mol. Inf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">37</span><span class="NLM_x">–</span> <span class="NLM_lpage">45</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2Fminf.201200088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntFKruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=37-45&issue=1&author=D.+Muthasauthor=S.+Boyer&title=Exploiting+Pharmacological+Similarity+to+Identify+Safety+Concerns+-+Listen+to+What+the+Data+Tells+You"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Exploiting Pharmacological Similarity to Identify Safety Concerns - Listen to What the Data Tells You</span></div><div class="casAuthors">Muthas, Daniel; Boyer, Scott</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Informatics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37-45</span>CODEN:
                <span class="NLM_cas:coden">MIONBS</span>;
        ISSN:<span class="NLM_cas:issn">1868-1743</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">While most new drugs are designed to act on a single target or a small no. of targets, many do show broad pharmacol. activity.  In some cases this can be beneficial and necessary for efficacy and in others it can be detrimental, leading to increased safety liability.  To probe off-target pharmacol. most drug discovery programs include screening against a broad panel of targets that represent known troublesome pharmacol.  Hits against any one of these targets can then be subjected to a risk assessment for potential safety problems in preclin. or clin. studies.  In addn., the secondary pharmacol. profile can also be thought of as an alternative description of the compd. and as such can be used as a method for assessing similarity'.  Consequently, inspection of the in vivo findings of pharmacol. neighbors can give important insights into potential safety liabilities that are neither identified by pure chem. similarity searches nor by risk assessment on individual targets.  Here we show that the pharmacol. profile contains addnl. information as compared to chem. similarity, and also demonstrate how this can be used in the hazard assessment done during drug discovery and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofUE1Sy23AN7Vg90H21EOLACvtfcHk0lgDy4EZWZxwUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntFKruw%253D%253D&md5=af95ecc021c2227be4f043bd467d6008</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fminf.201200088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fminf.201200088%26sid%3Dliteratum%253Aachs%26aulast%3DMuthas%26aufirst%3DD.%26aulast%3DBoyer%26aufirst%3DS.%26atitle%3DExploiting%2520Pharmacological%2520Similarity%2520to%2520Identify%2520Safety%2520Concerns%2520-%2520Listen%2520to%2520What%2520the%2520Data%2520Tells%2520You%26jtitle%3DMol.%2520Inf.%26date%3D2013%26volume%3D32%26issue%3D1%26spage%3D37%26epage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Migeon, J.</span><span> </span><span class="NLM_article-title">Prediction of side-effects based on fingerprint profiling and data mining</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed., <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=111-132&author=J.+Migeonauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch6%26sid%3Dliteratum%253Aachs%26aulast%3DMigeon%26aufirst%3DJ.%26atitle%3DPrediction%2520of%2520side-effects%2520based%2520on%2520fingerprint%2520profiling%2520and%2520data%2520mining%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D111%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Mason, J. S.; Migeon, J.; Dupuis, P.; Otto-Bruc, A.</span><span> </span><span class="NLM_article-title">Use of Broad Biological Profiling as a Relevant Descriptor to Describe and Differentiate Compounds: Structure–In Vitro (Pharmacology–ADME)–In Vivo (Safety) Relationships</span>. In  <span class="citation_source-book">Antitargets</span>; <span class="NLM_contrib-group">Vaz, R. J.; Klabunde, T.</span>, Eds.; <span class="NLM_publisher-name">Wiley-VCH</span>: <span class="NLM_publisher-loc">Weinheim</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=3-22&author=J.+S.+Mason&author=J.+Migeon&author=P.+Dupuis&author=A.+Otto-Brucauthor=R.+J.+Vaz&author=T.+Klabunde&title=Antitargets"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMason%26aufirst%3DJ.%2BS.%26atitle%3DUse%2520of%2520Broad%2520Biological%2520Profiling%2520as%2520a%2520Relevant%2520Descriptor%2520to%2520Describe%2520and%2520Differentiate%2520Compounds%253A%2520Structure%25E2%2580%2593In%2520Vitro%2520%2528Pharmacology%25E2%2580%2593ADME%2529%25E2%2580%2593In%2520Vivo%2520%2528Safety%2529%2520Relationships%26btitle%3DAntitargets%26aulast%3DVaz%26aufirst%3DR.%2BJ.%26pub%3DWiley-VCH%26date%3D2008%26spage%3D3%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Fliri, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loging, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thadeio, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volkmann, R. A.</span><span> </span><span class="NLM_article-title">Biospectra analysis: model proteome characterizations for linking molecular structure and biological response</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x"> (</span><span class="NLM_issue">22</span><span class="NLM_x">) </span> <span class="NLM_fpage">6918</span><span class="NLM_x">–</span> <span class="NLM_lpage">6925</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050494g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6918-6925&issue=22&author=A.+F.+Fliriauthor=W.+T.+Logingauthor=P.+F.+Thadeioauthor=R.+A.+Volkmann&title=Biospectra+analysis%3A+model+proteome+characterizations+for+linking+molecular+structure+and+biological+response"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm050494g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050494g%26sid%3Dliteratum%253Aachs%26aulast%3DFliri%26aufirst%3DA.%2BF.%26aulast%3DLoging%26aufirst%3DW.%2BT.%26aulast%3DThadeio%26aufirst%3DP.%2BF.%26aulast%3DVolkmann%26aufirst%3DR.%2BA.%26atitle%3DBiospectra%2520analysis%253A%2520model%2520proteome%2520characterizations%2520for%2520linking%2520molecular%2520structure%2520and%2520biological%2520response%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D22%26spage%3D6918%26epage%3D6925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Urban, L.</span><span> </span><span class="NLM_article-title">Translational value of early target-based safety assessment and associated risk mitigation</span>. 4th Annual Predictive Toxicology Summit, London, February 15–17,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=L.+Urban&title=Translational+value+of+early+target-based+safety+assessment+and+associated+risk+mitigation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DUrban%26aufirst%3DL.%26atitle%3DTranslational%2520value%2520of%2520early%2520target-based%2520safety%2520assessment%2520and%2520associated%2520risk%2520mitigation%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, N.</span><span> </span><span class="NLM_article-title">Comparing Measures of Promiscuity and Exploring Their Relationship to Toxicity</span> <span class="citation_source-journal">Mol. Inf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">145</span><span class="NLM_x">–</span> <span class="NLM_lpage">159</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2Fminf.201100148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKju70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2012&pages=145-159&issue=2&author=X.+Wangauthor=N.+Greene&title=Comparing+Measures+of+Promiscuity+and+Exploring+Their+Relationship+to+Toxicity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Comparing Measures of Promiscuity and Exploring Their Relationship to Toxicity</span></div><div class="casAuthors">Wang, Xiangyun; Greene, Nigel</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Informatics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">145-159</span>CODEN:
                <span class="NLM_cas:coden">MIONBS</span>;
        ISSN:<span class="NLM_cas:issn">1868-1743</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Recent research has focused on algorithms to derive numerical measures of selectivity based on panels of in vitro pharmacol. assays so that one mol.'s activity profile may be compared easily with that of another.  However, the questions concerning which method or algorithm is best to use, the optimal no. of assays required to give an accurate measure of selectivity and the correlation of these measures to in vivo toxicity have remained largely unexplored.  In this manuscript we describe a systematic approach to compare and contrast different calcn. methods for promiscuity and det. the optimal no. and constitution of a panel of assays to measure the selectivity/promiscuity of compds. across all targets.  We then go on to examine their relationship to toxicity using a Pfizer proprietary compd. set that has both selectivity profiles and exploratory toxicol. study results.  From this study we conclude that all five methods studied are useful in estg. compd. selectivity; that a small panel of between 15 to 30 binding assays can be used as a surrogate for a broader panel enabling higher throughput with lower costs and this panel will most likely have the highest prediction power when correlating this measure to in vivo effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroFZPz4tPdDrVg90H21EOLACvtfcHk0lhQwsy-gKAY9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKju70%253D&md5=1aa9606472722e3a7d18c153d34a8f10</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fminf.201100148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fminf.201100148%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGreene%26aufirst%3DN.%26atitle%3DComparing%2520Measures%2520of%2520Promiscuity%2520and%2520Exploring%2520Their%2520Relationship%2520to%2520Toxicity%26jtitle%3DMol.%2520Inf.%26date%3D2012%26volume%3D31%26issue%3D2%26spage%3D145%26epage%3D159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Bendels, S.; Bissantz, C.; Fasching, B.; Fischer, H.; Gerebtzoff, G.; Guba, W.; Hert, J.; Kansy, M.; Migeon, J.; Peters, J.-U.; Pflieger, P.; Tillier, F.</span><span> </span><span class="NLM_article-title">Safety screening in early drug discovery: An improved assay profile</span>. Poster presentation at the Gordon Research Conference on Computer Aided Drug Design, Mount Snow (VT), USA, July 21–26,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=S.+Bendels&author=C.+Bissantz&author=B.+Fasching&author=H.+Fischer&author=G.+Gerebtzoff&author=W.+Guba&author=J.+Hert&author=M.+Kansy&author=J.+Migeon&author=J.-U.+Peters&author=P.+Pflieger&author=F.+Tillier&title=Safety+screening+in+early+drug+discovery%3A+An+improved+assay+profile"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DBendels%26aufirst%3DS.%26atitle%3DSafety%2520screening%2520in%2520early%2520drug%2520discovery%253A%2520An%2520improved%2520assay%2520profile%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Bowes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarolimek, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridhar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waldron, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitebread, S.</span><span> </span><span class="NLM_article-title">Reducing safety-related drug attrition: the use of in vitro pharmacological profiling</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">909</span><span class="NLM_x">–</span> <span class="NLM_lpage">922</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fnrd3845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=23197038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslCnur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=909-922&issue=12&author=J.+Bowesauthor=A.+J.+Brownauthor=J.+Hamonauthor=W.+Jarolimekauthor=A.+Sridharauthor=G.+Waldronauthor=S.+Whitebread&title=Reducing+safety-related+drug+attrition%3A+the+use+of+in+vitro+pharmacological+profiling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Reducing safety-related drug attrition: the use of in vitro pharmacological profiling</span></div><div class="casAuthors">Bowes, Joanne; Brown, Andrew J.; Hamon, Jacques; Jarolimek, Wolfgang; Sridhar, Arun; Waldron, Gareth; Whitebread, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">909-922</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In vitro pharmacol. profiling is increasingly being used earlier in the drug discovery process to identify undesirable off-target activity profiles that could hinder or halt the development of candidate drugs or even lead to market withdrawal if discovered after a drug is approved.  Here, for the first time, the rationale, strategies and methodologies for in vitro pharmacol. profiling at four major pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Novartis and Pfizer) are presented and illustrated with examples of their impact on the drug discovery process.  We hope that this will enable other companies and academic institutions to benefit from this knowledge and consider joining us in our collaborative knowledge sharing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomVp3wnTONWrVg90H21EOLACvtfcHk0lhQwsy-gKAY9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslCnur%252FJ&md5=7559001563ef3febd610535b8f096a45</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fnrd3845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3845%26sid%3Dliteratum%253Aachs%26aulast%3DBowes%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DA.%2BJ.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DJarolimek%26aufirst%3DW.%26aulast%3DSridhar%26aufirst%3DA.%26aulast%3DWaldron%26aufirst%3DG.%26aulast%3DWhitebread%26aufirst%3DS.%26atitle%3DReducing%2520safety-related%2520drug%2520attrition%253A%2520the%2520use%2520of%2520in%2520vitro%2520pharmacological%2520profiling%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26issue%3D12%26spage%3D909%26epage%3D922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Volk, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagy, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kostyalik, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simig, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagdy, G.</span><span> </span><span class="NLM_article-title">Medicinal chemistry of 5-HT5A receptor ligands: a receptor subtype with unique therapeutical potential</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">554</span><span class="NLM_x">–</span> <span class="NLM_lpage">578</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.2174%2F156802610791111588" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=20166946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsFKnur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=554-578&issue=5&author=B.+Volkauthor=B.+J.+Nagyauthor=S.+Vasauthor=D.+Kostyalikauthor=G.+Simigauthor=G.+Bagdy&title=Medicinal+chemistry+of+5-HT5A+receptor+ligands%3A+a+receptor+subtype+with+unique+therapeutical+potential"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of 5-HT5A receptor ligands: a receptor subtype with unique therapeutical potential</span></div><div class="casAuthors">Volk, Balazs; Nagy, Bence J.; Vas, Szilvia; Kostyalik, Diana; Simig, Gyula; Bagdy, Gyorgy</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">554-578</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Although the 5-HT5 receptor subfamily was discovered more than 15 years ago, it is unambiguously the least known 5-HT receptor subtype.  The Gi/G0-mediated signal transduction and its intensive presence in raphe and other brainstem and pons nuclei suggest mechanisms similar to those of 5-HT1 receptors, the ligands of which are already applied in the treatment of e.g. anxiety and migraine.  In addn., a unique coupling and inhibition of ADP-ribosyl cyclase have also been described.  High concns. of 5-HT5 receptor in other key regions including, e.g. locus coeruleus, nucleus of the solitary tract, arcuate and suprachiasmatic nuclei of the hypothalamus indicate a wide range of physiol. effects, thus its ligands are potential drug candidates in various areas, e.g. anxiety, sleep, incontinence, food intake, learning and memory, pain or chemoreception pathways.  These findings have motivated several institutes and pharmaceutical companies to participate in the research of this field.  Despite extensive research, no selective agonist and only two selective antagonists have been identified until now.  Beyond these compds., the present review provides a complete overview on all other published 5-HT5A receptor ligands as well as on the structure, function, distribution, genetics and possible therapeutic applications of this receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplqydEbNRArLVg90H21EOLACvtfcHk0lhQwsy-gKAY9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsFKnur4%253D&md5=45fab50aa5ba9248fd7cbf6f0eaf0990</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.2174%2F156802610791111588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802610791111588%26sid%3Dliteratum%253Aachs%26aulast%3DVolk%26aufirst%3DB.%26aulast%3DNagy%26aufirst%3DB.%2BJ.%26aulast%3DVas%26aufirst%3DS.%26aulast%3DKostyalik%26aufirst%3DD.%26aulast%3DSimig%26aufirst%3DG.%26aulast%3DBagdy%26aufirst%3DG.%26atitle%3DMedicinal%2520chemistry%2520of%25205-HT5A%2520receptor%2520ligands%253A%2520a%2520receptor%2520subtype%2520with%2520unique%2520therapeutical%2520potential%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2010%26volume%3D10%26issue%3D5%26spage%3D554%26epage%3D578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Grailhe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waeber, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dulawa, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornung, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunner, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geyer, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hen, R.</span><span> </span><span class="NLM_article-title">Increased exploratory activity and altered response to LSD in mice lacking the 5-HT5A receptor</span> <span class="citation_source-journal">Neuron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">581</span><span class="NLM_x">–</span> <span class="NLM_lpage">591</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1999&pages=581-591&issue=3&author=R.+Grailheauthor=C.+Waeberauthor=S.+C.+Dulawaauthor=J.+P.+Hornungauthor=X.+Zhuangauthor=D.+Brunnerauthor=M.+A.+Geyerauthor=R.+Hen&title=Increased+exploratory+activity+and+altered+response+to+LSD+in+mice+lacking+the+5-HT5A+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGrailhe%26aufirst%3DR.%26aulast%3DWaeber%26aufirst%3DC.%26aulast%3DDulawa%26aufirst%3DS.%2BC.%26aulast%3DHornung%26aufirst%3DJ.%2BP.%26aulast%3DZhuang%26aufirst%3DX.%26aulast%3DBrunner%26aufirst%3DD.%26aulast%3DGeyer%26aufirst%3DM.%2BA.%26aulast%3DHen%26aufirst%3DR.%26atitle%3DIncreased%2520exploratory%2520activity%2520and%2520altered%2520response%2520to%2520LSD%2520in%2520mice%2520lacking%2520the%25205-HT5A%2520receptor%26jtitle%3DNeuron%26date%3D1999%26volume%3D22%26issue%3D3%26spage%3D581%26epage%3D591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Peters, J.-U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bissantz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hillebrecht, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerebtzoff, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendels, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tillier, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migeon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guba, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kansy, M.</span><span> </span><span class="NLM_article-title">Can we discover pharmacological promiscuity early in the drug discovery process?</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">7–8</span><span class="NLM_x">) </span> <span class="NLM_fpage">325</span><span class="NLM_x">–</span> <span class="NLM_lpage">335</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=325-335&issue=7%E2%80%938&author=J.-U.+Petersauthor=J.+Hertauthor=C.+Bissantzauthor=A.+Hillebrechtauthor=G.+Gerebtzoffauthor=S.+Bendelsauthor=F.+Tillierauthor=J.+Migeonauthor=H.+Fischerauthor=W.+Gubaauthor=M.+Kansy&title=Can+we+discover+pharmacological+promiscuity+early+in+the+drug+discovery+process%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.-U.%26aulast%3DHert%26aufirst%3DJ.%26aulast%3DBissantz%26aufirst%3DC.%26aulast%3DHillebrecht%26aufirst%3DA.%26aulast%3DGerebtzoff%26aufirst%3DG.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DTillier%26aufirst%3DF.%26aulast%3DMigeon%26aufirst%3DJ.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DGuba%26aufirst%3DW.%26aulast%3DKansy%26aufirst%3DM.%26atitle%3DCan%2520we%2520discover%2520pharmacological%2520promiscuity%2520early%2520in%2520the%2520drug%2520discovery%2520process%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26issue%3D7%25E2%2580%25938%26spage%3D325%26epage%3D335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Hamon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitebread, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Techer-Etienne, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Coq, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azzaoui, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, L.</span><span> </span><span class="NLM_article-title">vitro safety pharmacology profiling: what else beyond hERG?</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">645</span><span class="NLM_x">–</span> <span class="NLM_lpage">665</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.4155%2Ffmc.09.51" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFSgtbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2009&pages=645-665&issue=4&author=J.+Hamonauthor=S.+Whitebreadauthor=V.+Techer-Etienneauthor=H.+Le+Coqauthor=K.+Azzaouiauthor=L.+Urban&title=vitro+safety+pharmacology+profiling%3A+what+else+beyond+hERG%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro safety pharmacology profiling: what else beyond hERG?</span></div><div class="casAuthors">Hamon, Jacques; Whitebread, Steven; Techer-Etienne, Valerie; Le Coq, Helene; Azzaoui, Kamal; Urban, Laszlo</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">645-665</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  One of the main reasons for drug failures in clin. development, or postmarket launch, is lacking or compromised safety margins at therapeutic doses.  Organ toxicity with poorly defined mechanisms and adverse drug reactions assocd. with on- and off-target effects are the major contributors to safety-related shortfalls of many clin. drug candidates.  Therefore, to avoid high attrition rates in clin. trials, it is imperative to test compds. for potential adverse reactions during early drug discovery.  Beyond a small no. of targets assocd. with clin. acknowledged adverse drug reactions, there is little consensus on other targets that are important to consider at an early stage for in vitro safety pharmacol. assessment.  We consider here a limited no. of safety-related targets, from different target families, which were selected as part of in vitro safety pharmacol. profiling panels integrated in the drug-development process at Novartis.  The best way to assess these targets, using a biochem. or a functional readout, is discussed.  In particular, the importance of using cell-based profiling assays for the characterization of an agonist action at some GPCRs is highlighted.  A careful design of in vitro safety pharmacol. profiling panels allows better prediction of potential adverse effects of new chem. entities early in the drug-discovery process.  This contributes to the selection of the best candidate for clin. development and, ultimately, should contribute to a decreased attrition rate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdXUdqWitZC7Vg90H21EOLACvtfcHk0ljSNdjDOsfKGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFSgtbbJ&md5=85e16bf431d07804e6bce443ffab0ed6</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.4155%2Ffmc.09.51&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.09.51%26sid%3Dliteratum%253Aachs%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DWhitebread%26aufirst%3DS.%26aulast%3DTecher-Etienne%26aufirst%3DV.%26aulast%3DLe%2BCoq%26aufirst%3DH.%26aulast%3DAzzaoui%26aufirst%3DK.%26aulast%3DUrban%26aufirst%3DL.%26atitle%3Dvitro%2520safety%2520pharmacology%2520profiling%253A%2520what%2520else%2520beyond%2520hERG%253F%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2009%26volume%3D1%26issue%3D4%26spage%3D645%26epage%3D665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Kvernmo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houben, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sylte, I.</span><span> </span><span class="NLM_article-title">Receptor-Binding and Pharmacokinetic Properties of Dopaminergic Agonists</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">1049</span><span class="NLM_x">–</span> <span class="NLM_lpage">1067</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.2174%2F156802608785161457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Ohtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=1049-1067&issue=12&author=T.+Kvernmoauthor=J.+Houbenauthor=I.+Sylte&title=Receptor-Binding+and+Pharmacokinetic+Properties+of+Dopaminergic+Agonists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor-binding and pharmacokinetic properties of dopaminergic agonists</span></div><div class="casAuthors">Kvernmo, Trond; Houben, John; Sylte, Ingebrigt</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1049-1067</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  This review describes symptoms and pathophysiol. of Parkinson's diseases (PD) and restless legs syndrome (RLS), and discusses the relation between clin. outcome of DA agonists and their receptor-binding and pharmacokinetics.  Oral DA agonists are divided into 2 classes; the ergots and the non-ergots.  Both classes are in general equally effective against PD motor symptoms.  Ergots (apart from bromocriptine) stimulate the DA D1 subreceptor and increase dyskinesia.  Furthermore, valvular heart disease (VHD) and pulmonary and retroperitoneal fibrosis appear to represent a class effect of 8β-aminoergolines as cabergoline and pergolide.  The side effects profile therefore seems more beneficial for non-ergots than ergots.  The main improvement of motor functions by DA agonists is related to D2 agonism.  However, in monotherapy, the selective D2-receptor DA agonist sumanirole seemed less effective than ropinirole which is selective for D2- like DA-receptors (D2, D3 and D4).  Given as adjunctive to L-dopa both drugs had equal efficacy on motor-symptoms, indicating that D2-receptor activity must be accompanied with stimulation of other DA receptors for optimizing the efficacy on motor symptoms.  Striatal D3 receptor loss may be more important than D2 receptor loss for reduced response to dopaminergic treatment.  D3 stimulation may also be beneficial for the non-motor symptom depression/mood in PD and for neuron-protection.  This makes D3-receptors a potential therapeutic target in PD.  5-HT1A-receptor agonism and α2 adrenergic antagonism may contribute to prevention of dyskinesia.  However, 5-HT-receptor activity is also assocd. with side effects.  5-HT2B agonism (and possibly 5-HT1B agonism) is assocd. with fibrotic reactions, and valvular heart disease (VHD).  By interfering with the CYP450 system DA agonists may contribute to drug-drug interactions.  Lack of CYP2D6 activity is also suggested as important for etiol. and CNS-symptoms of PD.  Based on current knowledge D2-like receptor activities (preferences for the D3 receptor) seem most beneficial.  5-HT1A-receptor agonism (prevention of dyskinesia), 5-HT2B antagonism or no 5-HT2B-receptor activity also seems beneficial.  Development of DA agonists contg. these properties, without interfering with CYP2D6 may be beneficial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-irkKqsAQfrVg90H21EOLACvtfcHk0ljSNdjDOsfKGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Ohtb8%253D&md5=c966fbe7d38d1b376a654029d4706680</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.2174%2F156802608785161457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802608785161457%26sid%3Dliteratum%253Aachs%26aulast%3DKvernmo%26aufirst%3DT.%26aulast%3DHouben%26aufirst%3DJ.%26aulast%3DSylte%26aufirst%3DI.%26atitle%3DReceptor-Binding%2520and%2520Pharmacokinetic%2520Properties%2520of%2520Dopaminergic%2520Agonists%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26issue%3D12%26spage%3D1049%26epage%3D1067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Peters, J.-U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnider, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattei, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kansy, M.</span><span> </span><span class="NLM_article-title">Pharmacological Promiscuity: Dependence on Compound Properties and Target Specificity in a Set of Recent Roche Compounds</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">680</span><span class="NLM_x">–</span> <span class="NLM_lpage">686</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=680-686&issue=4&author=J.-U.+Petersauthor=P.+Schniderauthor=P.+Matteiauthor=M.+Kansy&title=Pharmacological+Promiscuity%3A+Dependence+on+Compound+Properties+and+Target+Specificity+in+a+Set+of+Recent+Roche+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.-U.%26aulast%3DSchnider%26aufirst%3DP.%26aulast%3DMattei%26aufirst%3DP.%26aulast%3DKansy%26aufirst%3DM.%26atitle%3DPharmacological%2520Promiscuity%253A%2520Dependence%2520on%2520Compound%2520Properties%2520and%2520Target%2520Specificity%2520in%2520a%2520Set%2520of%2520Recent%2520Roche%2520Compounds%26jtitle%3DChemMedChem%26date%3D2009%26volume%3D4%26issue%3D4%26spage%3D680%26epage%3D686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Huang, X.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yadav, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogan, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Revankar, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doucette, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">710</span><span class="NLM_x">–</span> <span class="NLM_lpage">722</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2009&pages=710-722&issue=4&author=X.-P.+Huangauthor=V.+Setolaauthor=P.+N.+Yadavauthor=J.+A.+Allenauthor=S.+C.+Roganauthor=B.+J.+Hansonauthor=C.+Revankarauthor=M.+Robersauthor=C.+Doucetteauthor=B.+L.+Roth&title=Parallel+functional+activity+profiling+reveals+valvulopathogens+are+potent+5-hydroxytryptamine%282B%29+receptor+agonists%3A+implications+for+drug+safety+assessment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DYadav%26aufirst%3DP.%2BN.%26aulast%3DAllen%26aufirst%3DJ.%2BA.%26aulast%3DRogan%26aufirst%3DS.%2BC.%26aulast%3DHanson%26aufirst%3DB.%2BJ.%26aulast%3DRevankar%26aufirst%3DC.%26aulast%3DRobers%26aufirst%3DM.%26aulast%3DDoucette%26aufirst%3DC.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DParallel%2520functional%2520activity%2520profiling%2520reveals%2520valvulopathogens%2520are%2520potent%25205-hydroxytryptamine%25282B%2529%2520receptor%2520agonists%253A%2520implications%2520for%2520drug%2520safety%2520assessment%26jtitle%3DMol.%2520Pharmacol.%26date%3D2009%26volume%3D76%26issue%3D4%26spage%3D710%26epage%3D722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Bell, I. M.; Bilodeau, M. T.; Lagrutta, A. A.</span><span> </span><span class="NLM_article-title">Activity at Cardiovascular Ion Channels: A Key Issue for Drug Discovery</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed., <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">83</span><span class="NLM_x">–</span> <span class="NLM_lpage">109</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=83-109&author=I.+M.+Bell&author=M.+T.+Bilodeau&author=A.+A.+Lagruttaauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch5%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DI.%2BM.%26atitle%3DActivity%2520at%2520Cardiovascular%2520Ion%2520Channels%253A%2520A%2520Key%2520Issue%2520for%2520Drug%2520Discovery%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D83%26epage%3D109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Redfern, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlsson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKenzie, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palethorpe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegl, P. K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strang, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cammi, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammond, T. G.</span><span> </span><span class="NLM_article-title">Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development</span> <span class="citation_source-journal">Cardiovasc. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">32</span><span class="NLM_x">–</span> <span class="NLM_lpage">45</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1016%2FS0008-6363%2802%2900846-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=12667944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit12gsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2003&pages=32-45&issue=1&author=W.+S.+Redfernauthor=L.+Carlssonauthor=A.+S.+Davisauthor=W.+G.+Lynchauthor=I.+MacKenzieauthor=S.+Palethorpeauthor=P.+K.+S.+Sieglauthor=I.+Strangauthor=A.+T.+Sullivanauthor=R.+Wallisauthor=A.+J.+Cammiauthor=T.+G.+Hammond&title=Relationships+between+preclinical+cardiac+electrophysiology%2C+clinical+QT+interval+prolongation+and+torsade+de+pointes+for+a+broad+range+of+drugs%3A+evidence+for+a+provisional+safety+margin+in+drug+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development</span></div><div class="casAuthors">Redfern, W. S.; Carlsson, L.; Davis, A. S.; Lynch, W. G.; MacKenzie, I.; Palethorpe, S.; Siegl, P. K. S.; Strang, I.; Sullivan, A. T.; Wallis, R.; Camm, A. J.; Hammond, T. G.</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-45</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review discussing attempts to det. the relative value of preclin. cardiac electrophysiol. data (in vitro and in vivo) for predicting risk of torsades de pointes (TdP) in clin. use.  Published data on human ether-a-go-go-related gene-encoded voltage-dependent potassium channel (hERG) (or IKr) activity, cardiac action potential duration (at 90% repolarization; APD90), and QT prolongation in dogs were compared against QT effects and reports of TdP in humans for 100 drugs.  These data were set against the free plasma concns. attained during clin. use (effective therapeutic plasma concns.; ETPCunbound).  The drugs were divided into five categories: (1) Class Ia and III antiarrhythmics; (2) withdrawn from market due to TdP; (3) measurable incidence/numerous reports of TdP in humans; (4) isolated reports of TdP in humans; (5) no reports of TdP in humans.  Data from hERG (or IKr) assays in addn. to ETPCunbound data were available for 52 drugs.  For Category 1 drugs, data for hERG/IKr IC50, APD90, QTc in animals and QTc in humans were generally close to or superimposed on the ETPCunbound values.  This relationship was uncoupled in the other categories, with more complex relationships between the data.  In Category 1 (except amiodarone), the ratios between hERG/IKr IC50 and ETPCunbound (max) ranged 0.1-31-fold.  Similar ranges were obtained for drugs in Category 2 (0.31-13-fold) and Category 3 (0.03-35-fold).  A large spread was found for Category 4 drugs (0.13-35,700-fold); this category embraced an assortment of mechanisms ranging from drugs which may well be affecting IKr currents in clin. use (e.g., sparfloxacin) to others such as nifedipine (35,700-fold) where channel block is not involved.  Finally, for the majority of Category 5 drugs there was a >30-fold sepn. between hERG/IKr activity and ETPCunbound values, with the notable exception of verapamil (1.7-fold), which is free from QT prolongation in man; this is probably explained by its multiple interactions with cardiac ion channels.  The dataset confirms the widely held belief that most drugs assocd. with TdP in humans are also assocd. with hERG K+ channel block at concns. close to or superimposed upon the free plasma concns. found in clin. use.  A 30-fold margin between Cmax and hERG IC50 may suffice for drugs currently undergoing clin. evaluation, but for future drug discovery programs, pharmaceutical companies should consider increasing this margin, particularly for drugs aimed at nondebilitating diseases.  However, interactions with multiple cardiac ion channels can either mitigate or exacerbate the prolongation of APD and QT that would ensue from block of IKr currents alone, and delay of repolarization per se is not necessarily torsadogenic.  Clearly, an integrated assessment of in vitro and in vivo data is required in order to predict the torsadogenic risk of a new candidate drug in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkpRDUH0rhyrVg90H21EOLACvtfcHk0lhZuNpzX4hfsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit12gsb8%253D&md5=a236c07febd2e05fe70e61604619bf2e</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2FS0008-6363%2802%2900846-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0008-6363%252802%252900846-5%26sid%3Dliteratum%253Aachs%26aulast%3DRedfern%26aufirst%3DW.%2BS.%26aulast%3DCarlsson%26aufirst%3DL.%26aulast%3DDavis%26aufirst%3DA.%2BS.%26aulast%3DLynch%26aufirst%3DW.%2BG.%26aulast%3DMacKenzie%26aufirst%3DI.%26aulast%3DPalethorpe%26aufirst%3DS.%26aulast%3DSiegl%26aufirst%3DP.%2BK.%2BS.%26aulast%3DStrang%26aufirst%3DI.%26aulast%3DSullivan%26aufirst%3DA.%2BT.%26aulast%3DWallis%26aufirst%3DR.%26aulast%3DCammi%26aufirst%3DA.%2BJ.%26aulast%3DHammond%26aufirst%3DT.%2BG.%26atitle%3DRelationships%2520between%2520preclinical%2520cardiac%2520electrophysiology%252C%2520clinical%2520QT%2520interval%2520prolongation%2520and%2520torsade%2520de%2520pointes%2520for%2520a%2520broad%2520range%2520of%2520drugs%253A%2520evidence%2520for%2520a%2520provisional%2520safety%2520margin%2520in%2520drug%2520development%26jtitle%3DCardiovasc.%2520Res.%26date%3D2003%26volume%3D58%26issue%3D1%26spage%3D32%26epage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Murphy, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poole, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padegimas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunady, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danzig, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ting, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherf, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunden, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stricker-Krongrad, A.</span><span> </span><span class="NLM_article-title">Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel</span> <span class="citation_source-journal">J. Pharmacol. Toxicol. Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">42</span><span class="NLM_x">–</span> <span class="NLM_lpage">55</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1016%2Fj.vascn.2005.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsFSktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2006&pages=42-55&issue=1&author=S.+M.+Murphyauthor=M.+Palmerauthor=M.+F.+Pooleauthor=L.+Padegimasauthor=K.+Hunadyauthor=J.+Danzigauthor=S.+Gillauthor=R.+Gillauthor=A.+Tingauthor=B.+Sherfauthor=K.+Brundenauthor=A.+Stricker-Krongrad&title=Evaluation+of+functional+and+binding+assays+in+cells+expressing+either+recombinant+or+endogenous+hERG+channel"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel</span></div><div class="casAuthors">Murphy, Steven M.; Palmer, Marc; Poole, Michelle Fontilla; Padegimas, Linas; Hunady, Karen; Danzig, Joel; Gill, Sikander; Gill, Rajwant; Ting, Anthony; Sherf, Bruce; Brunden, Kurt; Stricker-Krongrad, Alain</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">42-55</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The hERG (human ether-a-go-go related gene) potassium channel is required for normal cardiac repolarization, is susceptible to inhibition by a wide variety of compds., and its blockage can lead to cardiac QT interval prolongation and life threatening arrhythmias.  The present report examines the ability of hERG binding and functional assays to identify compds. with potential cardiovascular liabilities at the earliest stages of drug discovery.  Competitive binding assays were developed using 3H-dofetilide and membranes from HEK293EBNA cells stably expressing recombinant hERG (HEK293-hERG) and IMR-32 cells expressing hERG endogenously.  HERG functional assays were also developed using membrane potential indicator dye and rubidium efflux.  The ability of these assays to identify compds. with potential adverse cardiac effects was examd. using drugs with known cardiac effects ranging from those with no known adverse effects to drugs that were withdrawn from the market due to increased risk of sudden death assocd. with Torsades de Points.  Binding assays using HEK293-hERG membranes and 3H-dofetilide were robust (Z' = 0.69 ± 0.015, mean ± S.E.M.), highly reproducible (test-retest slope = 1.04, r2 = 0.98), and correlated well with IC50 values obtained by patch clamp (slope = 0.98, r 2 = 0.89).  Binding assays using IMR-32 membranes were less sensitive (Z' = 0.4±0.03, mean ± S.E.M., false neg. rate = 0.4) but still correlated well with patch clamp data (slope = 1.06, r2 = 0.83).  The hERG membrane potential assay could detect potent hERG inhibitors (defined by hERG patch clamp IC50 < 0.1 μM) using HEK293-hERG cells, but were prone to generate false-neg. results with less potent inhibitors (false neg. rate = 0.5).  Finally, the rubidium efflux assay gave highly reproducible results (Z' = 0.80 ± 0.02, mean ± S.E.M.) that correlated with patch clamp IC50 values (slope = 0.87, r2 = 0.73).  The hERG binding and rubidium efflux assays are robust, predictive of patch clamp results, and can be used at the earliest stages of drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtnBvVMZ8tdbVg90H21EOLACvtfcHk0lhZuNpzX4hfsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsFSktbc%253D&md5=7ec9afa4e333e5bd4fa3fbc69e0d8457</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.vascn.2005.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vascn.2005.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DS.%2BM.%26aulast%3DPalmer%26aufirst%3DM.%26aulast%3DPoole%26aufirst%3DM.%2BF.%26aulast%3DPadegimas%26aufirst%3DL.%26aulast%3DHunady%26aufirst%3DK.%26aulast%3DDanzig%26aufirst%3DJ.%26aulast%3DGill%26aufirst%3DS.%26aulast%3DGill%26aufirst%3DR.%26aulast%3DTing%26aufirst%3DA.%26aulast%3DSherf%26aufirst%3DB.%26aulast%3DBrunden%26aufirst%3DK.%26aulast%3DStricker-Krongrad%26aufirst%3DA.%26atitle%3DEvaluation%2520of%2520functional%2520and%2520binding%2520assays%2520in%2520cells%2520expressing%2520either%2520recombinant%2520or%2520endogenous%2520hERG%2520channel%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2006%26volume%3D54%26issue%3D1%26spage%3D42%26epage%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Schmalhofer, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swensen, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felix, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haedo, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solly, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiss, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaczorowski, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, M. L.</span><span> </span><span class="NLM_article-title">A Pharmacologically Validated, High-Capacity, Functional Thallium Flux Assay for the Human Ether-a-go-go Related Gene Potassium Channel</span> <span class="citation_source-journal">Assay Drug Dev. Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">714</span><span class="NLM_x">–</span> <span class="NLM_lpage">726</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=714-726&issue=6&author=W.+A.+Schmalhoferauthor=A.+M.+Swensenauthor=B.+S.+Thomasauthor=J.+P.+Felixauthor=R.+J.+Haedoauthor=K.+Sollyauthor=L.+Kissauthor=G.+J.+Kaczorowskiauthor=M.+L.+Garcia&title=A+Pharmacologically+Validated%2C+High-Capacity%2C+Functional+Thallium+Flux+Assay+for+the+Human+Ether-a-go-go+Related+Gene+Potassium+Channel"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchmalhofer%26aufirst%3DW.%2BA.%26aulast%3DSwensen%26aufirst%3DA.%2BM.%26aulast%3DThomas%26aufirst%3DB.%2BS.%26aulast%3DFelix%26aufirst%3DJ.%2BP.%26aulast%3DHaedo%26aufirst%3DR.%2BJ.%26aulast%3DSolly%26aufirst%3DK.%26aulast%3DKiss%26aufirst%3DL.%26aulast%3DKaczorowski%26aufirst%3DG.%2BJ.%26aulast%3DGarcia%26aufirst%3DM.%2BL.%26atitle%3DA%2520Pharmacologically%2520Validated%252C%2520High-Capacity%252C%2520Functional%2520Thallium%2520Flux%2520Assay%2520for%2520the%2520Human%2520Ether-a-go-go%2520Related%2520Gene%2520Potassium%2520Channel%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2010%26volume%3D8%26issue%3D6%26spage%3D714%26epage%3D726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Tarcsay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keseru, G. M.</span><span> </span><span class="NLM_article-title">Contributions of Molecular Properties to Drug Promiscuity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">1789</span><span class="NLM_x">–</span> <span class="NLM_lpage">1795</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm301514n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1789-1795&issue=5&author=A.+Tarcsayauthor=G.+M.+Keseru&title=Contributions+of+Molecular+Properties+to+Drug+Promiscuity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm301514n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301514n%26sid%3Dliteratum%253Aachs%26aulast%3DTarcsay%26aufirst%3DA.%26aulast%3DKeseru%26aufirst%3DG.%2BM.%26atitle%3DContributions%2520of%2520Molecular%2520Properties%2520to%2520Drug%2520Promiscuity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D5%26spage%3D1789%26epage%3D1795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Peters, J.-U.</span><span> </span><span class="NLM_article-title">Pharmacological Promiscuity and Molecular Properties</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed.; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">62</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=47-62&author=J.-U.+Petersauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch3%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.-U.%26atitle%3DPharmacological%2520Promiscuity%2520and%2520Molecular%2520Properties%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D47%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Hopkins, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overington, J. P.</span><span> </span><span class="NLM_article-title">Can we rationally design promiscuous drugs?</span> <span class="citation_source-journal">Curr. Opin. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">136</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1016%2Fj.sbi.2006.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=16442279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsFOjsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=127-136&issue=1&author=A.+L.+Hopkinsauthor=J.+S.+Masonauthor=J.+P.+Overington&title=Can+we+rationally+design+promiscuous+drugs%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Can we rationally design promiscuous drugs?</span></div><div class="casAuthors">Hopkins, Andrew L.; Mason, Jonathan S.; Overington, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-136</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Structure-based drug design is now used widely in modern medicinal chem.  The application of structural biol. to medicinal chem. has heralded the 'rational drug design' vision of discovering exquisitely selective ligands.  However, recent advances in post-genomic biol. are indicating that polypharmacol. may be a necessary trait for the efficacy of many drugs, therefore questioning the 'one drug, one target' assumption of current rational drug design.  By combining advances in chemoinformatics and structural biol., it might be possible to rationally design the next generation of promiscuous drugs with polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQWdh60x9AHrVg90H21EOLACvtfcHk0lgo8QECyLGkFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsFOjsrc%253D&md5=8f9e95a41976b8e3ac790f2fff2c406f</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2006.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2006.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26atitle%3DCan%2520we%2520rationally%2520design%2520promiscuous%2520drugs%253F%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2006%26volume%3D16%26issue%3D1%26spage%3D127%26epage%3D136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><div class="note"><p class="first last">For a description of the BioPrint panel, see:</p></div><span class="NLM_contrib-group">Krejsa, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horvath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogalski, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penzotti, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migeon, J. C.</span><span> </span><span class="NLM_article-title">Predicting ADME properties and side-effects: The BioPrint approach</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">470</span><span class="NLM_x">–</span> <span class="NLM_lpage">480</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2003&pages=470-480&issue=4&author=C.+M.+Krejsaauthor=D.+Horvathauthor=S.+L.+Rogalskiauthor=J.+E.+Penzottiauthor=B.+Maoauthor=F.+Barbosaauthor=J.+C.+Migeon&title=Predicting+ADME+properties+and+side-effects%3A+The+BioPrint+approach"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKrejsa%26aufirst%3DC.%2BM.%26aulast%3DHorvath%26aufirst%3DD.%26aulast%3DRogalski%26aufirst%3DS.%2BL.%26aulast%3DPenzotti%26aufirst%3DJ.%2BE.%26aulast%3DMao%26aufirst%3DB.%26aulast%3DBarbosa%26aufirst%3DF.%26aulast%3DMigeon%26aufirst%3DJ.%2BC.%26atitle%3DPredicting%2520ADME%2520properties%2520and%2520side-effects%253A%2520The%2520BioPrint%2520approach%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2003%26volume%3D6%26issue%3D4%26spage%3D470%26epage%3D480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Peters, J.-U.</span><span> </span><span class="NLM_article-title">Opportunities and Challenges in Polypharmacological Drug Discovery</span>; AAPS Annual Meeting and Exposition, Chicago, October 14–18,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Peters%2C+J.-U.+Opportunities+and+Challenges+in+Polypharmacological+Drug+Discovery%3B+AAPS+Annual+Meeting+and+Exposition%2C+Chicago%2C+October+14%E2%80%9318%2C+2012."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1002%2F9781118098141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.-U.%26atitle%3DOpportunities%2520and%2520Challenges%2520in%2520Polypharmacological%2520Drug%2520Discovery%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Whitlock, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fish, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fray, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stobie, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakenhut, F.</span><span> </span><span class="NLM_article-title">Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">2896</span><span class="NLM_x">–</span> <span class="NLM_lpage">2899</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=2896-2899&issue=9&author=G.+A.+Whitlockauthor=P.+V.+Fishauthor=M.+J.+Frayauthor=A.+Stobieauthor=F.+Wakenhut&title=Pyridyl-phenyl+ether+monoamine+reuptake+inhibitors%3A+Impact+of+lipophilicity+on+dual+SNRI+pharmacology+and+off-target+promiscuity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWhitlock%26aufirst%3DG.%2BA.%26aulast%3DFish%26aufirst%3DP.%2BV.%26aulast%3DFray%26aufirst%3DM.%2BJ.%26aulast%3DStobie%26aufirst%3DA.%26aulast%3DWakenhut%26aufirst%3DF.%26atitle%3DPyridyl-phenyl%2520ether%2520monoamine%2520reuptake%2520inhibitors%253A%2520Impact%2520of%2520lipophilicity%2520on%2520dual%2520SNRI%2520pharmacology%2520and%2520off-target%2520promiscuity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26issue%3D9%26spage%3D2896%26epage%3D2899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springthorpe, B.</span><span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision-making in medicinal chemistry</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">881</span><span class="NLM_x">–</span> <span class="NLM_lpage">890</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&issue=11&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0lgo8QECyLGkFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26issue%3D11%26spage%3D881%26epage%3D890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wager, T.</span><span> </span><span class="NLM_article-title">Physicochemical drug properties associated with in vivo toxicological outcomes: a review</span> <span class="citation_source-journal">Expert Opin. Drug Metab. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">921</span><span class="NLM_x">–</span> <span class="NLM_lpage">931</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1517%2F17425250903042318" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=19519283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1MXovVCjtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=921-931&issue=8&author=D.+A.+Priceauthor=J.+Blaggauthor=L.+Jonesauthor=N.+Greeneauthor=T.+Wager&title=Physicochemical+drug+properties+associated+with+in+vivo+toxicological+outcomes%3A+a+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Physicochemical drug properties associated with in vivo toxicological outcomes: a review</span></div><div class="casAuthors">Price, David A.; Blagg, Julian; Jones, Lyn; Greene, Nigel; Wager, Travis</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">921-931</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The genesis of any toxicol. or safety outcome is multifactorial and complex; for this reason, it can be difficult for drug discovery projects to factor the avoidance of toxicity outcomes into their target design.  A focus on readily measurable parameters from high-throughput in vitro assays (e.g., primary potency, clearance) is easier to handle and have become the mainstays of drug discovery projects.  However, the fundamental origins of adverse safety or toxicity findings can be considered as deriving from four parameters, all of which are in the control of the drug designer.  These can be described as primary pharmacol., off target pharmacol., the presence of a defined structural fragment that can be assocd. with adverse outcomes and the overall physicochem. properties of the mol. that may predispose it to adverse outcomes.  In the drug discovery community, there has been recognition for many years of the influence of physicochem. drug properties (in particular lipophilicity) on the toxicol. profile of compds., and recent research is now beginning to quantify that risk in a probabilistic sense.  This review focuses on the overall properties of classes of mols. that are assocd. with an increased probability of adverse outcomes in in vivo studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU8kwwUsaFIrVg90H21EOLACvtfcHk0lj60PbdOJ4i1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXovVCjtb0%253D&md5=bd1cca3634afda14de2f8aa115d7d55e</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1517%2F17425250903042318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425250903042318%26sid%3Dliteratum%253Aachs%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DL.%26aulast%3DGreene%26aufirst%3DN.%26aulast%3DWager%26aufirst%3DT.%26atitle%3DPhysicochemical%2520drug%2520properties%2520associated%2520with%2520in%2520vivo%2520toxicological%2520outcomes%253A%2520a%2520review%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2009%26volume%3D5%26issue%3D8%26spage%3D921%26epage%3D931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">van de Waterbeemd, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, B. C.</span><span> </span><span class="NLM_article-title">Lipophilicity in PK design: methyl, ethyl, futile</span> <span class="citation_source-journal">J. Comput.-Aided Mol. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">273</span><span class="NLM_x">–</span> <span class="NLM_lpage">286</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1023%2FA%3A1008192010023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=11289080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitlWjtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2001&pages=273-286&issue=3&author=H.+van+de+Waterbeemdauthor=D.+A.+Smithauthor=B.+C.+Jones&title=Lipophilicity+in+PK+design%3A+methyl%2C+ethyl%2C+futile"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Lipophilicity in PK design: methyl, ethyl, futile</span></div><div class="casAuthors">Van de Waterbeemd, Han; Smith, Dennis A.; Jones, Barry C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computer-Aided Molecular Design</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">273-286</span>CODEN:
                <span class="NLM_cas:coden">JCADEQ</span>;
        ISSN:<span class="NLM_cas:issn">0920-654X</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">A review with 39 refs.  Lipophilicity, often expressed as distribution coeffs. (log D) in octanol/water, is an important physicochem. parameter influencing processes such as oral absorption, brain uptake and various pharmacokinetic (PK) properties.  Increasing log D values increases oral absorption, plasma protein binding and vol. of distribution.  However, more lipophilic compds. also become more vulnerable to P 450 metab., leading to higher clearance.  Mol. size and hydrogen bonding capacity are two other properties often considered as important for membrane permeation and pharmacokinetics.  Interrelationships among these physicochem. properties are discussed.  Increasing size (mol. wt.) often gives higher potency, but inevitably also leads to either higher lipophilicity, and hence poorer dissoln./soly., or to more hydrogen bonding capacity, which limits oral absorption.  Differences in optimal properties between gastrointestinal absorption and uptake into the brain are addressed.  Special attention is given to the desired lipophilicity of CNS drugs.  In examples using β-blockers, Ca channel antagonists and peptidic renin inhibitors we will demonstrate how potency and pharmacokinetic properties need to be balanced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohNJonr7f2hbVg90H21EOLACvtfcHk0lj60PbdOJ4i1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitlWjtLo%253D&md5=04f94add93edc2b1a211bb53f676d908</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1023%2FA%3A1008192010023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1008192010023%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bde%2BWaterbeemd%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DJones%26aufirst%3DB.%2BC.%26atitle%3DLipophilicity%2520in%2520PK%2520design%253A%2520methyl%252C%2520ethyl%252C%2520futile%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2001%26volume%3D15%26issue%3D3%26spage%3D273%26epage%3D286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Arnott, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planey, S. L.</span><span> </span><span class="NLM_article-title">The influence of lipophilicity in drug discovery and design</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">863</span><span class="NLM_x">–</span> <span class="NLM_lpage">875</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=863-875&issue=10&author=J.+A.+Arnottauthor=S.+L.+Planey&title=The+influence+of+lipophilicity+in+drug+discovery+and+design"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DArnott%26aufirst%3DJ.%2BA.%26aulast%3DPlaney%26aufirst%3DS.%2BL.%26atitle%3DThe%2520influence%2520of%2520lipophilicity%2520in%2520drug%2520discovery%2520and%2520design%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2012%26volume%3D7%26issue%3D10%26spage%3D863%26epage%3D875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Yildirim, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cusick, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barabasi, A.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vidal, M.</span><span> </span><span class="NLM_article-title">Drug-target network</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">1119</span><span class="NLM_x">–</span> <span class="NLM_lpage">1126</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=1119-1126&issue=10&author=M.+A.+Yildirimauthor=K.-I.+Gohauthor=M.+E.+Cusickauthor=A.-L.+Barabasiauthor=M.+Vidal&title=Drug-target+network"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYildirim%26aufirst%3DM.%2BA.%26aulast%3DGoh%26aufirst%3DK.-I.%26aulast%3DCusick%26aufirst%3DM.%2BE.%26aulast%3DBarabasi%26aufirst%3DA.-L.%26aulast%3DVidal%26aufirst%3DM.%26atitle%3DDrug-target%2520network%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26issue%3D10%26spage%3D1119%26epage%3D1126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Gregori-Puigjane, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestres, J.</span><span> </span><span class="NLM_article-title">A ligand-based approach to mining the chemogenomic space of drugs</span> <span class="citation_source-journal">Comb. Chem. High Throughput Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">669</span><span class="NLM_x">–</span> <span class="NLM_lpage">676</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=669-676&issue=8&author=E.+Gregori-Puigjaneauthor=J.+Mestres&title=A+ligand-based+approach+to+mining+the+chemogenomic+space+of+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGregori-Puigjane%26aufirst%3DE.%26aulast%3DMestres%26aufirst%3DJ.%26atitle%3DA%2520ligand-based%2520approach%2520to%2520mining%2520the%2520chemogenomic%2520space%2520of%2520drugs%26jtitle%3DComb.%2520Chem.%2520High%2520Throughput%2520Screening%26date%3D2008%26volume%3D11%26issue%3D8%26spage%3D669%26epage%3D676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Cases, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestres, J.</span><span> </span><span class="NLM_article-title">A chemogenomic approach to drug discovery: focus on cardiovascular diseases</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x"> (</span><span class="NLM_issue">9/10</span><span class="NLM_x">) </span> <span class="NLM_fpage">479</span><span class="NLM_x">–</span> <span class="NLM_lpage">485</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=479-485&issue=9%2F10&author=M.+Casesauthor=J.+Mestres&title=A+chemogenomic+approach+to+drug+discovery%3A+focus+on+cardiovascular+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCases%26aufirst%3DM.%26aulast%3DMestres%26aufirst%3DJ.%26atitle%3DA%2520chemogenomic%2520approach%2520to%2520drug%2520discovery%253A%2520focus%2520on%2520cardiovascular%2520diseases%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26issue%3D9%252F10%26spage%3D479%26epage%3D485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Brianso, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrascosa, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oprea, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestres, J.</span><span> </span><span class="NLM_article-title">Cross-pharmacology analysis of G protein-coupled receptors</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">15</span><span class="NLM_x">) </span> <span class="NLM_fpage">1956</span><span class="NLM_x">–</span> <span class="NLM_lpage">1963</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.2174%2F156802611796391285" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVSmsLzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=1956-1963&issue=15&author=F.+Briansoauthor=M.+C.+Carrascosaauthor=T.+I.+Opreaauthor=J.+Mestres&title=Cross-pharmacology+analysis+of+G+protein-coupled+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Cross-pharmacology analysis of G protein-coupled receptors</span></div><div class="casAuthors">Brianso, Ferran; Carrascosa, Maria C.; Oprea, Tudor I.; Mestres, Jordi</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1956-1963</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The degree of applicability of chemogenomic approaches to protein families depends on the accuracy and completeness of pharmacol. data and the corresponding level of pharmacol. similarity obsd. among their protein members.  The recent public domain availability of pharmacol. data for thousands of small mols. on 204 G protein-coupled receptors (GPCRs) provides a firm basis for an in-depth cross-pharmacol. anal. of this superfamily.  The no. of protein targets included in the cross-pharmacol. profile of the different GPCRs changes significantly upon varying the ligand similarity and binding affinity criteria.  However, with the exception of muscarinic receptors, aminergic GPCRs distinguish themselves from the rest of the members in the family by their remarkably high levels of pharmacol. similarity among them.  Clusters of non-GPCR targets related by cross-pharmacol. with particular GPCRs are identified and the implications for unwanted side-effects, as well as for repurposing opportunities, discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcxMaSMU_YxLVg90H21EOLACvtfcHk0lgzmqrCEVkkkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVSmsLzO&md5=7805626c0844e84d16b56ed953823486</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.2174%2F156802611796391285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611796391285%26sid%3Dliteratum%253Aachs%26aulast%3DBrianso%26aufirst%3DF.%26aulast%3DCarrascosa%26aufirst%3DM.%2BC.%26aulast%3DOprea%26aufirst%3DT.%2BI.%26aulast%3DMestres%26aufirst%3DJ.%26atitle%3DCross-pharmacology%2520analysis%2520of%2520G%2520protein-coupled%2520receptors%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26issue%3D15%26spage%3D1956%26epage%3D1963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Mestres, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregori-Puigjane, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valverde, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sole, R.</span><span> </span><span class="NLM_article-title">V.The topology of drug-target interaction networks: Implicit dependence on drug properties and target families</span> <span class="citation_source-journal">Mol. BioSyst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1051</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1039%2Fb905821b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1MXps1Kksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=1051&issue=9&author=J.+Mestresauthor=E.+Gregori-Puigjaneauthor=S.+Valverdeauthor=R.+Sole&title=V.The+topology+of+drug-target+interaction+networks%3A+Implicit+dependence+on+drug+properties+and+target+families"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">The topology of drug-target interaction networks: Implicit dependence on drug properties and target families</span></div><div class="casAuthors">Mestres, Jordi; Gregori-Puigjane, Elisabet; Valverde, Sergi; Sole, Ricard V.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1051-1057</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-206X</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The availability of interaction data between small mol. drugs and protein targets has increased substantially in recent years.  Using seven different databases, we were able to assemble a total of 4767 unique interactions between 802 drugs and 480 targets, which means that on av. every drug is currently acknowledged to interact with 6 targets.  The application of network theory to the anal. of these data reveals an unexpectedly complex picture of drug-target interactions.  The results confirm that the topol. of drug-target networks depends implicitly on data completeness, drug properties, and target families.  The implications for drug discovery are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNAnnU4e6Jl7Vg90H21EOLACvtfcHk0lgzmqrCEVkkkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXps1Kksbo%253D&md5=a0999bf0521936fba03400554411e8d7</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1039%2Fb905821b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb905821b%26sid%3Dliteratum%253Aachs%26aulast%3DMestres%26aufirst%3DJ.%26aulast%3DGregori-Puigjane%26aufirst%3DE.%26aulast%3DValverde%26aufirst%3DS.%26aulast%3DSole%26aufirst%3DR.%26atitle%3DV.The%2520topology%2520of%2520drug-target%2520interaction%2520networks%253A%2520Implicit%2520dependence%2520on%2520drug%2520properties%2520and%2520target%2520families%26jtitle%3DMol.%2520BioSyst.%26date%3D2009%26volume%3D5%26issue%3D9%26spage%3D1051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Jalencas, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestres, J.</span><span> </span><span class="NLM_article-title">On the origins of drug polypharmacology</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">87</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=80-87&issue=1&author=X.+Jalencasauthor=J.+Mestres&title=On+the+origins+of+drug+polypharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJalencas%26aufirst%3DX.%26aulast%3DMestres%26aufirst%3DJ.%26atitle%3DOn%2520the%2520origins%2520of%2520drug%2520polypharmacology%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26issue%3D1%26spage%3D80%26epage%3D87" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Azzaoui, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faller, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitebread, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacoby, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, L.</span><span> </span><span class="NLM_article-title">Modeling promiscuity based on in vitro safety pharmacology profiling data</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">874</span><span class="NLM_x">–</span> <span class="NLM_lpage">880</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=874-880&issue=6&author=K.+Azzaouiauthor=J.+Hamonauthor=B.+Fallerauthor=S.+Whitebreadauthor=E.+Jacobyauthor=A.+Benderauthor=J.+L.+Jenkinsauthor=L.+Urban&title=Modeling+promiscuity+based+on+in+vitro+safety+pharmacology+profiling+data"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAzzaoui%26aufirst%3DK.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DFaller%26aufirst%3DB.%26aulast%3DWhitebread%26aufirst%3DS.%26aulast%3DJacoby%26aufirst%3DE.%26aulast%3DBender%26aufirst%3DA.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26aulast%3DUrban%26aufirst%3DL.%26atitle%3DModeling%2520promiscuity%2520based%2520on%2520in%2520vitro%2520safety%2520pharmacology%2520profiling%2520data%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26issue%3D6%26spage%3D874%26epage%3D880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Haupt, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daminelli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, M.</span><span> </span><span class="NLM_article-title">Drug promiscuity in PDB: protein binding site similarity is key</span> <span class="citation_source-journal">PLoS ONE</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">e65894</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e65894&issue=6&author=V.+J.+Hauptauthor=S.+Daminelliauthor=M.+Schroeder&title=Drug+promiscuity+in+PDB%3A+protein+binding+site+similarity+is+key"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHaupt%26aufirst%3DV.%2BJ.%26aulast%3DDaminelli%26aufirst%3DS.%26aulast%3DSchroeder%26aufirst%3DM.%26atitle%3DDrug%2520promiscuity%2520in%2520PDB%253A%2520protein%2520binding%2520site%2520similarity%2520is%2520key%26jtitle%3DPLoS%2520ONE%26date%3D2013%26volume%3D8%26issue%3D6%26spage%3De65894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Hughes, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeCrescenzo, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devraj, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellsworth, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fobian, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbs, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilles, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krieger-Burke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loesel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wager, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiteley, Y. Z.</span><span> </span><span class="NLM_article-title">Physiochemical drug properties associated with in vivo toxicological outcomes</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">4872</span><span class="NLM_x">–</span> <span class="NLM_lpage">4875</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1016%2Fj.bmcl.2008.07.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=18691886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsbjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4872-4875&issue=17&author=J.+D.+Hughesauthor=J.+Blaggauthor=D.+A.+Priceauthor=S.+Baileyauthor=G.+A.+DeCrescenzoauthor=R.+V.+Devrajauthor=E.+Ellsworthauthor=Y.+M.+Fobianauthor=M.+E.+Gibbsauthor=R.+W.+Gillesauthor=N.+Greeneauthor=E.+Huangauthor=T.+Krieger-Burkeauthor=J.+Loeselauthor=T.+Wagerauthor=Y.+Z.+Whiteley&title=Physiochemical+drug+properties+associated+with+in+vivo+toxicological+outcomes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Physiochemical drug properties associated with in vivo toxicological outcomes</span></div><div class="casAuthors">Hughes, Jason D.; Blagg, Julian; Price, David A.; Bailey, Simon; DeCrescenzo, Gary A.; Devraj, Rajesh V.; Ellsworth, Edmund; Fobian, Yvette M.; Gibbs, Michael E.; Gilles, Richard W.; Greene, Nigel; Huang, Enoch; Krieger-Burke, Teresa; Loesel, Jens; Wager, Travis; Whiteley, Larry; Zhang, Yao</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4872-4875</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Relationships between physicochem. drug properties and toxicity were inferred from a data set consisting of animal in vivo toleration (IVT) studies on 245 preclin. Pfizer compds.; an increased likelihood of toxic events was found for less polar, more lipophilic compds.  This trend held across a wide range of types of toxicity and across a broad swath of chem. space.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPMmGEpVF0mbVg90H21EOLACvtfcHk0ljEV6QrBK4oBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsbjE&md5=80ea5ced359112a363f38b3545cd7646</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.07.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.07.071%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DJ.%2BD.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DDeCrescenzo%26aufirst%3DG.%2BA.%26aulast%3DDevraj%26aufirst%3DR.%2BV.%26aulast%3DEllsworth%26aufirst%3DE.%26aulast%3DFobian%26aufirst%3DY.%2BM.%26aulast%3DGibbs%26aufirst%3DM.%2BE.%26aulast%3DGilles%26aufirst%3DR.%2BW.%26aulast%3DGreene%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DE.%26aulast%3DKrieger-Burke%26aufirst%3DT.%26aulast%3DLoesel%26aufirst%3DJ.%26aulast%3DWager%26aufirst%3DT.%26aulast%3DWhiteley%26aufirst%3DY.%2BZ.%26atitle%3DPhysiochemical%2520drug%2520properties%2520associated%2520with%2520in%2520vivo%2520toxicological%2520outcomes%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26issue%3D17%26spage%3D4872%26epage%3D4875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Young, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, D. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luscombe, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, A. P.</span><span> </span><span class="NLM_article-title">Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">17–18</span><span class="NLM_x">) </span> <span class="NLM_fpage">822</span><span class="NLM_x">–</span> <span class="NLM_lpage">830</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1016%2Fj.drudis.2011.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=21704184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFCru7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=822-830&issue=17%E2%80%9318&author=R.+J.+Youngauthor=D.+V.+Greenauthor=C.+N.+Luscombeauthor=A.+P.+Hill&title=Getting+physical+in+drug+discovery+II%3A+the+impact+of+chromatographic+hydrophobicity+measurements+and+aromaticity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity</span></div><div class="casAuthors">Young, Robert J.; Green, Darren V. S.; Luscombe, Christopher N.; Hill, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">17/18</span>),
    <span class="NLM_cas:pages">822-830</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Here, we review the performance of chromatog. hydrophobicity measurements in a data set of 100 000 GlaxoSmithKline compds., demonstrating the advantages of the method over octanol-water partitioning and highlighting new insights for drug discovery.  The value of chromatog. measurements, vs. other hydrophobicity ests., was supported by improved relationships with soly., permeation, cytochrome P450s, intrinsic clearance, hERG binding and promiscuity.  We also obsd. marked differentiation of the relative influence of intrinsic and effective hydrophobicity.  The summing of hydrophobicity values plus arom. ring count [log D pH7.4 (or log P) + #Ar], indicated a wide relevance for simplistic property forecast indexes' in developability assays, clearly enhanced by chromatog. values; therefore establishing new foundations for enriching property-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmIJyWi-DBW7Vg90H21EOLACvtfcHk0ljEV6QrBK4oBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFCru7vF&md5=22788603a45aa77537e8666433473d14</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DGreen%26aufirst%3DD.%2BV.%26aulast%3DLuscombe%26aufirst%3DC.%2BN.%26aulast%3DHill%26aufirst%3DA.%2BP.%26atitle%3DGetting%2520physical%2520in%2520drug%2520discovery%2520II%253A%2520the%2520impact%2520of%2520chromatographic%2520hydrophobicity%2520measurements%2520and%2520aromaticity%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26issue%3D17%25E2%2580%259318%26spage%3D822%26epage%3D830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Sturm, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desaphy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rognan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kellenberger, E.</span><span> </span><span class="NLM_article-title">Structural Insights into the Molecular Basis of the Ligand Promiscuity</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">2410</span><span class="NLM_x">–</span> <span class="NLM_lpage">2421</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci300196g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1GhurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=2410-2421&issue=9&author=N.+Sturmauthor=J.+Desaphyauthor=R.+J.+Quinnauthor=D.+Rognanauthor=E.+Kellenberger&title=Structural+Insights+into+the+Molecular+Basis+of+the+Ligand+Promiscuity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Insights into the Molecular Basis of the Ligand Promiscuity</span></div><div class="casAuthors">Sturm, Noe; Desaphy, Jeremy; Quinn, Ronald J.; Rognan, Didier; Kellenberger, Esther</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2410-2421</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Selectivity is a key factor in drug development.  In this paper, we questioned the Protein Data Bank to better understand the reasons for the promiscuity of bioactive compds.  We assembled a data set of >1000 pairs of three-dimensional structures of complexes between a "drug-like" ligand (as its physicochem. properties overlap that of approved drugs) and two distinct "druggable" protein targets (as their binding sites are likely to accommodate "drug-like" ligands).  Studying the similarity between the ligand-binding sites in the different targets revealed that the lack of selectivity of a ligand can be due (i) to the fact that Nature has created the same binding pocket in different proteins, which do not necessarily have otherwise sequence or fold similarity, or (ii) to specific characteristics of the ligand itself.  In particular, we demonstrated that many ligands can adapt to different protein environments by changing their conformation, by using different chem. moieties to anchor to different targets, or by adopting unusual extreme binding modes (e.g., only apolar contact between the ligand and the protein, even though polar groups are present on the ligand or at the protein surface).  Lastly, we provided new elements in support to the recent studies which suggest that the promiscuity of a ligand might be inferred from its mol. complexity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaq6HYzXDUl7Vg90H21EOLACvtfcHk0ljEV6QrBK4oBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1GhurbF&md5=808b3192a4110ec1bb26ddd41165d60d</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Fci300196g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci300196g%26sid%3Dliteratum%253Aachs%26aulast%3DSturm%26aufirst%3DN.%26aulast%3DDesaphy%26aufirst%3DJ.%26aulast%3DQuinn%26aufirst%3DR.%2BJ.%26aulast%3DRognan%26aufirst%3DD.%26aulast%3DKellenberger%26aufirst%3DE.%26atitle%3DStructural%2520Insights%2520into%2520the%2520Molecular%2520Basis%2520of%2520the%2520Ligand%2520Promiscuity%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2012%26volume%3D52%26issue%3D9%26spage%3D2410%26epage%3D2421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Lovering, F.</span><span> </span><span class="NLM_article-title">Escape from Flatland 2: complexity and promiscuity</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">515</span><span class="NLM_x">–</span> <span class="NLM_lpage">519</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=515-519&issue=3&author=F.+Lovering&title=Escape+from+Flatland+2%3A+complexity+and+promiscuity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26atitle%3DEscape%2520from%2520Flatland%25202%253A%2520complexity%2520and%2520promiscuity%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26issue%3D3%26spage%3D515%26epage%3D519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muresan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engkvist, O.</span><span> </span><span class="NLM_article-title">Investigation of the Relationship between Topology and Selectivity for Drug-like Molecules</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x"> (</span><span class="NLM_issue">21</span><span class="NLM_x">) </span> <span class="NLM_fpage">7709</span><span class="NLM_x">–</span> <span class="NLM_lpage">7714</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1008456" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7709-7714&issue=21&author=Y.+Yangauthor=H.+Chenauthor=I.+Nilssonauthor=S.+Muresanauthor=O.+Engkvist&title=Investigation+of+the+Relationship+between+Topology+and+Selectivity+for+Drug-like+Molecules"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fjm1008456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1008456%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DNilsson%26aufirst%3DI.%26aulast%3DMuresan%26aufirst%3DS.%26aulast%3DEngkvist%26aufirst%3DO.%26atitle%3DInvestigation%2520of%2520the%2520Relationship%2520between%2520Topology%2520and%2520Selectivity%2520for%2520Drug-like%2520Molecules%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D21%26spage%3D7709%26epage%3D7714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Hann, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, G.</span><span> </span><span class="NLM_article-title">Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery</span> <span class="citation_source-journal">J. Chem. Inf. Comp. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">856</span><span class="NLM_x">–</span> <span class="NLM_lpage">864</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci000403i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivFynt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2001&pages=856-864&issue=3&author=M.+M.+Hannauthor=A.+R.+Leachauthor=G.+Harper&title=Molecular+Complexity+and+Its+Impact+on+the+Probability+of+Finding+Leads+for+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery</span></div><div class="casAuthors">Hann, Michael M.; Leach, Andrew R.; Harper, Gavin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Computer Sciences</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">856-864</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">0095-2338</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Using a simple model of ligand-receptor interactions, the interactions between ligands and receptors of varying complexities are studied and the probabilities of binding calcd.  It is obsd. that as the systems become more complex the chance of observing a useful interaction for a randomly chosen ligand falls dramatically.  The implications of this for the design of combinatorial libraries is explored.  A large set of drug leads and optimized compds. is profiled using several different properties relevant to mol. recognition.  The changes obsd. for these properties during the drug optimization phase support the hypothesis that less complex mols. are more common starting points for the discovery of drugs.  An extreme example of the use of simple mols. for directed screening against thrombin is provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7ed40mt9qb7Vg90H21EOLACvtfcHk0liKrhF_5mwWvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivFynt7w%253D&md5=e89e76c8fb83fc5012369ae30f20e6b7</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fci000403i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci000403i%26sid%3Dliteratum%253Aachs%26aulast%3DHann%26aufirst%3DM.%2BM.%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DHarper%26aufirst%3DG.%26atitle%3DMolecular%2520Complexity%2520and%2520Its%2520Impact%2520on%2520the%2520Probability%2520of%2520Finding%2520Leads%2520for%2520Drug%2520Discovery%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Comp.%2520Sci.%26date%3D2001%26volume%3D41%26issue%3D3%26spage%3D856%26epage%3D864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Leach, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hann, M. M.</span><span> </span><span class="NLM_article-title">Molecular complexity and fragment-based drug discovery: ten years on</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">489</span><span class="NLM_x">–</span> <span class="NLM_lpage">496</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1016%2Fj.cbpa.2011.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=21665521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvFCltrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=489-496&issue=4&author=A.+R.+Leachauthor=M.+M.+Hann&title=Molecular+complexity+and+fragment-based+drug+discovery%3A+ten+years+on"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular complexity and fragment-based drug discovery: ten years on</span></div><div class="casAuthors">Leach, Andrew R.; Hann, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">489-496</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We review the concept of mol. complexity in the context of the very simple model of mol. interactions that we introduced over 10 years ago.  A summary is presented of efforts to validate this simple model using screening data.  The relationship between the complexity model and the problem of sampling chem. space is discussed, together with the relevance of these theor. concepts to fragment-based drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNcMgTT6eLC7Vg90H21EOLACvtfcHk0liKrhF_5mwWvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvFCltrg%253D&md5=19c2d65de80a8bab1059468828da6ce2</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2011.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2011.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DHann%26aufirst%3DM.%2BM.%26atitle%3DMolecular%2520complexity%2520and%2520fragment-based%2520drug%2520discovery%253A%2520ten%2520years%2520on%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D15%26issue%3D4%26spage%3D489%26epage%3D496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Andrews, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lloyd, E. J.</span><span> </span><span class="NLM_article-title">Molecular conformation and biological activity of central nervous system active drugs</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">393</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2Fmed.2610020404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADyaL38XmtVOmsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1982&pages=355-393&issue=4&author=P.+R.+Andrewsauthor=E.+J.+Lloyd&title=Molecular+conformation+and+biological+activity+of+central+nervous+system+active+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular conformation and biological activity of central nervous system active drugs</span></div><div class="casAuthors">Andrews, P. R.; Lloyd, E. J.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">355-93</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    </div><div class="casAbstract">A review with 135 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUsPpCqHa32bVg90H21EOLACvtfcHk0liKrhF_5mwWvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XmtVOmsro%253D&md5=d6bd57937e21326815b5ca8adc831247</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1002%2Fmed.2610020404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.2610020404%26sid%3Dliteratum%253Aachs%26aulast%3DAndrews%26aufirst%3DP.%2BR.%26aulast%3DLloyd%26aufirst%3DE.%2BJ.%26atitle%3DMolecular%2520conformation%2520and%2520biological%2520activity%2520of%2520central%2520nervous%2520system%2520active%2520drugs%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D1982%26volume%3D2%26issue%3D4%26spage%3D355%26epage%3D393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">LaBella, Frank, S.</span><span> </span><span class="NLM_article-title">Molecular basis for binding promiscuity of antagonist drugs</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">S1</span><span class="NLM_x">–</span> <span class="NLM_lpage">S8</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1991&pages=S1-S8&issue=Suppl&author=S.+LaBella%2C+Frank&title=Molecular+basis+for+binding+promiscuity+of+antagonist+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLaBella%252C%2BFrank%26aufirst%3DS.%26atitle%3DMolecular%2520basis%2520for%2520binding%2520promiscuity%2520of%2520antagonist%2520drugs%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1991%26volume%3D42%26issue%3DSuppl%26spage%3DS1%26epage%3DS8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Targeting cancer with small molecule kinase inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fnrc2559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=19104514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1yg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=28-39&issue=1&author=J.+Zhangauthor=P.+L.+Yangauthor=N.+S.+Gray&title=Targeting+cancer+with+small+molecule+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer with small molecule kinase inhibitors</span></div><div class="casAuthors">Zhang, Jianming; Yang, Priscilla L.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-39</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiol. constraints on growth and survival.  To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small mol. inhibitors for a host of other kinases that are implicated in cancer and other diseases.  Herein we discuss the current challenges in the field, such as designing selective inhibitors and developing strategies to overcome resistance mutations.  This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriSM3BN_uEz7Vg90H21EOLACvtfcHk0liFV6dkM-a_wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1yg&md5=35bc38f414cd21eef5e61ce181b580fb</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1038%2Fnrc2559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2559%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520cancer%2520with%2520small%2520molecule%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26issue%3D1%26spage%3D28%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Kirchner, S.</span><span> </span><span class="NLM_article-title">Kinases as Antitargets in Genotoxicity</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed., <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">63</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=63-81&author=S.+Kirchnerauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch4%26sid%3Dliteratum%253Aachs%26aulast%3DKirchner%26aufirst%3DS.%26atitle%3DKinases%2520as%2520Antitargets%2520in%2520Genotoxicity%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D63%26epage%3D81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Aronov, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McClain, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuver Moody, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murcko, M. A.</span><span> </span><span class="NLM_article-title">Kinase-likeness and Kinase-Privileged Fragments: Toward Virtual Polypharmacology</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">1214</span><span class="NLM_x">–</span> <span class="NLM_lpage">1222</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701021b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1214-1222&issue=5&author=A.+M.+Aronovauthor=B.+McClainauthor=C.+Stuver+Moodyauthor=M.+A.+Murcko&title=Kinase-likeness+and+Kinase-Privileged+Fragments%3A+Toward+Virtual+Polypharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Fjm701021b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701021b%26sid%3Dliteratum%253Aachs%26aulast%3DAronov%26aufirst%3DA.%2BM.%26aulast%3DMcClain%26aufirst%3DB.%26aulast%3DStuver%2BMoody%26aufirst%3DC.%26aulast%3DMurcko%26aufirst%3DM.%2BA.%26atitle%3DKinase-likeness%2520and%2520Kinase-Privileged%2520Fragments%253A%2520Toward%2520Virtual%2520Polypharmacology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D5%26spage%3D1214%26epage%3D1222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Brandt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, J.</span><span> </span><span class="NLM_article-title">Small kinase assay panels can provide a measure of selectivity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x"> (</span><span class="NLM_issue">20</span><span class="NLM_x">) </span> <span class="NLM_fpage">5861</span><span class="NLM_x">–</span> <span class="NLM_lpage">5863</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5861-5863&issue=20&author=P.+Brandtauthor=A.+J.+Jensenauthor=J.+Nilsson&title=Small+kinase+assay+panels+can+provide+a+measure+of+selectivity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrandt%26aufirst%3DP.%26aulast%3DJensen%26aufirst%3DA.%2BJ.%26aulast%3DNilsson%26aufirst%3DJ.%26atitle%3DSmall%2520kinase%2520assay%2520panels%2520can%2520provide%2520a%2520measure%2520of%2520selectivity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26issue%3D20%26spage%3D5861%26epage%3D5863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Supuran, C. T.</span><span> </span><span class="NLM_article-title">Carbonic Anhydrases: Off Targets, Add-on Activities, or Emerging Novel Targets?</span> In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed., <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">459</span><span class="NLM_x">–</span> <span class="NLM_lpage">491</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch23" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=459-491&author=C.+T.+Supuranauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch23%26sid%3Dliteratum%253Aachs%26aulast%3DSupuran%26aufirst%3DC.%2BT.%26atitle%3DCarbonic%2520Anhydrases%253A%2520Off%2520Targets%252C%2520Add-on%2520Activities%252C%2520or%2520Emerging%2520Novel%2520Targets%253F%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D459%26epage%3D491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Yadav, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patil, V. M.</span><span> </span><span class="NLM_article-title">Recent advances in studies on hydroxamates as matrix metalloproteinase inhibitors: a review</span> <span class="citation_source-journal">Curr.Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">1704</span><span class="NLM_x">–</span> <span class="NLM_lpage">1722</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.2174%2F092986711795471329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpslOiu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=1704-1722&issue=11&author=R.+K.+Yadavauthor=S.+P.+Guptaauthor=P.+K.+Sharmaauthor=V.+M.+Patil&title=Recent+advances+in+studies+on+hydroxamates+as+matrix+metalloproteinase+inhibitors%3A+a+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in studies on hydroxamates as matrix metalloproteinase inhibitors: a review</span></div><div class="casAuthors">Yadav, R. K.; Gupta, S. P.; Sharma, P. K.; Patil, V. M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1704-1722</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Matrix metalloproteinases (MMPs) are a large family of calcium-dependent zinc- contg. endopeptidases, which are responsible for the tissue remodeling and degrdn. of the extracellular matrix (ECM), including collagens, elastins, gelatin, matrix glycoproteins, and proteoglycan.  The inappropriate expression of these MMPs constitutes part of the pathogenic mechanism in several diseases, therefore they are subject to inhibition.  They can be inhibited by endogenous proteinase inhibitors such as 2-macroglobulin or by the family of tissue inhibitors of metalloproteinases (TIMPs), which are glycoproteins of mol. wt. 21-30 kDa, consisting of 184-194 amino acid residues.  Recently, many different classes of synthetic inhibitors have been developed in which the hydroxamic acidbased class of compds. (hydroxamates) have been most widely studied, as their hydroxamic acid group (CONHOH) enables them to act as a bidentate ligand with the zinc ion present in MMPs, leading to much stronger interaction with the receptor as compared to any other class of inhibitors.  The present review describes in detail the recent development on this class of MMP inihibitors.  Compds. like 12,17e, f, g and h, 45j, 45k, 50f, 62a, 63a, and 63b have been reported to be highly promising for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_CdMJAf2dWbVg90H21EOLACvtfcHk0liFV6dkM-a_wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpslOiu7c%253D&md5=a9a615faba9fca05433b6e2a452e2e56</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.2174%2F092986711795471329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711795471329%26sid%3Dliteratum%253Aachs%26aulast%3DYadav%26aufirst%3DR.%2BK.%26aulast%3DGupta%26aufirst%3DS.%2BP.%26aulast%3DSharma%26aufirst%3DP.%2BK.%26aulast%3DPatil%26aufirst%3DV.%2BM.%26atitle%3DRecent%2520advances%2520in%2520studies%2520on%2520hydroxamates%2520as%2520matrix%2520metalloproteinase%2520inhibitors%253A%2520a%2520review%26jtitle%3DCurr.Med.%2520Chem.%26date%3D2011%26volume%3D18%26issue%3D11%26spage%3D1704%26epage%3D1722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Lounkine, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keiser, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitebread, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikhailov, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doak, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cote, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, L.</span><span> </span><span class="NLM_article-title">Large-scale prediction and testing of drug activity on side-effect targets</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">486</span><span class="NLM_x"> (</span><span class="NLM_issue">7403</span><span class="NLM_x">) </span> <span class="NLM_fpage">361</span><span class="NLM_x">–</span> <span class="NLM_lpage">367</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fnature11159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=22722194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFyrtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=486&publication_year=2012&pages=361-367&issue=7403&author=E.+Lounkineauthor=M.+J.+Keiserauthor=S.+Whitebreadauthor=D.+Mikhailovauthor=J.+Hamonauthor=J.+L.+Jenkinsauthor=P.+Lavanauthor=E.+Weberauthor=A.+K.+Doakauthor=S.+Coteauthor=B.+K.+Shoichetauthor=L.+Urban&title=Large-scale+prediction+and+testing+of+drug+activity+on+side-effect+targets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Large-scale prediction and testing of drug activity on side-effect targets</span></div><div class="casAuthors">Lounkine, Eugen; Keiser, Michael J.; Whitebread, Steven; Mikhailov, Dmitri; Hamon, Jacques; Jenkins, Jeremy L.; Lavan, Paul; Weber, Eckhard; Doak, Allison K.; Cote, Serge; Shoichet, Brian K.; Urban, Laszlo</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">486</span>
        (<span class="NLM_cas:issue">7403</span>),
    <span class="NLM_cas:pages">361-367</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Discovering the unintended off-targets' that predict adverse drug reactions is daunting by empirical methods alone.  Drugs can act on several protein targets, some of which can be unrelated by conventional mol. metrics, and hundreds of proteins have been implicated in side effects.  Here we use a computational strategy to predict the activity of 656 marketed drugs on 73 unintended side-effect' targets.  Approx. half of the predictions were confirmed, either from proprietary databases unknown to the method or by new exptl. assays.  Affinities for these new off-targets ranged from 1 nM to 30 μM.  To explore relevance, we developed an assocn. metric to prioritize those new off-targets that explained side effects better than any known target of a given drug, creating a drug-target-adverse drug reaction network.  Among these new assocns. was the prediction that the abdominal pain side effect of the synthetic estrogen chlorotrianisene was mediated through its newly discovered inhibition of the enzyme cyclooxygenase-1.  The clin. relevance of this inhibition was borne out in whole human blood platelet aggregation assays.  This approach may have wide application to de-risking toxicol. liabilities in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5sVjfn4mgLLVg90H21EOLACvtfcHk0lhaUVKBdCrZLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFyrtb0%253D&md5=9c133b839d9527818a27a5834e4dfe11</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1038%2Fnature11159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11159%26sid%3Dliteratum%253Aachs%26aulast%3DLounkine%26aufirst%3DE.%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DWhitebread%26aufirst%3DS.%26aulast%3DMikhailov%26aufirst%3DD.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26aulast%3DLavan%26aufirst%3DP.%26aulast%3DWeber%26aufirst%3DE.%26aulast%3DDoak%26aufirst%3DA.%2BK.%26aulast%3DCote%26aufirst%3DS.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DUrban%26aufirst%3DL.%26atitle%3DLarge-scale%2520prediction%2520and%2520testing%2520of%2520drug%2520activity%2520on%2520side-effect%2520targets%26jtitle%3DNature%26date%3D2012%26volume%3D486%26issue%3D7403%26spage%3D361%26epage%3D367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Keiser, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armbruster, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernsberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span> </span><span class="NLM_article-title">Relating protein pharmacology by ligand chemistry</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">197</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fnbt1284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=17287757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOrsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=197-206&issue=2&author=M.+J.+Keiserauthor=B.+L.+Rothauthor=B.+N.+Armbrusterauthor=P.+Ernsbergerauthor=J.+J.+Irwinauthor=B.+K.+Shoichet&title=Relating+protein+pharmacology+by+ligand+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Relating protein pharmacology by ligand chemistry</span></div><div class="casAuthors">Keiser, Michael J.; Roth, Bryan L.; Armbruster, Blaine N.; Ernsberger, Paul; Irwin, John J.; Shoichet, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">197-206</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The identification of protein function based on biol. information is an area of intense research.  Here the authors consider a complementary technique that quant. groups and relates proteins based on the chem. similarity of their ligands.  The authors began with 65,000 ligands annotated into sets for hundreds of drug targets.  The similarity score between each set was calcd. using ligand topol.  A statistical model was developed to rank the significance of the resulting similarity scores, which are expressed as a min. spanning tree to map the sets together.  Although these maps are connected solely by chem. similarity, biol. sensible clusters nevertheless emerged.  Links among unexpected targets also emerged, among them that methadone, emetine and loperamide (Imodium) may antagonize muscarinic M3, α2 adrenergic and neurokinin NK2 receptors, resp.  These predictions were subsequently confirmed exptl.  Relating receptors by ligand chem. organizes biol. to reveal unexpected relationships that may be assayed using the ligands themselves.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNKEMguhmluLVg90H21EOLACvtfcHk0lhaUVKBdCrZLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOrsLo%253D&md5=1b7373d52563fca5fe1e893d85f70573</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1038%2Fnbt1284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1284%26sid%3Dliteratum%253Aachs%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DArmbruster%26aufirst%3DB.%2BN.%26aulast%3DErnsberger%26aufirst%3DP.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26atitle%3DRelating%2520protein%2520pharmacology%2520by%2520ligand%2520chemistry%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26issue%3D2%26spage%3D197%26epage%3D206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Keiser, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laggner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbas, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hufeisen, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuijer, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matos, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whaley, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glennon, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, K. L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, L. R.</span><span> </span><span class="NLM_article-title">Predicting new molecular targets for known drugs</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x"> (</span><span class="NLM_issue">7270</span><span class="NLM_x">) </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fnature08506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=19881490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlers7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=175-181&issue=7270&author=M.+J.+Keiserauthor=V.+Setolaauthor=J.+J.+Irwinauthor=C.+Laggnerauthor=A.+I.+Abbasauthor=S.+J.+Hufeisenauthor=N.+H.+Jensenauthor=M.+B.+Kuijerauthor=R.+C.+Matosauthor=T.+B.+Tranauthor=R.+Whaleyauthor=R.+A.+Glennonauthor=J.+Hertauthor=K.+L.+H.+Thomasauthor=D.+D.+Edwardsauthor=B.+K.+Shoichetauthor=L.+R.+Roth&title=Predicting+new+molecular+targets+for+known+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting new molecular targets for known drugs</span></div><div class="casAuthors">Keiser, Michael J.; Setola, Vincent; Irwin, John J.; Laggner, Christian; Abbas, Atheir I.; Hufeisen, Sandra J.; Jensen, Niels H.; Kuijer, Michael B.; Matos, Roberto C.; Tran, Thuy B.; Whaley, Ryan; Glennon, Richard A.; Hert, Jerome; Thomas, Kelan L. H.; Edwards, Douglas D.; Shoichet, Brian K.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7270</span>),
    <span class="NLM_cas:pages">175-181</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although drugs are intended to be selective, at least some bind to several physiol. targets, explaining side effects and efficacy.  Because many drug-target combinations exist, it would be useful to explore possible interactions computationally.  Here we compared 3665 US Food and Drug Administration (FDA)-approved and investigational drugs against hundreds of targets, defining each target by its ligands.  Chem. similarities between drugs and ligand sets predicted thousands of unanticipated assocns.  Thirty were tested exptl., including the antagonism of the β1 receptor by the transporter inhibitor Prozac, the inhibition of the 5-hydroxytryptamine (5-HT) transporter by the ion channel drug Vadilex, and antagonism of the histamine H4 receptor by the enzyme inhibitor Rescriptor.  Overall, 23 new drug-target assocns. were confirmed, five of which were potent (<100 nM).  The physiol. relevance of one, the drug N,N-dimethyltryptamine (DMT) on serotonergic receptors, was confirmed in a knockout mouse.  The chem. similarity approach is systematic and comprehensive, and may suggest side-effects and new indications for many drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozd-8cCXUskrVg90H21EOLACvtfcHk0lhaUVKBdCrZLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlers7vO&md5=974e65f5d5b4dabde1a463c429215546</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1038%2Fnature08506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08506%26sid%3Dliteratum%253Aachs%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DLaggner%26aufirst%3DC.%26aulast%3DAbbas%26aufirst%3DA.%2BI.%26aulast%3DHufeisen%26aufirst%3DS.%2BJ.%26aulast%3DJensen%26aufirst%3DN.%2BH.%26aulast%3DKuijer%26aufirst%3DM.%2BB.%26aulast%3DMatos%26aufirst%3DR.%2BC.%26aulast%3DTran%26aufirst%3DT.%2BB.%26aulast%3DWhaley%26aufirst%3DR.%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26aulast%3DHert%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DK.%2BL.%2BH.%26aulast%3DEdwards%26aufirst%3DD.%2BD.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DRoth%26aufirst%3DL.%2BR.%26atitle%3DPredicting%2520new%2520molecular%2520targets%2520for%2520known%2520drugs%26jtitle%3DNature%26date%3D2009%26volume%3D462%26issue%3D7270%26spage%3D175%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Bender, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheiber, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azzaoui, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitebread, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, J. L.</span><span> </span><span class="NLM_article-title">Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">861</span><span class="NLM_x">–</span> <span class="NLM_lpage">873</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=861-873&issue=6&author=A.+Benderauthor=J.+Scheiberauthor=M.+Glickauthor=J.+W.+Daviesauthor=K.+Azzaouiauthor=J.+Hamonauthor=L.+Urbanauthor=S.+Whitebreadauthor=J.+L.+Jenkins&title=Analysis+of+pharmacology+data+and+the+prediction+of+adverse+drug+reactions+and+off-target+effects+from+chemical+structure"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DA.%26aulast%3DScheiber%26aufirst%3DJ.%26aulast%3DGlick%26aufirst%3DM.%26aulast%3DDavies%26aufirst%3DJ.%2BW.%26aulast%3DAzzaoui%26aufirst%3DK.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DUrban%26aufirst%3DL.%26aulast%3DWhitebread%26aufirst%3DS.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26atitle%3DAnalysis%2520of%2520pharmacology%2520data%2520and%2520the%2520prediction%2520of%2520adverse%2520drug%2520reactions%2520and%2520off-target%2520effects%2520from%2520chemical%2520structure%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26issue%3D6%26spage%3D861%26epage%3D873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">Perez-Nueno, V. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkatraman, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mavridis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ritchie, D. W.</span><span> </span><span class="NLM_article-title">Predicting drug promiscuity using spherical harmonic surface shape-based similarity comparisons</span> <span class="citation_source-journal">Open Conference Proc. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">129</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.2174%2F2210289201102010113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVShsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=113-129&author=V.+I.+Perez-Nuenoauthor=V.+Venkatramanauthor=L.+Mavridisauthor=D.+W.+Ritchie&title=Predicting+drug+promiscuity+using+spherical+harmonic+surface+shape-based+similarity+comparisons"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting drug promiscuity using spherical harmonic surface shape-based similarity comparisons</span></div><div class="casAuthors">Perez-Nueno, Violeta I.; Venkatraman, Vishwesh; Mavridis, Lazaros; Ritchie, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Open Conference Proceedings Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113-129</span>CODEN:
                <span class="NLM_cas:coden">OCPJC2</span>;
        ISSN:<span class="NLM_cas:issn">2210-2892</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Polypharmacol. is becoming an increasingly important aspect in drug design.  Pharmaceutical companies are discovering more and more cases in which multiple drugs bind to a given target (promiscuous targets) and in which a given drug binds to more than one target (promiscuous ligands).  These phenomena are clearly of great importance when considering drug side-effects.  In the last 4 years, more than 30 drugs have been tested against more than 40 novel secondary targets based on promiscuity predictions.  Current methods for predicting promiscuity typically aim to relate protein receptors according to their primary sequences, the similarity of their ligands, and more recently, the similarity of their ligand binding pockets.  Here, we present a spherical harmonic (SH) surface shape-based approach to predict rapidly promiscuous ligands and targets by comparing sets of SH ligand and protein shapes, resp.  We present details of our approach applied to a wide range of PDB complexes comprising ligands in a selected subset of the MDL Drug Data Report (MDDR) database which are distributed over 249 diverse pharmacol. targets.  The shape similarity of each ligand to each target's ligand set is quantified and used to predict promiscuity.  We also analyze the correlation between binding pocket and ligand shapes.  We compare our promiscuity predictions with exptl. activity values extd. from the BindingDB database.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXiXDlEVxlF7Vg90H21EOLACvtfcHk0lgk0uldKqqMVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVShsro%253D&md5=e1d2b8ece7f775cff0c9c0520fe1f06f</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.2174%2F2210289201102010113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F2210289201102010113%26sid%3Dliteratum%253Aachs%26aulast%3DPerez-Nueno%26aufirst%3DV.%2BI.%26aulast%3DVenkatraman%26aufirst%3DV.%26aulast%3DMavridis%26aufirst%3DL.%26aulast%3DRitchie%26aufirst%3DD.%2BW.%26atitle%3DPredicting%2520drug%2520promiscuity%2520using%2520spherical%2520harmonic%2520surface%2520shape-based%2520similarity%2520comparisons%26jtitle%3DOpen%2520Conference%2520Proc.%2520J.%26date%3D2011%26volume%3D2%26spage%3D113%26epage%3D129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Hopkins, A. L.</span><span> </span><span class="NLM_article-title">Drug discovery: Predicting promiscuity</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x"> (</span><span class="NLM_issue">7270</span><span class="NLM_x">) </span> <span class="NLM_fpage">167</span><span class="NLM_x">–</span> <span class="NLM_lpage">168</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=167-168&issue=7270&author=A.+L.+Hopkins&title=Drug+discovery%3A+Predicting+promiscuity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DDrug%2520discovery%253A%2520Predicting%2520promiscuity%26jtitle%3DNature%26date%3D2009%26volume%3D462%26issue%3D7270%26spage%3D167%26epage%3D168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Ekins, S.</span><span> </span><span class="NLM_article-title">Predicting undesirable drug interactions with promiscuous proteins in silico</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">276</span><span class="NLM_x">–</span> <span class="NLM_lpage">285</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=276-285&issue=6&author=S.+Ekins&title=Predicting+undesirable+drug+interactions+with+promiscuous+proteins+in+silico"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26atitle%3DPredicting%2520undesirable%2520drug%2520interactions%2520with%2520promiscuous%2520proteins%2520in%2520silico%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26issue%3D6%26spage%3D276%26epage%3D285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">Klabunde, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evers, A.</span><span> </span><span class="NLM_article-title">GPCR anti-target modeling: Pharmacophore models for biogenic amine binding GPCRs to avoid GPCR-mediated side-effects</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">876</span><span class="NLM_x">–</span> <span class="NLM_lpage">889</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=876-889&issue=5&author=T.+Klabundeauthor=A.+Evers&title=GPCR+anti-target+modeling%3A+Pharmacophore+models+for+biogenic+amine+binding+GPCRs+to+avoid+GPCR-mediated+side-effects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKlabunde%26aufirst%3DT.%26aulast%3DEvers%26aufirst%3DA.%26atitle%3DGPCR%2520anti-target%2520modeling%253A%2520Pharmacophore%2520models%2520for%2520biogenic%2520amine%2520binding%2520GPCRs%2520to%2520avoid%2520GPCR-mediated%2520side-effects%26jtitle%3DChemBioChem%26date%3D2005%26volume%3D6%26issue%3D5%26spage%3D876%26epage%3D889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">Zakharov, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagunin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filimonov, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poroikov, V. V.</span><span> </span><span class="NLM_article-title">Quantitative Prediction of Anti-target Interaction Profiles for Chemical Compounds</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">2378</span><span class="NLM_x">–</span> <span class="NLM_lpage">2385</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx300247r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=2378-2385&issue=11&author=A.+V.+Zakharovauthor=A.+A.+Laguninauthor=D.+A.+Filimonovauthor=V.+V.+Poroikov&title=Quantitative+Prediction+of+Anti-target+Interaction+Profiles+for+Chemical+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Ftx300247r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx300247r%26sid%3Dliteratum%253Aachs%26aulast%3DZakharov%26aufirst%3DA.%2BV.%26aulast%3DLagunin%26aufirst%3DA.%2BA.%26aulast%3DFilimonov%26aufirst%3DD.%2BA.%26aulast%3DPoroikov%26aufirst%3DV.%2BV.%26atitle%3DQuantitative%2520Prediction%2520of%2520Anti-target%2520Interaction%2520Profiles%2520for%2520Chemical%2520Compounds%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2012%26volume%3D25%26issue%3D11%26spage%3D2378%26epage%3D2385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group">Mestres, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregori-Puigjane, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valverde, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sole, R. V.</span><span> </span><span class="NLM_article-title">Data completeness-the Achilles heel of drug-target networks</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">983</span><span class="NLM_x">–</span> <span class="NLM_lpage">984</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=983-984&issue=9&author=J.+Mestresauthor=E.+Gregori-Puigjaneauthor=S.+Valverdeauthor=R.+V.+Sole&title=Data+completeness-the+Achilles+heel+of+drug-target+networks"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMestres%26aufirst%3DJ.%26aulast%3DGregori-Puigjane%26aufirst%3DE.%26aulast%3DValverde%26aufirst%3DS.%26aulast%3DSole%26aufirst%3DR.%2BV.%26atitle%3DData%2520completeness-the%2520Achilles%2520heel%2520of%2520drug-target%2520networks%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26issue%3D9%26spage%3D983%26epage%3D984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span> </span><span class="NLM_article-title">Compound promiscuity: what can we learn from current data?</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">13/14</span><span class="NLM_x">) </span> <span class="NLM_fpage">644</span><span class="NLM_x">–</span> <span class="NLM_lpage">650</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=644-650&issue=13%2F14&author=Y.+Huauthor=J.+Bajorath&title=Compound+promiscuity%3A+what+can+we+learn+from+current+data%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DY.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DCompound%2520promiscuity%253A%2520what%2520can%2520we%2520learn%2520from%2520current%2520data%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26issue%3D13%252F14%26spage%3D644%26epage%3D650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group">Paolini, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapland, R. H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Hoorn, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, A. L.</span><span> </span><span class="NLM_article-title">Global mapping of pharmacological space</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">805</span><span class="NLM_x">–</span> <span class="NLM_lpage">815</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=805-815&issue=7&author=G.+V.+Paoliniauthor=R.+H.+B.+Shaplandauthor=W.+P.+van+Hoornauthor=J.+S.+Masonauthor=A.+L.+Hopkins&title=Global+mapping+of+pharmacological+space"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPaolini%26aufirst%3DG.%2BV.%26aulast%3DShapland%26aufirst%3DR.%2BH.%2BB.%26aulast%3Dvan%2BHoorn%26aufirst%3DW.%2BP.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DGlobal%2520mapping%2520of%2520pharmacological%2520space%26jtitle%3DNat.%2520Biotechnol.%26date%3D2006%26volume%3D24%26issue%3D7%26spage%3D805%26epage%3D815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span> </span><span class="NLM_article-title">How Promiscuous Are Pharmaceutically Relevant Compounds? A Data-Driven Assessment</span> <span class="citation_source-journal">AAPS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">104</span><span class="NLM_x">–</span> <span class="NLM_lpage">111</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=104-111&issue=1&author=Y.+Huauthor=J.+Bajorath&title=How+Promiscuous+Are+Pharmaceutically+Relevant+Compounds%3F+A+Data-Driven+Assessment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DY.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DHow%2520Promiscuous%2520Are%2520Pharmaceutically%2520Relevant%2520Compounds%253F%2520A%2520Data-Driven%2520Assessment%26jtitle%3DAAPS%2520J.%26date%3D2013%26volume%3D15%26issue%3D1%26spage%3D104%26epage%3D111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span> </span><span class="NLM_article-title">What is the Likelihood of an Active Compound to Be Promiscuous? Systematic Assessment of Compound Promiscuity on the Basis of PubChem Confirmatory Bioassay Data</span> <span class="citation_source-journal">AAPS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">808</span><span class="NLM_x">–</span> <span class="NLM_lpage">815</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=808-815&issue=3&author=Y.+Huauthor=J.+Bajorath&title=What+is+the+Likelihood+of+an+Active+Compound+to+Be+Promiscuous%3F+Systematic+Assessment+of+Compound+Promiscuity+on+the+Basis+of+PubChem+Confirmatory+Bioassay+Data"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DY.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DWhat%2520is%2520the%2520Likelihood%2520of%2520an%2520Active%2520Compound%2520to%2520Be%2520Promiscuous%253F%2520Systematic%2520Assessment%2520of%2520Compound%2520Promiscuity%2520on%2520the%2520Basis%2520of%2520PubChem%2520Confirmatory%2520Bioassay%2520Data%26jtitle%3DAAPS%2520J.%26date%3D2013%26volume%3D15%26issue%3D3%26spage%3D808%26epage%3D815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group">Overington, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Lazikani, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, A. L.</span><span> </span><span class="NLM_article-title">How many drug targets are there?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">993</span><span class="NLM_x">–</span> <span class="NLM_lpage">996</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=993-996&issue=12&author=J.+P.+Overingtonauthor=B.+Al-Lazikaniauthor=A.+L.+Hopkins&title=How+many+drug+targets+are+there%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26aulast%3DAl-Lazikani%26aufirst%3DB.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DHow%2520many%2520drug%2520targets%2520are%2520there%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26issue%3D12%26spage%3D993%26epage%3D996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group">Garcia-Serna, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestres, J.</span><span> </span><span class="NLM_article-title">Chemical probes for biological systems</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">3/4</span><span class="NLM_x">) </span> <span class="NLM_fpage">99</span><span class="NLM_x">–</span> <span class="NLM_lpage">106</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=99-106&issue=3%2F4&author=R.+Garcia-Sernaauthor=J.+Mestres&title=Chemical+probes+for+biological+systems"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Serna%26aufirst%3DR.%26aulast%3DMestres%26aufirst%3DJ.%26atitle%3DChemical%2520probes%2520for%2520biological%2520systems%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26issue%3D3%252F4%26spage%3D99%26epage%3D106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group">Ruffolo, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feuerstein, G. Z.</span><span> </span><span class="NLM_article-title">Carvedilol case history: the discovery and development of the first β-blocker for the treatment of congestive heart failure</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">85</span><span class="NLM_x">–</span> <span class="NLM_lpage">89</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=85-89&issue=1&author=R.+R.+Ruffoloauthor=G.+Z.+Feuerstein&title=Carvedilol+case+history%3A+the+discovery+and+development+of+the+first+%CE%B2-blocker+for+the+treatment+of+congestive+heart+failure"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRuffolo%26aufirst%3DR.%2BR.%26aulast%3DFeuerstein%26aufirst%3DG.%2BZ.%26atitle%3DCarvedilol%2520case%2520history%253A%2520the%2520discovery%2520and%2520development%2520of%2520the%2520first%2520%25CE%25B2-blocker%2520for%2520the%2520treatment%2520of%2520congestive%2520heart%2520failure%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2006%26volume%3D1%26issue%3D1%26spage%3D85%26epage%3D89" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group">Carreira, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteiro, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goncalves, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Providencia, L. A.</span><span> </span><span class="NLM_article-title">Carvedilol: just another beta-blocker or a powerful cardioprotector?</span> <span class="citation_source-journal">Cardiovasc. Hematol. Disorders: Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">257</span><span class="NLM_x">–</span> <span class="NLM_lpage">266</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.2174%2F187152906779010746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1SmsrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=257-266&issue=4&author=R.+S.+Carreiraauthor=P.+Monteiroauthor=L.+M.+Goncalvesauthor=L.+A.+Providencia&title=Carvedilol%3A+just+another+beta-blocker+or+a+powerful+cardioprotector%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Carvedilol: just another beta-blocker or a powerful cardioprotector?</span></div><div class="casAuthors">Carreira, R. S.; Monteiro, P.; Goncalves, L. M.; Providencia, L. A.</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular & Hematological Disorders: Drug Targets</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">257-266</span>CODEN:
                <span class="NLM_cas:coden">CHDDBU</span>;
        ISSN:<span class="NLM_cas:issn">1871-529X</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Beta-blockers have been used to treat ischemic heart disease, due to neg. chronotropic and inotropic properties, thus inducing a decrease in myocardial consumption of oxygen and nutrients, allowing a better balance between nutritional needs and the supply provided by the coronary blood flow.  Recent developments in cell biol. allowed to understand that not all beta-blockers are equal, as their intracellular mechanisms of action can be very different.  This paper focuses on Carvedilol, a non-selective beta-blocker with alfa-blocker properties, currently used to treat hypertension, heart failure, and coronary artery disease.  Effects of Carvedilol on cardiac mitochondria, their relation to its antioxidant properties, and how these can improve cardiomyocyte resistance to aggression and cardiac function are discussed.  The authors begin by depicting the effect of Carvedilol on mitochondrial parameters, namely, oxidative phosphorylation, calcium homeostasis, and energy prodn.  Then they focus on the mitochondrial permeability transition (MPT) and how the antioxidant properties of Carvedilol can be used to minimize oxidative stress, a powerful inducer of MPT.  Carvedilol is also highlighted as an enzyme modulator, focusing on its importance to prevent doxorubicin (DOX) cardiotoxicity.  The mitochondrial-related mechanism of cardioprotection involving Carvedilol is also addressed, as the authors discuss some clin. pieces of evidence showing the importance of mechanisms previously depicted.  In conclusion, based upon its mol. mechanisms of action, Carvedilol seems to be an unique beta-blocker.  These unique characteristics can help understand the pos. impact of Carvedilol on the prognosis of patients with heart disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYA7M3Es-rYLVg90H21EOLACvtfcHk0ljlR8vlfhhSqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1SmsrvK&md5=6346a3d8aff3ae3055a8bb9f437736a3</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.2174%2F187152906779010746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152906779010746%26sid%3Dliteratum%253Aachs%26aulast%3DCarreira%26aufirst%3DR.%2BS.%26aulast%3DMonteiro%26aufirst%3DP.%26aulast%3DGoncalves%26aufirst%3DL.%2BM.%26aulast%3DProvidencia%26aufirst%3DL.%2BA.%26atitle%3DCarvedilol%253A%2520just%2520another%2520beta-blocker%2520or%2520a%2520powerful%2520cardioprotector%253F%26jtitle%3DCardiovasc.%2520Hematol.%2520Disorders%253A%2520Drug%2520Targets%26date%3D2006%26volume%3D6%26issue%3D4%26spage%3D257%26epage%3D266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group">Fishback, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, R. R.</span><span> </span><span class="NLM_article-title">Sigma receptors: Potential targets for a new class of antidepressant drug</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">127</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">271</span><span class="NLM_x">–</span> <span class="NLM_lpage">282</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1016%2Fj.pharmthera.2010.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC3cXosV2htro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2010&pages=271-282&issue=3&author=J.+A.+Fishbackauthor=M.+J.+Robsonauthor=Y.-T.+Xuauthor=R.+R.+Matsumoto&title=Sigma+receptors%3A+Potential+targets+for+a+new+class+of+antidepressant+drug"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma receptors: Potential targets for a new class of antidepressant drug</span></div><div class="casAuthors">Fishback, James A.; Robson, Matthew J.; Xu, Yan-Tong; Matsumoto, Rae R.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">271-282</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Despite the widespread and devastating impact of depression on society, our current understanding of its pathogenesis is limited.  Likewise, existing treatments are inadequate, providing relief to only a subset of people suffering from depression.  The search for more effective antidepressant drugs includes the investigation of new mol. targets.  Among them, current data suggests that sigma receptors are involved in multiple processes effecting antidepressant-like actions in vivo and in vitro.  This review summarizes accumulated evidence supporting a role for sigma receptors in antidepressant effects and provides a conceptual framework for delineating their potential roles over the course of antidepressant treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLgoPQq-jsCbVg90H21EOLACvtfcHk0ljlR8vlfhhSqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXosV2htro%253D&md5=8bc10680890e356f82ccd21b7885e9db</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2010.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2010.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DFishback%26aufirst%3DJ.%2BA.%26aulast%3DRobson%26aufirst%3DM.%2BJ.%26aulast%3DXu%26aufirst%3DY.-T.%26aulast%3DMatsumoto%26aufirst%3DR.%2BR.%26atitle%3DSigma%2520receptors%253A%2520Potential%2520targets%2520for%2520a%2520new%2520class%2520of%2520antidepressant%2520drug%26jtitle%3DPharmacol.%2520Ther.%26date%3D2010%26volume%3D127%26issue%3D3%26spage%3D271%26epage%3D282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group">Cobos, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Entrena, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nieto, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cendan, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">del Pozo, E.</span><span> </span><span class="NLM_article-title">Pharmacology and therapeutic potential of sigma1 receptor ligands</span> <span class="citation_source-journal">Curr. Neuropharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">344</span><span class="NLM_x">–</span> <span class="NLM_lpage">366</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.2174%2F157015908787386113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVSqu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=344-366&issue=4&author=E.+J.+Cobosauthor=J.+M.+Entrenaauthor=F.+R.+Nietoauthor=C.+M.+Cendanauthor=E.+del+Pozo&title=Pharmacology+and+therapeutic+potential+of+sigma1+receptor+ligands"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology and therapeutic potential of sigma1 receptor ligands</span></div><div class="casAuthors">Cobos, E. J.; Entrena, J. M.; Nieto, F. R.; Cendan, C. M.; del Pozo, E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Neuropharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">344-366</span>CODEN:
                <span class="NLM_cas:coden">CNUEAN</span>;
        ISSN:<span class="NLM_cas:issn">1875-6190</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Sigma (σ) receptors, initially described as a subtype of opioid receptors, are now considered unique receptors.  Pharmacol. studies have distinguished two types of σ receptors, termed σ1 and σ2.  Of these two subtypes, the σ1 receptor has been cloned in humans and rodents, and its amino acid sequence shows no homol. with other mammalian proteins.  Several psychoactive drugs show high to moderate affinity for σ1 receptors, including the antipsychotic haloperidol, the antidepressant drugs fluvoxamine and sertraline, and the psychostimulants cocaine and methamphetamine; in addn., the anticonvulsant drug phenytoin allosterically modulates σ1 receptors.  Certain neurosteroids are known to interact with σ1 receptors, and have been proposed to be their endogenous ligands.  These receptors are located in the plasma membrane and in subcellular membranes, particularly in the endoplasmic reticulum, where they play a modulatory role in intracellular Ca2+ signaling.  Sigma1 receptors also play a modulatory role in the activity of some ion channels and in several neurotransmitter systems, mainly in glutamatergic neurotransmission.  In accordance with their widespread modulatory role, σ1 receptor ligands have been proposed to be useful in several therapeutic fields such as amnesic and cognitive deficits, depression and anxiety, schizophrenia, analgesia, and against some effects of drugs of abuse (such as cocaine and methamphetamine).  In this review we provide an overview of the present knowledge of σ1 receptors, focusing on σ1 ligand neuropharmacol. and the role of σ1 receptors in behavioral animal studies, which have contributed greatly to the potential therapeutic applications of σ1 ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTkDMnDR6uN7Vg90H21EOLACvtfcHk0ljlR8vlfhhSqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVSqu7w%253D&md5=37895c10c7ef1bb7077d0782f73d5776</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.2174%2F157015908787386113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157015908787386113%26sid%3Dliteratum%253Aachs%26aulast%3DCobos%26aufirst%3DE.%2BJ.%26aulast%3DEntrena%26aufirst%3DJ.%2BM.%26aulast%3DNieto%26aufirst%3DF.%2BR.%26aulast%3DCendan%26aufirst%3DC.%2BM.%26aulast%3Ddel%2BPozo%26aufirst%3DE.%26atitle%3DPharmacology%2520and%2520therapeutic%2520potential%2520of%2520sigma1%2520receptor%2520ligands%26jtitle%3DCurr.%2520Neuropharmacol.%26date%3D2008%26volume%3D6%26issue%3D4%26spage%3D344%26epage%3D366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group">Smith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, E. F.</span><span> </span><span class="NLM_article-title">Drug withdrawals and the lessons within</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">38</span><span class="NLM_x">–</span> <span class="NLM_lpage">45</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2006&pages=38-45&issue=1&author=D.+A.+Smithauthor=E.+F.+Schmid&title=Drug+withdrawals+and+the+lessons+within"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DSchmid%26aufirst%3DE.%2BF.%26atitle%3DDrug%2520withdrawals%2520and%2520the%2520lessons%2520within%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2006%26volume%3D9%26issue%3D1%26spage%3D38%26epage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group">Issa, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Bebber, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nidamarthy, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haas, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alldredge, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wachter, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bates, D. W.</span><span> </span><span class="NLM_article-title">Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends</span> <span class="citation_source-journal">Curr. Drug Safety</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">177</span><span class="NLM_x">–</span> <span class="NLM_lpage">185</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.2174%2F157488607781668855" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFGqtbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=177-185&issue=3&author=A.+M.+Issaauthor=K.+A.+Phillipsauthor=S.+Van+Bebberauthor=H.+G.+Nidamarthyauthor=K.+E.+Lasserauthor=J.+S.+Haasauthor=B.+K.+Alldredgeauthor=R.+M.+Wachterauthor=D.+W.+Bates&title=Drug+withdrawals+in+the+United+States%3A+a+systematic+review+of+the+evidence+and+analysis+of+trends"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends</span></div><div class="casAuthors">Issa, Amalia M.; Phillips, Kathryn A.; Van Bebber, Stephanie; Nidamarthy, Hima G.; Lasser, Karen E.; Haas, Jennifer S.; Alldredge, Brian K.; Wachter, Robert M.; Bates, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Safety</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">177-185</span>CODEN:
                <span class="NLM_cas:coden">CDSUBQ</span>;
        ISSN:<span class="NLM_cas:issn">1574-8863</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  There have been a no. of highly publicized safety-based drug withdrawals in the United States in recent years.  We conducted a review of drugs withdrawn since 1993 and examd. trends in drug withdrawals.  Our objective was to det. the frequency and characteristics of withdrawn drugs and trends since 1993, and to discuss the implications of the findings.  We found that a mean of 1.5 drugs per yr have been withdrawn since 1993, and that the no. of withdrawals has not increased over time.  However, some recent drug withdrawals have impacted large nos. of people.  The rate of withdrawals alone is not an adequate measure of the status of drug safety in the US, and there is a serious dearth of data that can be used to examine the impact of drug withdrawals.  Although drug withdrawals are an important issue to address, drug safety policies need to be developed within the broader context of drug safety and effectiveness.  A comprehensive approach will be needed to address the improvement of drug safety.  We propose improvements to the evidence base to increase drug safety and assess how new scientific evidence can be incorporated into drug safety efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoylL9cuj41PrVg90H21EOLACvtfcHk0lhmadY3olvbHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFGqtbjI&md5=33dce2a8204f3c5f6bdcc3a90d133aa3</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.2174%2F157488607781668855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157488607781668855%26sid%3Dliteratum%253Aachs%26aulast%3DIssa%26aufirst%3DA.%2BM.%26aulast%3DPhillips%26aufirst%3DK.%2BA.%26aulast%3DVan%2BBebber%26aufirst%3DS.%26aulast%3DNidamarthy%26aufirst%3DH.%2BG.%26aulast%3DLasser%26aufirst%3DK.%2BE.%26aulast%3DHaas%26aufirst%3DJ.%2BS.%26aulast%3DAlldredge%26aufirst%3DB.%2BK.%26aulast%3DWachter%26aufirst%3DR.%2BM.%26aulast%3DBates%26aufirst%3DD.%2BW.%26atitle%3DDrug%2520withdrawals%2520in%2520the%2520United%2520States%253A%2520a%2520systematic%2520review%2520of%2520the%2520evidence%2520and%2520analysis%2520of%2520trends%26jtitle%3DCurr.%2520Drug%2520Safety%26date%3D2007%26volume%3D2%26issue%3D3%26spage%3D177%26epage%3D185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group">Schuster, D.; Laggner, C.; Langer, T.</span><span> </span><span class="NLM_article-title">Why drugs fail - a study on side-effects in new chemical entities</span>. In  <span class="citation_source-book">Antitargets</span>; <span class="NLM_contrib-group">Vaz, R. J.; Klabunde, T.</span>, Eds.; <span class="NLM_publisher-name">Wiley-VCH</span>: <span class="NLM_publisher-loc">Weinheim</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=3-22&author=D.+Schuster&author=C.+Laggner&author=T.+Langerauthor=R.+J.+Vaz&author=T.+Klabunde&title=Antitargets"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DSchuster%26aufirst%3DD.%26atitle%3DWhy%2520drugs%2520fail%2520-%2520a%2520study%2520on%2520side-effects%2520in%2520new%2520chemical%2520entities%26btitle%3DAntitargets%26aulast%3DVaz%26aufirst%3DR.%2BJ.%26pub%3DWiley-VCH%26date%3D2008%26spage%3D3%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group">Kalgutkar, A. S.; Dalvie, D.; Obach, R. S.; Smith, D. A.</span> <span class="citation_source-book">Reactive Drug Metabolites</span>; <span class="NLM_publisher-name">Wiley-VCH</span>: <span class="NLM_publisher-loc">Weinheim</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=A.+S.+Kalgutkar&author=D.+Dalvie&author=R.+S.+Obach&author=D.+A.+Smith&title=Reactive+Drug+Metabolites"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26btitle%3DReactive%2520Drug%2520Metabolites%26pub%3DWiley-VCH%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group">Stepan, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aleo, M. D.</span><span> </span><span class="NLM_article-title">Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: A perspective based on the critical examination of trends in the top 200 drugs marketed in the United States</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1345</span><span class="NLM_x">–</span> <span class="NLM_lpage">1410</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx200168d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1345-1410&issue=9&author=A.+F.+Stepanauthor=D.+P.+Walkerauthor=J.+Baumanauthor=D.+A.+Priceauthor=T.+A.+Baillieauthor=A.+S.+Kalgutkarauthor=M.+D.+Aleo&title=Structural+alert%2Freactive+metabolite+concept+as+applied+in+medicinal+chemistry+to+mitigate+the+risk+of+idiosyncratic+drug+toxicity%3A+A+perspective+based+on+the+critical+examination+of+trends+in+the+top+200+drugs+marketed+in+the+United+States"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Ftx200168d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx200168d%26sid%3Dliteratum%253Aachs%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DWalker%26aufirst%3DD.%2BP.%26aulast%3DBauman%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DAleo%26aufirst%3DM.%2BD.%26atitle%3DStructural%2520alert%252Freactive%2520metabolite%2520concept%2520as%2520applied%2520in%2520medicinal%2520chemistry%2520to%2520mitigate%2520the%2520risk%2520of%2520idiosyncratic%2520drug%2520toxicity%253A%2520A%2520perspective%2520based%2520on%2520the%2520critical%2520examination%2520of%2520trends%2520in%2520the%2520top%2520200%2520drugs%2520marketed%2520in%2520the%2520United%2520States%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26issue%3D9%26spage%3D1345%26epage%3D1410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group">Muthas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasselgren, C.</span><span> </span><span class="NLM_article-title">A critical assessment of modeling safety-related drug attrition</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1058</span><span class="NLM_x">–</span> <span class="NLM_lpage">1065</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1058-1065&issue=7&author=D.+Muthasauthor=S.+Boyerauthor=C.+Hasselgren&title=A+critical+assessment+of+modeling+safety-related+drug+attrition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMuthas%26aufirst%3DD.%26aulast%3DBoyer%26aufirst%3DS.%26aulast%3DHasselgren%26aufirst%3DC.%26atitle%3DA%2520critical%2520assessment%2520of%2520modeling%2520safety-related%2520drug%2520attrition%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26issue%3D7%26spage%3D1058%26epage%3D1065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group">Kroeze, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hufeisen, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popadak, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renock, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernsberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayathilake, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">H1-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and Atypical Antipsychotic Drugs</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">519</span><span class="NLM_x">–</span> <span class="NLM_lpage">526</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=519-526&issue=3&author=W.+K.+Kroezeauthor=S.+J.+Hufeisenauthor=B.+A.+Popadakauthor=S.+M.+Renockauthor=S.+Steinbergauthor=P.+Ernsbergerauthor=K.+Jayathilakeauthor=H.+Y.+Meltzerauthor=B.+L.+Roth&title=H1-Histamine+Receptor+Affinity+Predicts+Short-Term+Weight+Gain+for+Typical+and+Atypical+Antipsychotic+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26aulast%3DHufeisen%26aufirst%3DS.%2BJ.%26aulast%3DPopadak%26aufirst%3DB.%2BA.%26aulast%3DRenock%26aufirst%3DS.%2BM.%26aulast%3DSteinberg%26aufirst%3DS.%26aulast%3DErnsberger%26aufirst%3DP.%26aulast%3DJayathilake%26aufirst%3DK.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DH1-Histamine%2520Receptor%2520Affinity%2520Predicts%2520Short-Term%2520Weight%2520Gain%2520for%2520Typical%2520and%2520Atypical%2520Antipsychotic%2520Drugs%26jtitle%3DNeuropsychopharmacology%26date%3D2003%26volume%3D28%26issue%3D3%26spage%3D519%26epage%3D526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group">Michelsen, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, J. M.</span><span> </span><span class="NLM_article-title">Cardiovascular effects of antipsychotics</span> <span class="citation_source-journal">Expert Rev. Neurotherap.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">829</span><span class="NLM_x">–</span> <span class="NLM_lpage">839</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1586%2F14737175.7.7.829" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=829-839&issue=7&author=J.+W.+Michelsenauthor=J.+M.+Meyer&title=Cardiovascular+effects+of+antipsychotics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1586%2F14737175.7.7.829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737175.7.7.829%26sid%3Dliteratum%253Aachs%26aulast%3DMichelsen%26aufirst%3DJ.%2BW.%26aulast%3DMeyer%26aufirst%3DJ.%2BM.%26atitle%3DCardiovascular%2520effects%2520of%2520antipsychotics%26jtitle%3DExpert%2520Rev.%2520Neurotherap.%26date%3D2007%26volume%3D7%26issue%3D7%26spage%3D829%26epage%3D839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group">Gray, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">Developing selectively nonselective drugs for treating CNS disorders</span> <span class="citation_source-journal">Drug Discovery Today: Therapeutic Strategies</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">413</span><span class="NLM_x">–</span> <span class="NLM_lpage">419</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=413-419&issue=4&author=J.+A.+Grayauthor=B.+L.+Roth&title=Developing+selectively+nonselective+drugs+for+treating+CNS+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DJ.%2BA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DDeveloping%2520selectively%2520nonselective%2520drugs%2520for%2520treating%2520CNS%2520disorders%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Therapeutic%2520Strategies%26date%3D2006%26volume%3D3%26issue%3D4%26spage%3D413%26epage%3D419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group">Riemer, C.</span><span> </span><span class="NLM_article-title">Antipsychotics</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed.; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">343</span><span class="NLM_x">–</span> <span class="NLM_lpage">362</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch17" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=343-362&author=C.+Riemerauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch17%26sid%3Dliteratum%253Aachs%26aulast%3DRiemer%26aufirst%3DC.%26atitle%3DAntipsychotics%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D343%26epage%3D362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group">Miyamoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyake, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarskog, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleischhacker, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieberman, J. A.</span><span> </span><span class="NLM_article-title">Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">1206</span><span class="NLM_x">–</span> <span class="NLM_lpage">1227</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fmp.2012.47" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=22584864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslahtrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=1206-1227&issue=12&author=S.+Miyamotoauthor=N.+Miyakeauthor=L.+F.+Jarskogauthor=W.+W.+Fleischhackerauthor=J.+A.+Lieberman&title=Pharmacological+treatment+of+schizophrenia%3A+a+critical+review+of+the+pharmacology+and+clinical+effects+of+current+and+future+therapeutic+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents</span></div><div class="casAuthors">Miyamoto, S.; Miyake, N.; Jarskog, L. F.; Fleischhacker, W. W.; Lieberman, J. A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1206-1227</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since the introduction of chlorpromazine and throughout the development of the new-generation antipsychotic drugs (APDs) beginning with clozapine, the D2 receptor has been the target for the development of APDs.  Pharmacol. actions to reduce neurotransmission through the D2 receptor have been the only proven therapeutic mechanism for psychoses.  A no. of novel non-D2 mechanisms of action of APDs have been explored over the past 40 years but none has definitively been proven effective.  At the same time, the effectiveness of treatments and range of outcomes for patients are far from satisfactory.  The relative success of antipsychotics in treating pos. symptoms is limited by the fact that a substantial no. of patients are refractory to current medications and by their lack of efficacy for neg. and cognitive symptoms, which often det. the level of functional impairment.  In addn., while the newer antipsychotics produce fewer motor side effects, safety and tolerability concerns about wt. gain and endocrinopathies have emerged.  Consequently, there is an urgent need for more effective and better-tolerated antipsychotic agents, and to identify new mol. targets and develop mechanistically novel compds. that can address the various symptom dimensions of schizophrenia.  In recent years, a variety of new exptl. pharmacol. approaches have emerged, including compds. acting on targets other than the dopamine D2 receptor.  However, there is still an ongoing debate as to whether drugs selective for singe mol. targets (i.e., magic bullets') or drugs selectively non-selective for several mol. targets (i.e., magic shotguns', multifunctional drugs' or intramol. polypharmacy') will lead to more effective new medications for schizophrenia.  In this context, current and future drug development strategies can be seen to fall into three categories: (1) refinement of precedented mechanisms of action to provide drugs of comparable or superior efficacy and side-effect profiles to existing APDs; (2) development of novel (and presumably non-D2) mechanism APDs; (3) development of compds. to be used as adjuncts to APDs to augment efficacy by targeting specific symptom dimensions of schizophrenia and particularly those not responsive to traditional APD treatment.  In addn., efforts are being made to det. if the products of susceptibility genes in schizophrenia, identified by genetic linkage and assocn. studies, may be viable targets for drug development.  Finally, a focus on early detection and early intervention aimed at halting or reversing progressive pathophysiol. processes in schizophrenia has gained great influence.  This has encouraged future drug development and therapeutic strategies that are neuroprotective.  This article provides an update and crit. review of the pharmacol. and clin. profiles of current APDs and drugs acting on novel targets with potential to be therapeutic agents in the future.  Mol. Psychiatry (2012) 17, 1206-1227; doi:10.1038/mp.2012.47; published online 15 May 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8qXbq8buMvLVg90H21EOLACvtfcHk0lhV5Wv0c6Jzdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslahtrbI&md5=f0240f40a88e012daaebd216efc438b1</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1038%2Fmp.2012.47&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmp.2012.47%26sid%3Dliteratum%253Aachs%26aulast%3DMiyamoto%26aufirst%3DS.%26aulast%3DMiyake%26aufirst%3DN.%26aulast%3DJarskog%26aufirst%3DL.%2BF.%26aulast%3DFleischhacker%26aufirst%3DW.%2BW.%26aulast%3DLieberman%26aufirst%3DJ.%2BA.%26atitle%3DPharmacological%2520treatment%2520of%2520schizophrenia%253A%2520a%2520critical%2520review%2520of%2520the%2520pharmacology%2520and%2520clinical%2520effects%2520of%2520current%2520and%2520future%2520therapeutic%2520agents%26jtitle%3DMol.%2520Psychiatry%26date%3D2012%26volume%3D17%26issue%3D12%26spage%3D1206%26epage%3D1227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group">Emsley, R.</span><span> </span><span class="NLM_article-title">Drugs in development for the treatment of schizophrenia</span> <span class="citation_source-journal">Expert Opin. Investig. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">1103</span><span class="NLM_x">–</span> <span class="NLM_lpage">1118</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=1103-1118&issue=8&author=R.+Emsley&title=Drugs+in+development+for+the+treatment+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DR.%26atitle%3DDrugs%2520in%2520development%2520for%2520the%2520treatment%2520of%2520schizophrenia%26jtitle%3DExpert%2520Opin.%2520Investig.%2520Drugs%26date%3D2009%26volume%3D18%26issue%3D8%26spage%3D1103%26epage%3D1118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group">Yadav, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbas, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrell, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sciaky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroeze, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piel, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keiser, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deneris, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingrich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">The Presynaptic Component of the Serotonergic System is Required for Clozapine’s Efficacy</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">638</span><span class="NLM_x">–</span> <span class="NLM_lpage">651</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2011&pages=638-651&issue=3&author=P.+N.+Yadavauthor=A.+I.+Abbasauthor=M.+S.+Farrellauthor=V.+Setolaauthor=N.+Sciakyauthor=X.-P.+Huangauthor=W.+K.+Kroezeauthor=L.+K.+Crawfordauthor=D.+A.+Pielauthor=M.+J.+Keiserauthor=J.+J.+Irwinauthor=B.+K.+Shoichetauthor=E.+S.+Denerisauthor=J.+Gingrichauthor=S.+G.+Beckauthor=B.+L.+Roth&title=The+Presynaptic+Component+of+the+Serotonergic+System+is+Required+for+Clozapine%E2%80%99s+Efficacy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYadav%26aufirst%3DP.%2BN.%26aulast%3DAbbas%26aufirst%3DA.%2BI.%26aulast%3DFarrell%26aufirst%3DM.%2BS.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DSciaky%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26aulast%3DCrawford%26aufirst%3DL.%2BK.%26aulast%3DPiel%26aufirst%3DD.%2BA.%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DDeneris%26aufirst%3DE.%2BS.%26aulast%3DGingrich%26aufirst%3DJ.%26aulast%3DBeck%26aufirst%3DS.%2BG.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DThe%2520Presynaptic%2520Component%2520of%2520the%2520Serotonergic%2520System%2520is%2520Required%2520for%2520Clozapine%25E2%2580%2599s%2520Efficacy%26jtitle%3DNeuropsychopharmacology%26date%3D2011%26volume%3D36%26issue%3D3%26spage%3D638%26epage%3D651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group">Boran, A. D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyengar, R.</span><span> </span><span class="NLM_article-title">Systems approaches to polypharmacology and drug discovery</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Devel.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">297</span><span class="NLM_x">–</span> <span class="NLM_lpage">309</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=20443163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFCqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=297-309&issue=3&author=A.+D.+W.+Boranauthor=R.+Iyengar&title=Systems+approaches+to+polypharmacology+and+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Systems approaches to polypharmacology and drug discovery</span></div><div class="casAuthors">Boran, Aislyn D. W.; Iyengar, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">297-309</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">2040-3437</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Systems biol. uses exptl. and computational approaches to characterize large sample populations systematically, process large datasets, examine and analyze regulatory networks, and model reactions to det. how components are joined to form functional systems.  Systems biol. technologies, data and knowledge are particularly useful in understanding disease processes and drug actions.  An important area of integration between systems biol. and drug discovery is the concept of polypharmacol.: the treatment of diseases by modulating more than one target.  Polypharmacol. for complex diseases is likely to involve multiple drugs acting on distinct targets that are part of a network regulating physiol. responses.  This review discusses the current state of the systems-level understanding of diseases and both the therapeutic and adverse mechanisms of drug actions.  Drug-target networks can be used to identify multiple targets and to det. suitable combinations of drug targets or drugs.  Thus, the discovery of new drug therapies for complex diseases may be greatly aided by systems biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7lrjWtBIXI7Vg90H21EOLACvtfcHk0lhV5Wv0c6Jzdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFCqtrk%253D&md5=b26a44ecd76a605816e08985ff8a576f</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoran%26aufirst%3DA.%2BD.%2BW.%26aulast%3DIyengar%26aufirst%3DR.%26atitle%3DSystems%2520approaches%2520to%2520polypharmacology%2520and%2520drug%2520discovery%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Devel.%26date%3D2010%26volume%3D13%26issue%3D3%26spage%3D297%26epage%3D309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group">Barabasi, A.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oltvai, Z. N.</span><span> </span><span class="NLM_article-title">Network biology: Understanding the cell’s functional organization</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">427</span><span class="NLM_x"> (</span><span class="NLM_issue">6977</span><span class="NLM_x">) </span> <span class="NLM_fpage">839</span><span class="NLM_x">–</span> <span class="NLM_lpage">843</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=427&publication_year=2004&pages=839-843&issue=6977&author=A.-L.+Barabasiauthor=Z.+N.+Oltvai&title=Network+biology%3A+Understanding+the+cell%E2%80%99s+functional+organization"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBarabasi%26aufirst%3DA.-L.%26aulast%3DOltvai%26aufirst%3DZ.%2BN.%26atitle%3DNetwork%2520biology%253A%2520Understanding%2520the%2520cell%25E2%2580%2599s%2520functional%2520organization%26jtitle%3DNature%26date%3D2004%26volume%3D427%26issue%3D6977%26spage%3D839%26epage%3D843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group">Csermely, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agoston, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pongor, S.</span><span> </span><span class="NLM_article-title">The efficiency of multi-target drugs: the network approach might help drug design</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">178</span><span class="NLM_x">–</span> <span class="NLM_lpage">182</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2005&pages=178-182&issue=4&author=P.+Csermelyauthor=V.+Agostonauthor=S.+Pongor&title=The+efficiency+of+multi-target+drugs%3A+the+network+approach+might+help+drug+design"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCsermely%26aufirst%3DP.%26aulast%3DAgoston%26aufirst%3DV.%26aulast%3DPongor%26aufirst%3DS.%26atitle%3DThe%2520efficiency%2520of%2520multi-target%2520drugs%253A%2520the%2520network%2520approach%2520might%2520help%2520drug%2520design%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2005%26volume%3D26%26issue%3D4%26spage%3D178%26epage%3D182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group">Korcsmaros, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szalay, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovacs, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Csermely, P.</span><span> </span><span class="NLM_article-title">How to design multi-target drugs: target search options in cellular networks</span> <span class="citation_source-journal">Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">799</span><span class="NLM_x">–</span> <span class="NLM_lpage">808</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=799-808&issue=6&author=T.+Korcsmarosauthor=M.+S.+Szalayauthor=C.+Bodeauthor=I.+A.+Kovacsauthor=P.+Csermely&title=How+to+design+multi-target+drugs%3A+target+search+options+in+cellular+networks"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKorcsmaros%26aufirst%3DT.%26aulast%3DSzalay%26aufirst%3DM.%2BS.%26aulast%3DBode%26aufirst%3DC.%26aulast%3DKovacs%26aufirst%3DI.%2BA.%26aulast%3DCsermely%26aufirst%3DP.%26atitle%3DHow%2520to%2520design%2520multi-target%2520drugs%253A%2520target%2520search%2520options%2520in%2520cellular%2520networks%26jtitle%3DDrug%2520Discovery%26date%3D2007%26volume%3D2%26issue%3D6%26spage%3D799%26epage%3D808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group">Azmi, A. S.</span><span> </span><span class="NLM_article-title">Network pharmacology for cancer drug discovery: are we there yet?</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">939</span><span class="NLM_x">–</span> <span class="NLM_lpage">941</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.4155%2Ffmc.12.44" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvVOrsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=939-941&issue=8&author=A.+S.+Azmi&title=Network+pharmacology+for+cancer+drug+discovery%3A+are+we+there+yet%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Network pharmacology for cancer drug discovery: are we there yet?</span></div><div class="casAuthors">Azmi, Asfar S.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">939-941</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The emergence of network biol. has improved the knowledge of multi-pathway interactions in cancer and helped to make sense of drug-response signature datasets that collectively decode the complex mechanisms of drug action.  Network pharmacol. showed that promiscuity often engages a synergistic combination of appropriate high-value targets in cancer cells to develop treatment success.  In general, it holds promise to revolutionize the approach towards next-generation cancer drug design and development.  Thus, it certainly has the potential to modify the view of drug design and understanding mechanisms of action and, if used correctly, is predicted to significantly de-risk cancer drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-nEGlIwnic7Vg90H21EOLACvtfcHk0lgklKbwAzHifw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvVOrsrc%253D&md5=b545e162e850a4ada587a447bf9b82b6</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.44&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.44%26sid%3Dliteratum%253Aachs%26aulast%3DAzmi%26aufirst%3DA.%2BS.%26atitle%3DNetwork%2520pharmacology%2520for%2520cancer%2520drug%2520discovery%253A%2520are%2520we%2520there%2520yet%253F%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2012%26volume%3D4%26issue%3D8%26spage%3D939%26epage%3D941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Targeting the cancer kinome through polypharmacology</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fnrc2787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=20094047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=130-137&issue=2&author=Z.+A.+Knightauthor=H.+Linauthor=K.+M.+Shokat&title=Targeting+the+cancer+kinome+through+polypharmacology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cancer kinome through polypharmacology</span></div><div class="casAuthors">Knight, Zachary A.; Lin, Henry; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-137</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Kinase inhibitors are the largest class of new cancer drugs.  However, it is already apparent that most tumors can escape from the inhibition of any single kinase.  If it is necessary to inhibit multiple kinases, how do we choose which ones.  In this Opinion article, we discuss some of the strategies that are currently being used to identify new therapeutic combinations of kinase targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkDv2FeeH58rVg90H21EOLACvtfcHk0lgklKbwAzHifw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D&md5=9aaa314e54b43889e147a9f11ac77072</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1038%2Fnrc2787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2787%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DTargeting%2520the%2520cancer%2520kinome%2520through%2520polypharmacology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26issue%3D2%26spage%3D130%26epage%3D137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group">Faivre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sargent, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raymond, E.</span><span> </span><span class="NLM_article-title">Molecular basis for sunitinib efficacy and future clinical development</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">734</span><span class="NLM_x">–</span> <span class="NLM_lpage">745</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=734-745&issue=9&author=S.+Faivreauthor=G.+Demetriauthor=W.+Sargentauthor=E.+Raymond&title=Molecular+basis+for+sunitinib+efficacy+and+future+clinical+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFaivre%26aufirst%3DS.%26aulast%3DDemetri%26aufirst%3DG.%26aulast%3DSargent%26aufirst%3DW.%26aulast%3DRaymond%26aufirst%3DE.%26atitle%3DMolecular%2520basis%2520for%2520sunitinib%2520efficacy%2520and%2520future%2520clinical%2520development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26issue%3D9%26spage%3D734%26epage%3D745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group">Hampton, T.</span><span> </span><span class="NLM_article-title">“Promiscuous” anticancer drugs that hit multiple targets may thwart resistance</span> <span class="citation_source-journal">JAMA</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">292</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">419</span><span class="NLM_x">–</span> <span class="NLM_lpage">422</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=2004&pages=419-422&issue=4&author=T.+Hampton&title=%E2%80%9CPromiscuous%E2%80%9D+anticancer+drugs+that+hit+multiple+targets+may+thwart+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHampton%26aufirst%3DT.%26atitle%3D%25E2%2580%259CPromiscuous%25E2%2580%259D%2520anticancer%2520drugs%2520that%2520hit%2520multiple%2520targets%2520may%2520thwart%2520resistance%26jtitle%3DJAMA%26date%3D2004%26volume%3D292%26issue%3D4%26spage%3D419%26epage%3D422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group">Silver, L. L.</span><span> </span><span class="NLM_article-title">Polypharmacology as an Emerging Trend in Antibacterial Discovery</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed.; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">167</span><span class="NLM_x">–</span> <span class="NLM_lpage">202</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=167-202&author=L.+L.+Silverauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch9%26sid%3Dliteratum%253Aachs%26aulast%3DSilver%26aufirst%3DL.%2BL.%26atitle%3DPolypharmacology%2520as%2520an%2520Emerging%2520Trend%2520in%2520Antibacterial%2520Discovery%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D167%26epage%3D202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group">East, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silver, L. L.</span><span> </span><span class="NLM_article-title">Multitarget ligands in antibacterial research: progress and opportunities</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">143</span><span class="NLM_x">–</span> <span class="NLM_lpage">156</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=143-156&issue=2&author=S.+P.+Eastauthor=L.+L.+Silver&title=Multitarget+ligands+in+antibacterial+research%3A+progress+and+opportunities"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEast%26aufirst%3DS.%2BP.%26aulast%3DSilver%26aufirst%3DL.%2BL.%26atitle%3DMultitarget%2520ligands%2520in%2520antibacterial%2520research%253A%2520progress%2520and%2520opportunities%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2013%26volume%3D8%26issue%3D2%26spage%3D143%26epage%3D156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group">Broetz-Oesterhelt, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunner, N. A.</span><span> </span><span class="NLM_article-title">How many modes of action should an antibiotic have?</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">564</span><span class="NLM_x">–</span> <span class="NLM_lpage">573</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1016%2Fj.coph.2008.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlaqsLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=564-573&issue=5&author=H.+Broetz-Oesterheltauthor=N.+A.+Brunner&title=How+many+modes+of+action+should+an+antibiotic+have%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">How many modes of action should an antibiotic have?</span></div><div class="casAuthors">Broetz-Oesterhelt, Heike; Brunner, Nina A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">564-573</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  All antibiotics that have been successfully employed for decades as monotherapeutics in the treatment of bacterial infections rely on mechanisms of bacterial growth inhibition which are by far more complex than inhibition of a single enzyme.  Such successful antibiotics have in common that they address several targets in parallel and/or that their targets are encoded by multiple genes.  Such multiplicity of targets and of target genes has the advantage that the emergence of spontaneous target-related resistance is a comparatively slow process.  Recently registered antibiotics and novel antibiotics in development are discussed in the light of this promising concept of antibacterial polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp12RSKM_6SirVg90H21EOLACvtfcHk0lhrXkErYNs3Tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlaqsLvP&md5=9bfd80d8766beb8f6212be6bf3407c2c</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2008.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2008.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DBroetz-Oesterhelt%26aufirst%3DH.%26aulast%3DBrunner%26aufirst%3DN.%2BA.%26atitle%3DHow%2520many%2520modes%2520of%2520action%2520should%2520an%2520antibiotic%2520have%253F%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2008%26volume%3D8%26issue%3D5%26spage%3D564%26epage%3D573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group">Bolognesi, M. L.</span><span> </span><span class="NLM_article-title">Multi-target-directed ligands as innovative tools to combat trypanosomatid diseases</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">22</span><span class="NLM_x">) </span> <span class="NLM_fpage">2824</span><span class="NLM_x">–</span> <span class="NLM_lpage">2833</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.2174%2F156802611798184391" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ehtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=2824-2833&issue=22&author=M.+L.+Bolognesi&title=Multi-target-directed+ligands+as+innovative+tools+to+combat+trypanosomatid+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target-directed ligands as innovative tools to combat trypanosomatid diseases</span></div><div class="casAuthors">Bolognesi, Maria Laura</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2824-2833</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Of the tropical diseases, trypanosomiases and leishmaniases should most concern the pharmaceutical community because of their high prevalence in developing countries and the lack of effective drug treatments.  Despite this, they have not historically received much attention in terms of investment and research effort, nor do they now.  In very recent years, thanks to the involvement of several nonprofit organizations, the chemotherapeutic options have expanded with the introduction of the first combination therapy.  The optimal efficacy and safety of nifurtimox-eflornithine combination against second-stage human African trypanosomiasis is an encouraging first step towards simpler and more affordable therapies.  Along the same line, I propose that single chem. entities able to modulate more than one target may prove more efficacious and tolerable than the available arsenal of drugs.  Herein, I discuss the pros and cons of this approach, together with examples taken from the recent literature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1kcKEh6X7xrVg90H21EOLACvtfcHk0lhrXkErYNs3Tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ehtbg%253D&md5=8c6ae7cf628d2b7888a7e9fb833b3a62</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.2174%2F156802611798184391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611798184391%26sid%3Dliteratum%253Aachs%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DMulti-target-directed%2520ligands%2520as%2520innovative%2520tools%2520to%2520combat%2520trypanosomatid%2520diseases%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26issue%3D22%26spage%3D2824%26epage%3D2833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group">Espinoza-Fonseca, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trujillo-Ferrara, J. G.</span><span> </span><span class="NLM_article-title">Toward a rational design of selective multi-trypanosomatid inhibitors: A computational docking study</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">24</span><span class="NLM_x">) </span> <span class="NLM_fpage">6288</span><span class="NLM_x">–</span> <span class="NLM_lpage">6292</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=6288-6292&issue=24&author=L.+M.+Espinoza-Fonsecaauthor=J.+G.+Trujillo-Ferrara&title=Toward+a+rational+design+of+selective+multi-trypanosomatid+inhibitors%3A+A+computational+docking+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEspinoza-Fonseca%26aufirst%3DL.%2BM.%26aulast%3DTrujillo-Ferrara%26aufirst%3DJ.%2BG.%26atitle%3DToward%2520a%2520rational%2520design%2520of%2520selective%2520multi-trypanosomatid%2520inhibitors%253A%2520A%2520computational%2520docking%2520study%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26issue%3D24%26spage%3D6288%26epage%3D6292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolognesi, M. L.</span><span> </span><span class="NLM_article-title">Neglected Tropical Diseases: Multi-Target-Directed Ligands in the Search for Novel Lead Candidates against Trypanosoma and Leishmania</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">7339</span><span class="NLM_x">–</span> <span class="NLM_lpage">7359</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9004835" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7339-7359&author=A.+Cavalliauthor=M.+L.+Bolognesi&title=Neglected+Tropical+Diseases%3A+Multi-Target-Directed+Ligands+in+the+Search+for+Novel+Lead+Candidates+against+Trypanosoma+and+Leishmania"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1021%2Fjm9004835&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9004835%26sid%3Dliteratum%253Aachs%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DNeglected%2520Tropical%2520Diseases%253A%2520Multi-Target-Directed%2520Ligands%2520in%2520the%2520Search%2520for%2520Novel%2520Lead%2520Candidates%2520against%2520Trypanosoma%2520and%2520Leishmania%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7339%26epage%3D7359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group">Aminake, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahajan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hans, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesner, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Kock, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grobler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirschner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rethwilm, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pradel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chibale, K.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of hybrid drugs for a potential HIV/AIDS-malaria combination therapy</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">5277</span><span class="NLM_x">–</span> <span class="NLM_lpage">5289</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=5277-5289&issue=17&author=M.+N.+Aminakeauthor=A.+Mahajanauthor=V.+Kumarauthor=R.+Hansauthor=L.+Wiesnerauthor=D.+Taylorauthor=C.+de+Kockauthor=A.+Groblerauthor=P.+J.+Smithauthor=M.+Kirschnerauthor=A.+Rethwilmauthor=G.+Pradelauthor=K.+Chibale&title=Synthesis+and+evaluation+of+hybrid+drugs+for+a+potential+HIV%2FAIDS-malaria+combination+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAminake%26aufirst%3DM.%2BN.%26aulast%3DMahajan%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DHans%26aufirst%3DR.%26aulast%3DWiesner%26aufirst%3DL.%26aulast%3DTaylor%26aufirst%3DD.%26aulast%3Dde%2BKock%26aufirst%3DC.%26aulast%3DGrobler%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DP.%2BJ.%26aulast%3DKirschner%26aufirst%3DM.%26aulast%3DRethwilm%26aufirst%3DA.%26aulast%3DPradel%26aufirst%3DG.%26aulast%3DChibale%26aufirst%3DK.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520hybrid%2520drugs%2520for%2520a%2520potential%2520HIV%252FAIDS-malaria%2520combination%2520therapy%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26issue%3D17%26spage%3D5277%26epage%3D5289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group">Millan, Mark, J.</span><span> </span><span class="NLM_article-title">Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">135</span><span class="NLM_x">–</span> <span class="NLM_lpage">370</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1016%2Fj.pharmthera.2005.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtFCqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2006&pages=135-370&issue=2&author=J.+Millan%2C+Mark&title=Multi-target+strategies+for+the+improved+treatment+of+depressive+states%3A+Conceptual+foundations+and+neuronal+substrates%2C+drug+discovery+and+therapeutic+application"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application</span></div><div class="casAuthors">Millan, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">135-370</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Major depression is a debilitating and recurrent disorder with a substantial lifetime risk and a high social cost.  Depressed patients generally display co-morbid symptoms, and depression frequently accompanies other serious disorders.  Currently available drugs display limited efficacy and a pronounced delay to onset of action, and all provoke distressing side effects.  Cloning of the human genome has fuelled expectations that symptomatic treatment may soon become more rapid and effective, and that depressive states may ultimately be "prevented" or "cured".  In pursuing these objectives, in particular for genome-derived, non-monoaminergic targets, "specificity" of drug actions is often emphasized.  That is, priority is afforded to agents that interact exclusively with a single site hypothesized as critically involved in the pathogenesis and/or control of depression.  Certain highly selective drugs may prove effective, and they remain indispensable in the exptl. (and clin.) evaluation of the significance of novel mechanisms.  However, by analogy to other multifactorial disorders, "multi-target" agents may be better adapted to the improved treatment of depressive states.  Support for this contention is garnered from a broad palette of observations, ranging from mechanisms of action of adjunctive drug combinations and electroconvulsive therapy to "network theory" anal. of the etiol. and management of depressive states.  The review also outlines opportunities to be exploited, and challenges to be addressed, in the discovery and characterization of drugs recognizing multiple targets.  Finally, a diversity of multi-target strategies is proposed for the more efficacious and rapid control of core and co-morbid symptoms of depression, together with improved tolerance relative to currently available agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxf3nCB4E-O7Vg90H21EOLACvtfcHk0lhrXkErYNs3Tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtFCqtr4%253D&md5=dbca7f1b7bba52c69d9c6b95eea01d69</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2005.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2005.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DMillan%252C%2BMark%26aufirst%3DJ.%26atitle%3DMulti-target%2520strategies%2520for%2520the%2520improved%2520treatment%2520of%2520depressive%2520states%253A%2520Conceptual%2520foundations%2520and%2520neuronal%2520substrates%252C%2520drug%2520discovery%2520and%2520therapeutic%2520application%26jtitle%3DPharmacol.%2520Ther.%26date%3D2006%26volume%3D110%26issue%3D2%26spage%3D135%26epage%3D370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group">Millan, Mark, J.</span><span> </span><span class="NLM_article-title">Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs</span> <span class="citation_source-journal">Neurotherapeutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">53</span><span class="NLM_x">–</span> <span class="NLM_lpage">77</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=53-77&issue=1&author=J.+Millan%2C+Mark&title=Dual-+and+triple-acting+agents+for+treating+core+and+co-morbid+symptoms+of+major+depression%3A+novel+concepts%2C+new+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMillan%252C%2BMark%26aufirst%3DJ.%26atitle%3DDual-%2520and%2520triple-acting%2520agents%2520for%2520treating%2520core%2520and%2520co-morbid%2520symptoms%2520of%2520major%2520depression%253A%2520novel%2520concepts%252C%2520new%2520drugs%26jtitle%3DNeurotherapeutics%26date%3D2009%26volume%3D6%26issue%3D1%26spage%3D53%26epage%3D77" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group">Connolly, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thase, M. E.</span><span> </span><span class="NLM_article-title">Emerging drugs for major depressive disorder</span> <span class="citation_source-journal">Expert Opin. Emerging Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">105</span><span class="NLM_x">–</span> <span class="NLM_lpage">126</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1517%2F14728214.2012.660146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC38XksVOktrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=105-126&issue=1&author=K.+R.+Connollyauthor=M.+E.+Thase&title=Emerging+drugs+for+major+depressive+disorder"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging drugs for major depressive disorder</span></div><div class="casAuthors">Connolly, Kevin Ryan; Thase, Michael E.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Emerging Drugs</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">105-126</span>CODEN:
                <span class="NLM_cas:coden">EOEDA3</span>;
        ISSN:<span class="NLM_cas:issn">1472-8214</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Major depressive disorder (MDD) remains a major public health concern, and one that continues to suffer an incompletely-met need for effective and acceptable treatments. The development of antidepressants, to date,has focused primarily on increasing monoamine neurotransmission with increasing efficacy while minimizing adverse effects. Medications currently recommended as 'first-line' are far more tolerable than the older medications they replaced, but as many as 70% of patients continue to suffer significant depressive symptoms after treatment with one of these agents, and as many as 50% will discontinue a trial due to issues with acceptability. This review will summarize antidepressants that have recently entered the market as well as those still in development to help characterize the current state of antidepressant development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplUBvx97MRkrVg90H21EOLACvtfcHk0lgiB6cUUfEoAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksVOktrs%253D&md5=deb3b11ec5798d8d979542ef01b1d5db</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1517%2F14728214.2012.660146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728214.2012.660146%26sid%3Dliteratum%253Aachs%26aulast%3DConnolly%26aufirst%3DK.%2BR.%26aulast%3DThase%26aufirst%3DM.%2BE.%26atitle%3DEmerging%2520drugs%2520for%2520major%2520depressive%2520disorder%26jtitle%3DExpert%2520Opin.%2520Emerging%2520Drugs%26date%3D2012%26volume%3D17%26issue%3D1%26spage%3D105%26epage%3D126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group">Shahid, M.</span><span> </span><span class="NLM_article-title">Clinical Need and Rationale for Multi-Target Drugs in Psychiatry</span>. In  <span class="citation_source-book">Designing Multi-Target Drugs</span>; <span class="NLM_contrib-group">Morphy, J. R.; Harris, C. J.</span>, Eds.; <span class="NLM_publisher-name">RSC Publishing</span>: <span class="NLM_publisher-loc">Cambridge</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">14</span><span class="NLM_x">–</span> <span class="NLM_lpage">31</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1039%2F9781849734912-00014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=14-31&author=M.+Shahidauthor=J.+R.+Morphy&author=C.+J.+Harris&title=Designing+Multi-Target+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1039%2F9781849734912-00014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1039%252F9781849734912-00014%26sid%3Dliteratum%253Aachs%26aulast%3DShahid%26aufirst%3DM.%26atitle%3DClinical%2520Need%2520and%2520Rationale%2520for%2520Multi-Target%2520Drugs%2520in%2520Psychiatry%26btitle%3DDesigning%2520Multi-Target%2520Drugs%26aulast%3DMorphy%26aufirst%3DJ.%2BR.%26pub%3DRSC%2520Publishing%26date%3D2012%26spage%3D14%26epage%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelton, R. C.</span><span> </span><span class="NLM_article-title">Review of Pharmacological Treatment in Mood Disorders and Future Directions for Drug Development</span> <span class="citation_source-journal">Neuropsychopharmacology.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">77</span><span class="NLM_x">–</span> <span class="NLM_lpage">101</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2012&pages=77-101&issue=1&author=X.+Liauthor=M.+A.+Fryeauthor=R.+C.+Shelton&title=Review+of+Pharmacological+Treatment+in+Mood+Disorders+and+Future+Directions+for+Drug+Development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DFrye%26aufirst%3DM.%2BA.%26aulast%3DShelton%26aufirst%3DR.%2BC.%26atitle%3DReview%2520of%2520Pharmacological%2520Treatment%2520in%2520Mood%2520Disorders%2520and%2520Future%2520Directions%2520for%2520Drug%2520Development%26jtitle%3DNeuropsychopharmacology.%26date%3D2012%26volume%3D37%26issue%3D1%26spage%3D77%26epage%3D101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group">Cavalli, A.; Bolognesi, M. L.</span><span> </span><span class="NLM_article-title">Multitargeted Drugs for Treatment of Alzheimer’s Disease</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed.; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">458</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch22" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=441-458&author=A.+Cavalli&author=M.+L.+Bolognesiauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch22%26sid%3Dliteratum%253Aachs%26aulast%3DCavalli%26aufirst%3DA.%26atitle%3DMultitargeted%2520Drugs%2520for%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D441%26epage%3D458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group">Van der Schyf, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geldenhuys, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amit, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avramovich, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridkin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinreb, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Am, O. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sagi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youdim, M. B. H.</span><span> </span><span class="NLM_article-title">Novel multifunctional anti-alzheimer drugs with various CNS neurotransmitter targets and neuroprotective moieties</span> <span class="citation_source-journal">Curr. Alzheimer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">522</span><span class="NLM_x">–</span> <span class="NLM_lpage">536</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.2174%2F156720507783018226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisVGruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&pages=522-536&issue=5&author=C.+J.+Van+der+Schyfauthor=S.+Mandelauthor=W.+J.+Geldenhuysauthor=T.+Amitauthor=Y.+Avramovichauthor=H.+Zhengauthor=M.+Fridkinauthor=S.+Galauthor=O.+Weinrebauthor=O.+B.+Amauthor=Y.+Sagiauthor=M.+B.+H.+Youdim&title=Novel+multifunctional+anti-alzheimer+drugs+with+various+CNS+neurotransmitter+targets+and+neuroprotective+moieties"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Novel multifunctional anti-alzheimer drugs with various CNS neurotransmitter targets and neuroprotective moieties</span></div><div class="casAuthors">Van der Schyf, Cornelis J.; Mandel, Silvia; Geldenhuys, Werner J.; Amit, Tamar; Avramovich, Yael; Zheng, Hailin; Fridkin, Mati; Gal, Shunit; Weinreb, Orly; Am, Orit Bar; Sagi, Yotam; Youdim, Moussa B. H.</div><div class="citationInfo"><span class="NLM_cas:title">Current Alzheimer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">522-536</span>CODEN:
                <span class="NLM_cas:coden">CARUBY</span>;
        ISSN:<span class="NLM_cas:issn">1567-2050</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Traditionally, drug design programs are focused on optimizing the specificity of lead compds. against a carefully selected drug target.  Disappointingly, this approach to discover a "magic bullet" drug has not met with the expected success for CNS disorders.  Transcriptomics and proteomic profiling of neurodegenerative diseases have indicated that they are poly-etiol. in origin and that the processes leading to neuronal death are multifactorial.  An emerging concept is the design of drug ligands that modulate multiple drug targets identified for a particular disease.  In this review we explore some examples of multifunctional drugs which may be useful in the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFYARzHINRR7Vg90H21EOLACvtfcHk0lgiB6cUUfEoAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisVGruw%253D%253D&md5=d4e893f60f8657b7f762147366dbdedb</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.2174%2F156720507783018226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156720507783018226%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bder%2BSchyf%26aufirst%3DC.%2BJ.%26aulast%3DMandel%26aufirst%3DS.%26aulast%3DGeldenhuys%26aufirst%3DW.%2BJ.%26aulast%3DAmit%26aufirst%3DT.%26aulast%3DAvramovich%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DH.%26aulast%3DFridkin%26aufirst%3DM.%26aulast%3DGal%26aufirst%3DS.%26aulast%3DWeinreb%26aufirst%3DO.%26aulast%3DAm%26aufirst%3DO.%2BB.%26aulast%3DSagi%26aufirst%3DY.%26aulast%3DYoudim%26aufirst%3DM.%2BB.%2BH.%26atitle%3DNovel%2520multifunctional%2520anti-alzheimer%2520drugs%2520with%2520various%2520CNS%2520neurotransmitter%2520targets%2520and%2520neuroprotective%2520moieties%26jtitle%3DCurr.%2520Alzheimer%2520Res.%26date%3D2007%26volume%3D4%26issue%3D5%26spage%3D522%26epage%3D536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolognesi, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minarini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tumiatti, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Recanatini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melchiorre, C.</span><span> </span><span class="NLM_article-title">Multi-target-Directed Ligands to Combat Neurodegenerative Diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">347</span><span class="NLM_x">–</span> <span class="NLM_lpage">372</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm7009364" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsl2qsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=347-372&issue=3&author=A.+Cavalliauthor=M.+L.+Bolognesiauthor=A.+Minariniauthor=M.+Rosiniauthor=V.+Tumiattiauthor=M.+Recanatiniauthor=C.+Melchiorre&title=Multi-target-Directed+Ligands+to+Combat+Neurodegenerative+Diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target-Directed Ligands to Combat Neurodegenerative Diseases</span></div><div class="casAuthors">Cavalli, Andrea; Bolognesi, Maria Laura; Minarini, Anna; Rosini, Michela; Tumiatti, Vincenzo; Recanatini, Maurizio; Melchiorre, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">347-372</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The authors review the investigations reported in the past decade that illustrate the ability of medicinal chemists to design multi-target-directed ligands (MTDLs) to confront neurodegenerative diseases.  The authors briefly illustrate the multifactorial nature of these diseases before discussing the possible development of MTDLs in light of the known mol. bases of the main neurodegenerative pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYY0I0UHEir7Vg90H21EOLACvtfcHk0ljqcEjW0s7Prg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsl2qsbk%253D&md5=c682235151489316d043cf97f78e56f3</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1021%2Fjm7009364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7009364%26sid%3Dliteratum%253Aachs%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DMinarini%26aufirst%3DA.%26aulast%3DRosini%26aufirst%3DM.%26aulast%3DTumiatti%26aufirst%3DV.%26aulast%3DRecanatini%26aufirst%3DM.%26aulast%3DMelchiorre%26aufirst%3DC.%26atitle%3DMulti-target-Directed%2520Ligands%2520to%2520Combat%2520Neurodegenerative%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D3%26spage%3D347%26epage%3D372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group">Bajda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzior, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ignasik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malawska, B.</span><span> </span><span class="NLM_article-title">Multi-target-directed ligands in Alzheimer’s disease treatment</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">32</span><span class="NLM_x">) </span> <span class="NLM_fpage">4949</span><span class="NLM_x">–</span> <span class="NLM_lpage">4975</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.2174%2F092986711797535245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVOrtL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=4949-4975&issue=32&author=M.+Bajdaauthor=N.+Guziorauthor=M.+Ignasikauthor=B.+Malawska&title=Multi-target-directed+ligands+in+Alzheimer%E2%80%99s+disease+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target-directed ligands in Alzheimer's disease treatment</span></div><div class="casAuthors">Bajda, M.; Guzior, N.; Ignasik, M.; Malawska, B.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">4949-4975</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Among the various drug discovery methods, a very promising modern approach consists in designing multi-target-directed ligands (MTDLs).  This methodol. has been specifically developed for treatment of disorders with complex pathol. mechanisms.  One such disorder is Alzheimer's disease (AD), currently the most common multifactorial neurodegenerative disease.  AD is related to increased levels of the amyloid β peptide (Aβ) and the hyperphosphorylated tau protein, along with loss of neurons and synapses.  Moreover, there is some evidence pointing to the role of oxidative stress, metal ion deregulation, inflammation and cell cycle regulatory failure in its pathogenesis.  There are many attractive targets for the development of anti-AD drugs, and the multi-factor nature of this disease calls for multi-target-directed compds. which can be beneficial for AD treatment.  This review presents the discovery of dual- and multi-acting anti-AD drug candidates, focusing on the novel design strategy and the compds. it yields - particularly hybrids obtained by linking structurally active moieties interacting with different targets.  The first group of compds. includes cholinesterase inhibitors acting as dual binding site inhibitors and/or inhibitors with addnl. properties.  These compds. are characterized by increased potency against acetylcholinesterase (AChE) and Aβ plaque formation with addnl. properties such as antioxidant activity, neuroprotective, and metal-complexing property, voltage-dependent calcium channel antagonistic activity, inhibitory activity against glutamate-induced excitotoxicity, histamine H3 receptor antagonism, cannabinoid CB1 receptor antagonism and β-secretase (BACE1) inhibition.  A novel class of compds. represents the combination of dual BACE1 inhibitors with metal chelators, and dual modulators of γ-secretase with peroxisome proliferator-activated receptor γ (PPARγ).  We have reviewed the latest reports (2008-2011) presenting new multi-target-directed compds. in Alzheimer's disease treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZHSluHvxy4bVg90H21EOLACvtfcHk0ljqcEjW0s7Prg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVOrtL3F&md5=c8f35f849c399d43c90570f71ca10e13</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.2174%2F092986711797535245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711797535245%26sid%3Dliteratum%253Aachs%26aulast%3DBajda%26aufirst%3DM.%26aulast%3DGuzior%26aufirst%3DN.%26aulast%3DIgnasik%26aufirst%3DM.%26aulast%3DMalawska%26aufirst%3DB.%26atitle%3DMulti-target-directed%2520ligands%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520treatment%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26issue%3D32%26spage%3D4949%26epage%3D4975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group">Bianchi, M. T.; Chuang, K.</span><span> </span><span class="NLM_article-title">A Magic Shotgun Perspective on Anticonvulsant Mechanisms</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed.; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">225</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch10" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=203-225&author=M.+T.+Bianchi&author=K.+Chuangauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch10%26sid%3Dliteratum%253Aachs%26aulast%3DBianchi%26aufirst%3DM.%2BT.%26atitle%3DA%2520Magic%2520Shotgun%2520Perspective%2520on%2520Anticonvulsant%2520Mechanisms%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D203%26epage%3D225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group">Daull, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeng, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battistini, B.</span><span> </span><span class="NLM_article-title">Towards Triple Vasopeptidase Inhibitors for the Treatment of Cardiovascular Diseases</span> <span class="citation_source-journal">J. Cardiovasc. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">247</span><span class="NLM_x">–</span> <span class="NLM_lpage">256</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=247-256&issue=3&author=P.+Daullauthor=A.+Y.+Jengauthor=B.+Battistini&title=Towards+Triple+Vasopeptidase+Inhibitors+for+the+Treatment+of+Cardiovascular+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDaull%26aufirst%3DP.%26aulast%3DJeng%26aufirst%3DA.%2BY.%26aulast%3DBattistini%26aufirst%3DB.%26atitle%3DTowards%2520Triple%2520Vasopeptidase%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Cardiovascular%2520Diseases%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D2007%26volume%3D50%26issue%3D3%26spage%3D247%26epage%3D256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group">Calhoun, D. A.</span><span> </span><span class="NLM_article-title">Use of single-pill combination therapy in the evolving paradigm of hypertension management</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">1869</span><span class="NLM_x">–</span> <span class="NLM_lpage">1874</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1517%2F14656560902980210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1MXoslaqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=1869-1874&issue=12&author=D.+A.+Calhoun&title=Use+of+single-pill+combination+therapy+in+the+evolving+paradigm+of+hypertension+management"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Use of single-pill combination therapy in the evolving paradigm of hypertension management</span></div><div class="casAuthors">Calhoun, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1869-1874</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The use of antihypertensive therapy is an evolving paradigm.  Although blood pressure (BP) control rates remain low, there have been improvements that may be attributable in part to a recent shift in clin. guidelines that recognizes that most patients will require multiple drugs to reach BP goals and encourages clinicians to use combination therapy as first-line treatment in selected patients.  Single-pill combinations of two complementary antihypertensive medications offer benefits beyond those of sep. administration of the individual component agents, providing a simpler medication regimen that is effective and well tolerated while enhancing patient adherence to therapy.  In the future, there may be single-pill combinations of three antihypertensive drugs to further enhance BP control rates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql2DUwqQH0UbVg90H21EOLACvtfcHk0ljqcEjW0s7Prg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXoslaqtb8%253D&md5=2d9c158e32d0db555dddef9c1316988f</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1517%2F14656560902980210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656560902980210%26sid%3Dliteratum%253Aachs%26aulast%3DCalhoun%26aufirst%3DD.%2BA.%26atitle%3DUse%2520of%2520single-pill%2520combination%2520therapy%2520in%2520the%2520evolving%2520paradigm%2520of%2520hypertension%2520management%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2009%26volume%3D10%26issue%3D12%26spage%3D1869%26epage%3D1874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group">Milnes, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madge, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. W.</span><span> </span><span class="NLM_article-title">New pharmacological approaches to atrial fibrillation</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">13–14</span><span class="NLM_x">) </span> <span class="NLM_fpage">654</span><span class="NLM_x">–</span> <span class="NLM_lpage">659</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=654-659&issue=13%E2%80%9314&author=J.+T.+Milnesauthor=D.+J.+Madgeauthor=J.+W.+Ford&title=New+pharmacological+approaches+to+atrial+fibrillation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMilnes%26aufirst%3DJ.%2BT.%26aulast%3DMadge%26aufirst%3DD.%2BJ.%26aulast%3DFord%26aufirst%3DJ.%2BW.%26atitle%3DNew%2520pharmacological%2520approaches%2520to%2520atrial%2520fibrillation%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26issue%3D13%25E2%2580%259314%26spage%3D654%26epage%3D659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group">Dobrev, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlsson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nattel, S.</span><span> </span><span class="NLM_article-title">Novel molecular targets for atrial fibrillation therapy</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">275</span><span class="NLM_x">–</span> <span class="NLM_lpage">291</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=275-291&issue=4&author=D.+Dobrevauthor=L.+Carlssonauthor=S.+Nattel&title=Novel+molecular+targets+for+atrial+fibrillation+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDobrev%26aufirst%3DD.%26aulast%3DCarlsson%26aufirst%3DL.%26aulast%3DNattel%26aufirst%3DS.%26atitle%3DNovel%2520molecular%2520targets%2520for%2520atrial%2520fibrillation%2520therapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26issue%3D4%26spage%3D275%26epage%3D291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group">Krishnamoorthy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lip, G. Y. H.</span><span> </span><span class="NLM_article-title">Novel antiarrhythmic drugs in atrial fibrillation: focus on tedisamil</span> <span class="citation_source-journal">Expert Opin. Investig. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">1191</span><span class="NLM_x">–</span> <span class="NLM_lpage">1196</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=1191-1196&issue=8&author=S.+Krishnamoorthyauthor=G.+Y.+H.+Lip&title=Novel+antiarrhythmic+drugs+in+atrial+fibrillation%3A+focus+on+tedisamil"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKrishnamoorthy%26aufirst%3DS.%26aulast%3DLip%26aufirst%3DG.%2BY.%2BH.%26atitle%3DNovel%2520antiarrhythmic%2520drugs%2520in%2520atrial%2520fibrillation%253A%2520focus%2520on%2520tedisamil%26jtitle%3DExpert%2520Opin.%2520Investig.%2520Drugs%26date%3D2009%26volume%3D18%26issue%3D8%26spage%3D1191%26epage%3D1196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group">Sabroe, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calverley, P. M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dower, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whyte, M. K. B.</span><span> </span><span class="NLM_article-title">Pathological networking: a new approach to understanding COPD</span> <span class="citation_source-journal">Thorax</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">733</span><span class="NLM_x">–</span> <span class="NLM_lpage">738</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2007&pages=733-738&issue=8&author=I.+Sabroeauthor=L.+C.+Parkerauthor=P.+M.+A.+Calverleyauthor=S.+K.+Dowerauthor=M.+K.+B.+Whyte&title=Pathological+networking%3A+a+new+approach+to+understanding+COPD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSabroe%26aufirst%3DI.%26aulast%3DParker%26aufirst%3DL.%2BC.%26aulast%3DCalverley%26aufirst%3DP.%2BM.%2BA.%26aulast%3DDower%26aufirst%3DS.%2BK.%26aulast%3DWhyte%26aufirst%3DM.%2BK.%2BB.%26atitle%3DPathological%2520networking%253A%2520a%2520new%2520approach%2520to%2520understanding%2520COPD%26jtitle%3DThorax%26date%3D2007%26volume%3D62%26issue%3D8%26spage%3D733%26epage%3D738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basu, A.</span><span> </span><span class="NLM_article-title">Network medicine in drug design: implications for neuroinflammation</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">11–12</span><span class="NLM_x">) </span> <span class="NLM_fpage">600</span><span class="NLM_x">–</span> <span class="NLM_lpage">607</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=600-607&issue=11%E2%80%9312&author=S.+Ghoshauthor=A.+Basu&title=Network+medicine+in+drug+design%3A+implications+for+neuroinflammation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DBasu%26aufirst%3DA.%26atitle%3DNetwork%2520medicine%2520in%2520drug%2520design%253A%2520implications%2520for%2520neuroinflammation%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26issue%3D11%25E2%2580%259312%26spage%3D600%26epage%3D607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group">Albrecht, W.; Laufer, S.</span><span> </span><span class="NLM_article-title">Therapeutic Potential of Small Molecules Modulating the Cyclooxygenase-5-lipoxygenase Pathway</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed.; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">383</span><span class="NLM_x">–</span> <span class="NLM_lpage">408</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch19" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=383-408&author=W.+Albrecht&author=S.+Lauferauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch19%26sid%3Dliteratum%253Aachs%26aulast%3DAlbrecht%26aufirst%3DW.%26atitle%3DTherapeutic%2520Potential%2520of%2520Small%2520Molecules%2520Modulating%2520the%2520Cyclooxygenase-5-lipoxygenase%2520Pathway%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D383%26epage%3D408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group">Borisy, A. A.; Zimmermann, G. R.; Lehar, J.</span><span> </span><span class="NLM_article-title">Multicomponent Therapeutics</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed.; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">315</span><span class="NLM_x">–</span> <span class="NLM_lpage">321</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch15" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=315-321&author=A.+A.+Borisy&author=G.+R.+Zimmermann&author=J.+Leharauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch15%26sid%3Dliteratum%253Aachs%26aulast%3DBorisy%26aufirst%3DA.%2BA.%26atitle%3DMulticomponent%2520Therapeutics%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D315%26epage%3D321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group">Keith, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borisy, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stockwell, B. R.</span><span> </span><span class="NLM_article-title">Innovation: Multicomponent therapeutics for networked systems</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">71</span><span class="NLM_x">–</span> <span class="NLM_lpage">78</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=71-78&issue=1&author=C.+T.+Keithauthor=A.+A.+Borisyauthor=B.+R.+Stockwell&title=Innovation%3A+Multicomponent+therapeutics+for+networked+systems"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKeith%26aufirst%3DC.%2BT.%26aulast%3DBorisy%26aufirst%3DA.%2BA.%26aulast%3DStockwell%26aufirst%3DB.%2BR.%26atitle%3DInnovation%253A%2520Multicomponent%2520therapeutics%2520for%2520networked%2520systems%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26issue%3D1%26spage%3D71%26epage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group">Tzschentke, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christoph, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koegel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiene, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennies, H.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Englberger, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haurand, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jahnel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cremers, T. I. F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friderichs, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vry, J.</span><span> </span><span class="NLM_article-title">(−)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel μ-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties</span> <span class="citation_source-journal">J. Pharmacol. Exp. Therap.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">323</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">265</span><span class="NLM_x">–</span> <span class="NLM_lpage">276</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1124%2Fjpet.107.126052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFahsb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=2007&pages=265-276&issue=1&author=T.+M.+Tzschentkeauthor=T.+Christophauthor=B.+Koegelauthor=K.+Schieneauthor=H.-H.+Henniesauthor=W.+Englbergerauthor=M.+Haurandauthor=U.+Jahnelauthor=T.+I.+F.+H.+Cremersauthor=E.+Friderichsauthor=J.+De+Vry&title=%28%E2%88%92%29-%281R%2C2R%29-3-%283-Dimethylamino-1-ethyl-2-methyl-propyl%29-phenol+hydrochloride+%28tapentadol+HCl%29%3A+a+novel+%CE%BC-opioid+receptor+agonist%2Fnorepinephrine+reuptake+inhibitor+with+broad-spectrum+analgesic+properties"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">(-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel μ-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties</span></div><div class="casAuthors">Tzschentke, Thomas M.; Christoph, Thomas; Koegel, Babette; Schiene, Klaus; Hennies, Hagen-Heinrich; Englberger, Werner; Haurand, Michael; Jahnel, Ulrich; Cremers, Thomas I. F. H.; Friderichs, Elmar; De Vry, Jean</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">265-276</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">(-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl) is a novel μ-opioid receptor (MOR) agonist (Ki = 0.1 μM; relative efficacy compared with morphine 88% in a [35S]guanosine 5'-3-O-(thio)triphosphate binding assay) and NE reuptake inhibitor (Ki = 0.5 μM for synaptosomal reuptake inhibition).  In vivo intracerebral microdialysis showed that tapentadol, in contrast to morphine, produces large increases in extracellular levels of NE (+450% at 10 mg/kg i.p.).  Tapentadol exhibited analgesic effects in a wide range of animal models of acute and chronic pain [hot plate, tail-flick, writhing, Randall-Selitto, mustard oil colitis, chronic constriction injury (CCI), and spinal nerve ligation (SNL)], with ED50 values ranging from 8.2 to 13 mg/kg after i.p. administration in rats.  Despite a 50-fold lower binding affinity to MOR, the analgesic potency of tapentadol was only two to three times lower than that of morphine, suggesting that the dual mode of action of tapentadol may result in an opiate-sparing effect.  A role of NE in the analgesic efficacy of tapentadol was directly demonstrated in the SNL model, where the analgesic effect of tapentadol was strongly reduced by the α2-adrenoceptor antagonist yohimbine but only moderately attenuated by the MOR antagonist naloxone, whereas the opposite was seen for morphine.  Tolerance development to the analgesic effect of tapentadol in the CCI model was twice as slow as that of morphine.  It is suggested that the broad analgesic profile of tapentadol and its relative resistance to tolerance development may be due to a dual mode of action consisting of both MOR activation and NE reuptake inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEuKmQM4JgvrVg90H21EOLACvtfcHk0lglLldO_u2ZOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFahsb7P&md5=b2e196297096bac7c057f0e4a8d90bfb</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.126052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.126052%26sid%3Dliteratum%253Aachs%26aulast%3DTzschentke%26aufirst%3DT.%2BM.%26aulast%3DChristoph%26aufirst%3DT.%26aulast%3DKoegel%26aufirst%3DB.%26aulast%3DSchiene%26aufirst%3DK.%26aulast%3DHennies%26aufirst%3DH.-H.%26aulast%3DEnglberger%26aufirst%3DW.%26aulast%3DHaurand%26aufirst%3DM.%26aulast%3DJahnel%26aufirst%3DU.%26aulast%3DCremers%26aufirst%3DT.%2BI.%2BF.%2BH.%26aulast%3DFriderichs%26aufirst%3DE.%26aulast%3DDe%2BVry%26aufirst%3DJ.%26atitle%3D%2528%25E2%2588%2592%2529-%25281R%252C2R%2529-3-%25283-Dimethylamino-1-ethyl-2-methyl-propyl%2529-phenol%2520hydrochloride%2520%2528tapentadol%2520HCl%2529%253A%2520a%2520novel%2520%25CE%25BC-opioid%2520receptor%2520agonist%252Fnorepinephrine%2520reuptake%2520inhibitor%2520with%2520broad-spectrum%2520analgesic%2520properties%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Therap.%26date%3D2007%26volume%3D323%26issue%3D1%26spage%3D265%26epage%3D276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group">Khanna, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khanna, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furst, D. E.</span><span> </span><span class="NLM_article-title">COX-2 controversy: where are we and where do we go from here?</span> <span class="citation_source-journal">Inflammopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">395</span><span class="NLM_x">–</span> <span class="NLM_lpage">402</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=395-402&issue=4&author=D.+Khannaauthor=P.+P.+Khannaauthor=D.+E.+Furst&title=COX-2+controversy%3A+where+are+we+and+where+do+we+go+from+here%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKhanna%26aufirst%3DD.%26aulast%3DKhanna%26aufirst%3DP.%2BP.%26aulast%3DFurst%26aufirst%3DD.%2BE.%26atitle%3DCOX-2%2520controversy%253A%2520where%2520are%2520we%2520and%2520where%2520do%2520we%2520go%2520from%2520here%253F%26jtitle%3DInflammopharmacology%26date%3D2005%26volume%3D13%26issue%3D4%26spage%3D395%26epage%3D402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group">Jooste, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emala, C. W.</span><span> </span><span class="NLM_article-title">Rapacuronium Preferentially Antagonizes the Function of M2 versus M3Muscarinic Receptors in Guinea Pig Airway Smooth Muscle</span> <span class="citation_source-journal">Anesthesiology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=117-124&issue=1&author=E.+Joosteauthor=Y.+Zhangauthor=C.+W.+Emala&title=Rapacuronium+Preferentially+Antagonizes+the+Function+of+M2+versus+M3Muscarinic+Receptors+in+Guinea+Pig+Airway+Smooth+Muscle"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJooste%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DEmala%26aufirst%3DC.%2BW.%26atitle%3DRapacuronium%2520Preferentially%2520Antagonizes%2520the%2520Function%2520of%2520M2%2520versus%2520M3Muscarinic%2520Receptors%2520in%2520Guinea%2520Pig%2520Airway%2520Smooth%2520Muscle%26jtitle%3DAnesthesiology%26date%3D2005%26volume%3D102%26issue%3D1%26spage%3D117%26epage%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group">Hou, V. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirshman, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emala, C. W.</span><span> </span><span class="NLM_article-title">Neuromuscular relaxants as antagonists for M2 and M3 muscarinic receptors</span> <span class="citation_source-journal">Anesthesiology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">744</span><span class="NLM_x">–</span> <span class="NLM_lpage">750</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1998&pages=744-750&issue=3&author=V.+Y.+Houauthor=C.+A.+Hirshmanauthor=C.+W.+Emala&title=Neuromuscular+relaxants+as+antagonists+for+M2+and+M3+muscarinic+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHou%26aufirst%3DV.%2BY.%26aulast%3DHirshman%26aufirst%3DC.%2BA.%26aulast%3DEmala%26aufirst%3DC.%2BW.%26atitle%3DNeuromuscular%2520relaxants%2520as%2520antagonists%2520for%2520M2%2520and%2520M3%2520muscarinic%2520receptors%26jtitle%3DAnesthesiology%26date%3D1998%26volume%3D88%26issue%3D3%26spage%3D744%26epage%3D750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group">Martin, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salmen, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmatier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gintant, G. A.</span><span> </span><span class="NLM_article-title">The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block</span> <span class="citation_source-journal">J. Cardiovasc. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">369</span><span class="NLM_x">–</span> <span class="NLM_lpage">379</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2004&pages=369-379&issue=3&author=R.+L.+Martinauthor=J.+S.+McDermottauthor=H.+J.+Salmenauthor=J.+Palmatierauthor=B.+F.+Coxauthor=G.+A.+Gintant&title=The+utility+of+hERG+and+repolarization+assays+in+evaluating+delayed+cardiac+repolarization%3A+influence+of+multi-channel+block"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DR.%2BL.%26aulast%3DMcDermott%26aufirst%3DJ.%2BS.%26aulast%3DSalmen%26aufirst%3DH.%2BJ.%26aulast%3DPalmatier%26aufirst%3DJ.%26aulast%3DCox%26aufirst%3DB.%2BF.%26aulast%3DGintant%26aufirst%3DG.%2BA.%26atitle%3DThe%2520utility%2520of%2520hERG%2520and%2520repolarization%2520assays%2520in%2520evaluating%2520delayed%2520cardiac%2520repolarization%253A%2520influence%2520of%2520multi-channel%2520block%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D2004%26volume%3D43%26issue%3D3%26spage%3D369%26epage%3D379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group">Sala, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coppa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappucciati, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brambilla, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">d’Allio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caverzasi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barale, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Ferrari, G. M.</span><span> </span><span class="NLM_article-title">Antidepressants: their effects on cardiac channels, QT prolongation and Torsade de Pointes</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">256</span><span class="NLM_x">–</span> <span class="NLM_lpage">263</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=256-263&issue=3&author=M.+Salaauthor=F.+Coppaauthor=C.+Cappucciatiauthor=P.+Brambillaauthor=G.+d%E2%80%99Allioauthor=E.+Caverzasiauthor=F.+Baraleauthor=G.+M.+De+Ferrari&title=Antidepressants%3A+their+effects+on+cardiac+channels%2C+QT+prolongation+and+Torsade+de+Pointes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSala%26aufirst%3DM.%26aulast%3DCoppa%26aufirst%3DF.%26aulast%3DCappucciati%26aufirst%3DC.%26aulast%3DBrambilla%26aufirst%3DP.%26aulast%3Dd%25E2%2580%2599Allio%26aufirst%3DG.%26aulast%3DCaverzasi%26aufirst%3DE.%26aulast%3DBarale%26aufirst%3DF.%26aulast%3DDe%2BFerrari%26aufirst%3DG.%2BM.%26atitle%3DAntidepressants%253A%2520their%2520effects%2520on%2520cardiac%2520channels%252C%2520QT%2520prolongation%2520and%2520Torsade%2520de%2520Pointes%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2006%26volume%3D7%26issue%3D3%26spage%3D256%26epage%3D263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group">Tobinick, E. L.</span><span> </span><span class="NLM_article-title">The value of drug repositioning in the current pharmaceutical market</span> <span class="citation_source-journal">Drug News Perspect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">119</span><span class="NLM_x">–</span> <span class="NLM_lpage">125</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1358%2Fdnp.2009.22.2.1343228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A280%3ADC%252BD1M3kt1anuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=119-125&issue=2&author=E.+L.+Tobinick&title=The+value+of+drug+repositioning+in+the+current+pharmaceutical+market"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">The value of drug repositioning in the current pharmaceutical market</span></div><div class="casAuthors">Tobinick Edward L</div><div class="citationInfo"><span class="NLM_cas:title">Drug news & perspectives</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">119-25</span>
        ISSN:<span class="NLM_cas:issn">0214-0934</span>.
    </div><div class="casAbstract">Drug repositioning is the process of developing new indications for existing drugs or biologics.  Increasing interest in drug repositioning has occurred due to sustained high failure rates and costs involved in attempts to bring new drugs to market.  It has been estimated that it may cost more than USD 800 million to develop a new drug de novo.  In addition, due to regulatory requirements regarding safety, efficacy and quality, the time required to develop a new drug de novo has been estimated to be 10 to 17 years.  De novo drug discovery has failed to efficiently supply pharmaceutical company pipelines.  A rational approach to drug repositioning may include a cross-disciplinary focus on the elucidation of the mechanisms of disease, allowing matching of disease pathways with appropriately targeted therapeutic agents.  Repurposed drugs or biologics have the advantage of decreased development costs and decreased time to launch due to previously collected pharmacokinetic, toxicology and safety data.  For these reasons, repurposing should be a primary strategy in drug discovery for every broadly focused, research-based pharmaceutical company.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRHCgc-C0DhQZagfuraLLzSfW6udTcc2eYXgKXcRHKoi7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M3kt1anuw%253D%253D&md5=d55a5f23cb69258c0f06189e2c4d9011</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1358%2Fdnp.2009.22.2.1343228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdnp.2009.22.2.1343228%26sid%3Dliteratum%253Aachs%26aulast%3DTobinick%26aufirst%3DE.%2BL.%26atitle%3DThe%2520value%2520of%2520drug%2520repositioning%2520in%2520the%2520current%2520pharmaceutical%2520market%26jtitle%3DDrug%2520News%2520Perspect.%26date%3D2009%26volume%3D22%26issue%3D2%26spage%3D119%26epage%3D125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group">Ashburn, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thor, K. B.</span><span> </span><span class="NLM_article-title">Drug repositioning: identifying and developing new uses for existing drugs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">673</span><span class="NLM_x">–</span> <span class="NLM_lpage">683</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fnrd1468" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=15286734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVOhtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=673-683&issue=8&author=T.+T.+Ashburnauthor=K.+B.+Thor&title=Drug+repositioning%3A+identifying+and+developing+new+uses+for+existing+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Drug repositioning: identifying and developing new uses for existing drugs</span></div><div class="casAuthors">Ashburn, Ted T.; Thor, Karl B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">673-683</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Biopharmaceutical companies attempting to increase productivity through novel discovery technologies have fallen short of achieving the desired results.  Repositioning existing drugs for new indications could deliver the productivity increases that the industry needs while shifting the locus of prodn. to biotechnol. companies.  More and more companies are scanning the existing pharmacopeia for repositioning candidates, and the no. of repositioning success stories is increasing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLkWl3DnePhrVg90H21EOLACvtfcHk0lhZA7mTAIfWYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVOhtL8%253D&md5=0145c02423ab81ace6e3b3d92585cccc</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1038%2Fnrd1468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1468%26sid%3Dliteratum%253Aachs%26aulast%3DAshburn%26aufirst%3DT.%2BT.%26aulast%3DThor%26aufirst%3DK.%2BB.%26atitle%3DDrug%2520repositioning%253A%2520identifying%2520and%2520developing%2520new%2520uses%2520for%2520existing%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26issue%3D8%26spage%3D673%26epage%3D683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group">Oprea, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauman, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">G. Bologa, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buranda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chigaev, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarvik, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gresham, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haynes, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hjelle, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hromas, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackenzie, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simons, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smagley, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strouse, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surviladze, Z.</span><span> </span><span class="NLM_article-title">Drug repurposing from an academic perspective</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">3–4</span><span class="NLM_x">) </span> <span class="NLM_fpage">61</span><span class="NLM_x">–</span> <span class="NLM_lpage">69</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=61-69&issue=3%E2%80%934&author=T.+I.+Opreaauthor=J.+E.+Baumanauthor=C.+G.+G.+Bologaauthor=T.+Burandaauthor=A.+Chigaevauthor=B.+S.+Edwardsauthor=J.+W.+Jarvikauthor=H.+D.+Greshamauthor=M.+K.+Haynesauthor=B.+Hjelleauthor=R.+Hromasauthor=L.+Hudsonauthor=D.+A.+Mackenzieauthor=C.+Y.+Mullerauthor=J.+C.+Reedauthor=P.+C.+Simonsauthor=Y.+Smagleyauthor=J.+Strouseauthor=Z.+Surviladze&title=Drug+repurposing+from+an+academic+perspective"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOprea%26aufirst%3DT.%2BI.%26aulast%3DBauman%26aufirst%3DJ.%2BE.%26aulast%3DG.%2BBologa%26aufirst%3DC.%2BG.%26aulast%3DBuranda%26aufirst%3DT.%26aulast%3DChigaev%26aufirst%3DA.%26aulast%3DEdwards%26aufirst%3DB.%2BS.%26aulast%3DJarvik%26aufirst%3DJ.%2BW.%26aulast%3DGresham%26aufirst%3DH.%2BD.%26aulast%3DHaynes%26aufirst%3DM.%2BK.%26aulast%3DHjelle%26aufirst%3DB.%26aulast%3DHromas%26aufirst%3DR.%26aulast%3DHudson%26aufirst%3DL.%26aulast%3DMackenzie%26aufirst%3DD.%2BA.%26aulast%3DMuller%26aufirst%3DC.%2BY.%26aulast%3DReed%26aufirst%3DJ.%2BC.%26aulast%3DSimons%26aufirst%3DP.%2BC.%26aulast%3DSmagley%26aufirst%3DY.%26aulast%3DStrouse%26aufirst%3DJ.%26aulast%3DSurviladze%26aufirst%3DZ.%26atitle%3DDrug%2520repurposing%2520from%2520an%2520academic%2520perspective%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D8%26issue%3D3%25E2%2580%25934%26spage%3D61%26epage%3D69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group">Hansen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, C.</span><span> </span><span class="NLM_article-title">A Novel Hypothesis for Thalidomide-Induced Limb Teratogenesis: Redox Misregulation of the NF-κB Pathway</span> <span class="citation_source-journal">Antiox. Redox Signal</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">14</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1089%2F152308604771978291" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=1-14&issue=1&author=J.+M.+Hansenauthor=C.+Harris&title=A+Novel+Hypothesis+for+Thalidomide-Induced+Limb+Teratogenesis%3A+Redox+Misregulation+of+the+NF-%CE%BAB+Pathway"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1089%2F152308604771978291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252F152308604771978291%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DJ.%2BM.%26aulast%3DHarris%26aufirst%3DC.%26atitle%3DA%2520Novel%2520Hypothesis%2520for%2520Thalidomide-Induced%2520Limb%2520Teratogenesis%253A%2520Redox%2520Misregulation%2520of%2520the%2520NF-%25CE%25BAB%2520Pathway%26jtitle%3DAntiox.%2520Redox%2520Signal%26date%3D2004%26volume%3D6%26issue%3D1%26spage%3D1%26epage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group">Meierhofer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunzendorfer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiedermann, C. J.</span><span> </span><span class="NLM_article-title">Theoretical basis for the activity of thalidomide</span> <span class="citation_source-journal">BioDrugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">681</span><span class="NLM_x">–</span> <span class="NLM_lpage">703</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2001&pages=681-703&issue=10&author=C.+Meierhoferauthor=S.+Dunzendorferauthor=C.+J.+Wiedermann&title=Theoretical+basis+for+the+activity+of+thalidomide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeierhofer%26aufirst%3DC.%26aulast%3DDunzendorfer%26aufirst%3DS.%26aulast%3DWiedermann%26aufirst%3DC.%2BJ.%26atitle%3DTheoretical%2520basis%2520for%2520the%2520activity%2520of%2520thalidomide%26jtitle%3DBioDrugs%26date%3D2001%26volume%3D15%26issue%3D10%26spage%3D681%26epage%3D703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group">Holzgrabe, U.</span><span> </span><span class="NLM_article-title">An old drug as a carcinostatic. The new career of thalidomide</span> <span class="citation_source-journal">Pharm. Z.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">446</span><span class="NLM_x">–</span> <span class="NLM_lpage">449</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2007&pages=446-449&issue=6&author=U.+Holzgrabe&title=An+old+drug+as+a+carcinostatic.+The+new+career+of+thalidomide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHolzgrabe%26aufirst%3DU.%26atitle%3DAn%2520old%2520drug%2520as%2520a%2520carcinostatic.%2520The%2520new%2520career%2520of%2520thalidomide%26jtitle%3DPharm.%2520Z.%26date%3D2007%26volume%3D36%26issue%3D6%26spage%3D446%26epage%3D449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group">Manley, P. W.; Zimmermann, J.</span><span> </span><span class="NLM_article-title">Drug Research Leading to Imatinib and Beyond to Nilotinib</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed.; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">409</span><span class="NLM_x">–</span> <span class="NLM_lpage">421</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch20" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=409-421&author=P.+W.+Manley&author=J.+Zimmermannauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch20&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch20%26sid%3Dliteratum%253Aachs%26aulast%3DManley%26aufirst%3DP.%2BW.%26atitle%3DDrug%2520Research%2520Leading%2520to%2520Imatinib%2520and%2520Beyond%2520to%2520Nilotinib%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D409%26epage%3D421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matter, A.</span><span> </span><span class="NLM_article-title">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">493</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=493-502&issue=7&author=R.+Capdevilleauthor=E.+Buchdungerauthor=J.+Zimmermannauthor=A.+Matter&title=Glivec+%28STI571%2C+imatinib%29%2C+a+rationally+developed%2C+targeted+anticancer+drug"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DMatter%26aufirst%3DA.%26atitle%3DGlivec%2520%2528STI571%252C%2520imatinib%2529%252C%2520a%2520rationally%2520developed%252C%2520targeted%2520anticancer%2520drug%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26issue%3D7%26spage%3D493%26epage%3D502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group">Hirota, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isozaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishiguro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurata, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tunio, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuzawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanakura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinomura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitamura, Y.</span><span> </span><span class="NLM_article-title">Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x"> (</span><span class="NLM_issue">5350</span><span class="NLM_x">) </span> <span class="NLM_fpage">577</span><span class="NLM_x">–</span> <span class="NLM_lpage">580</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=1998&pages=577-580&issue=5350&author=S.+Hirotaauthor=K.+Isozakiauthor=Y.+Moriyamaauthor=K.+Hashimotoauthor=T.+Nishidaauthor=S.+Ishiguroauthor=K.+Kawanoauthor=M.+Hanadaauthor=A.+Kurataauthor=M.+Takedaauthor=G.+M.+Tunioauthor=Y.+Matsuzawaauthor=Y.+Kanakuraauthor=Y.+Shinomuraauthor=Y.+Kitamura&title=Gain-of-function+mutations+of+c-kit+in+human+gastrointestinal+stromal+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHirota%26aufirst%3DS.%26aulast%3DIsozaki%26aufirst%3DK.%26aulast%3DMoriyama%26aufirst%3DY.%26aulast%3DHashimoto%26aufirst%3DK.%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DIshiguro%26aufirst%3DS.%26aulast%3DKawano%26aufirst%3DK.%26aulast%3DHanada%26aufirst%3DM.%26aulast%3DKurata%26aufirst%3DA.%26aulast%3DTakeda%26aufirst%3DM.%26aulast%3DTunio%26aufirst%3DG.%2BM.%26aulast%3DMatsuzawa%26aufirst%3DY.%26aulast%3DKanakura%26aufirst%3DY.%26aulast%3DShinomura%26aufirst%3DY.%26aulast%3DKitamura%26aufirst%3DY.%26atitle%3DGain-of-function%2520mutations%2520of%2520c-kit%2520in%2520human%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DScience%26date%3D1998%26volume%3D279%26issue%3D5350%26spage%3D577%26epage%3D580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group">Delbaldo, C.; Colichi, C.; Sablin, M.-P.; Dreyer, C.; Billemont, B.; Faivre, S.; Raymond, E.</span><span> </span><span class="NLM_article-title">Discovery of Sunitinib as a Multitarget Treatment of Cancer</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed.; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">325</span><span class="NLM_x">–</span> <span class="NLM_lpage">342</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=325-342&author=C.+Delbaldo&author=C.+Colichi&author=M.-P.+Sablin&author=C.+Dreyer&author=B.+Billemont&author=S.+Faivre&author=E.+Raymondauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDelbaldo%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520Sunitinib%2520as%2520a%2520Multitarget%2520Treatment%2520of%2520Cancer%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D325%26epage%3D342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group">Wilhelm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowinger, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simantov, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelley, S.</span><span> </span><span class="NLM_article-title">Discovery and development of sorafenib: a multikinase inhibitor for treating cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">835</span><span class="NLM_x">–</span> <span class="NLM_lpage">844</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=835-844&issue=10&author=S.+Wilhelmauthor=C.+Carterauthor=M.+Lynchauthor=T.+Lowingerauthor=J.+Dumasauthor=R.+A.+Smithauthor=B.+Schwartzauthor=R.+Simantovauthor=S.+Kelley&title=Discovery+and+development+of+sorafenib%3A+a+multikinase+inhibitor+for+treating+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DS.%26aulast%3DCarter%26aufirst%3DC.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DLowinger%26aufirst%3DT.%26aulast%3DDumas%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DR.%2BA.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DSimantov%26aufirst%3DR.%26aulast%3DKelley%26aufirst%3DS.%26atitle%3DDiscovery%2520and%2520development%2520of%2520sorafenib%253A%2520a%2520multikinase%2520inhibitor%2520for%2520treating%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26issue%3D10%26spage%3D835%26epage%3D844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group">Meyer, U.</span><span> </span><span class="NLM_article-title">The history of antihistamines</span> <span class="citation_source-journal">Pharm.  Z.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">86</span><span class="NLM_x">–</span> <span class="NLM_lpage">91</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2004&pages=86-91&issue=2&author=U.+Meyer&title=The+history+of+antihistamines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DU.%26atitle%3DThe%2520history%2520of%2520antihistamines%26jtitle%3DPharm.%2520%2520Z.%26date%3D2004%26volume%3D33%26issue%3D2%26spage%3D86%26epage%3D91" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group">Sneader, W.</span><span> </span><span class="NLM_article-title">The 50th anniversary of chlorpromazine</span> <span class="citation_source-journal">Drug News Perspect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">466</span><span class="NLM_x">–</span> <span class="NLM_lpage">471</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1358%2Fdnp.2002.15.7.840082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD38XptlShsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2002&pages=466-471&issue=7&author=W.+Sneader&title=The+50th+anniversary+of+chlorpromazine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">The 50th anniversary of chlorpromazine</span></div><div class="casAuthors">Sneader, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Drug News & Perspectives</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">466-471</span>CODEN:
                <span class="NLM_cas:coden">DNPEED</span>;
        ISSN:<span class="NLM_cas:issn">0214-0934</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A historical account of the origins of the work that led to the marketing of chlorpromazine is presented.  The marketing of chlorpromazine 50 yr ago can be traced back to investigations carried out in 1891 by the father of chemotherapy, Paul Ehrlich.  Ehrlich's studies on possible antimalarial effects of methylene blue prompted other studies with antimalarials, including phenothiazine analogs of the dye.  Henri Laborit's search to find a drug that would be of value in preventing the traumatic consequences of shock caused circulatory collapse during surgery led him to discover the important effects that antihistamines, particularly promethazine, had on the central nervous system.  Investigations of centrally acting phenothiazines suitable to Laborit's requirements, with more sedating properties, eventually led to the development of chloropromazine and its use as an antipsychotic drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkieGcMTylvbVg90H21EOLACvtfcHk0lhObDrTdOT81w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptlShsb0%253D&md5=895d09277b6bf74e3235e6eeaed90066</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1358%2Fdnp.2002.15.7.840082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdnp.2002.15.7.840082%26sid%3Dliteratum%253Aachs%26aulast%3DSneader%26aufirst%3DW.%26atitle%3DThe%252050th%2520anniversary%2520of%2520chlorpromazine%26jtitle%3DDrug%2520News%2520Perspect.%26date%3D2002%26volume%3D15%26issue%3D7%26spage%3D466%26epage%3D471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group">Lopez-Munoz, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alamo, C.</span><span> </span><span class="NLM_article-title">Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">14</span><span class="NLM_x">) </span> <span class="NLM_fpage">1563</span><span class="NLM_x">–</span> <span class="NLM_lpage">1586</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.2174%2F138161209788168001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtValtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=1563-1586&issue=14&author=F.+Lopez-Munozauthor=C.+Alamo&title=Monoaminergic+neurotransmission%3A+the+history+of+the+discovery+of+antidepressants+from+1950s+until+today"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today</span></div><div class="casAuthors">Lopez-Munoz, Francisco; Alamo, Cecilio</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1563-1586</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The 1950s saw the clin. introduction of the first two specifically antidepressant drugs: iproniazid, a monoamine-oxidase inhibitor that had been used in the treatment of tuberculosis, and imipramine, the first drug in the tricyclic antidepressant family.  Iproniazid and imipramine made two fundamental contributions to the development of psychiatry: one of a social-health nature, consisting in an authentic change in the psychiatric care of depressive patients; and the other of a purely pharmacol. nature, since these agents have constituted an indispensable research tool for neurobiol. and psychopharmacol., permitting, among other things, the postulation of the first etiopathogenic hypotheses of depressive disorders.  The clin. introduction of fluoxetine, a selective serotonin reuptake, inhibitor, in the late 1980s, once again revolutionized therapy for depression, opening the way for new families of antidepressants.  The present work reviews, from a historical perspective, the entire process that led to the discovery of these drugs, as well as their contribution to the development of the neuro-scientific disciplines.  However, all of these antidepressants, like the rest of those currently available for clin. practice, share the same action mechanism, which involves the modulation of monoaminergic neurotransmission at a synaptic level, so that the future of antidepressant therapy would seem to revolve around the search for extraneuronal non-aminergic mechanisms or mechanisms that modulate the intraneuronal biochem. pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtkMPhW4WjILVg90H21EOLACvtfcHk0lhObDrTdOT81w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtValtrc%253D&md5=e9f791ce372daa3bd12893356f89c715</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.2174%2F138161209788168001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161209788168001%26sid%3Dliteratum%253Aachs%26aulast%3DLopez-Munoz%26aufirst%3DF.%26aulast%3DAlamo%26aufirst%3DC.%26atitle%3DMonoaminergic%2520neurotransmission%253A%2520the%2520history%2520of%2520the%2520discovery%2520of%2520antidepressants%2520from%25201950s%2520until%2520today%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2009%26volume%3D15%26issue%3D14%26spage%3D1563%26epage%3D1586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group">Creese, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burt, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, S. H.</span><span> </span><span class="NLM_article-title">Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">192</span><span class="NLM_x"> (</span><span class="NLM_issue">4238</span><span class="NLM_x">) </span> <span class="NLM_fpage">481</span><span class="NLM_x">–</span> <span class="NLM_lpage">483</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=1976&pages=481-483&issue=4238&author=I.+Creeseauthor=D.+R.+Burtauthor=S.+H.+Snyder&title=Dopamine+receptor+binding+predicts+clinical+and+pharmacological+potencies+of+antischizophrenic+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCreese%26aufirst%3DI.%26aulast%3DBurt%26aufirst%3DD.%2BR.%26aulast%3DSnyder%26aufirst%3DS.%2BH.%26atitle%3DDopamine%2520receptor%2520binding%2520predicts%2520clinical%2520and%2520pharmacological%2520potencies%2520of%2520antischizophrenic%2520drugs%26jtitle%3DScience%26date%3D1976%26volume%3D192%26issue%3D4238%26spage%3D481%26epage%3D483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group">Seeman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chau-Wong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.</span><span> </span><span class="NLM_article-title">Antipsychotic drug doses and neuroleptic/dopamine receptors</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">261</span><span class="NLM_x"> (</span><span class="NLM_issue">5562</span><span class="NLM_x">) </span> <span class="NLM_fpage">717</span><span class="NLM_x">–</span> <span class="NLM_lpage">719</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=261&publication_year=1976&pages=717-719&issue=5562&author=P.+Seemanauthor=T.+Leeauthor=M.+Chau-Wongauthor=K.+Wong&title=Antipsychotic+drug+doses+and+neuroleptic%2Fdopamine+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSeeman%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DChau-Wong%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.%26atitle%3DAntipsychotic%2520drug%2520doses%2520and%2520neuroleptic%252Fdopamine%2520receptors%26jtitle%3DNature%26date%3D1976%26volume%3D261%26issue%3D5562%26spage%3D717%26epage%3D719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group">Glowinski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Axelrod, J.</span><span> </span><span class="NLM_article-title">Inhibition of uptake of tritiated noradrenaline in the intact rat brain by imipramine and structurally related compounds</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1964</span><span class="NLM_x">, </span> <span class="NLM_volume">204</span><span class="NLM_x"> (</span><span class="NLM_issue">4965</span><span class="NLM_x">) </span> <span class="NLM_fpage">1318</span><span class="NLM_x">–</span> <span class="NLM_lpage">1319</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=1964&pages=1318-1319&issue=4965&author=J.+Glowinskiauthor=J.+Axelrod&title=Inhibition+of+uptake+of+tritiated+noradrenaline+in+the+intact+rat+brain+by+imipramine+and+structurally+related+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGlowinski%26aufirst%3DJ.%26aulast%3DAxelrod%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520uptake%2520of%2520tritiated%2520noradrenaline%2520in%2520the%2520intact%2520rat%2520brain%2520by%2520imipramine%2520and%2520structurally%2520related%2520compounds%26jtitle%3DNature%26date%3D1964%26volume%3D204%26issue%3D4965%26spage%3D1318%26epage%3D1319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="note"><p class="first last">No generic name could be found for compound <b>1</b>. Today, Loranil is a trade name of the antihistamine, loratidine, which is an entirely different drug.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group">Meyer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuhmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedrich, C.</span><span> </span><span class="NLM_article-title">Chance and calculated development! The history of oral antidiabetics</span> <span class="citation_source-journal">Pharm. Z.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">242</span><span class="NLM_x">–</span> <span class="NLM_lpage">250</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2002&pages=242-250&issue=3&author=U.+Meyerauthor=A.+Schuhmannauthor=C.+Friedrich&title=Chance+and+calculated+development%21+The+history+of+oral+antidiabetics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DU.%26aulast%3DSchuhmann%26aufirst%3DA.%26aulast%3DFriedrich%26aufirst%3DC.%26atitle%3DChance%2520and%2520calculated%2520development%2521%2520The%2520history%2520of%2520oral%2520antidiabetics%26jtitle%3DPharm.%2520Z.%26date%3D2002%26volume%3D31%26issue%3D3%26spage%3D242%26epage%3D250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group">Sneader, W.</span> <span class="citation_source-book">Drug Discovery – A History</span>; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Chichester</span>,<span class="NLM_x"> </span><span class="NLM_year">2005</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">392</span><span class="NLM_x">–</span> <span class="NLM_lpage">393</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F0470015535" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&pages=392-393&author=W.+Sneader&title=Drug+Discovery+%E2%80%93+A+History"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1002%2F0470015535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F0470015535%26sid%3Dliteratum%253Aachs%26aulast%3DSneader%26aufirst%3DW.%26btitle%3DDrug%2520Discovery%2520%25E2%2580%2593%2520A%2520History%26pub%3DWiley%26date%3D2005%26spage%3D392%26epage%3D393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group">Langer, T.; Wermuth, C.-G.</span><span> </span><span class="NLM_article-title">Selective Optimization of Side Activities (SOSA): A Promising Way for Drug Discovery</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed.; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">227</span><span class="NLM_x">–</span> <span class="NLM_lpage">243</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch11" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=227-243&author=T.+Langer&author=C.-G.+Wermuthauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch11%26sid%3Dliteratum%253Aachs%26aulast%3DLanger%26aufirst%3DT.%26atitle%3DSelective%2520Optimization%2520of%2520Side%2520Activities%2520%2528SOSA%2529%253A%2520A%2520Promising%2520Way%2520for%2520Drug%2520Discovery%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D227%26epage%3D243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group">Wermuth, C. G.</span><span> </span><span class="NLM_article-title">Selective optimization of side activities: the SOSA approach</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">3 & 4</span><span class="NLM_x">) </span> <span class="NLM_fpage">160</span><span class="NLM_x">–</span> <span class="NLM_lpage">164</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2006&pages=160-164&issue=3+%26+4&author=C.+G.+Wermuth&title=Selective+optimization+of+side+activities%3A+the+SOSA+approach"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWermuth%26aufirst%3DC.%2BG.%26atitle%3DSelective%2520optimization%2520of%2520side%2520activities%253A%2520the%2520SOSA%2520approach%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2006%26volume%3D11%26issue%3D3%2520%2526%25204%26spage%3D160%26epage%3D164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group">Wermuth, C. G.</span><span> </span><span class="NLM_article-title">Selective Optimization of Side Activities: Another Way for Drug Discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">1303</span><span class="NLM_x">–</span> <span class="NLM_lpage">1314</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm030480f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1303-1314&issue=6&author=C.+G.+Wermuth&title=Selective+Optimization+of+Side+Activities%3A+Another+Way+for+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1021%2Fjm030480f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030480f%26sid%3Dliteratum%253Aachs%26aulast%3DWermuth%26aufirst%3DC.%2BG.%26atitle%3DSelective%2520Optimization%2520of%2520Side%2520Activities%253A%2520Another%2520Way%2520for%2520Drug%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26issue%3D6%26spage%3D1303%26epage%3D1314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group">Morphy, J. R.</span><span> </span><span class="NLM_article-title">The Challenges of Multi-Target Lead Optimization</span>. In  <span class="citation_source-book">Designing Multi-Target Drugs</span>; <span class="NLM_contrib-group">Morphy, J. R.; Harris, C. J.</span>, Eds.; <span class="NLM_publisher-name">RSC Publishing</span>: <span class="NLM_publisher-loc">Cambridge</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">141</span><span class="NLM_x">–</span> <span class="NLM_lpage">154</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1039%2F9781849734912-00141" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=141-154&author=J.+R.+Morphyauthor=J.+R.+Morphy&author=C.+J.+Harris&title=Designing+Multi-Target+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1039%2F9781849734912-00141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1039%252F9781849734912-00141%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520Challenges%2520of%2520Multi-Target%2520Lead%2520Optimization%26btitle%3DDesigning%2520Multi-Target%2520Drugs%26aulast%3DMorphy%26aufirst%3DJ.%2BR.%26pub%3DRSC%2520Publishing%26date%3D2012%26spage%3D141%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group">Marchand, C.</span><span> </span><span class="NLM_article-title">The elvitegravir Quad pill: the first once-daily dual-target anti-HIV tablet</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">901</span><span class="NLM_x">–</span> <span class="NLM_lpage">904</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=901-904&issue=7&author=C.+Marchand&title=The+elvitegravir+Quad+pill%3A+the+first+once-daily+dual-target+anti-HIV+tablet"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarchand%26aufirst%3DC.%26atitle%3DThe%2520elvitegravir%2520Quad%2520pill%253A%2520the%2520first%2520once-daily%2520dual-target%2520anti-HIV%2520tablet%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2012%26volume%3D21%26issue%3D7%26spage%3D901%26epage%3D904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group">Monzon, J. G.; Dancey, J.</span><span> </span><span class="NLM_article-title">Combination Agents Versus Multi-Targeted Agents – Pros and Cons</span>. In  <span class="citation_source-book">Designing Multi-Target Drugs</span>; <span class="NLM_contrib-group">Morphy, J. R.; Harris, C. J.</span>, Eds.; <span class="NLM_publisher-name">RSC Publishing</span>: <span class="NLM_publisher-loc">Cambridge</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">155</span><span class="NLM_x">–</span> <span class="NLM_lpage">175</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1039%2F9781849734912-00155" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=155-175&author=J.+G.+Monzon&author=J.+Danceyauthor=J.+R.+Morphy&author=C.+J.+Harris&title=Designing+Multi-Target+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1039%2F9781849734912-00155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1039%252F9781849734912-00155%26sid%3Dliteratum%253Aachs%26aulast%3DMonzon%26aufirst%3DJ.%2BG.%26atitle%3DCombination%2520Agents%2520Versus%2520Multi-Targeted%2520Agents%2520%25E2%2580%2593%2520Pros%2520and%2520Cons%26btitle%3DDesigning%2520Multi-Target%2520Drugs%26aulast%3DMorphy%26aufirst%3DJ.%2BR.%26pub%3DRSC%2520Publishing%26date%3D2012%26spage%3D155%26epage%3D175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group">Bolognesi, M. L.</span><span> </span><span class="NLM_article-title">Polypharmacology in a single drug: multitarget drugs</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x"> (</span><span class="NLM_issue">13</span><span class="NLM_x">) </span> <span class="NLM_fpage">1639</span><span class="NLM_x">–</span> <span class="NLM_lpage">1645</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.2174%2F0929867311320130004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=23410164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotl2jtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1639-1645&issue=13&author=M.+L.+Bolognesi&title=Polypharmacology+in+a+single+drug%3A+multitarget+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology in a single drug: multitarget drugs</span></div><div class="casAuthors">Bolognesi, M. L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1639-1645</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Polypharmacol. offers a model for the way drug discovery must evolve to develop therapies most suited to treating currently incurable diseases.  It is driven by a worldwide demand for safer, more effective, and affordable medicines against the most complex diseases, and by the failures of modern drug discovery to provide these.  Polypharmacol. can involve combinations and/or multitarget drugs (MTD).  Although not mutually exclusive, my premise is that MTDs have inherent advantages over combinations.  This review article focuses on MTDs from a medicinal chem. perspective.  I will explore their use in current clin. practice, their likely application in the future, and the challenges to be overcome to achieve this goal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeSnmeFeRpMrVg90H21EOLACvtfcHk0li2jhyW7IDRRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotl2jtLk%253D&md5=0e69395566711e018db8a61b1ae0f56e</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.2174%2F0929867311320130004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867311320130004%26sid%3Dliteratum%253Aachs%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DPolypharmacology%2520in%2520a%2520single%2520drug%253A%2520multitarget%2520drugs%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26issue%3D13%26spage%3D1639%26epage%3D1645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group">Morphy, R.</span><span> </span><span class="NLM_article-title">Selective Multitargeted Drugs</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed.; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">247</span><span class="NLM_x">–</span> <span class="NLM_lpage">262</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=247-262&author=R.+Morphyauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26atitle%3DSelective%2520Multitargeted%2520Drugs%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D247%26epage%3D262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group">Morphy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">Designing multiple ligands - medicinal chemistry strategies and challenges</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">587</span><span class="NLM_x">–</span> <span class="NLM_lpage">600</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.2174%2F138161209787315594" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=19199984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvVSns70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=587-600&issue=6&author=R.+Morphyauthor=Z.+Rankovic&title=Designing+multiple+ligands+-+medicinal+chemistry+strategies+and+challenges"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Designing multiple ligands - medicinal chemistry strategies and challenges</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">587-600</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  It has been widely recognized over the recent years that parallel modulation of multiple biol. targets can be beneficial for treatment of diseases with complex etiologies such as cancer asthma, and psychiatric disease.  In this article, current strategies for the generation of ligands with a specific multi-target profile (designed multiple ligands or DMLs) are described and a no. of illustrative example are given.  Designing multiple ligands is frequently a challenging endeavor for medicinal chemists, with the need to appropriately balance affinity for 2 or more targets while obtaining physicochem. and pharmacokinetic properties that are consistent with the administration of an oral drug.  Given that the properties of DMLs are influenced to a large extent by the proteomic superfamily to which the targets belong and the lead generation strategy that is pursued, an early assessment of the feasibility of any given DML project is essential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUo6NjoK5D-LVg90H21EOLACvtfcHk0li2jhyW7IDRRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvVSns70%253D&md5=fa34039be6e9c3b489f530fc74fd0346</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.2174%2F138161209787315594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161209787315594%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigning%2520multiple%2520ligands%2520-%2520medicinal%2520chemistry%2520strategies%2520and%2520challenges%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2009%26volume%3D15%26issue%3D6%26spage%3D587%26epage%3D600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group">Allan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cambridge, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hardy, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Follenfant, M. J.</span><span> </span><span class="NLM_article-title">BW A575C, a chemically novel agent with angiotensin converting enzyme inhibitor and β-adrenoceptorblocking properties</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">609</span><span class="NLM_x">–</span> <span class="NLM_lpage">615</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1111%2Fj.1476-5381.1987.tb11212.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADyaL2sXhvVylu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1987&pages=609-615&author=G.+Allanauthor=D.+Cambridgeauthor=G.+W.+Hardyauthor=M.+J.+Follenfant&title=BW+A575C%2C+a+chemically+novel+agent+with+angiotensin+converting+enzyme+inhibitor+and+%CE%B2-adrenoceptorblocking+properties"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">BW A575C, a chemically novel agent with angiotensin-converting enzyme-inhibitor and β-adrenoceptor-blocking properties</span></div><div class="casAuthors">Allan, G.; Cambridge, D.; Hardy, G. W.; Follenfant, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">609-15</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    </div><div class="casAbstract">BW A575C (I)  [103221-88-1] is a chem. novel agent which exhibits in a single mol. both angiotensin converting enzyme (ACE)  [9015-82-1] inhibition and β-adrenoceptor-blocking properties.  BW A575C produced a competitive blockade of heart rate responses to isoprenaline in a guinea-pig right atrial prepn.  BW A575C inhibited a partially purified prepn. of ACE obtained from rabbit lung.  I.v. administration of BW A575C to the pithed rat inhibited, in a dose-dependent fashion, both angiotensin I-induced pressor responses and isoprenaline-induced tachycardia.  Dose-ratios obtained from such studies demonstrated that, in this prepn., BW A575C was approx. 100 times more active as an ACE inhibitor than as a β-adrenoceptor blocking agent.  I.v. administration of BW A575C (1 mg/kg) to the conscious rat inhibited angiotensin I-induced pressor responses, being approx. equipotent to enalapril and 10 times more potent than captopril.  At the same dose, BW A575C had a similar duration of action as an ACE inhibitor to enalapril.  I.v. administration of BW A575C (1 mg/kg) to either conscious dogs or rats inhibited both angiotensin I-induced pressor responses and isoprenaline-induced heart rate responses.  Dose-ratios obtained from such studies demonstrated that in these species, BW A575C was 2-10 times more active as an ACE inhibitor than as a β-adrenoceptor blocking agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIubMbW41qXrVg90H21EOLACvtfcHk0lhEkQZXLwXEmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXhvVylu7s%253D&md5=4e8b54bc3031daf1c4dadc35aa6af979</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1987.tb11212.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1987.tb11212.x%26sid%3Dliteratum%253Aachs%26aulast%3DAllan%26aufirst%3DG.%26aulast%3DCambridge%26aufirst%3DD.%26aulast%3DHardy%26aufirst%3DG.%2BW.%26aulast%3DFollenfant%26aufirst%3DM.%2BJ.%26atitle%3DBW%2520A575C%252C%2520a%2520chemically%2520novel%2520agent%2520with%2520angiotensin%2520converting%2520enzyme%2520inhibitor%2520and%2520%25CE%25B2-adrenoceptorblocking%2520properties%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1987%26volume%3D90%26spage%3D609%26epage%3D615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group">Morphy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">From magic bullets to designed multiple ligands</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">15</span><span class="NLM_x">) </span> <span class="NLM_fpage">641</span><span class="NLM_x">–</span> <span class="NLM_lpage">651</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1016%2FS1359-6446%2804%2903163-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=15279847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=641-651&issue=15&author=R.+Morphyauthor=C.+Kayauthor=Z.+Rankovic&title=From+magic+bullets+to+designed+multiple+ligands"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">From magic bullets to designed multiple ligands</span></div><div class="casAuthors">Morphy, Richard; Kay, Corinne; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">641-651</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  A major trend in medicinal chem. in the coming years will be the rational design of ligands that are capable of modulating multiple disease-relevant targets in a specific manner.  Increasingly, it is being recognized that a balanced modulation of several targets can provide a superior therapeutic effect and side effect profile compared to the action of a selective ligand.  Rational approaches in which structural features from selective ligands are combined have produced designed multiple ligands that span a wide variety of targets and target classes.  A key challenge in the design of multiple ligands is attaining a balanced activity at each target of interest while simultaneously achieving a wider selectivity and a suitable pharmacokinetic profile.  An anal. of literature examples reveals trends and insights that might help medicinal chemists discover the next generation of these types of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcsGpfzZok5rVg90H21EOLACvtfcHk0lhEkQZXLwXEmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D&md5=cd2491baad707043dbee4f59ccad9e1d</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903163-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903163-0%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DKay%26aufirst%3DC.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFrom%2520magic%2520bullets%2520to%2520designed%2520multiple%2520ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26issue%3D15%26spage%3D641%26epage%3D651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group">Morphy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">Designed Multiple Ligands</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x"> (</span><span class="NLM_issue">21</span><span class="NLM_x">) </span> <span class="NLM_fpage">6523</span><span class="NLM_x">–</span> <span class="NLM_lpage">6543</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&issue=21&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+Multiple+Ligands"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520Multiple%2520Ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D21%26spage%3D6523%26epage%3D6543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group">Besnard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruda, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abecassis, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguiz, R. M</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norval, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sassano, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simeons, F. R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stojanovski, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidah, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Constam, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bickerton, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetsel, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, I. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, A. L.</span><span> </span><span class="NLM_article-title">Automated design of ligands to polypharmacological profiles</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">492</span><span class="NLM_x"> (</span><span class="NLM_issue">7428</span><span class="NLM_x">) </span> <span class="NLM_fpage">215</span><span class="NLM_x">–</span> <span class="NLM_lpage">220</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fnature11691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=23235874" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=492&publication_year=2012&pages=215-220&issue=7428&author=J.+Besnardauthor=G.+F.+Rudaauthor=V.+Setolaauthor=K.+Abecassisauthor=R.+M+Rodriguizauthor=X.-P.+Huangauthor=S.+Norvalauthor=M.+F.+Sassanoauthor=I.+Shinauthor=L.+A.+Websterauthor=F.+R.+C.+Simeonsauthor=L.+Stojanovskiauthor=A.+Pratauthor=N.+G.+Seidahauthor=D.+B.+Constamauthor=G.+R.+Bickertonauthor=K.+D.+Readauthor=W.+C.+Wetselauthor=I.+H.+Gilbertauthor=B.+L.+Rothauthor=A.+L.+Hopkins&title=Automated+design+of+ligands+to+polypharmacological+profiles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1038%2Fnature11691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11691%26sid%3Dliteratum%253Aachs%26aulast%3DBesnard%26aufirst%3DJ.%26aulast%3DRuda%26aufirst%3DG.%2BF.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DAbecassis%26aufirst%3DK.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DNorval%26aufirst%3DS.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DShin%26aufirst%3DI.%26aulast%3DWebster%26aufirst%3DL.%2BA.%26aulast%3DSimeons%26aufirst%3DF.%2BR.%2BC.%26aulast%3DStojanovski%26aufirst%3DL.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DSeidah%26aufirst%3DN.%2BG.%26aulast%3DConstam%26aufirst%3DD.%2BB.%26aulast%3DBickerton%26aufirst%3DG.%2BR.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DAutomated%2520design%2520of%2520ligands%2520to%2520polypharmacological%2520profiles%26jtitle%3DNature%26date%3D2012%26volume%3D492%26issue%3D7428%26spage%3D215%26epage%3D220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group">Day, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottaway, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelfanov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smiley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gidda, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Findeisen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruemmer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drucker, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaudhary, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holland, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hembree, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abplanalp, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruehl, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirchner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockie, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nogueiras, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfluger, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Tilve, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMarchi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tschöp, M. H.</span><span> </span><span class="NLM_article-title">A new glucagon and GLP-1 co-agonist eliminates obesity in rodents</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">749</span><span class="NLM_x">–</span> <span class="NLM_lpage">757</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1038%2Fnchembio.209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Fjm400856t&amp;key=19597507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosFWhsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=749-757&issue=10&author=J.+W.+Dayauthor=N.+Ottawayauthor=J.+T.+Pattersonauthor=V.+Gelfanovauthor=D.+Smileyauthor=J.+Giddaauthor=H.+Findeisenauthor=D.+Bruemmerauthor=D.+J.+Druckerauthor=N.+Chaudharyauthor=J.+Hollandauthor=J.+Hembreeauthor=W.+Abplanalpauthor=E.+Grantauthor=J.+Ruehlauthor=H.+Wilsonauthor=H.+Kirchnerauthor=S.+H.+Lockieauthor=S.+Hofmannauthor=S.+C.+Woodsauthor=R.+Nogueirasauthor=P.+T.+Pflugerauthor=D.+Perez-Tilveauthor=R.+DiMarchiauthor=M.+H.+Tsch%C3%B6p&title=A+new+glucagon+and+GLP-1+co-agonist+eliminates+obesity+in+rodents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">A new glucagon and GLP-1 co-agonist eliminates obesity in rodents</span></div><div class="casAuthors">Day, Jonathan W.; Ottaway, Nickki; Patterson, James T.; Gelfanov, Vasily; Smiley, David; Gidda, Jas; Findeisen, Hannes; Bruemmer, Dennis; Drucker, Daniel J.; Chaudhary, Nilika; Holland, Jenna; Hembree, Jazzminn; Abplanalp, William; Grant, Erin; Ruehl, Jennifer; Wilson, Hilary; Kirchner, Henriette; Lockie, Sarah Haas; Hofmann, Susanna; Woods, Stephen C.; Nogueiras, Ruben; Pfluger, Paul T.; Perez-Tilve, Diego; DiMarchi, Richard; Tschoep, Matthias H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">749-757</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We report the efficacy of a new peptide with agonism at the glucagon and GLP-1 receptors that has potent, sustained satiation-inducing and lipolytic effects.  Selective chem. modification to glucagon resulted in a loss of specificity, with minimal change to inherent activity.  The structural basis for the co-agonism appears to be a combination of local positional interactions and a change in secondary structure.  Two co-agonist peptides differing from each other only in their level of glucagon receptor agonism were studied in rodent obesity models.  Administration of PEGylated peptides once per wk normalized adiposity and glucose tolerance in diet-induced obese mice.  Redn. of body wt. was achieved by a loss of body fat resulting from decreased food intake and increased energy expenditure.  These preclin. studies indicate that when full GLP-1 agonism is augmented with an appropriate degree of glucagon receptor activation, body fat redn. can be substantially enhanced without any overt adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4K1-_eVTTKbVg90H21EOLACvtfcHk0lgUSfNl4dm5Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosFWhsLk%253D&md5=74b57672bfd375dd4d073624a25eab9b</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.209%26sid%3Dliteratum%253Aachs%26aulast%3DDay%26aufirst%3DJ.%2BW.%26aulast%3DOttaway%26aufirst%3DN.%26aulast%3DPatterson%26aufirst%3DJ.%2BT.%26aulast%3DGelfanov%26aufirst%3DV.%26aulast%3DSmiley%26aufirst%3DD.%26aulast%3DGidda%26aufirst%3DJ.%26aulast%3DFindeisen%26aufirst%3DH.%26aulast%3DBruemmer%26aufirst%3DD.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DChaudhary%26aufirst%3DN.%26aulast%3DHolland%26aufirst%3DJ.%26aulast%3DHembree%26aufirst%3DJ.%26aulast%3DAbplanalp%26aufirst%3DW.%26aulast%3DGrant%26aufirst%3DE.%26aulast%3DRuehl%26aufirst%3DJ.%26aulast%3DWilson%26aufirst%3DH.%26aulast%3DKirchner%26aufirst%3DH.%26aulast%3DLockie%26aufirst%3DS.%2BH.%26aulast%3DHofmann%26aufirst%3DS.%26aulast%3DWoods%26aufirst%3DS.%2BC.%26aulast%3DNogueiras%26aufirst%3DR.%26aulast%3DPfluger%26aufirst%3DP.%2BT.%26aulast%3DPerez-Tilve%26aufirst%3DD.%26aulast%3DDiMarchi%26aufirst%3DR.%26aulast%3DTsch%25C3%25B6p%26aufirst%3DM.%2BH.%26atitle%3DA%2520new%2520glucagon%2520and%2520GLP-1%2520co-agonist%2520eliminates%2520obesity%2520in%2520rodents%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D5%26issue%3D10%26spage%3D749%26epage%3D757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group">Fosgerau, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jessen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lind Tolborg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterlund, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaeffer Larsen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolsted, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brorson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jelsing, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skovlund Ryge Neerup, T.</span><span> </span><span class="NLM_article-title">The novel GLP-1-gastrin dual agonist, ZP3022, increases β-cell mass and prevents diabetes in db/db mice</span> <span class="citation_source-journal">Diabetes, Obesity Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">62</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1111%2Fj.1463-1326.2012.01676.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCksLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=62-71&issue=1&author=K.+Fosgerauauthor=L.+Jessenauthor=J.+Lind+Tolborgauthor=T.+Osterlundauthor=K.+Schaeffer+Larsenauthor=K.+Rolstedauthor=M.+Brorsonauthor=J.+Jelsingauthor=T.+Skovlund+Ryge+Neerup&title=The+novel+GLP-1-gastrin+dual+agonist%2C+ZP3022%2C+increases+%CE%B2-cell+mass+and+prevents+diabetes+in+db%2Fdb+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">The novel GLP-1-gastrin dual agonist, ZP3022, increases β-cell mass and prevents diabetes in db/db mice</span></div><div class="casAuthors">Fosgerau, K.; Jessen, L.; Lind Tolborg, J.; Osterlund, T.; Schaeffer Larsen, K.; Rolsted, K.; Brorson, M.; Jelsing, J.; Skovlund Ryge Neerup, T.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">62-71</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aim : Diabetes is characterized by β-cell deficiency, and therefore restoration of β-cell function has been suggested as a potential therapy.  We hypothesized that a novel glucagon-like peptide-1 (GLP-1)-gastrin dual agonist, ZP3022, improves glycemic control via improvement of β-cell status in db/db mice..  Methods : Diabetic mice were studied following short- or long-term treatment with either the GLP-1-gastrin dual agonist or the com. available GLP-1 agonists (exendin-4 and liraglutide).  The effects on glycemic control were addressed by repeated glucose tolerance tests and/or measurements of HbA1c levels, and pancreatic islet and β-cell masses were detd. by stereol.Results : ZP3022 and the pure GLP-1 agonists improved glycemic control after both short- and long-term treatment compared with vehicle.  Interestingly, the effect was sustainable only in mice treated with ZP3022.  Stereol. data displayed a dose-dependent increase of β-cell mass (p < 0.05) following treatment with ZP3022, whereas no significant effect of liraglutide was obsd. (β-cell mass: vehicle 3.7 ± 0.2 mg; liraglutide (30 nmol/kg) 3.4 ± 0.5 mg; ZP3022 (30 nmol/kg) 4.3 ± 0.4 mg and ZP3022 (100 nmol/kg) 5.2 ± 0.4 mg).Conclusion : The novel GLP-1-gastrin dual agonist, ZP3022, improved glycemic control in db/db mice, and pancreatic islet and β-cell mass increased significantly following treatment with ZP3022 compared with vehicle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8ta9zMqxjlbVg90H21EOLACvtfcHk0lgUSfNl4dm5Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCksLrE&md5=cc432fa85f778937f2c2113f189b8aa4</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1111%2Fj.1463-1326.2012.01676.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1463-1326.2012.01676.x%26sid%3Dliteratum%253Aachs%26aulast%3DFosgerau%26aufirst%3DK.%26aulast%3DJessen%26aufirst%3DL.%26aulast%3DLind%2BTolborg%26aufirst%3DJ.%26aulast%3DOsterlund%26aufirst%3DT.%26aulast%3DSchaeffer%2BLarsen%26aufirst%3DK.%26aulast%3DRolsted%26aufirst%3DK.%26aulast%3DBrorson%26aufirst%3DM.%26aulast%3DJelsing%26aufirst%3DJ.%26aulast%3DSkovlund%2BRyge%2BNeerup%26aufirst%3DT.%26atitle%3DThe%2520novel%2520GLP-1-gastrin%2520dual%2520agonist%252C%2520ZP3022%252C%2520increases%2520%25CE%25B2-cell%2520mass%2520and%2520prevents%2520diabetes%2520in%2520db%252Fdb%2520mice%26jtitle%3DDiabetes%252C%2520Obesity%2520Metab.%26date%3D2013%26volume%3D15%26issue%3D1%26spage%3D62%26epage%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group">Atkinson, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bromidge, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duxon, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaster, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadley, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammond, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middlemiss, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">North, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, G. W.</span><span> </span><span class="NLM_article-title">3,4-Dihydro-2H-benzoxazinones are 5-HT1A receptor antagonists with potent 5-HT reuptake inhibitory activity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">737</span><span class="NLM_x">–</span> <span class="NLM_lpage">741</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=737-741&issue=3&author=P.+J.+Atkinsonauthor=S.+M.+Bromidgeauthor=M.+S.+Duxonauthor=L.+M.+Gasterauthor=M.+S.+Hadleyauthor=B.+Hammondauthor=C.+N.+Johnsonauthor=D.+N.+Middlemissauthor=S.+E.+Northauthor=G.+W.+Price&title=3%2C4-Dihydro-2H-benzoxazinones+are+5-HT1A+receptor+antagonists+with+potent+5-HT+reuptake+inhibitory+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAtkinson%26aufirst%3DP.%2BJ.%26aulast%3DBromidge%26aufirst%3DS.%2BM.%26aulast%3DDuxon%26aufirst%3DM.%2BS.%26aulast%3DGaster%26aufirst%3DL.%2BM.%26aulast%3DHadley%26aufirst%3DM.%2BS.%26aulast%3DHammond%26aufirst%3DB.%26aulast%3DJohnson%26aufirst%3DC.%2BN.%26aulast%3DMiddlemiss%26aufirst%3DD.%2BN.%26aulast%3DNorth%26aufirst%3DS.%2BE.%26aulast%3DPrice%26aufirst%3DG.%2BW.%26atitle%3D3%252C4-Dihydro-2H-benzoxazinones%2520are%25205-HT1A%2520receptor%2520antagonists%2520with%2520potent%25205-HT%2520reuptake%2520inhibitory%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26issue%3D3%26spage%3D737%26epage%3D741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group">Chen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wild, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guha, R.</span><span> </span><span class="NLM_article-title">PubChem as a Source of Polypharmacology</span> <span class="citation_source-journal">J. Chem. Inf. Mod.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">2044</span><span class="NLM_x">–</span> <span class="NLM_lpage">2055</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci9001876" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVGjtbrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=2044-2055&issue=9&author=B.+Chenauthor=D.+Wildauthor=R.+Guha&title=PubChem+as+a+Source+of+Polypharmacology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">PubChem as a Source of Polypharmacology</span></div><div class="casAuthors">Chen, Bin; Wild, David; Guha, Rajarshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2044-2055</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polypharmacol. provides a new way to address the issue of high attrition rates arising from lack of efficacy and toxicity.  However, the development of polypharmacol. is hampered by the incomplete SAR data and limited resources for validating target combinations.  The PubChem bioassay collection, reporting the activity of compds. in multiple assays, allows us to study polypharmacol. behavior in the PubChem collection via cross-assay anal.  In this paper, we developed a network representation of the assay collection and then applied a bipartite mapping between this network and various biol. networks (i.e., PPI, pathway) as well as artificial networks (i.e., drug-target network).  Mapping to a drug-target network allows us to prioritize new selective compds., while mapping to other biol. networks enable us to observe interesting target pairs and their assocd. compds. in the context of biol. systems.  Our results indicate this approach could be a useful way to investigate polypharmacol. in the PubChem bioassay collection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRZbl2jMrHtrVg90H21EOLACvtfcHk0lgUSfNl4dm5Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVGjtbrK&md5=76b5e8c8aa3e71a6c17b702db6988548</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1021%2Fci9001876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci9001876%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DB.%26aulast%3DWild%26aufirst%3DD.%26aulast%3DGuha%26aufirst%3DR.%26atitle%3DPubChem%2520as%2520a%2520Source%2520of%2520Polypharmacology%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Mod.%26date%3D2009%26volume%3D49%26issue%3D9%26spage%3D2044%26epage%3D2055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group">Artis, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehra, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perreault, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erbe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krupka, H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">England, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, J.</span><span> </span><span class="NLM_article-title">Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">262</span><span class="NLM_x">–</span> <span class="NLM_lpage">267</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=262-267&issue=1&author=D.+R.+Artisauthor=J.+J.+Linauthor=C.+Zhangauthor=W.+Wangauthor=U.+Mehraauthor=M.+Perreaultauthor=D.+Erbeauthor=H.+I.+Krupkaauthor=B.+P.+Englandauthor=J.+Arnold&title=Scaffold-based+discovery+of+indeglitazar%2C+a+PPAR+pan-active+anti-diabetic+agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DLin%26aufirst%3DJ.%2BJ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DMehra%26aufirst%3DU.%26aulast%3DPerreault%26aufirst%3DM.%26aulast%3DErbe%26aufirst%3DD.%26aulast%3DKrupka%26aufirst%3DH.%2BI.%26aulast%3DEngland%26aufirst%3DB.%2BP.%26aulast%3DArnold%26aufirst%3DJ.%26atitle%3DScaffold-based%2520discovery%2520of%2520indeglitazar%252C%2520a%2520PPAR%2520pan-active%2520anti-diabetic%2520agent%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26issue%3D1%26spage%3D262%26epage%3D267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group">Horst, J. A.; Laurenzi, A.; Bernard, B.; Samudrala, R.</span><span> </span><span class="NLM_article-title">Computational Multitarget Drug Discovery</span>. In  <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_contrib-group">Peters, J.-U.</span>, Ed.; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">263</span><span class="NLM_x">–</span> <span class="NLM_lpage">301</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.1002%2F9781118098141.ch13" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=263-301&author=J.+A.+Horst&author=A.+Laurenzi&author=B.+Bernard&author=R.+Samudralaauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch13%26sid%3Dliteratum%253Aachs%26aulast%3DHorst%26aufirst%3DJ.%2BA.%26atitle%3DComputational%2520Multitarget%2520Drug%2520Discovery%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DWiley%26date%3D2012%26spage%3D263%26epage%3D301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group">Jenwitheesuk, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horst, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivas, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Voorhis, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samudrala, R.</span><span> </span><span class="NLM_article-title">Novel paradigms for drug discovery: computational multitarget screening</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">62</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=62-71&issue=2&author=E.+Jenwitheesukauthor=J.+A.+Horstauthor=K.+L.+Rivasauthor=W.+C.+Van+Voorhisauthor=R.+Samudrala&title=Novel+paradigms+for+drug+discovery%3A+computational+multitarget+screening"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJenwitheesuk%26aufirst%3DE.%26aulast%3DHorst%26aufirst%3DJ.%2BA.%26aulast%3DRivas%26aufirst%3DK.%2BL.%26aulast%3DVan%2BVoorhis%26aufirst%3DW.%2BC.%26aulast%3DSamudrala%26aufirst%3DR.%26atitle%3DNovel%2520paradigms%2520for%2520drug%2520discovery%253A%2520computational%2520multitarget%2520screening%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2008%26volume%3D29%26issue%3D2%26spage%3D62%26epage%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group">Carrieri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Nueno, V. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lentini, Gi.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ritchie, D. W.</span><span> </span><span class="NLM_article-title">Recent Trends And Future Prospects In Computational GPCR Drug Discovery: From Virtual Screening To Polypharmacology</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1069</span><span class="NLM_x">–</span> <span class="NLM_lpage">1097</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Fjm400856t&amp;key=10.2174%2F15680266113139990028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Wns7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=1069-1097&issue=9&author=A.+Carrieriauthor=V.+I.+Perez-Nuenoauthor=Gi.+Lentiniauthor=D.+W.+Ritchie&title=Recent+Trends+And+Future+Prospects+In+Computational+GPCR+Drug+Discovery%3A+From+Virtual+Screening+To+Polypharmacology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Trends and Future Prospects in Computational GPCR Drug Discovery: From Virtual Screening to Polypharmacology</span></div><div class="casAuthors">Carrieri, Antonio; Perez-Nueno, Violeta I.; Lentini, Giovanni; Ritchie, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1069-1097</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Extending virtual screening approaches to deal with multi-target drug design and polypharmacol. is an increasingly important aspect in drug design.  In light of this, the concept of accessible chem. space and its exploration should be reviewed.  The great advantages of re-using drugs with safe pharmacol. profiles with favorable pharmacokinetic properties highlights drug repositioning as a valid alternative to rational drug design, massive drug development efforts, and high-throughput screening, esp. when supported by in silico techniques.  Here, we discuss some of the advantages of multi-target approaches, and we review some significant examples of their application in the last decade to that well known class of pharmaceutical targets, the G-protein coupled receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXMiMDWYHyo7Vg90H21EOLACvtfcHk0lj9n1pFkj2a7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Wns7zK&md5=d651022fd90928c68e331199e10319c3</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.2174%2F15680266113139990028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F15680266113139990028%26sid%3Dliteratum%253Aachs%26aulast%3DCarrieri%26aufirst%3DA.%26aulast%3DPerez-Nueno%26aufirst%3DV.%2BI.%26aulast%3DLentini%26aufirst%3DGi.%26aulast%3DRitchie%26aufirst%3DD.%2BW.%26atitle%3DRecent%2520Trends%2520And%2520Future%2520Prospects%2520In%2520Computational%2520GPCR%2520Drug%2520Discovery%253A%2520From%2520Virtual%2520Screening%2520To%2520Polypharmacology%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26issue%3D9%26spage%3D1069%26epage%3D1097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group">Wei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, L.</span><span> </span><span class="NLM_article-title">Discovery of Multitarget Inhibitors by Combining Molecular Docking with Common Pharmacophore Matching</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x"> (</span><span class="NLM_issue">24</span><span class="NLM_x">) </span> <span class="NLM_fpage">7882</span><span class="NLM_x">–</span> <span class="NLM_lpage">7888</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8010096" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Fjm400856t&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVKlu7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7882-7888&issue=24&author=D.+Weiauthor=X.+Jiangauthor=L.+Zhouauthor=J.+Chenauthor=Z.+Chenauthor=C.+Heauthor=K.+Yangauthor=Y.+Liuauthor=J.+Peiauthor=L.+Lai&title=Discovery+of+Multitarget+Inhibitors+by+Combining+Molecular+Docking+with+Common+Pharmacophore+Matching"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Multitarget Inhibitors by Combining Molecular Docking with Common Pharmacophore Matching</span></div><div class="casAuthors">Wei, Dengguo; Jiang, Xiaolu; Zhou, Lu; Chen, Jing; Chen, Zheng; He, Chong; Yang, Kun; Liu, Ying; Pei, Jianfeng; Lai, Luhua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7882-7888</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multitarget drugs have been to be found effective in controlling complex diseases.  However, how to design multitarget drugs presents a great challenge. We have developed a computer-assisted strategy to screen for multitarget inhibitors using a combination of mol. docking and common pharmacophore matching.  This strategy was successfully applied to screen for dual-target inhibitors against both the human leukotriene A4 hydrolase (LTA4H-h) and the human nonpancreatic secretory phospholipase A2 (hnps-PLA2).  Three compds. screened from the chem. database MDL Available Chem. Directory were found to inhibit these two enzymes at the 10 μM level.  Moreover, one synthetic compd. matching the common pharmacophores inhibits LTA4H-h and hnps-PLA2 with IC50 values of 35 nM and 7.3 μM, resp.  The common pharmacophore model can also be used to search small mol. databases or collections of existing inhibitors, as well as to guide combinatorial library design to search for ideal multitarget inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJgzU8gGUcMrVg90H21EOLACvtfcHk0lj9n1pFkj2a7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVKlu7nK&md5=0039b1caccc0518b554a20ed1e2e42c9</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1021%2Fjm8010096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8010096%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DD.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DPei%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520Multitarget%2520Inhibitors%2520by%2520Combining%2520Molecular%2520Docking%2520with%2520Common%2520Pharmacophore%2520Matching%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D24%26spage%3D7882%26epage%3D7888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group">Hoffmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metternich, R.</span><span> </span><span class="NLM_article-title">The Future of Medicinal Chemistry</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x"> (</span><span class="NLM_issue">35</span><span class="NLM_x">) </span> <span class="NLM_fpage">8670</span><span class="NLM_x">–</span> <span class="NLM_lpage">8671</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=8670-8671&issue=35&author=T.+Hoffmannauthor=R.+Metternich&title=The+Future+of+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHoffmann%26aufirst%3DT.%26aulast%3DMetternich%26aufirst%3DR.%26atitle%3DThe%2520Future%2520of%2520Medicinal%2520Chemistry%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2012%26volume%3D51%26issue%3D35%26spage%3D8670%26epage%3D8671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group">Swinney, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anthony, J.</span><span> </span><span class="NLM_article-title">How were new medicines discovered?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">507</span><span class="NLM_x">–</span> <span class="NLM_lpage">519</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=507-519&issue=7&author=D.+C.+Swinneyauthor=J.+Anthony&title=How+were+new+medicines+discovered%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSwinney%26aufirst%3DD.%2BC.%26aulast%3DAnthony%26aufirst%3DJ.%26atitle%3DHow%2520were%2520new%2520medicines%2520discovered%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26issue%3D7%26spage%3D507%26epage%3D519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group">Dar, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cagan, R. L.</span><span> </span><span class="NLM_article-title">Chemical genetic discovery of targets and antitargets for cancer polypharmacology</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">486</span><span class="NLM_x"> (</span><span class="NLM_issue">7401</span><span class="NLM_x">) </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">84</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=486&publication_year=2012&pages=80-84&issue=7401&author=A.+C.+Darauthor=T.+K.+Dasauthor=K.+M.+Shokatauthor=R.+L.+Cagan&title=Chemical+genetic+discovery+of+targets+and+antitargets+for+cancer+polypharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDar%26aufirst%3DA.%2BC.%26aulast%3DDas%26aufirst%3DT.%2BK.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DCagan%26aufirst%3DR.%2BL.%26atitle%3DChemical%2520genetic%2520discovery%2520of%2520targets%2520and%2520antitargets%2520for%2520cancer%2520polypharmacology%26jtitle%3DNature%26date%3D2012%26volume%3D486%26issue%3D7401%26spage%3D80%26epage%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group">Pang, M.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, D. H.</span><span> </span><span class="NLM_article-title">A series of case studies: practical methodology for identifying antinociceptive multi-target drugs</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">9–10</span><span class="NLM_x">) </span> <span class="NLM_fpage">425</span><span class="NLM_x">–</span> <span class="NLM_lpage">434</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=425-434&issue=9%E2%80%9310&author=M.-H.+Pangauthor=Y.+Kimauthor=K.+W.+Jungauthor=S.+Choauthor=D.+H.+Lee&title=A+series+of+case+studies%3A+practical+methodology+for+identifying+antinociceptive+multi-target+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPang%26aufirst%3DM.-H.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DJung%26aufirst%3DK.%2BW.%26aulast%3DCho%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DD.%2BH.%26atitle%3DA%2520series%2520of%2520case%2520studies%253A%2520practical%2520methodology%2520for%2520identifying%2520antinociceptive%2520multi-target%2520drugs%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26issue%3D9%25E2%2580%259310%26spage%3D425%26epage%3D434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm400856t&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2013.56.issue-22%3Barticle%3Aarticle%3A10.1021%2Fjm400856t%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm400856t" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799b07f3a0c3cfa","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
